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Exploration of the cortical connectivity by means of transcranial
magnetic stimulation
Antonio Suppa
Department of Neurology and Psychiatry, ‘‘Sapienza’’, University of
Rome, Rome andNeuromed Institute, ‘‘Sapienza’’, University of Rome,
Rome
Over recent years, an increasing number of studies in humans
have investigated the functional connectivity between the primary
motor cortex (M1) and non-primary motor areas with the
transcranial magnetic stimulation (TMS) technique. One experi-
mental approach consisted of delivering repetitive TMS (rTMS)
over the dorsal premotor cortex (PMd) and measuring post-
intervention changes in motor evoked potential (MEP) amplitude
elicited by TMS over M1 [1]. By applying PMd-rTMS in patients
with Parkinson’s Disease (PD), we have demonstrated that altered
M1 responses also reﬂect abnormal PMd-to-M1 functional
connectivity in parkinsonian patients on and off L-dopa therapy
[2,3]. The functional connectivity between M1 and non-motor
cortical areas has been also investigated by modifying the original
paired associative stimulation (PAS) protocol. PAS implies rTMS
over M1 paired with repetitive electric stimulation of a mixed
peripheral nerve at speciﬁc interstimulus intervals (ISIs). Accord-
ing to the speciﬁc ISI used, PAS can increase or decrease MEP
amplitudes through functional sensori-motor connectivity (sen-
sori-motor integration). We have recently developed two PAS
protocols able to investigate the functional connectivity between
M1 and sensory areas other than those activated by the original
PAS. Laser-PAS implies rTMS paired with the nociceptive system
activation elicited by the laser evoked potential technique. Laser-
PAS is able to induce long-term changes in MEP amplitudes
through functional connectivity between brain regions involved in
pain processing and M1 (pain-motor integration) [4]. Laser-PAS
can be helpful to investigate pain-motor integration processes in
patients with different types of movement disorders including PD
and dystonia. Finally, Visual-PAS consists of rTMS paired with the
activation of the visual system as elicited by the visual evoked
potential technique. Visual-PAS induces long-term changes inMEP§ Joint Congress LIMPE/DISMOV-SIN.
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motor integration). Recent observations have found altered
responses to Visual-PAS in patients with photoparoxysmal
response (PPR) suggesting that abnormal visuo-motor integration
may contribute to the pathophysiology of PPR.
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Plasticity, adaptation and compensation: studies with functional
MRI
Alessandro Tessitore
Dipartimento di Scienze Neurologiche, Seconda Universita` degli Studi
di Napoli, Napoli
Functional MRI (fMRI), whereby a time series of MRI volumes is
collected over several minutes while the patient lies quietly in the
scanner or performs a cognitive or motor task, is used to assess
regions of altered activation or functional connectivity between
brain regions, or both. Changes in functional connectivity between
brain regions might underlie many of the clinical impairments
seen in PD, such as in the performance of simultaneous move-
ments. Changes in functional connectivity to or from the
supplementary motor area are associated with impaired motor
performance in PD and with difﬁculties in automatic movement.
Furthermore, functional connectivity assessed with fMRI might be
important for assessing systems-wide compensatory mechanisms
in PD. Onmotor tasks of increasing levels of difﬁculty, it seems that
individuals with PD tap into a motor reserve and activate normal
motor networks to a greater degree and at an earlier (simpler)
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compensatory activity in the rostral SMA and premotor cortex
in individuals who are heterozygous for mutations in PARK2 and
PINK1. In recent years, resting-state imaging has been more
extensively used in the investigation of neurodegenerative
disorders. This technique might be useful in PD. The resting-state
motor network is disrupted in PD patients with decreased
functional connectivity between the posterior putamen and the
inferior parietal cortex, and an increase in functional connectivity
with the anterior putamen. Assessment of resting-state fMRI is
closely related to studies examining the default mode network
(DMN; including the precuneus, medial, lateral and inferior
parietal cortex, medial temporal lobe, medial prefrontal, and
posterior cingulate cortex), which is active during wakeful rest.
However, few studies have addressed the DMN connectivity in PD
reporting conﬂicting results, with some authors detecting reduced
deactivation of posterior midline areas (PCC and precuneus) and
mPFC during different cognitive tasks, while others found no
altered deactivation during an executive task or a complex visual
scene-encoding task. Such discrepancy across studies may be due
to methodological differences in the fMRI analyses or heterogene-
ity in patient characteristics.
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Functional correlates of motor and non-motor symptoms in early
Parkinson’s disease
Roberto Ceravolo
Department of Neuroscience, Azienda Ospedaliero-Universitaria
Pisana, Pisa
The brain functional imaging by means of both functional MRI
and PET or SPECT allows to explore the network of synaptic
connectivity and/or the neurochemical changes even in the early or
prodromic phases of Parkinson’s Disease (PD). Moreover this
approach is useful for detecting the neurobiological basis of motor
and non motor symptoms of PD. Several studies have consistently
demonstrated that putaminal uptake of 18F-Dopa as well as DAT
density inversely and strongly correlates with rigidity and
bradykinesia but not with tremor. These evidences could suggest
that parkinsonian tremor is not directly due to degeneration of
nigro-striatal pathway. However the severity of dopaminergic
degeneration is time and disease related, since at the disease onset
the pallidal 18F-dopa uptake might be increased up to 50%, and
with disease progression pallidal uptakemight be much decreased
as expression of compensatory phenomena with increased
dopamine turnover. In a very recent report the ﬁnding of lower
levels of DAT availability in PD patients with tremor than in
patients without tremor suggested the internal pallidum could be
the main driver of parkinsonian tremor [1]. Finally the investiga-
tion of cortical and subcortical arrangements following the
dopamine depletion in the long preclinical phase of PD by meansof fMRI could help to understand and support the compensatory
mechanisms in PD. Depression affects 40-50% PD patients andmay
antedate the motor onset. It is long known that depression in PD is
related to change in monoaminergic systems, and a signiﬁcant
reduction of uptake of CTI-32, a PET ligand selective for dopamine
and noradrenaline, has been observed in the thalamus, ventral
striatum, locus coeruleus and amigdala in PDwith depression with
respects to PD without depression [2]. The correlation of
dopaminergic dysfunction with affective disorders has been
conﬁrmed in some SPECT studies with DATSCAN, even in the
presence of mild affective symptoms. Up to 15% of PD patientsmay
develop after dopamine replacement therapy impulse control
disorders. An increase of availability and release of dopamine in the
ventral striatum has been consistently demonstrated in PET and
SPECT studies [3], as well as an hyperactivation of frontal lobes and
anterior cingulate, other than ventral striatumhas been reported in
fMRI studies [4]. The next step will be to deﬁne in vivo which
neurochemical or functional pattern is related to the risk to
develop these complications in order to better tailor the therapy
since the early phases of PD.
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SESSION 2 ‘‘Molecular and clinical markers in Parkinson’s disease:
preclinical diagnosis and disease progression’’
L4
Molecular markers in Parkinson’s disease
Paolo Calabresi
Clinica Neurologica, Universita` degli Studi di Perugia, Perugia
Parkinson’s disease (PD) is a common neurodegenerative
disorder, in which the diagnosis is primarily based on clinical
criteria. The required clinical criteria suggest the presence of a full-
blown disease, while the neurodegenerative process in the PD
brain occurs much earlier than the clinical onset. Therefore, the
formulation of an early clinical diagnosis may be very difﬁcult,
impeding an accurate and focused therapeutical approach.
Accumulation and aggregation of a-synuclein, lysosome
dysfunction, and the dynamic interaction taking place along the
course of the disease between a-synuclein and other misfolding
proteins (such as tau protein and beta amyloid) should be
considered the key pathogenetic events in PD.
There is a high need of identifying peripheral biomarkers –
speciﬁcally, cerebrospinal ﬂuid (CSF) biomarkers - mirroring the
molecular changes occurring in the brain, which might allow both
an earlier diagnosis and a better prognosis. To this respect, CSF a-
synuclein-related markers, beta amyloid, and lysosomal enzymes
(namely, beta-glucocerebrosidase) deserve attention, according to
the evidences collected so far about their role in PD. Moreover, the
role of beta amyloid 1-42 as predictive factor for cognitive
Basal Ganglia 2S (2012) e1–e87 e3impairment in PD has consistently been reported. CSF biomarkers
are of value in PD diagnostic and prognostic work-up. To this
respect, it is important to combine different biomarkers for
improving the diagnostic approach to this neurodegenerative
disease.
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Sleep Disorders
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Synucleinophaties as Parkinson’s disease (PD), Multisystem
Atrophy (MSA) and Dementia with Lewy Bodies (DLB) are typically
characterized by motor and non motor symptoms. Among sleep
alterations, REM sleep behavior disorder (RBD) is notable for its
identity as a ‘‘preclinical’’ sign of synuclein-mediated neurodegen-
erative disease. In these pathologies the main suspected cause of
RBD is the degeneration of pontomedullary brainstem structures.
Longitudinal studies show that idiopathic RBD harbinger synuclei-
nophaties with a rate of conversion of 46-60% within 5-10 years.
There are a number of studies in which RBD is also considered a
reliable marker of disease progression. When PD patients present
RBD, they have a signiﬁcantly higher risk (odd’s ratio 2.7) of having
concomitant visual hallucinations. Further, RBD might be indica-
tive of a subtype of PD with more rapid progression to cognitive
impairment and dementia. Other sleep disorders investigated as
premotor sign are RLS, insomnia and excessive daytime sleepiness;
however, sleepiness and sleep attacks, probably due both to dys-
function of hypothalamic hypocretin neurons (Hcrt) and dopami-
nergic treatment are commonly correlated with disease severity
and cognitive decline. The Sleep Disordered Breathing (SDB) refers
to momentary, often cyclical, cessation in breathing rhythm
(apneas) or sustained reductions in the breath amplitude (hypop-
neas). They potentially increase the risk of paroxysmal nocturnal
motor events during both REM sleep (RBD) and during NREM sleep
(confusional arousal). Indeed, SDB could predispose to well docu-
mented neuropsychological deﬁcits in PD, involving the short- and
long-term memory, logical abilities and frontal functions. Finally,
there are ongoing studies on sleep structure in PD with associated
dementia (PDD) and in DLB. In these latter patients we observe a
severe disruption of sleep pattern; high percentage of ‘‘arousal’’
with confusional episodes of long duration, often associated to
delirium which arising from NREM sleep (NREM parasomnias).
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Early Parkinson biomarkers: abnormalities of mood and of the
sensory system
Angelo Antonini
Department for Parkinson’s disease, IRCCS San Camillo, Venice
The early identiﬁcation of Parkinson’s disease is complex and
the inaccuracy of using current clinical diagnostic is well
recognized raising the demand for a diagnostic biomarker. Markers
reﬂecting pathology may allow the earliest presymptomatic
diagnosis but based on our current understanding of the disorder
we recognize that several systems may be affected before nigral
dopaminergic neurons start degenerating. Moreover genetic forms
of parkinsonism may not share the same neuropathological
hallmark and do not develop Lewy bodies ad for idiopathic PD.
There is already evidence that this is possible to some extent
using PET or SPECT imaging of the dopamine system, but an
appealing alternativewould be to gain insight into the pathological
changes from a continuously variable biochemical marker that can
be assayed economically and easily.
Overall, it is clear that not a single but rather a combination
biomarker may be able to do it all in Parkinson’s disease. Given the
heterogeneity of disease, it is likely that a biomarker will only prove
useful in certain situations, whilst the strength of the clinical
examination is its breadth and ability to detect non-dopaminergic
symptoms. In the search for improved diagnostic ﬁdelity it may be
that a stepwise approach is required despite the potential pitfalls in
combining diagnostic tests. For example, clinical assessment might
be supplemented by a speciﬁc neuropsychological questionnaire or
physiological test, with subsequent conﬁrmation by imaging or a
biochemicalmarker. Finally, anybiomarkerused inclinical trials as a
surrogate end-point requires extensive evaluation over years in
different populations of Parkinson’s disease patients to ensure its
validity. The key in each situation is to appreciate the limitations of
the biomarker and what it actually measures.
Affective disorders
Prior to developing motor disability many PD patients complain a
seriesof rathernon-speciﬁcbehavioral symptoms, suchasdepression,
anxiety and musculoskeletal pain that might herald subsequent
diseasedevelopmentbuthave thedisadvantage tobehighlyprevalent
in the general population. Depression is probably the most suitable
and it has been extensively studied. Speciﬁc scales are available and
could applied to capture the relevant early depressive symptoms
although these scales have not been designed speciﬁcally for PD.
An alternative might be to develop tests that focus on certain
features of the depression that are more speciﬁc to Parkinson’s
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underlined by dopamine deﬁciency. Therefore a personality
questionnaire looking at such traitsmay go someway to predicting
mood disorder and support early diagnosis in potentially at-risk
individuals.
Olfaction
The loss of smell detection, identiﬁcation or discrimination
often goes unnoticed early in PD and generally occurs before the
development of extrapyramidal signs. In Parkinson’s disease this
may in part reﬂect neurodegeneration within the olfactory bulb
since there is evidence that this might precede both nigral
degeneration and symptoms. Support for the presymptomatic
deterioration of olfaction has been also provided who showed
olfactory dysfunction in ﬁrst-degree relatives of patients with
Parkinson’s disease together with reduced striatal dopamine
transporter binding, as assessed by 123I-b-CIT in four out of 25
SPECT scans of these hyposmic relatives. Two of the relatives with
hyposmia and reduced striatal dopamine transporter binding
subsequently developed Parkinson’s disease, suggesting that
olfaction might be a useful presymptomatic biomarker.
Once symptoms have developed, it has been suggested that
olfactory dysfunction might help distinguish patients with
idiopathic Parkinson’s disease from healthy subjects. Similarly, it
may be that alterations in the sense of smell may help
distinguishing true cases of Parkinson’s disease from atypical
parkinsonism. In a recent study it was found that patients with
idiopathic Parkinson’s disease were either anosmic or hyposmic,
whereas all but one of the patients with MSA or progressive
supranuclear palsy had only mild to moderate hyposmia, and
patients with corticobasal degeneration or psychogenicmovement
disorders were found to be normosmic.
Vision
Vision might be variably affected in Parkinson’s disease. For
example, it has been suggested that colour vision and contrast
sensitivity might be abnormal as a result of a change in intraretinal
dopaminergic transmission in amacrine and interplexiform cells,
and colour vision has indeed been found to be abnormal in some
PD patients. Furthermore, there seem to be differences in contrast
sensitivity, visual evoked responses and electroretinograms in
Parkinson’s disease patients compared with controls, but the
diseased and normal values overlap. Given that the pathological
process in Parkinson’s disease affects retinal cells, it may be that
tests of retinal function will correlate more closely with
pathological changes in the basal ganglia than clinical phenotype.
Abnormalities of eye movement may be more closely related to
motor phenotype than pathology since, for example, it seems that
visual landmarks improve antisaccade performance (a saccade
made in the opposite direction to a stimulus) in Parkinson’s disease
more than controls, in a fashion analogous to target-directed
pointing. Several studies have recorded eye movements in
Parkinson’s disease compared with controls, and although there
does seem to be some difference between Parkinson’s disease
patients and controls during voluntary saccade paradigms their
potential as biomarkers is not fully characterized.
Hearing
Hearing impairment and loss is frequent in elderly people but it
has been only marginally investigated in PD. The Brain Auditory
Evoked Potentials were reported both normal or prolonged but
little knowledge was available about auditory function until
recently. A case control study measured auditory function in over
100 PD patients vs. an age matched cohort of healthy controls and
found that PD patients are affected by high-frequency age-dependent, unilateral or bilateral hearing impairment compared
to healthy controls. The relevance of these ﬁndings needs to be
evaluated but certainly it expands the clinical spectrum of non-
motor disturbances in PD.
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SESSION 3 ‘‘Cognitive abnormalities in movement disorders’’
L7
Epidemiology of cognitive disturbances in movement disorders
Giovanni Defazio
Department of Neuroscience and Sensory Organs, ‘‘Aldo Moro’’
University of Bari, Bari
The common belief that primary forms of movement disorders
are purely motor disorder with no other accompanying neurologi-
cal dysfunction has recently been challenged. Anatomical and
imaging evidence have documented changes in several cortical and
subcortical regions of patients with different forms of Movement
Disorders. Moreover, there is also clinical evidence suggesting that
the basal ganglia, besides motor control, may also play a role in
emotional and cognitive functioning, and several studies have
demonstrated the presence of cognitive impairment in the most
common forms of Movement Disorders. In Parkinson’s disease,
mild cognitive impairment has been detected in 15% of newly
diagnosed patientswhereas the prevalence of dementia is between
20 and 40%, with estimates increasing with disease duration, In
Essential Tremor, cognitive abnormality is characterized by mild
frontal dysfunction that may have a functional impact, or by an
association with dementia particularly evident among those with
late onset of tremor (>65 years). In Dystonia, a few studies
observed that patients with either early onset dystonia or late
onset blepharospasm performed signiﬁcantly worse on some
cognitive tests than healthy controls. To date, however, no
systematic cognitive performance evaluation has been carried
out in patients with the various forms of primary adult-onset
dystonia and the frequency of the phenomenon remains unknown
L8
Cognitive dysfunction in movement disorders: clinical evaluation
Marianna Amboni
CEMAND, Universita` di Salerno, Salerno and IDC Hermitage-
Capodimonte, Napoli
Cognitive impairment is common in Parkinson’s disease (PD)
and can already be detected in patients with early-stage PD [1,3].
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been shown as the cognitive domains more affected with a
prevalent impairment in executive functions. Memory im-
pairment might be related to executive and attentional dis-
turbances rather than to primary memory domain dysfunctions
but this point is debated.
Williams-Gray and coll. [4] have reported that two distinct
cognitive syndromes could be recognized in PD, based on
genetic variations in cathecol-O-methyltransferase (COMT) gene
(Val-Met polymorphism) or in microtubule-associated protein
tau (MAPT) gene (H1-H2 polymorphism). The dementing
process in PD has resulted associated with more posterior
cortically based cognitive deﬁcits heavily depending on MAPT
genotype, while frontal-executive dysfunctions, with a more
dopaminergic basis linked to COMT gene variations, have
resulted to display no correlation with the development of
dementia.
The construct of mild cognitive impairment (MCI) is considered
a transition state between normal aging and dementia. Originally,
it was conceptualized as the transitional state between normalcy
and Alzheimer’s disease. More recently, it has been used to identify
a pre-dementia state in PD patients.
Most studies exploring cognition in nondemented PD patients
have employed selected neuropsychological tests rather than
comprehensive batteries/scales. A number of neuropsychological
tools are available for testing cognitive function in PD. Very
recently, speciﬁc guidelines to assess cognition and diagnose MCI
in PD have been published [2]. These guidelines include: 1) an
abbreviated assessment that provides a practical but with reduced
positive predictive value neuropsychological tool; 2) a compre-
hensive assessment that offers an extensive evaluation of the
whole spectrum of the cognitive domains commonly affected in
PD. The abbreviated assessment is based on the use of global scales
validated in PD like Montreal Cognitive Assessment (MoCA),
Parkinson’s disease Cognitive Rating Scale (PD-CRS), SCales for
Outcomes of PArkinson’s disease–cognition (SCOPA-COG), Mattis
Dementia Rating Scale (MDRS). The comprehensive assessment
should include at least two selected neuropsychological tests for
each of the typical cognitive domains (attention and working
memory, executive function, language, memory, visuospatial
function).
Mood disorders, apathy, psychosis, sleep disorders are common
in PD and may impair cognitive performances. Similarly, anxiety
and cognitive slowing during off periods can adversely affect
neuro-psychological test performance. Thus, patients with motor
ﬂuctuations should ideally be assessed in the on state, be devoid of
any drug potentially interfering with cognition and not display
other nonmotor features judged so severe to invalidate the results
of the neuropsychological assessment.
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Default mode network in Dementia/Parkinson
R. Franciotti1,2,3, N.W. Falasca4, L. Bonanni1,2,5, S. Comani1,4, A. Thomas1,2,
Marco Onofrj1,2.
1Department of Neuroscience and Imaging, G. d’Annunzio University,
Chieti, Italy
2Aging Research Centre, Ce.S.I., ‘‘G. d’Annunzio’’ University Founda-
tion, Chieti
3 ITAB, ‘‘G. d’Annunzio’’ University Foundation, Chieti
4BIND – Behavioral Imaging and Neural Dynamics Center, University
of Chieti-Pescara, Chieti
5Leonardo Foundation, Abano Terme (PD), Italy
During resting state, functional magnetic resonance imaging
(fMRI) shows synchronous activity of brain regions involving
ventral anterior and posterior cingulate cortex/precuneus, medial
prefrontal cortex and bilateral lateral and inferior parietal cortex.
This network is deﬁned ‘‘default mode network’’ (DMN) because it
is typically deactivated during processing of external stimuli, being
active instead in resting condition. Research on resting state brain
activity offers a novel approach for understanding brain organiza-
tion and dysfunction in presence of neurological disorders [2].
Recent studies have shown the DMN to be dysfunctional in
Alzheimer’s disease (AD) (Greicius et al., 2004; Zhang et al., 2010).
Spontaneous fMRI signal were measured to investigate connecti-
vity between key brain regions in the DMN of AD and patients
affected by dementia with Lewy bodies (DLB) (Galvin et al., 2011;
Kenny et al., 2012). Compared to controls, greater connectivity was
found between the right posterior cingulate cortex (PCC) and other
brain areas in DLB patients and in left hippocampus in AD patients
[1]. A deﬁnitive clariﬁcation of the DMN dysfunction in dementia
could come from studies assessing both task and rest conditions,
evidencing whether DMN as well as dorsal and ventral attention
systems are not inhibited in patients during task execution. Indeed
a previous study [2] proposed that visual misperception and
hallucinations in Parkinson Disease are related to a failure
occurring in competing complementary neural networks that
normally regulate attention and thereby the accurate perception of
visual stimuli. Speciﬁcally, perceptual errors arise in the context of
impaired signaling between both a ‘‘task negative’’ DMN and a
‘‘stimulus-driven’’ ventral attentional network (VAN). Normally
these perceptual errors would be corrected by a ‘‘goal-directed’’
dorsal attentional network (DAN) which probably is impaired in
patients with visual misperception and hallucinations, allowing
the reinforcement of false images.
If the patient is unable to activate the DAN, it is proposed that
the conﬂict resolution is processed by neural networks unprepared
for this task, such as the DMN and/or the VAN [4]. In accordance
with this hypothesis, a previous study [3] investigating visual task
related neural changes in DLB found reduced DMN inhibition
during a series of visual tasks.
Given the greater attentional deﬁcits in DLB than AD (Calderon
et al., 2001; Collerton et al., 2003) and the link between DMN
deactivation and attentional demand (McKiernan et al., 2003), one
would predict that the DMN will be more dysfunctional in DLB
than AD. Based on this hypothesis we performed a resting state
fMRI study on DLB patients with ﬂuctuating cognition, AD patients
without ﬂuctuating cognition and age-matched healthy controls.
Our ﬁndings showed a preservation of PCC activity and connectiv-
ity inside the DMN in DLB patients and a reduced PCC activity and
connectivity in AD patients. Our hypothesis is that DMN
dysfunctionmight have a role in determining different phenotypes
in dementia.
Basal Ganglia 2S (2012) e1–e87e6References:[1] Kenny, E.R., Blamire, A.M., Firbank, M.J., O’Brien, J.T. 2012.
Functional connectivity in cortical regions in dementia with
Lewy bodies and Alzheimer’s disease. Brain 135, 569-581.[2] Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. 2011.
Functional network disruption in the degenerative dementias.
Lancet Neurol. 10, 829-43. Review.[3] Sauer, J., ffytche, D.H., Ballard, C., Brown, R.G., Howard, R. 2006.
Differences between Alzheimer’s disease and dementia with
Lewy bodies: an fMRI study of task-related brain activity. Brain
129, 1780-1788.[4] Shine, J.M., Halliday, G.M., Naismith, S.L., Lewis, S.J. 2011. Visual
misperceptions and hallucinations in Parkinson’s disease:
dysfunction of attentional control networks? Mov. Disord.
26, 2154-2159.
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Cognitive impairment consistent with a diagnosis of Mild
Cognitive Impairment (MCI) is detectable already in newly
diagnosed drug-naı¨ve Parkinson’s Disease (PD) patients and
prospective studies showed that up to 75-80% of PD patients
may develop dementia (PDD) during the course of the disease. At
different disease stages dopaminergic and cholinergic deﬁcit have
been implicated in cognitive dysfunction and from a pathological
point of view cortical Lewy body diffusion, Alzheimer like
pathology and vascular lesion are detected in PD-MCI and PDD
patients.
On the basis of the evidence of a severe cholinergic dysfunction
in PDD cholinesterase inhibitors have been proposed as treatment
of cognitive dysfunction in PD. Very recently the Cochrane Library
has reviewed the effect of cholinesterase inhibitors in PDD and the
examination of literature supports the use of such drugs because of
a positive impact on global assessment, cognitive functions,
behavioural disturbances and activities of daily living rating scales
with lower tolerability than placebo but no serious adverse events
and non-signiﬁcant effect on motor symptoms [1].
Memantine, a low-afﬁnity antagonist to glutamate NMDA
receptors, has been tested in three parallel-group, randomized
placebo-controlled trials in PDD but due to conﬂicting results the
Movement Disorders Society evidence-based review concluded for
insufﬁcient evidence for memantine to be rated for the treatment
of dementia in PD [2].
To date, clinical research trials and therapeutic interventions
speciﬁcally for PD-MCI are limited. Cholinesterase inhibitors have
been tested in PD-MCI only once and althoughwith positive results
newer and larger studies are needed to provide a conclusive
opinion [1].
Dopaminergic medications such as levodopa or dopamine
agonistsmay have variable effects on cognition,with improvement
in some executive function tasks in PD patients and in others,
worsening or no effect. The ‘‘Dopamine overdose hypothesis’’,
suggests that the administration of dopaminergicmedication to PD
patients may replete dopamine depleted circuits, but overdose
relatively intact ones. The treatmentwith levodopa has a beneﬁcial
effect on Dorso Lateral Prefrontal Cortex related functions,
including planning, attention, set-switching, working memory
but has a detrimental effect on Orbito Frontal Cortex related
functions causing poor performances in tasks evaluating decision
making and reversal learning [3]. Recently the beneﬁcial effect of
Rasagiline on cognitive functions in PD has been tested in arandomized, double blind, placebo-controlled, multi-center study
in non-demented PD patients. Rasagiline has been reported to
improve performance in tasks exploring executive and attentional
functions when compared to placebo. Larger placebo controlled
studies are ongoing in PD-MCI patients to conﬁrm beneﬁcial effect
of Rasagiline. Atomoxetine, a norepinephrine reuptake inhibitor
indicated for attention deﬁcit hyperactivity disorder, has been
studied in a pilot trial in 12 non-demented PD patients with
moderate executive dysfunction with beneﬁcial effect on Clinical
Global Impression-Change Scale and on behavioral measures of
executive dysfunction.
Treatment of co-morbid conditions such as hallucinations,
depression, apathy and sleep dysfunction may play a role in
treating PDD and PD-MCI as well as the withdrawal of PD and non
PD related drugswith possible detrimental effect on cognition such
as anti-cholinergics should be evaluated in patients with cognitive
impairment. Moreover emerging literature on cognitive rehabili-
tation in Alzheimer disease and PD showed the beneﬁcial effect of
cognitive training on neuropsychological performance however in
preliminary reports [4].
References:[1] Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase
inhibitors for dementia with Lewy bodies, Parkinson’s disease
dementia and cognitive impairment in Parkinson’s disease. The
Cochrane Library 2012, Issue 3.[2] Seppi K, Weintraub D, Coelho M et al. The Movement Disorder
Society Evidence-Based Medicine Review Update: Treatments
for the Non-Motor Symptoms of Parkinson’s Disease. Mov
Disord, 2011; 26:S42-S80.[3] Cools R. Dopaminergic modulation of cognitive function-
implications for L-DOPA treatment in Parkinson’s disease.
Neurosci Biobehav Rev 2006;30:1-23.[4] Burn D. The Treatment of Cognitive Impairment Associated
with Parkinson’s Disease. Brain Pathology 2010; 20:672–678
SESSION 4 ‘‘Choreic Syndromes’’
L11
Hereditary choreas: when and which test?
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Chorea is a not uncommon movement disorder characterised
by abnormal involuntary movements that are irregularly timed,
randomly distributed and abrupt. Chorea can be inherited or
acquired and can be caused by structural, neurochemical, or
metabolic disturbances to basal ganglia function.
Advances in molecular genetics medicine have identiﬁed the
causes of many inherited choreic disorders and have expanded the
phenotype of recognized conditions. The pattern of inheritance
provides a guide to possible diagnoses, however, the absence of a
family history does not exclude a genetic cause.
Huntington’s disease (HD), a progressive autosomal dominant
neurodegenerative disorder, represents the most common inheri-
ted cause of chorea. Onset is usually in adult life although juvenile
and elderly onset are described. HD is caused by an expanded
trinucleotide CAG repeat, encoding for a polyglutamine stretch,
within the HTT gene on chromosome 4p16.3. This gene encodes for
the protein huntingtin whose function is not yet known, but the
expanded polyglutamine tract appears to interfere with a number
of cellular functions. The CAG repeat ranges between 10 and 29
copies on normal chromosomes, and is expanded to 36–121 on HD
Basal Ganglia 2S (2012) e1–e87 e7chromosomes. CAG repeats above 40 are fully penetrant, with a
borderline range between 36 and 39 associated with reduced
penetrance. Abnormal CAG repeats are liable to expand in
subsequent generations, particularly when transmitted through
the paternal lineage. There is an inverse correlation between CAG
repeat size and age of onset.
Huntington’s disease-like 2 (HDL2), another autosomal domi-
nant disorder, is caused by a CTG/CAG expansion within
junctophilin-3 (JPH3). HDL2 has only been reported in families
of African ancestry. Symptoms develop in adulthood,with an age of
onset inversely related to size of the trinucleotide repeat
expansion, and look very similar to those of HD.
Among the autosomal dominant spinocerebellar ataxias
(SCAs), SCA17 may cause parkinsonism, dystonia, and chorea,
in addition to the typical phenotype of ataxia, dementia, and
psychiatric symptoms. Also SCA1, SCA2, and SCA3 are possible
cause of chorea. Chorea and myoclonus can be seen in
dentatorubro-pallidoluysian atrophy (DRPLA), usually in addition
to ataxia and dementia.
Benign hereditary chorea is a dominantly inherited disorder
caused by mutations in TITF1 gene, which encodes thyroid
transcription factor 1. It is usually of young-onset with very
slowly progressive choreawithout cognitive decline. It may be also
associated with congenital hypothyroidism.
Abnormal brain iron accumulation in the basal ganglia is seen in
an increasing number of disorders. Neuroferritinopathy is an
autosomal-dominant form of neurodegeneration with brain iron
accumulation (NBIA). The disorder is due to a mutation of the gene
for the light chain of ferritin. Onset is in adulthoodwith a variety of
movement disorders, including chorea, dystonia, parkinsonism,
and occasional cognitive impairment.
Pantothenate-kinase–associated neurodegeneration (PKAN),
once known as Hallevorden-Spatz syndrome, is an autosomal
recessive form of NBIA caused by mutations in PANK2 (encoding
pantothenate-kinase 2). Chorea may be associated to the typical
phenotype characterized by pigmentary retinopathy, dystonia,
intellectual decline, and neuropsychiatric features.
Ataxia-telangiectasia and ataxia with oculomotor apraxia types
1 and 2 are autosomal recessive diseases caused by mutations in
genes involved in DNA repair. They typically present with ataxia
during infancy and childhood, and may present with or develop
chorea. Serum levels of a-fetoprotein, albumin, and cholesterol
may be abnormal and may suggest the diagnosis.
Chorea-acanthocytosis (ChAc) is an autosomal recessive
disorder due to mutations of VPS13A, which codes for chorein.
It presents in young or middle adulthood with tics, chorea,
lingual-buccal-facial dystonia, psychiatric disturbances, cogni-
tive dysfunction, seizures, peripheral neuropathy. Elevated
creatine kinase and liver enzymes are common. Detection of
acanthocytosis may be enhanced by use of a standard protocol,
but a negative result does not exclude the diagnosis. Acerulo-
plasminemia is an autosomal recessive disorder due tomutations
of the gene for ceruloplasmin, with onset in adulthood, usually
characterized by retinal degeneration, diabetes mellitus, cogni-
tive impairment, ataxia, orofacial dystonia, parkinsonism, and
chorea.
McLeod neuroacanthocytosis syndrome (MLS) is similar in
presentation to autosomal-recessive ChAc, with the additional
involvement of other organ systems. It is diagnosed by decreased
expression of Kell and Kx antigens on erythrocytes, caused by
mutation of the XK gene. The neurologic symptoms of MLS
develop in middle-aged males with neuropsychiatric changes,
chorea, dystonia, tics, parkinsonism, peripheral neuropathy, and
seizures. Cardiac involvement is often seen. As in ChAc, liver
enzymes and CK are often elevated and acanthocytosis may be
detected.References:[1] Bhidayasiri R, Truong DD. Chorea and related disorders.
Postgrad Med J. 2004 Sep;80(947):527-34.[2] Schneider SA, Walker RH, Bhatia KP. The Huntington’s disease-
like syndromes: what to consider in patients with a negative
Huntington’s disease gene test. Nat Clin Pract Neurol. 2007
Sep;3(9):517-25.[3] Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract
Neurol. 2007 Nov;7(6):360-73.[4] Ross CA, Tabrizi SJ. Huntington’s disease: from molecular
pathogenesis to clinical treatment. Lancet Neurol. 2011
Jan;10(1):83-98. Review.
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Patients with sporadic chorea require a thorough diagnostic
work up because numerous causes can lead to this condition.
Stroke (ischemic or hemorrhagic) is the main cause of sporadic
chorea. Streptococcal infection in children can cause, in a small
percentage of cases, neurological and psychiatric symptoms:
Sydenham’s chorea (or rheumatic chorea) is the result of an
autoimmune response that occurs following infection by group A
b-hemolytic streptococci destroying cells in the corpus striatum of
the basal ganglia.
Sydenham’s chorea is characterised by the acute onset
(sometimes a few hours) of neurologic symptoms, classically
chorea, usually affecting all limbs. Other neurologic symptoms
include behavioral changes, dysarthria, gait disturbances, head-
ache, slowed cognition, facial grimacing and hypotonia. Fifty
percent of patients with acute Sydenham’s chorea spontaneously
recover after 2 to 6 months, whilst mild or moderate chorea or
other motor symptoms can persist for up to and over 2 years.
Sydenham’s chorea may be also associated with psychiatric
symptoms, obsessive compulsive disorder being themost frequent
manifestation.
The PANDAS (Pediatric Autoimmune Neuropsychiatric Disor-
ders Associated with Streptococcal Infections) syndrome has some
similaritieswith Sydenham’s chorea, but differs from it for the type
of motor dysfunction. PANDAS usually presents with tics and/or
with psychological disturbances (OCD) occurring earlier, days to
weeks after GABHS infection rather than 6–9 months. It may be
confused with other conditions such as SLE and Tourette
syndrome. Likewise Sydenham’s chorea, PANDAS is thought to
involve autoimmunity directed to the basal ganglia. Unlike
Sydenham’s chorea, PANDAS is not associated with other
manifestations of acute rheumatic fever, such as inﬂammation
of the heart. In addition to OCD or tics, children may have other
symptoms associated with exacerbations such as emotional
lability, enuresis, anxiety, and deterioration in handwriting.
Other causes of autoimmune chorea include: systemic lupus
erythematous, antiphospholipid syndrome, chorea gravidarum
and paraneoplastic syndromes. The neoplasms most often
associated with choreic syndrome are: small cell lung cancer
(60%), other pulmonary cancer, kidney cancer, testicular germi-
noma and lymphoma.
Secondary choreas may recognize also infectious or endocrine
causes. Among infectious agents HIV is often implicated in the
genesis of chorea, while among endocrine causes hyperthyroidism
is the most frequent condition; possibly related to an increased
Basal Ganglia 2S (2012) e1–e87e8response of striatal dopamine receptors to dopamine. Other
endocrine causes are: parathyroid dysfunctions (hypo- or hyper-
parathyroidism) and ketotic hyper-glycemia; choreic syndromes
can occur in association with hepatic encephalopathy (acquired
hepato-cerebral degeneration) and renal failure.
Finally, there is a growing list of drugs associated with
chorea, including: lamotrigine, methadone, lithium, neurolep-
tics, antiparkinsonian drugs, alcohol, cotrimossazole and oral
contraceptive.
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Huntington disease (HD) is a genetic neurodegenerative
disorder characterized by choreo-dystonicmovements, psychiatric
disorders and dementia. The therapies most widely used are
symptomatic treatments to control abnormal movements, mainly
chorea, as haloperidol or tetrabenazine, and psychiatric symptoms,
as SSRI, olanzapine and quietapine. Recent and growing advances
in the knowledge of the molecular and cellular pathways under-
lining the disease, are prompting the development of new
compounds that are currently tested in cellular and transgenic
animal models with the aim of downregulate the expression of the
expanded alleles or to interfere with the pathological mechanism
of neuro-degeneration. In the last years severalmulticentre clinical
trials have been carried out with drugs either for the control of
motor or cognitive symptoms. A clinical trial, testing an inhibitor of
sirtuine, which plays a role in neurodegeneration in HD, is ongoing.
Other non pharmacological approaches in HD have been proposed
in these years and are currently experimented in various European
countries, mainly fetal neurons transplants and DBS for the control
of severe chorea.
References:[1] W.G. Ondo et al.: Tetrabenazine treatment for Huntington’s
disease-associated chorea Clin Neuropharmacol, 25(2002),pp
300-302[2] T. Mestre et al.: Therapeutic intervention for symptomatic
treatment in Huntington’s disease -Cochrane Database Syst
Rev, 3 (2009) CD006456[3] M.L. Lombardi et al.: A majority of Huntington’s disease
patients may be treatable by individualized allele-speciﬁc RNA
interference - Experimental Neurology, 217 (2009), pp312-319[4] J. Garcia de Yebenes: Pridopidine for treatment of motor
function in patient with Huntington’s disease (MermaiHD): a
phase 3, randomized, double-blind, placebo- controlled trial
The Lancet Neurology,10(2011),pp 10049-1057
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Pathophysiology of postural abnormalities in Parkinson’s disease
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Postural abnormalities of the trunk are frequent and often
disabling complications of Parkinson’s disease (PD) and atypical
parkinsonisms. These abnormalities include camptocormia,anterocollis and Pisa Syndrome. Although the pathophysiology
of these abnormalities is not fully understood, there is evidence
suggesting that they may account for a multifactorial pathophysi-
ology. Contributing factors include muscular rigidity, axial
dystonia, weakness caused by myopathy, body scheme defects
due to dysfunction of proprioceptive and vestibular systems, and
ﬁnally structural changes in the spine. The relative contribution of
these different factors varies between patients and across speciﬁc
syndromes. A better understanding of the pathophysiology of
these postural abnormalities in PD might ultimately lead us to
more effective management strategies for these disabling and
drug-refractory complications.
References:[1] Tiple D, Fabbrini G, Colosimo C, Ottaviani D, Camerota F,
Defazio G, Berardelli A. Camptocormia in Parkinson’s disease:
an epidemiological and clinical study. JNNP 2009; 80: 145-148.[2] Di Matteo A, Fasano A, Squintani G, Ricciardi L, Bovi T, Fiaschi A,
Barone P, Tinazzi M. Lateral trunk ﬂexion in Parkinson’s
disease: EMG features disclose two different underlying
pathophysiological mechanisms. J Neurol 2011; 258: 740-5.[3] Fasano A, Di Matteo A, Vitale C, Squintani G, Ferigo L, Bombieri
F, Santangelo G, AmboniM, Barone P, Tinazzi M. Reversible Pisa
syndrome in patients with Parkinson’s disease on rasagiline
therapy. Mov Disord 2011; 26: 2578-80.[4] Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-
Moriyama L, Azulay JP, Gershanic OS, Bloem BR. Postural
deformities in Parkinson’s disease. Lancet Neurol 2011; 10:
538-549.
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Human gait appears to be a simple innate ability, but it is an
extraordinarily complex motor behavior with multiple contribu-
tions from all parts of the brain [1]. Indeed, locomotion requires the
automatic and coordinate intervention of functional modules
controlling: 1. Anti-gravity support of the body; 2. Stepping;
3. Dynamic stability; and 4. Body propulsion [2]. Normal gait
requires a delicate balance between various interacting systems:
three major afferent systems (visual, proprioception, and vestibu-
lar), a locomotor efferent system (including nerves,muscles, bones,
joints and tendons) and the strict surveillance of several structures
of central nervous system.
Gait disorders are one of the most common problems
encountered in neurological patients, being present in more than
half of 493 consecutive, non-bed-bound patients admitted to a
neurological service [3]. It is now well recognized that gait
impairment is a major determinant of quality of life. Gait disorders
have devastating consequences: the most notorious corollary is
falling and reduced mobility, which leads to loss of independence.
Clinical experience and lesions in humans indicate that, though
being integrated in a complex interplay, functional domains
corresponding to less anatomically deﬁned structuresmay actually
being hypothesized. In the Patla’s model [4], a control system
(placed into the central nervous system) controls an effector
system (muscles, tendons, ligaments, and skeletal structures). The
pathophysiology of gait disorders is tightly connected with their
clinical features: phenomenologywill guide our classiﬁcation, thus
representing our contribute to the ongoing debate on the nosology
of gait disorders.
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well as a plethora of names for speciﬁc conditions. The many
deﬁnitions of high level gait disorders (HLGD) or of freezing of gait
are good examples and certainly have delayed gait research [5].
The seminal paper by Nutt and colleagues hierarchically classiﬁed
gait disorders into lowest level (affecting one afferent system),
middle level (more afferent system involvement), and highest level
(characterized by planning deﬁcits) disorders. This effort has
certainly highlighted the relevance of nosology but has introduced
toomany terms of HLGD, leading to amore recent revision of them.
Other clinical classiﬁcations have been based on anatomy (e.g.
frontal gait disorder) or on etiology (e.g. vascular), thus introducing
the bias of terms that cannot refer to clinic per se. Every
classiﬁcation has its own limits and, as recently pointed out, a
classiﬁcation based on clinical phenomenology appears as a good
compromise between speciﬁcity and sensibility of a diagnosis
based on the naked eye assessment.
References:[1] Hallett M. The intrinsic and extrinsic aspects of freezing of gait.
Mov Disord 2008;23 Suppl 2:S439-443.[2] Martin JP, Hurwitz LJ. Locomotion and the basal ganglia. Brain
1962;85:261-276.[3] Stolze H, Klebe S, Baecker C, et al. Prevalence of gait disorders in
hospitalized neurological patients. Mov Disord 2005;20:89-94.[4] Patla AE. Understanding the control of human locomotion: A
‘Janus’ perspective. In: Patla AE, ed. Adaptability of Human
Gait: Implication for the Control of Locomotion. New York:
Elsevier Publishers, 1991: 3-17.[5] Nutt JG, Marsden CD, Thompson PD. Human walking and
higher-level gait disorders, particularly in the elderly. Neurol-
ogy 1993;43:268-279.
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Posture is often affected in Parkinson’s disease (PD) and atypical
parkinsonism. Postural abnormalities are related to disease
progression, neurochemical alterations, and antiparkinsonian
treatment [1].
These deformities include marked anterior ﬂexion of thora-
columbar spinewhich is called camptocormia, lateral ﬂexion of the
trunk or Pisa syndrome, and dropped head as a form of extreme
anterior ﬂexion of the neck. The broad variability with which these
abnormal postures occur with regard to clinical presentation,
temporal course, and clinical evolution renders their nosological
characterization uncertain and complicates the identiﬁcation of a
pathophysiologic explanation.
The evidence to date suggests that postural deformities have a
multifactorial pathophysiology. Contributing factors include mus-
cular rigidity; axial dystonia; weakness caused by myopathy [2].
Posture also depends on the appropriate integration of visual,
proprioceptive, and vestibular signals that leads to the generation
of an optimal motor response to counteract postural perturbation
[3]. It has been recently established that motor deﬁcits are not
isolated deﬁcits and that PD is also associated with impairments in
sensory-motor integration [4]. Therefore, it seemed worth
investigating the possibility that sensorimotor integration deﬁcitsmay be also at least in part responsible for the postural
abnormalities observed in PD patients.
The relative contribution of these different factors varies
between patients and across speciﬁc clinical pictures. Further
studies are warranted aiming at understanding the mechanisms
underlying postural deformities in PD and identifying more
speciﬁc treatment strategies for these often disabling and drug-
refractory complications.
References:[1] Yokochi F. Lateral ﬂexion in Parkinson’s disease and Pisa
syndrome. J Neurol 2006;253(Suppl 7):VII17–VII20[2] Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-
Moriyama L, Azulay JP, Gershanik OS, Bloem BR. Postural
deformities in Parkinson’s disease. Lancet Neurol 2011; 10:
538–49[3] Vitale C, Marcelli V, Furia T, Santangelo G, Cozzolino A, Longo K,
Allocca R, Amboni M, Marciano E, Barone P. Vestibular
impairment and adaptive postural imbalance in parkinsonian
patients with lateral trunk ﬂexion. Movement Disorder 2011;
26(8): 1458-63[4] Vaugoyeau M, Viel S, Assaiante C, Amblard B, Azulay JP.
Impaired vertical postural control and proprioceptive integra-
tion deﬁcits in Parkinson’s disease. Neuroscience
2007;146:852–863
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Treatment of motor symptoms in Parkinson’s disease
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Parkinson’s disease (PD) is the second most common age-
related neurodegenerative disorder, characterized by the progres-
sive loss of substantia nigra pars compacta dopamine neurons and
the consequent decrease in the neurotransmitter dopamine.
Patients exhibit a range of clinical symptoms, with the most
common affecting motor function and including resting tremor,
rigidity, akinesia, bradykinesia and postural instability. Current
pharmacological interventions are palliative and largely aimed at
increasing either dopamine levels through increased production
and/or inhibition of metabolism of this key neurotransmitter or
dopaminergic activity through increased stimulation of dopami-
nergic receptors. Initial treatment aims at replacing dopamine
through the administration of oral levodopa or dopamine agonists.
Although oral therapy can signiﬁcantly improve clinical features
for many years, motor response complications, characterized by
‘‘wearing off’’ and dyskinesias (potentially associated with OFF-
period dystonia), emerge in up to 80-100% of patients. Their
development leads to worsening disability with a signiﬁcant
impact on patient and caregiver quality of life. Moreover, axial
motor symptoms like gait problems, freezing and postural insta-
bility, may not respond to dopamine replacement therapy as these
symptoms are related to non dopaminergic neuron degeneration.
The concept of continuous dopaminergic stimulation or continu-
ous dopaminergic delivery has guided during the more recent
years the treatment of PD. Levodopa shows a peculiar pharmaco-
kinetics because of it is absorbed only in the small intestine and
lasts shortly in the plasma (half life of about 100 min). Long term
failure of levodopa due to the appearance of motor complications
has been attributed to the intermittent and pulsatile dopaminergic
stimulation operated by levodopa itself and dopamine agonists,
used ﬁrstly as add on therapy to advanced PD patients under
levodopa treatment, subsequently have replaced levodopa as
Basal Ganglia 2S (2012) e1–e87e10initial PD treatment specially in younger patients. Common clinical
experience and several long term studies [1,2] have clearly shown
a lower propensity of dopamine agonist to provoke ﬂuctuations
and dyskinesias, but aftermore or less 3 years levodopa needs to be
added due to the loss of efﬁcacy of dopamine agonists mono-
therapy. In any case the concept of continuous dopaminergic stim-
ulation isprovenonlyex contrario: levodopahas a shorthalf-life and
provokes ﬂuctuations and dyskinesias, dopamine agonists have a
long half life and do not determine ﬂuctuations and dyskinesias,
thereby the causeofmotor complications is representedby the short
half life of dopaminergic agent. It is possible that also the pharma-
cological differences between levodopa anddopamine agonistsmay
explain their different propensity to inducemotor complications. In
any case, continuous dopaminergic delivery may effectively reduce
motor complications in PD patients already showing these pro-
blems. New formulations of ropinirole and pramipexole have been
recently introduced and these agents together with the rotigotine
transdermal patch ensure a constant delivery of the dopamine
agonist throughout 24 hours. Apomorphine is the most potent
dopamine agonist and its administration can provide symptom
relief comparable to levodopa. The drug has a rapid absorption after
subcutaneous injection (Cmax 20 min), and a short half-life (almost
40 min): clinical studies support a role for continuous subcutaneous
apomorphine infusion as an effective option for patients with ad-
vanced PD poorly controlled by oral drug treatment. Constant
levodopa infusion aims to achieve continuous delivery with an
optimised dose that can be kept stable within the patient’s individ-
ual therapeutic window but for reaching this goal gastric emptying
must be bypassed. The development of a stable concentrated levo-
dopa-carbidopa gel (Duodopa1) (levodopa/carbidopa 20/5 mg/ml
in a carboxymethylcellulose mix) combined with progress in the
construction and application of portable duodenal infusion systems
using percutaneous endoscopic gastrostomy (PEG), has intro-
duced it in the clinical arena [3]. The levodopa-carbidopa gel,
which is administered inside the upper intestine via a small tube
inserted via PEG into the duodenum to facilitate permanent use,
has proven to be a successful therapeutic strategy. It provides
constant plasma levodopa levels, reducingmotor ﬂuctuations and
dyskinesias ensuring more continuous and predictable clinical
beneﬁts for patients.
Chronic high-frequency stimulation of the ventral intermediate
nucleus was ﬁrst described in 1991 with the demonstration of
effectiveness of the technique, expecially on the symptom tremor,
in PD. In the following years new DBS-targets have been studied
and the Bilateral Subthalamic Nucleus (STN) DBS has showed to
represent the more powerful treatment for complicated PD
expecially in patients with disabling akinetic-rigid and severe
motor ﬂuctuations [4]. Another DBS-target is represented by the
globus pallidus internal, with an improvement in bradykinesia,
rigididity and mainly in dyskinesias. STN-DBS is however limited
by strict inclusion criteria and although the scores in the off-
medication state improve by an average of 50%, the L-dopa dose
loads reduced by 50-60% and on medication dyskinesias by 90%
after 12 months of STN-DBS a higher incidence of depression,
cognitive decline, speech difﬁculty, and gait disturbance has been
reported. Thus, despite improved motor control, quality of life in
patients treated with DBS is signiﬁcantly hampered by the risk of
non-motor complication such as cognitive and behavioural
problems. This limitation of the procedure must be considered
when these treatment is proposed to PD patients.
References:[1] Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang
AE. A ﬁve-year study of the incidence of dyskinesia in patients
with early Parkinson’s disease who were treated withropinirole or levodopa. 056 Study Group. N Engl J Med.
2000;342(20):1484-91[2] Parkinson Study Group- Pramipexole vs levodopa as initial
treatment for Parkinson disease: A randomized controlled trial.
Parkinson Study Group. JAMA.2000;284(15):1931-8)[3] Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R,
Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal
levodopa infusion monotherapy vs oral polypharmacy in
advanced Parkinson disease. Neurology. 2005; 64(2):216-23.[4] Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the
Subthalamic nucleus in advanced Parkinson’s disease. N Engl J
Med 1998;339:1105–11
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Treatment of non motor symptoms in Parkinson’s disease
Giovanni Fabbrini
Department of Neurology and Psychiatry, Sapienza University of
Rome, Rome
Non motor symptoms are a signiﬁcant problem in Parkinson
disease. Non motor symptoms may precede the appearance of the
typical motor signs, and more frequently complicate the advanced
phases of the disease. The most important non motor symptoms
are: sleep disturbances (excessive daytime somnolence, sleep
attacks, insomnia, parasomnias), neuropsychiatric disturbances
(anxiety, depression, hallucinations, psychosis, impulse control
disorder), cognitive disturbances (changes in executive functions,
dementia), vegetative disturbances (urinary disturbances, consti-
pation, sexual dysfunction, orthostatic hypotension) and sensory
disturbances (particularly pain). The treatment of non motor
symptoms is mostly based on small, uncontrolled, open studies.
Some of the nonmotor disturbances are clearly correlatedwith the
dopaminergic deﬁcit and improve with a better control of motor
symptoms. Other non motor symptoms are completely indepen-
dent of the dopaminergic stimulation, and the correct treatment
depends particularly on the correct diagnosis. Controlled studies
are however needed to improve our ability to treat non motor
symptoms in Parkinson disease.
References:[1] Friedman JH, Factor SA. Atypical antipsychotics in the
treatment of drug-induced psychosis in Parkinson’s disease.
Mov Disord. 2000 Mar;15(2):201-11.[2] Emre M, Aarsland D, Albanese A et al. Rivastigmine for
dementia associated with Parkinson’s disease. N Engl J Med
2004; 351:2509-18.[3] Poewe W, Hogl B. Parkinson’s disease and sleep. Curr Opin
Neurol 2000;13:423-26.[4] Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease.
Lancet Neurol 2003;2:107-116
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How Parkinson’s disease changed and how it may change in the
future
Fabrizio Stocchi
IRCCS San Raffaele Pisana, Roma
The introduction of levodopa in the treatment of Parkinson’s
disease (PD) in 1970 was one of the most extraordinary success in
medicine. However quite soon levodopa therapy showed limita-
tions like motor complications and dyskinesia.
Basal Ganglia 2S (2012) e1–e87 e11To treat or avoid motor complications dopamine agonists (DA)
were introduced. This class of drugs showed to be effective in
monotherapy in mild to moderate patients, to delay motor
complications and dyskinesia and to improve levodopa therapy
when administered in combination. New formulations of DA
agonists (slow release and patch) produced very interesting results
in clinical trials and have advantage compared to the immediate
release formulations.
Meanwhile more attention has been given to non motor
symptoms of PD therefore drugs with potential effect on motor
symptoms have been explored. DA can improve some non motor
symptoms such as depression or sleep problems.
These drugs have been extensively used but in the recent years
the use ofDAhas been limitedby the appearance of side effects such
as somnolence, hypotension but especially impulse control dis-
orders.
The research also focused on disease progression and treat-
ments that may modify disease progression. Many trial had been
conducted but the results were disappointing. Recently a study
showed that the MAOB-I rasagiline may modify disease progres-
sion in PD, however the effect has been showed onlywith 1 mg day
but not with 2 mg day.
MAOB-I, selegeline, rasagilinewere introduced in the treatment
because they can improve symptoms of the disease in mono-
therapy and ameliorate levodopa therapy when administered in
combination.
Levodopa remain the most effective drug but it is limited by its
short half-life. Slow release formulations introduced in late
eighties are not very efﬁcacious and their effect is unpredictable.
Levodopa half life can be improved adding to the dopadecar-
boxilase inhibitors a COMT inhibitor. Tolcapone and entacapone
showed to be efﬁcacious in improving and optimize levodopa
treatment. Unfortunately, tolcapone use is limited by its potential
lever toxicity, whereas entacapone can be administered in a single
tablet containing levodopa, carbidopa and entacapone. The
research for a better levodopa lead to a new formulation of
levodopa (IPX066) with a longer half life and stable plasma level.
IPX066 has been tested in different clinical trials and may be used
in the next future.
Other drugs may change PD therapy looking to new mecha-
nisms and pathways.
Saﬁnamide is an a-aminoamide with MAO-B and dopamine
reuptake inhibition action. Saﬁnamide (100 mg day) improved
motor performance added to a dopamine agonist (DA). More
recently, saﬁnamide reduced L–dopa-induced dyskinesia in parkin-
sonian monkeys.
A2A antagonists provide beneﬁt for patients with motor
complications based on their capacity to decrease overactive ﬁring
in striatal neurons that bear dopamine D2 receptors and comprise
the indirect pathway. In MPTP monkeys Preladenant reduced
dyskinesias associatedwith the introductionof levodopa. Istradefyl-
line showed improvement in off time on patients with motor
complications. Preladenant is now going in the phase III program.
AFQ056 is a novel, selective mGluR5 antagonist. Two random-
ized, double-blind, placebo-controlled, proof-of-concept studies of
AFQ056 demonstrated anti-dyskinetic efﬁcacy in moderate-to-
severe PD-LID.
Talampanel, a non-competitive, selective antagonist of the
a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) glu-
tamate receptor has been reported to signiﬁcantly reduce L-dopa-
induced dyskinesia in Parkinsonian monkeys.
Gene therapy is producing interesting results and may change
the treatment of PD in the future.
Of course brain surgery and in particular deep brain stimulation
has been a major change in the treatment of PD and this topic will
be extensively discussed in other part.SESSION 7 ‘‘Overlaps in movement disorders’’
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Phenotypic and genotypic overlaps in Parkinson’s disease and
parkinsonisms
Enza Maria ValenteIstituto CSS-Mendel, Roma and Universita` di
Messina, Messina
Over the past few years, several genes have been identiﬁed that
causemendelian forms of Parkinson’s diseasewith autosomal dom-
inant or recessive inheritance, as well as genetic factors that signiﬁ-
cantly increase the risk to develop the disease. The identiﬁcation of a
growing number of subjects carrying mutations in these genes has
allowed on one hand to demonstrate that mutations in the same
genemaycause awidearrayofdistinctphenotypes in termsofageat
onset, progression, disease severity and prevalence of non-motor
symptoms, on the other hand it has shown amarked clinical overlap
inpatients carriers ofmutations indistinct genes. This phenomenon,
known in genetics as ‘‘splitting and lumping’’, is typical of several
clinically and genetically heterogeneous disorders, and it is well
represented in PD and parkinsonisms. For instance, duplications of
theSNCAgene, encoding for theprotein alpha-synuclein, can cause a
wide spectrum ranging from a late onset clinical presentation
indistinguishable from idiopathic PD to earlier onset, clinically
aggressive forms of parkinsonism, with rapid onset of non-motor
symptoms such as dysautonomia, psychiatric disturbances and
cognitive impairment, that overlapwith thediagnosis of PD-demen-
tia or even Lewy BodyDementia. These severe phenotypes are often
associated to triplications of the SNCA gene, but are also foundwith
relative frequency in patients who are heterozygous carriers of GBA
mutations. Another relevant example of ‘‘splitting and lumping’’ is
represented by autosomal recessive parkinsonisms. Indeed, muta-
tions in the Parkin or PINK1 genes have been associated to several
clinical presentations, with variable age at onset, response to thera-
py and presence of atypical features (such as hyper-reﬂexia, dysto-
nia, psychiatric disturbances), it is also true that the phenotypic
spectrumof the three recessive genes (Parkin, PINK1andDJ-1) tends
to be similar, being often characterized by early onset (<40 years),
slow progression and good response to levodopa therapy. Such
marked clinical and genetic variability still remains largely unex-
plainedby the knownmechanismsof neurodegeneration associated
to speciﬁc gene mutations. The complexity of our genome, that is
clearly emerging in these years thanks to the many projects of
massive resequencing, suggests that the deﬁnition of ‘‘monogenic
PDandparkinsonisms’’ is over-simplistic,whileweare facingamore
complex scenario in which, besides the main mutation, several
genetic variations (including common polymorphisms and rare
variants) may interplay with environmental factors to inﬂuence
the phenotypic presentation of the disease. The identiﬁcation of
such variants and the deﬁnition of their role in determining the
parkinsonian phenotype represent one of the most interesting
challenges of genetic research of these days.
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Tremor in primary adult-onset dystonia
Alfredo Berardelli
Department of Neurology and Psychiatry, Sapienza Universita`
di Roma, Roma
Tremor, deﬁned as a rhythmic, involuntary, oscillatory move-
ment in a body part, is frequent in patients with dystonia. Its
clinical features in dystonic patients may be clinically indistin-
guishable from those in patients with essential tremor. We
Basal Ganglia 2S (2012) e1–e87e12investigated the frequency and the main phenotypic features of
tremor in 429 patients with primary adult-onset dystonia from
eight movement disorder centres. Of the 429 dystonic patients, 72
(16.7%) had tremor (43 dystonic tremor, 23 tremor associatedwith
dystonia, 6 both tremor types, according to Deuschl’s classiﬁca-
tion). Although sex and age at dystonia onset were similar in
dystonic patients who had tremor and those who did not, patients
who had tremor were more frequently affected by focal cervical
dystonia and less frequently affected by focal blepharospasm;
dystonia also had a greater tendency to spread in patients with
tremor. Taking into account potential confounding by age at onset
and body distribution of the corresponding dystonia type, all the
clinical features in patients with dystonic tremor and in those with
tremor associated with dystonia were comparable except the
tendency of dystonia to spread, which was greater in patients with
dystonic tremor. In conclusion tremor is relatively frequent in
primary adult-onset dystonia and its main phenotypic features
differ from those of essential tremor. Numerous clinical/demo-
graphic similarities suggest that dystonic tremor and tremor
associated with dystonia are manifestations of the same disease,
though dystonic tremor seems to be characterized by a greater
tendency of dystonia to spread.
To investigate whether psychophysical techniques assessing
temporal discrimination could help in differentiating patients who
have tremor associatedwith dystonia or essential tremorwe tested
somatosensory temporal discrimination thresholds (TDT) and
temporal discrimination movement thresholds (TDMT) in 39
patients who had tremor associated with dystonia or essential
tremor presenting with upper-limb tremor of comparable severity
and compared their ﬁndingswith those from a group of 25 sex- and
age-matched healthy control subjects. TDT and TDMT testing
proved to be a useful tool for differentiating tremor associatedwith
dystonia and essential tremor. These ﬁndings imply that the
pathophysiological mechanisms underlying tremor associated
with dystonia differ from those for essential tremor.
References:[1] Abbruzzese G, Berardelli A, Girlanda P, et al. Long-term
assessment of the risk of spread in primary late-onset focal
dystonia. J Neurol Neurosurg Psychiatry 2008; 79:392-396.[2] Conte A, Rocchi L, Nardella A, et al. Theta-burst stimulation-
induced plasticity over primary somatosensory cortex changes
somatosensory temporal discrimination in healthy humans.
PLoS One 2012;7:e32979. Epub 32012 Mar 32977.[3] Deuschl G, Bain P, Brin M. Consensus statement of the
Movement Disorder Society on Tremor. Ad Hoc Scientiﬁc
Committee. Mov Disord 1998;13 Suppl 3:2-23.[4] Scontrini A, Conte A, Defazio G, et al. Somatosensory temporal
discrimination in patients with primary focal dystonia. J Neurol
Neurosurg Psychiatry 2009;80:1315-1319
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Overlaps in Tauopathies
Helen Ling
Reta Lila Weston Institute of Neurological Studies and Queen Square
Brain Bank for Neurological Studies, Institute of Neurology, University
College London, London, UK
Normal tau protein binds to microtubules in axons in the brain,
but in some neurodegenerative diseases it accumulates in the cell
body to form insoluble, ﬁbrillary deposits. Diseases with accumu-
lation of pathological tau protein are known as tauopathies. More
than 20 different disorders are characterized by tau-positive
neuroﬁbrillary tangle pathology [1], most of which cause dementiaand abnormalities in the motor system. Common tauopathies
include Alzheimer’s disease, progressive supranuclear palsy [2,3],
corticobasal degeneration [4], frontotemporal dementia with
parkinsonism linked to chromosome 17, Pick’s disease, post-
encephalitic parkinsonism, dementia pugilistica and argyrophilic
grain disease. This talk will highlight the clinical and pathological
similarities and differences between some of these tauopathies.
References:[1] Kara E, Ling H, Pittman AM, et al. TheMAPT p.A152T variant is a
risk factor associated with tauopathies with atypical clinical
and neuropathological features. Neurobiology of aging
2012;33:2231 e2237-2231 e2214.[2] Williams DR, de Silva R, Paviour DC, et al. Characteristics of two
distinct clinical phenotypes in pathologically proven progres-
sive supranuclear palsy: Richardson’s syndrome and PSP-
parkinsonism. Brain 2005;128:1247-1258.[3] Ling H, Massey LA, Lees AJ, Brown P, Day BL. Hypokinesia
without decrement distinguishes progressive supranuclear
palsy from Parkinson’s disease. Brain: a journal of neurology
2012;135:1141-1153.[4] Ling H, O’Sullivan SS, Holton JL, et al. Does corticobasal
degeneration exist? A clinicopathological re-evaluation. Brain
2010;133:2045-2057.
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Overlap in a-synucleinopathies
Gregor K. Wenning
Division of Neurobiology, Department of Neurology, Medical
University, Innsbruck, Austria
There is increasing recognition that the a-synucleinopathies
Parkinson‘s disease and multiple system atrophy overlap at mul-
tiple levels. Both disorders are characterized by deposition of
abnormally phosphorylated ﬁbrillar a-synuclein within the cen-
tral nervous system supporting the notion that these two diseases
are causally linked. Moreover, there is a well-established clinical
overlap causing difﬁculties in the differential diagnosis, particu-
larly early in the disease. I will review emerging evidence suggest-
ing thatmultiple system atrophy and Parkinson’s disease aswell as
related Lewy body disorders represent similar phenotypes within
the spectrum of a-synucleinopathies. Recognizing the links be-
tween multiple system atrophy and Lewy body disorders has
fundamental implications for accelerated therapeutic discoveries
including a-synuclein immunization programs.
COURSE ‘‘Diagnosis and treatment of autonomic system disorders’’
C1
Why and how to evaluate the cardiovascular system in Parkinson
disease
Pietro Cortelli
Department of Neurological Sciences, Alma Mater Studiorum, IRCCS,
Institute of Neurological Sciences, University of Bologna, Bologna
A dysfunction of the Autonomic Nervous System (ANS) is
frequently observed in patients with Parkinson disease (PD). Be-
sides the typical motor signs and symptoms, PD patients can
develop during the disease course a wide spectrum of autonomic
disorders, including gastrointestinal, urogenital, cardiovascular,
sudomotor, thermoregulatory and respiratory dysfunctions, auto-
nomic disorders during sleep and pupillary abnormalities.
Basal Ganglia 2S (2012) e1–e87 e13The overall prevalence of the autonomic disturbances in PD is
considerably variable, ranging from 2% for urinary incontinence to
30% for orthostatic hypotension and 72% for constipation. Further
autonomic impairment may be related to disease duration and
severity as well as to use of antiparkinsonian drugs.
The development of the neurodegenerative process responsible
forPDhasbeensupposed to followadistinct caudal-rostral pathway
throughout the brain. This process also progressively involves in an
ascendingmanner several areas of the nervous system implicated in
the control of autonomic functions: from the post-ganglionic
sympathetic neurons of the intermediate cells columns, to the
dorsal glossopharyngeal nerve nucleus, the dorsal motor nucleus of
the vagus nerve and eventually to the anterior-medial temporal
cerebral mesocortex and the prefrontal areas. Therefore, the
occurrence of autonomic disturbances in PD can precede the onset
ofmotor symptoms, increases in frequencywithdiseaseprogression
and becomes nearly a constant ﬁnding in advanced disease stages.
A prompt recognition of these disturbances is useful not only
for diagnostic purposes, e.g. the differential diagnosis of the
parkinsonian syndromes, but also to choose the most correct
therapeutic approach and formulate a reliable prognosis. The
instrumental diagnosis of the autonomic dysfunction could in fact
help in the differential diagnosis between PD and atypical
parkinsonisms but could also allow to disclose the iatrogenic
aetiology of the autonomic disturbance.
The majority of ANS functions cannot be directly evaluated,
therefore the assessment on ANS integrity frequently relies on
indirect methods, whichmeasure the reﬂex responses of the target
organs to physiological and pathological stimuli. The cardiovascu-
lar reﬂex testing represents the most useful approach in clinical
practice to evaluate the integrity of the ANS branch which controls
heart rate and blood pressure response. These tests are easy to
perform, non-invasive, reproducible, sensitive and speciﬁc and
suitable for longitudinal ANS evaluations.
The present teaching course aims to provide clinical and
physiopathological basis for understanding the results of standard
cardiovascular reﬂex tests in patients with movement disorders.
The course comprises also a practical section during which
participants will be taught correct methods of cardiovascular
reﬂex tests’ execution and interpretation, including recognition of
speciﬁc artefacts.
The ﬁnal section will deal with the treatment of orthostatic
hypotension - supine hypertension, a condition that represents an
important cause of PD patient disability.
References:[1] Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunc-
tion in Parkinson’s disease. J Neurol Sci. 2010;289:74-80[2] Low PA. Clinical Autonomic Disorders, 2nd edition. Lippincott-
Raven 1997[3] Lahrmann H, Cortelli P, Hilz M, Mathias CJ, StruhalW, Tassinari
M. EFNS guidelines on the diagnosis and management of
orthostatic hypotension. Eur J Neurol. 2006; 13: 930-6[4] Weimer LH. Autonomic testing: common techniques and
clinical applications. Neurologist. 2010;16:215-22
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Clinical features and management of ‘‘orthostatic hypotension -
supine hypertension’’
Giovanna Calandra-Buonaura
Department of Neurological Sciences, Alma Mater Studiorum, IRCCS,
Institute of Neurological Sciences, University of Bologna, Bologna, ItalyOrthostaticHypotension (OH) is deﬁned as a sustained reduction
of systolic blood pressure of at least 20 mmHg or diastolic blood
pressureof 10 mmHgwithin3 minutesof standingorhead-up tilt to
at least 608 ona tilt table [1]. Orthostatic hypotension canbe theﬁrst
clinical sign of a dysfunction of the autonomic nervous system and
may be symptomatic or asymptomatic. OH occurs in patients with
neurodegenerative disorders such as Parkinson disease (PD),
Multiple System Atrophy (MSA), Lewy Body Dementia and pure
autonomic failure. This condition affects approximately 30% of
patients with PD being symptomatic in 18% of these patients and
therefore representing an important cause of disability. Usually the
treatment of OH follows an integrated approach, consisting of both
non-pharmacological and pharmacological interventions [2-4]. It is
important to state that treatment of OH should not be focused on
normalizing blood pressure values; instead it should be directed
toward improving symptoms and patient functional status, and
reducing the risk of falls and syncope.
First of all patients must be educated to avoid factors which
precipitate OH, like sudden postural changes from clinostatic to
orthostatic position, standing still for long periods, large meals
rich of carbohydrates, alcohol intake, hot showers and excessive
heat, straining during micturition or defecation and excessive
physical efforts. Drugs that can exacerbate OH (e.g. alpha-
blockers, diuretics, dopaminergic antiparkinsonian drugs) should
be discontinued or the dosage should be reduced. The second
step of non-pharmacological treatment is to educate patient
about the use of physical manoeuvres that contribute to raise
blood pressure by increasing venous return and peripheral
resistance (e.g. crossing legs on standing, squatting). The rapid
ingestion of approximately 500 cc of tap water is recommended
as a rescue measure when patients are symptomatic to raise
blood pressure values and improve symptoms. Finally patients
should follow some suggestions to increase blood volume (e.g.
addition of salt and water to the diet, use of custom ﬁtted elastic
stockings).
Pharmacological treatment should be implemented only in case
of symptoms’ persistence.
First line treatment intervention includes drugs which induce
volume expansion (ﬂudrocortisone acetate) and peripherally
acting alpha-1-adrenoceptor agonist (midodrine). The noradrena-
line precursor, Droxidopa, has also been demonstrated to
effectively improve orthostatic blood pressure values and OH
related symptoms in both PD and MSA patients.
Supplementary agents (e.g. acetylcholinesterase inhibitor,
erythropoietin, caffeine, ocreotide, acarbose) could provide an
additive therapeutic effect in patients, which do not respond to
ﬁrst line treatment interventions.
Finally supine hypertension is frequently observed in patients
with neurogenic OH and could be aggravate by the treatment of OH.
This condition increases the risk of developing ventricular cardiac
hypertrophy and cerebrovascular and cardiovascular events.
As for OH, treatment of supine hypertension should start with
non-pharmacological interventions (e.g. avoid the use of pressor
agents or water intake close to bedtime, raise the head of the bed
by 20-25 cm during night-time, allow sweet snack or minimal
alcohol consumption before bedtime). If the non-pharmacological
approach failed to control blood pressure, the use during bedtime
of short active antihypertensive drugs or of phosphodiesterase
inhibitors should be suggested [4].
References:[1] Freeman R, Wieling W, Axelrod FB, et al. Consensus statement
on the deﬁnition of orthostatic hypotension, neurallymediated
syncope and the postural tachycardia syndrome. Clin Auton Res
2011; 21:69–72.
Basal Ganglia 2S (2012) e1–e87e14[2] Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the
diagnosis and management of orthostatic hypotension. Eur J
Neurol 2006; 13:930-6.[3] Low PA and Singer W. Update on management of neurogenic
orthostatic hypotension. Lancet Neurol 2008; 7:451-8.[4] Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of
autonomic failure. Pharmacol Ther 2012;134:279-86.
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Gastrointestinal and genitourinary dysfunction in Parkinson’s
disease
Giuseppe Pelliccioni, B. Gobbi, D. Sabbatini, O. Scarpino
Neurology Unit, INRCA, Ancona
Parkinson’s disease (PD) is a chronic-progressive neurodegen-
erative disorder with varying patterns of impairment in dopami-
nergic and non-dopaminergic (cholinergic, noradrenergic and
serotoninergic) neuronal systems. Bradykinesia, muscolar rigidity,
resting tremor, postural reﬂex impairment and gait disturbances
are the most relevant motor dysfunctions. Rarely in the very
beginning and frequently with disease progression, the patients
affected by PD develop non-motor disabling autonomic symptoms
due to cardiovascular, bladder, sexual and gastrointestinal
dysfunctions. The prevalence of overactive bladder symptoms in
PD was found to be 27% to 39%. The most common complaint is
nocturia followed by frequency, urgency and urge-incontinence.
Winge et al., [1] demonstrated that the presence of bladder
symptoms is related to the decrease in the total number of
dopaminergic neurones in the striatum and that relative degener-
ation of the caudate correlates to the severity of bladder
symptoms. Urodynamic evaluation suggests that the most
common abnormality is detrusor overactivity, presumably as a
result of loss of normal inhibition exerted by the basal ganglia on
the sacral spinal cord [2]. L-dopa treatment improves storage
urodynamic parameters in de novo patients but the results are less
consistent in patients with L-dopa related motor ﬂuctuations.
Sexual dysfunctions are common and distressing symptoms in PD
patients of both genders. Women reported difﬁculties with arousal
(87%) and reaching orgasm (75%), and low sexual desire (47%);
men referred erectile dysfunction (68%), premature ejaculation
(40%) and sexual dissatisfaction (65%). Typically erectile dysfunc-
tion affects men several years after the diagnosis and the risk
increases with advancing Hoehn-Yahr stage and contributes to
deterioration of their quality of life. Intermittent subcutaneous
apomorphine improves erectile function, probably through central
D2 receptors stimulation. However the phospohodiesterase-5
selective inhibitors (sildenaﬁl, vardenaﬁl and tadalaﬁl) are the
most commonly used drugs for the treatment of erectile
dysfunction also in these patients [3]. Hypersexuality and
compulsive sexual behaviour are side effects of dopaminergic
therapy, particularly by dopaminergic agonists. Gastrointestinal
motility is frequently disturbed in PD, manifesting chieﬂy as
dysphagia, esophageal dysmotility with acalasia, impaired gastric
emptying and constipation [4]. Dysphagia is usually identiﬁed by
its consecutive symptom sialorrhea, though salivation is not
increased. In the late stage of the disease defective swallowing
induces aspiration pneumonia. Impaired gastric motility leads to
nonspeciﬁc symptoms such as sensation of fullness, belching and
heartburn. An important consequence of delayed gastric emptying
is impaired delivery of L-dopa to the absortive sites in the
duodenum. Constipation is the most prominent manifestation of
lower gastrointestinal dysfunction, resulting primarily from
decreased transport and/or disturbed anorectal evacuation. A
major mechanism of constipation is defecatory dysfunction whichresults in dyschezia and outlet-type constipation. In conclusion,
impairment of gastrointestinal and genitourinary functions
frequently represent clinically relevant, pervasive problem, with
considerable impact in daily life activities in all stages of the
disease.
References:[1] Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H.
Relationship between nigrostriatal dopaminergic degeneration,
urinary symptoms, and bladder control in Parkinson’s disease.
Eur J Neurol 2005;12(11):842-50.[2] Blackett H, Walker R, Wood B. Urinary dysfunction in
Parkinson’s disease: a review. Parkinsonism Relat Disord
2009;15(2):81-7.[3] Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S.
Erectile dysfunction in Parkinson’s disease. Urology
2006;67(3):447-51.[4] Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J
Neurol Sci 2010;289(1-2):69-73.
COURSE ‘‘Semeiologic evaluation of patients with movement dis-
orders’’
C4
Examination of eye movements
Silvia Ramat1, Stefano Ramat2
1SOD Neurologia 1, Dipartimento di Neuroscienze, AOU Careggi,
Firenze
2Dipartimento di Ingegneria Industriale e dell’Informazione, Univer-
sita` di Pavia, Pavia
Oculomotor abnormalities can be observed in all Parkinsonian
syndromes. Nevertheless, due to the considerable overlap of
oculomotor pathology in Parkinsonism, oculomotor changes are
not generally considered to contribute substantially to the
differential diagnosis of PS. There are subtle differences between
apparently similar oculomotor alterations in Parkinson’s disease
and atypical neurodegenerative PS that can contribute to the early
differential diagnosis of these entities.
Parkinson’s disease is the most common movement disorder,
and the most frequently reported neuro-ophthalmological ﬁnd-
ings include square wave jerks, hypometric saccades, mild
impairment of upgaze, convergence insufﬁciency, and visual
hallucinations. Most of these disturbances are best detected
through electrophysiologic testing rather than by neurological
examination.
Progressive supranuclear palsy (PSP), corticobasal degeneration
(CBD), andmultiple system atrophy (MSA) sharemany clinical and
neuropathologic features. Of the three, progressive supranuclear
palsy has the most neuro-ophthalmologic manifestations, often
present early in the disease course. PSP patients develop slowed
saccades (vertical before horizontal), frequent square-wave jerks,
loss of convergence, and tend to have an initially preserved
vestibulo-ocular reﬂex. Corticobasal degeneration does not usually
cause slow saccades, but is associated with increased saccadic
latency. Even at an early stage of the disease, CBD patients could be
differentiated from PSP patients by increased horizontal saccadic
latency and lack of impairment of vertical saccades. Multiple
system atrophy patients differ from PSP patients by having normal
vertical saccadic velocities.
Saccades may be also impaired in Parkinson’s disease dementia
and in dementia with Lewy bodies where cortical and subcortical
neurodegeneration coexist.
Basal Ganglia 2S (2012) e1–e87 e15References:[1] Pinkhardt EH, Jan Kassubek J Ocular motor abnormalities in
Parkinsonian syndromes Parkinsonism and Related Disorders
17 (2011) 223-230.[2] Ramat S, Leigh RJ, Zee DS, Optican LM. What clinical disorders
tell us about the neural control of saccadic eye movements.
Brain 2007 Jan;130(Pt 1):10-35.[3] Archibald NK, Clarke MP, Mosimann UP, Burn DJ Visual
symptoms in Parkinson’s disease and Parkinson’s disease
dementia Mov Disord. 2011 Nov;26(13):2387-95.[4] Mosimann UP, Muri RM, Burn DJ, Felblinger J, O’Brien JT,
McKeith IG Saccadic eye movement changes in Parkinson’s
disease dementia and dementia with Lewy bodies Brain (2005),
128, 1267–1276
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Tremor evaluation
Paolo Martinelli
Department of Neurological Sciences University of Bologna, Bologna
Tremor is the commonest movement disorder detected in
neurological practice, encountered in more than a hundred
neurological diseases. Tremor can be deﬁned as an involuntary
oscillation of a body segment around a central axis in both the
space and time domains. Tremor should be differentiated from
hyperkinesias without a constant periodic oscillation, i.e. pseudo-
periodic myoclonic jerks. A correct tremor evaluation requires not
only the appropriate clinical assessment, but also personal and
family history-taking and, in a few cases, electrophysiologic study.
Clinical classiﬁcation is largely linked to the phenomenology
observed: rest, postural, and kinetic types of tremor are the ﬁrst
diagnostichallmarks in theclassiﬁcationofa rhythmichyperkinesia.
More details however, are required: the body segment involved, the
frequency of the hyperkinetic movement, the onset, disappearance
or increase in the tremor during speciﬁc actions are all key pieces of
information for a correct semeiotical and hence clinical diagnosis.
Clinical rating scales and electrophysiologic investigations, e.g.
electromyographic recordings, power and frequency spectra analy-
sis, may add further details to clinical assessment.
Thepresent reviewdescribes the clinical featuresof the following
tremors: i) para-physiologic tremor, i.e. accentuated physiological
tremor; ii) essential tremor; iii) tremors due to cortical, sub-cortical,
cerebellar, brainstem involvement; iv) tremors associated with
neuronal and neural diseases; v) tremor non directly linked to
speciﬁc structures or systems, i.e. so-called psychogenic tremor.
References:[1] Fahn S. Classiﬁcation of movement disorders. Mov Disord 2011
May 26 (6):947-57.[2] Elble R, Deusch G. Milestones in tremor research Mov Disord
2011may (26):1096-105[3] Lang AE, Voon V. Psychogenic movement disorders: past
developments, current status, and future directions. Mov
Disord 2011 May 26(6):1175-86.[4] Bain PG. Task-speciﬁc tremor Handb Clin Neurol 2011;
100:711-8.
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Rating scales in Parkinson’s disease
Maria Teresa Pellecchia
Center for Neurodegenerative Disorders, University of Salerno,
SalernoSeveral rating scales are available to evaluate different motor
and non motor signs and symptoms of Parkinson’s disease, quality
of life and disease severity. They are useful to objectively monitor
disease progression and assess the efﬁcacy of either pharmaco-
logical or non-pharmacological treatments.
Some new rating scales for PD have been recently developed
and validated. The Movement Disorder Society-sponsored revision
of the Uniﬁed Parkinson’s Disease rating scale (MDS-UPDRS) has
been available in English since 2008 and its Italian translation has
been recently validated in 377 Italian PD patients, showing a
Comparative Fit Index relative to the English version higher than
0.94 [1]. The Italian version of the Parkinson’s disease sleep scale
(PDSS) has been recently validated in 221 patients showing a
satisfactory internal consistency and a good validity to assess sleep
disturbances [2]. A patients self-rated 19-item wearing-off
questionnaire (WOQ-19) was shown to be a potent screening tool
for wearing off in PD patients. The Italian version of WOQ-19
showed an excellent linguistic validity and psychometric proper-
ties [3].
The Snaith-Hamilton Pleasure Scale (SHAPS) has been validated
in 274 Italian PD patients and then administered to more than
1300 patients with different types of parkinsonism to evaluate
relationship between anhedonia and clinical features. SHAPS score
were related to type of parkinsonism, apathy, depression and
cognitive impairment [4].
References:[1] Antonini A, Abbruzzese G, Ferini-Strambi L, et al. Validation of
the Italian version of the Movement Disorder Society-Uniﬁed
Parkinson’s Disease Rating Scale. Neurol Sci 2012 Jun 8. [Epub
ahead of print][2] Pellecchia MT, Antonini A, Bonucelli U,et al. Observational
study of sleep-related disorders in Italian patients with
Parkinson’s disease: usefulness of the Italian version of
Parkinson’s disease sleep scale. Neurol Sci 2012;33:689-694.[3] Abbruzzese G, Antonini A, Barone P, et al. Linguistic,
psychometric validation and diagnostic ability assessment of
an Italian version of a 19-item wearing-off questionnaire for
wearing-off detection in Parkinson’s disease. Neurol Sci 2012
Feb 4. [Epub ahead of print][4] Santangelo G, Morgante L, Savica R, et al. Anhedonia and
cognitive impairment in Parkinson’s disease: Italian validation
of the Snaith Hamilton Pleasure Scale and its application in the
clinical routine practice during the PRIAMO study. Parkinson-
ism Relat Disord 2009; 15:576-581.
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Rehabilitation in Parkinson’s disease: when, what, how much?
Maria Gabriella Ceravolo
Dipartimento di Medicina Sperimentale e Clinica, Sezione Neuro-
scienze Cliniche, Universita` Politecnica delle Marche, Ancona
Parkinson’s Disease (PD) shows a multifaceted progressive
course, whose severity and clinical manifestations vary so much
across individuals and, especially, over time, that, in the advanced
phase, unpredictable shifts from a well-being condition to
complete dependence may often alternate in the same subject,
within few minutes.
Although replacement therapymay provide an effective control
ofmotor symptoms throughout the disease course, disability onset
cannot be averted in any patient due to both levodopa-refractory
symptoms and late complications of dopaminergic treatment.
Basal Ganglia 2S (2012) e1–e87e16International guidelines underscore the usefulness, for PD
patients, of receiving a tailored program of education, psychologi-
cal support, exercise and nutritional interventions aimed at
improving social interaction, reducing psychological distress,
increasing ﬁtness and independence in activities of daily life,
and promoting relearning of motor and communication skills [1].
By contrast, reports addressing the unmet needs of these
subjects highlight an unbalanced access to specialists (i.e.
neurologists), with respect to non-medical providers of health
care, with physiotherapists, occupational therapists and speech
and language therapists seen less often than wanted.
Such discrepancy has different likely sources: a) the striking
anti-symptomatic effect of drug treatment, releasing patients from
motor troubles in the very short time of tablet assumption, drives
individual attention towards passive ways of coping with
disability, thus reducing their motivation to engage themselves
in demanding proactive behaviour, as required by the rehabilita-
tion concept; b) the neurodegenerative mechanism underlying the
occurrence of movement disorder in PD is also assumed to be
responsible for the loss of initiative that often characterise these
subjects, thus further contributing to their inactivity; c) the lack of
evidence supporting rehabilitation effectiveness at improving
motor, swallowing or communication abilities in PD subjects has
so far hindered the standardization of non pharmacological care
provision and reduced the conﬁdence of the stakeholders (carers,
patients, public health system administrators) in allocating
resources to this purpose.
Therefore, even if a few recent reports underscored the
potential beneﬁts of exercise with regard to physical functioning,
quality of life, balance and gait speed, no guidelines have yet
disclosed what is the recommended content (dosing, techniques)
and timing of exercise interventions (when to start, how long to
continue) for PD patients.
Some Authors described an improvement in either gait
parameters or motor symptoms and physical ﬁtness in PD patients
that did supported-body-weight treadmill aerobic training in
comparison to conventional physical therapy. Other studies
showed that regular aerobic exercise helps preventing brain tissue
loss, thus prompting some researchers to check whether even PD
people would beneﬁt from a similar advantage and improve their
executive functions after prolonged generalised exercise [2].
Parallel to the development of evidences concerning endurance
training, a wide range of studies focused on the efﬁcacy of cued
exercises. The rationale of applying sensory cues is linked to their
ability in directing subject’s attention to the task of walking.
Cognitive strategies (internally generated cues such as thinking
about step length) are equally as effective as external visual spatial
cues. However, attention strategies potentially have a high cost in
terms of mental effort and fatigue as a result of using cognitive
resources to generate the internal cue. External cues may thus
require less effort and attention, and their use during more
complex activities could facilitatewalking. Dance therapy has been
referred to as a valuable method of combining the different key
components of a rehabilitation program designed for PD people.
Dance is an integrated approach including cuedmovements (music
supplies auditory cues, while the dance partner gives rhythmic
somatosensory inputs), cognitive movement strategies, joint
motion and muscle strength and endurance exercises. Further-
more, it has the adjunct value of training subjects while amusing
them thus potentially increasing their adherence to the exercise
program [3].
An important pitfall of even high-quality randomised con-
trolled trials of rehabilitation efﬁcacy in PD concerns the
demonstration of a carryover effect long after treatment end.
It has been extensively studied as an intact striatum is required
to retain newly learned motor skill over the long-term, as it werepart of a motor skill consolidation system. It has also been
postulated that the striatum and other cerebral regions including
the premotor area, supplementary motor area, and cerebellum
probably collaborate in the acquisition of new skills, and even
when the striatum is abnormal, the other regions may support
motor skill performance. According to some Authors, however,
improvements inmotor performancewould not be retained unless
the striatum is intact. Such a conclusion bears important
consequences on rehabilitation provision to subjects whose basal
ganglia suffer from a degenerative process [4].
References:[1] Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR.
Physical therapy in Parkinson’s disease: evolution and future
challenges. Mov Disord. 2009 Jan 15;24(1):1-14.[2] Herman T, Giladi N, Hausdorff JM. Treadmill training for the
treatment of gait disturbances in people with Parkinson’s
disease: amini-review. J Neural Transm. 2009Mar;116(3):307-
18. Epub 2008 Nov 4.[3] Earhart GM. Dance as therapy for individuals with Parkinson
disease. Eur J Phys Rehabil Med. 2009 Jun;45(2):231-8.[4] Rochester L, Baker K, Hetherington V, Jones D, Willems AM,
Kwakkel G, Van Wegen E, Lim I, Nieuwboer A. Evidence for
motor learning in Parkinson’s disease: acquisition, automatici-
ty and retention of cued gait performance after training with
external rhythmical cues. Brain Res. 2010Mar 10;1319:103-11.
Epub 2010 Jan 11.
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Rehabilitation of dystonia
Cristina Tassorelli
Unit of Neurorehabilitation, National Institute of Neurology Founda-
tion ‘‘C. Mondino’’, Pavia and Department of Public Health, Neuro-
sciences, Experimental and Forensic Medicine, Section of
Neurological Sciences, University of Pavia, Pavia
Rehabilitation represents one of the most direct and effective
treatments for several forms of dystonia. Quality of life is improved
by reducing general disability, increasing range of motion,
recovering normal gait or voice, reduction of tremors, rigidity,
pain and ﬁghting depression.
Dystonia rehabilitation strategies should be comprehensive
and include active exercise, motor, sensory, and cognitive
retraining, often combined with other therapeutic interventions,
which range from botulinum toxin injection to electrical stimula-
tion. Furthermore, since assessment of success in rehabilitation
therapies is often subjective, more efforts should be devoted to
adopt qualitative indicators of success, both in the daily practice
and even more so in clinical trial design.
In the deﬁnition of the rehabilitative approach, several issues
must be considered and adapted to the individual situation.
Identiﬁcation and avoidance of triggers or, on the contrary, the
positive use of suppressionmodalities (i.e. a contact stimulus, such
as placing a hand on the ipsilateral or contralateral side of the face
or neck in a patient with spasmodic torticollis) represents useful
means to improve dystonia.
Some dystonic movements may last seconds or minutes, but
others may last hours or weeks. These latters can lead to
permanent contractures, cause bone deformity, or can signiﬁcantly
impair function. Appropriate use of upper and lower extremity
splints and orthotics to support, guide, reduce, or stabilize
movements can help prevent orthopedic deformities.
Physical therapy techniques (e.g., massage), slow stretching,
and physical modalities (e.g., ultrasonography, biofeedback) may
Basal Ganglia 2S (2012) e1–e87 e17be helpful in personswith focal or regional dystonias. Patientswith
generalized dystonia often beneﬁt from gait and mobility training
and instruction in the use of assistive devices.
Various physiatric therapies and modalities have been used
with limited success for the treatment of dystonia symptoms.
These include relaxation training, sensory stimulation, biofeed-
back, transcutaneous electrical nerve stimulation, and percutane-
ous dorsal column stimulation.
Occupational therapy is similarly important for training of
activities of daily living and for the adoption of proper postures in
patients with impaired mobility. Adaptive equipment should be
provided to enhance function.
Speech therapists can offer training and communication aids to
patients with oromandibular or laryngeal dystonia.
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Rehabilitation of postural instability
Elisa Pelosin
Department of Neurosciences, Opthalmology and Genetics, Universi-
ty of Genoa, Genoa
Postural instability represent an important and widespread
problem inmost of themovement disorders and related conditions.
AlthoughParkinsondisease, CorticobasalDegeneration,Generalized
Dystonia, Huntington’s Disease, Multiple System Atrophy, Progres-
sive Supranuclear Palsy and some of drug-induced movement
disorders have a different pathophysiology, certainly share some
motor symptoms such as postural instability and gait problems.
Reduced balance is known to be an important risk factor for falls
in this population and is often associated with poor mobility,
disability, and reduced quality of life in these patients.
Balance requires maintenance of the body’s center of mass
within the limits of the base of support while sitting or standing,
and control of the center of mass while moving to a new base of
support during walking or running. Balance is often assessed with
tasks designed tomake controlling the center ofmass over the base
of support difﬁcult. However, many daily activities, such as
walking or standing up from a chair, are also balance-related, as
they require control of the center of mass while moving to a new
base of support. Therefore, balance can be measured indirectly by
tests of the individual’s ability to perform balance-related
activities, particularly in individuals with impaired mobility.
Most people with movement disorders will ultimately develop
reduced balance, which worsens with disease progression.
Reduced balance is associated with falls, poor mobility, disability,
and reduced quality of life in most of these movement disorders.
Furthermore, it is well known, that postural instability and some
related problems respond only partially to the standard medica-
tion treatment in this group of patients.
In addition, it has been recently pointed out that cognitive
impairments represent an independent contributing factor to
increase the risk of falls in a variety of neurological patients
population among which a lot of movement disorders.
For all these reasons, in the last years a pressing need to explore
interventions that may signiﬁcantly improve balance and so that
preventing falls is growing rapidly.
In clinical practice, different modalities of treatment have been
developed and found to be helpful in improving balance in these
patients such as: stretching, progressive/aerobic exercise training,
relaxation and muscle activation, strength and balance training,
unweighted or weighted treadmill, proprioceptive training and
augmented feedback. In addition, new techniques has been
successfully used on balance recovery, taking advantage of the
basis of somemartial ars. Tai-Chi and Qigong training have shown asigniﬁcant improvement in balance, especially in ParkinsonDisease.
All these approacheswere found tohave apositive effect onpostural
instability as well as a moderate effect on gait velocity, and step/
stride length. However, the effect of exercise and motor training on
balance-related activities and then on prevention of falls is still
unclear. Indeed ithasbeendemonstratedthatall these interventions
are not sufﬁcient to improve mobility and prevent falls in severely
affected patients. In addition, it is important to underline that most
of researches have been developed and tested in Parkinson patients,
while data on theefﬁcacyofphysical therapy in theothermovement
disorders are still poor and conﬂicting. Moreover, across all of these
studies, the interventions were clinically heterogeneous with
regards to the type of exercise, to the frequency and duration of
exercise being undertaken (between 6 and 36 hours spread over 4–
12 weeks) and to the target group (some studies used a group
intervention while other used an individual approach).
Altogether these results suggest that physical-therapists should
consider including highly challenging balance training in exercise
programs for people with postural instability and balance
problems. Although many forms of exercise and motor training
improve the performance of balance-related activities in this
population, exercise that speciﬁcally involves movement of the
center of mass, narrowing of the base of support, and minimizing
upper limb support may produce the best results. Moreover, the
growing possibility to combined physical therapy training with
new technologies (wearable audio-biofeedback, virtual reality,
game console) is paving the way to the development of innovative
rehabilitation protocols, focused on balance and falls prevention.
Recently, Mirelman and co-workers have demonstrated interest-
ing results in PD patients and Mild Cognitive Impairment using
both audio-biofeedback and virtual reality combined with
treadmill training. Even if these preliminary results are encourag-
ing, it is important to underline that the longer-term effects of
exercise and motor training in patients with movement disorders
remain unclear. For that reason, the possibility to test and verify
these new approaches also in movement disorders other than PD
patients is required.
Certainly, the progressive nature of all these disorders suggests
that balance training would be required to be ongoing. Providing
highly challenging balance training in a sustainable way for this
population is problematic, as it is difﬁcult to achieve the required
level of challenge while maintaining safety in group or semi-
supervised home-based programs. For these reasons, future
research working toward the development of effective programs
that are sustainable for the long term would be an important step
in solving this problem.
References:[1] Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL.
The effectiveness of exercise interventions for people with
Parkinson’s disease: a systematicreview and meta-analysis.
MovDisord. 2008 Apr 15;23(5):631-40. Review.[2] Allen NE, Sherrington C, Paul SS, Canning CG. Balance and falls
in Parkinson’sdisease: a meta-analysis of the effect of exercise
and motor training. MovDisord. 2011 Aug 1;26(9):1605-15.
doi: 10.1002/mds.23790. Epub 2011 Jun 14.[3] Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J,
Maddalozzo G,Batya SS. Tai chi and postural stability in
patients with Parkinson’s disease. N Engl J Med. 2012 Feb
9;366(6):511-9.[4] Mirelman A, Maidan I, Herman T, Deutsch JE, Giladi N,
Hausdorff JM. Virtualreality for gait training: can it induce
motor learning to enhance complexwalking and reduce fall risk
in patients with Parkinson’s disease? J Gerontol A Biol Sci Med
Sci. 2011 Feb;66(2):234-40.
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Infusional therapies in Parkinson’s disease
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2Dipartimento di Neuroscienze, Azienda Ospedaliera Citta` della
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Progression of striatal denervation and short half-life (60–
90 min) of oral levodopa cause severe motor complications in
Parkinson’s disease (PD) patients with advanced disease, such as
unpredictable ﬂuctuations, delayed ON, dose failures and dyski-
nesia. Deep Brain Stimulation (DBS) is recommended in PD to
manage such complications; however, a subset of patients is not
eligible for surgery because of comorbid cerebrovascular disease,
brain atrophy, presence of major depression or mild cognitive
decline, older age. In such cases infusion therapies may be used to
promote a continuous dopaminergic administration and improve
those motor complications secondary to troublesome gastric
emptying and intestinal absorption problems.
Apomorphine (APO) is a powerful D1 and D2 agonist
characterized by an efﬁcacy equivalent to oral levodopa, but with
a signiﬁcantly faster onset and shorter duration of effect. APO is
administered as continuous subcutaneous infusion (APO-INF) by
means of a portable mini-pump, usually activated during the
waking day. The aim is to reduce oral medication as much as
possible to avoid pulsatile therapy. Eligible patients for APO-INF
are those with severe motor ﬂuctuation and/or dyskinesia in spite
of optimized medical therapy causing severe disability and poor
quality of life. Moreover, good compliance of the patient and the
caregiver is required in order to manage daily infusion. Exclusion
criteria are: clinically signiﬁcant orthostatic hypotension, current
drug-induced psychosis not controlled by atypical antipsychotics,
dementia, severe cardiac arrhythmias, severe liver or renal
insufﬁciency, respiratory or cardiovascular disease.
After 3 days of domperidone p.o. (60 mg/day), the start of APO-
INF in a naı¨ve patient can be done according to twomodalities: 1) all
antiparkinson drugs, including levodopa, have to be discontinued
12 hours before starting APO-INF. Add-on of levodopa can be done
successively according to patient’s needs; 2) antiparkinson drugs,
excluding levodopa, have to be discontinued 12 hours before
starting APO-INF. The process of tailing down levodopa will be
done slowly over the months, until reaching the minimum
efﬁcacious dose. This secondmodality of APO-INF was demonstrat-
ed tobemoreefﬁcacious incontrolling levodopa induceddyskinesia.
At the starting day, apomorphine is infused at a dosage of 1 mg/
hour and ﬂow rate will be gradually increased of 1 mg with time
intervals of 1 hour, until reaching a good clinical effect without
signiﬁcant side effects. Mean APO-INF dosages are 4-8 mg/hour
during the waking day, with discontinuation at sleep time.
Clinical studies (level II and III trials) have demonstrated that
APO-INF is efﬁcacious in controlling severe motor ﬂuctuations in
PDwith an amplitude of the response comparable to Levodopa and
a reduction of ‘‘off’’ periods (from -40% to -87% according to the
studies) and of levodopa daily dose. Dyskinesia are reported to be
both decreased or unchanged; the only three studies directly
comparing APO-INF and subthalamic deep brain stimulation (STN-
DBS) demonstrated that surgery decreases dyskinesia at a higher
extent compared to infusion therapy.
The most common side effect of APO-INF is the formation of
local skin nodules, reﬂecting focal panniculitis, in most of the
patients. Sometimes these nodules can get infected, requiringantibiotics treatment or excision and rarely causing APO-INF
discontinuation. Abdominal wall nodules can be minimized by
regularly rotating injection sites, respecting scrupulous aseptic
technique of needle insertion, using of very thin needles, massaging
the injection site after removing the needle; moreover, low
frequency ultrasound treatments have been found to be of beneﬁt
in reducingnodule formation aswell not usinghigher concentration
than 5 mg/ml apomorphine. Haemolytic anaemia is a rare compli-
cation which can be monitored by performing blood test every six
months (full blood count, reticulocyte count andCoombs test). Short
follow-up studies showed that psychosis and cognitive decline do
notworsen in appropriately selected patients treatedwith APO-INF.
There have not been reports of higher frequency of impulse control
disorders in PDpatients treatedwith APO-INF, althoughprospective
studies are lacking; retrospective analysis of published cases have
demonstrated that APO-INF is more frequently associated to
punding and compulsive use of levodopa.
In conclusion, APO-INF is an efﬁcacious treatment in PD
patients with motor complications causing severe disability and
poor quality of life. This treatment can be reserved in patients not
fulﬁlling selection criteria for DBS, either due to brain atrophy/
vascular comorbidity or co-occurrence of mild cognitive dysfunc-
tion and severe depression.
Intraduodenal delivery of levodopa/carbidopa gel (Duodopa) is
an effective therapeutic option for the treatment of advanced PD
complicated by motor ﬂuctuations and dyskinesias. The direct
intestinal infusion is generally maintained for 12-14 hours daily
and has been shown to provide a more stable plasma levodopa
concentration, allowing a better control of motor ﬂuctuations and
dyskinesias.
Duodopa is indicated for the treatment of advanced idiopathic
PD patients with a sustained response to levodopa, with severe
motor ﬂuctuations and dyskinesia that are not adequately
controlled by all combinations of oral medications available. The
procedure is feasible also in patients over 70 years of age, in good
general conditions andwithout a signiﬁcant cognitive impairment.
On the other hand, Duodopa is not recommended in patients with
atypical parkinsonian syndromes, not responsive to dopaminergic
treatment. The presence of a caregiver is very helpful for the
correct use of the infusion device. Duodopa represents a further
treatment option that is being added to various other consolidated
treatments of the advanced phase (traditional oral poly-therapy,
APO-INF, DBS). The most relevant negative aspects of Duodopa are
the high cost of this therapy and the frequent technical problems
with the infusion system (dislocation, kinking or obstruction of the
intestinal tube). Furthermore, some cases of subacute axonal
neuropathy during Duodopa treatment have been reported,
possibly in relation to vitamin B6 deﬁciency.
References:[1] Antonini A and Tolosa E: Apomorphine and levodopa infusion
therapies for advanced Parkinson’s disease: selection criteria
and patient management. Expert Rev Neurother 2009;9:859-
67[2] Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F
et al: Continuous apomorphine infusion (CAI) and neuropsy-
chiatric disorders in patients with advanced Parkinson’s
disease: a follow-up of two years. Arch Gerontol Geriatr Suppl
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treatment of advanced Parkinson’s disease. Curr Med Res Opin
2011;27:907-919.
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DBS and stimulation
Leonardo Lopiano
Dipartimento di Neuroscienze, Universita` di Torino, Torino
Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
or Globus pallidus internus (Gpi) is an effective therapeutic option
for the treatment of advanced Parkinson’s disease (PD); in fact,
many short-term studies have showed that continuous high
frequency stimulation (130 Hz) of the target signiﬁcantly improves
PD cardinal symptoms and motor complications. More recently,
large randomized controlled trials have demonstrated that after 6
to 12 months, STN-DBS is more effective than best medical
therapy, while studies with 5 to 6 years of follow-up have shown
that the improvement is maintened over time.
However, aworsening of axial symptoms is often observedwith
a consequent impairment of activities of daily living (ADL) and a
worsening in the quality of life. Recent studies with a follow-up of
8-10 years of continuos high frequency stimulation showed a
worsening of the functional state of operated PD patients, despite a
persistent positive effect on motor symptoms. The development of
L-dopa–unresponsive symptoms, mainly related to the disease
progression, signiﬁcantly inﬂuences the long-term outcome of
DBS. In addition, cognitive impairment is progressively more
relevant during the progression of PD and may contribute to the
worse functional state of the patients.
In order to obtain the best outcome of PD-stimulated patients is
fundamental a correct selection of patients and a correct choice of
the target; moreover, the modulation of the frequency of
stimulation as well as alternative modality of stimulation or
new targets are under evaluation.
References:[1] Castrioto A, Lozano AM, Poon YY, Lang AE, FallisM,Moro E. Ten-
year outcome of subthalamic stimulation in Parkinson disease:
a blinded evaluation. Arch Neurol. 2011 Dec; 68 (12):1550-6[2] Zibetti M, Merola A, Rizzi L, Ricchi V, Angrisano S, Azzaro C,
Artusi CA, Arduino N, Marchisio A, Lanotte M, Rizzone M,
Lopiano L. Beyond nine years of continuous subthalamic
nucleus deep brain stimulation in Parkinson’s disease. Mov
Disord. 2011 Nov; 26 (13):2327-34[3] Vitek JL. Long-term beneﬁt from deep brain stimulation of the
subthalamic nucleus: is it for everyone? Alzheimers Res Ther.
2012 May 9; 4 (3):13[4] Vingerhoets FJ, Tagliati M. Treating PD axial signs with DBS: is
two better than one? Neurology. 2012 Apr 3; 78 (14):1036-7
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During this sessionwewill provide practical information on the
use of the various techniques employed in the treatment of the
advanced phase of Parkinson’s Disease. Participants will be able to
familiarise with the different devices in use (continuous subcuta-
neous apomorphine pump, intrajejunal levodopa infusion pump,
setting of different deep brain stimulation parameters) with videos
of clinical cases and eventually with the presence of patients.COURSE ‘‘Medico-legal aspects in clinical practice of patients with
movement disorders’’
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Adverse reaction due to anti-parkinsonian treatment
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The treatment of Parkinson’s disease (PD) is still symptomatic
and based on the use of drugs belonging to a few pharmacological
classes: levodopa, dopamine-agonists, iMAO-B, iCOMT, amanta-
dine and anti-cholinergics.
All of these drugs, alone or in combination, can determine
adverse reactions in PD patients.
Generally, an adverse drug reaction is deﬁned as ‘an appreciably
harmful or unpleasant reaction, resulting from an intervention
related to the use of a medicinal product, which predicts hazard
from future administration and warrants prevention or speciﬁc
treatment, or alteration of the dosage regimen, or withdrawal of
the product’.
Adverse drug reactions can be classiﬁed in different types; the
principals are type A and type B reactions.
Type A reactions are dose-related, generally predictable,
expected and usually linked to the pharmacological properties
of the drug. They are usually not severe or deadly, but often their
prevalence is high. Type B reactions are not dose-related; they are
rare, unpredictable, unexpected but often serious, and they
frequently require the drug withdrawal.
In the last decades the attention of the scientiﬁc community
focused on potentially severe adverse reactions due to use of
antiparkinsonian drugs: from the pleuro-pulmonary, pericardiac
or retroperitoneal ﬁbrosis due to ergot dopamine-agonists, to the
‘sleep attacks’ referred to the use of dopamine-agonists, to the
most recent problem of the link between dopaminergic drugs and
impulse-control disorders.
Those observations continue to raise both clinical and medico-
legal relevant issues, requiring a multidisciplinary approach to the
problem.
Reference:[1] Edwards, I.R., Aronson J.K., 2000. Adverse drug reactions:
deﬁnitions, diagnosis andmanagement. Lancet. 356, 1255-1259.[2] Antonini, A., Cilia, R., 2009. Behavioural adverse effects of
dopaminergic treatments in Parkinson’s disease: incidence,
neurobiological basis, management and prevention. Drug
safety: an international journal of medical toxicology and drug
experience. 32, 475-563.[3] Bhatt, M.H. et al., 1991. Pleuropulmonary disease associated
with dopamine agonist therapy. Ann Neurol. 30, 613-6.[4] Frucht, S. et al., 1999. Falling asleep at the wheel: motor vehicle
mishaps in persons taking pramipexole and ropinirole.
Neurology. 52, 1908-1918.
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Two categories of side-effects related to dopaminergic medica-
tions used in Parkinson’s disease have particular relevance from
the medico-legal point of view:
Basal Ganglia 2S (2012) e1–e87e201 – Patients with Parkinson’s disease may have excessive
daytime somnolence and the so-called sleep attacks at the wheel
while taking dopaminergic drugs (it is believed that all dopamine
agonists can induce sleep attacks, and also levodopa).
2 – They may also show the so-called impulse control disorders
(ICDs); these are common phenomena in Parkinson’s disease, with
a frequency of 13.6%. These abnormal behaviors are associated
with impaired functioning and with depressive, anxiety and
obsessive symptoms, novelty seeking and impulsivity. They are
mainly associatedwith the use of the non-ergot dopamine agonists
and may frequently lead patients to ﬁnancial and legal problems.
References:[1] Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling
asleep at the wheel: motor vehicle mishaps in persons taking
pramipexole and ropinirole. Neurology 1999 Jun 10; 52 (9):
1908-10.[2] Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson’s
disease: a wake-up call. Mov Disord 2000 Jul; 15 (4): 601-3.[3] Park A, Stacy M. Dopamine-induced nonmotor symptoms of
Parkinson’s disease. Parkinsons Dis 2011; 2011: 485063. Epub
2011 Apr 11.[4] Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD,
Whetteckey J, Weintraub D, Wunderlich GR, Stacy M. Impulse
control disorders in Parkinson disease: a multicenter case–
control study. Ann Neurol 2011 Jun; 69(6): 986-96
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Stefano Ferracuti
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sita` di Roma, Roma
Besides the motor symptomatology, Parkinson disease patients
typically display variable cognitive deﬁcits, that may even
conﬁgure a clear disesecutive symptomatology or a dementia.
The possible and often frequent occurrence of psychiatric
syndromes, usually with depressive manifestation, or, less
frequently, with psychotic symptoms, may create dilemmas about
the competency of these patients. The major problems in civil law
regarding Parkinson disease patients will be discussed.
Iatrogenic manifestation may stem from dopaminergic drugs,
such as stalking and gambling, behaviors that may have with
possible forensic psychiatric implications. Finally the medical
liability of such cases will be discussed under the current Italian
legislation.
COURSE ‘‘Body-mind therapies’’
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Rational for conventional therapies in PD: from epigenetic to
neuronal plasticity
Francesca Mancini
Parkinson’s Disease andMovement Disorders Center, San Pio X Clinic,
Milano
Parkinson’s Disease (PD) is a chronic disease characterized by
the progressive degeneration of substantia nigra pars compact
neurons associated to the loss of striatal dopamine. This alteration
is correlated also to an increase in glutamatergic corticostriatal
drive, contributing to motor symptoms that are not responding to
dopaminergic treatments.Neural degeneration is due to the combination of different
events: cellular oxidative stress, glutamatergic toxic action,
apoptosis and intracellular proteins accumulation.
Although pharmacological therapies allow a fair control of
motor symptoms, both in early and advanced phases, several
treatment issues, such as the management of non motor
symptoms, or the control of motor symptoms which may be
either resistant to dopaminergic treatment or caused by the
treatment itself, are still open.
In the last years, several studies have shown the beneﬁcial
effects of exercise in PD, but it’s not clear yet whether its
mechanism of action is compensatory or neuroprotective, and how
it stimulates neuro-plasticity.
The phenomenon named ‘‘activity-dependent neuroplasticity’’
is deﬁned as the modiﬁcation within the Central Nervous System
(CNS) in response to physical activity and that promotes a skill
acquisition process. This phenomenon is demonstrated in patients
with acute lesions of CNS, when exercise is able to activate the
genetic modulation and consequently neural re-adaptation with
re-learning. Less clear is the role of this mechanism in chronic
neurodegenerative diseases, like PD.
Anyway, the genetic modulation stimulated by exercise is
based on epigenetic mechanisms.
Epigenetic is the branch of biology that studies the causal
interactions between genes and their product, or the cellular
phenotype. Epigenetic mechanisms play a main role in acute
regulation of genes expression as reply to environmental stimuli
and experience. They refer, in the medium term, to functionally
relevant modiﬁcations of the genome that do not involve a change
in the nucleotide sequence. In particular, environmental stimuli or
experiences, through epigenetic signals, act by means of DNA
methylation and histone modiﬁcation. These modiﬁcations of
genetic expression promote, for example, the activation ad
secretion of growth factors (Brain Derived Neurotrophic Factors).
Several animal studies have demonstrated that motor training
triggers lasting neuronal changes throughout the brain such as
glial cell proliferation, changes in neurotransmitter levels, changes
in the expression of endogenous neurotrophic factors which are
associated with a protective/preventing effect to onset of
extrapyramidal symptoms.
Other studies have demonstrated that exercise is able to
activate compensatory strategies increasing dopamine release
from dorsolateral striatum and reducing the dopamine transporter
(DAT), which is the main clearance mechanism of dopamine from
extracellular space. DAT inhibition allows a greater availability of
dopamine, in terms of diffusion and permanence time.
To conﬁrm these data, many studies highlight exercise efﬁcacy
on extrapyramidalmotor and nonmotor symptoms in humans too,
with positive effects on motor global function and disability.
Nowadays, exercise is recommended by the main scientiﬁc
societies because higher level of exercise my reduce the risk of PD
(class IV evidence), may improve parkinsonian motor impairment
and disability (class II and III), may improve gait and reduce
episodes of freezing (class III and IV). In particular, four speciﬁc
treatment recommendations reached level II of evidence: cueing
strategies to improve gait, cognitive movement strategies to
improve transfers, exercise to improve balance and training of joint
mobility and muscle power to improve physical capacity.
The selection of a particular physical activity has to take into
account some speciﬁc issues that are needed to inﬂuence
neuroplasticity. These issues are intensity, speciﬁcity, difﬁculty
and complexity.
Exercise intensity is proportional to its ability of increase
synaptic plasticity (neuronal activity); exercise has to be speciﬁc
for the targeted symptoms (posture, equilibrium, etc); higher is the
complexity of the activity, better is the structural adaptation;
Basal Ganglia 2S (2012) e1–e87 e21physical activity should be progressively more difﬁcult to carry
out, with a learning curve. Moreover, if the physical activity is
pleasant and rewarding, it is able to increase dopamine levels,
promote learning and favor compliance. This last property is
important because dopaminergic neurons are reactive to activity
and inactivity (use it or lose it) and removal of activity can decrease
or reverse the beneﬁcial effects of exercise.
Thus, many are the evidences that show how exercise has to be
considered a fundamental treatment, to recommend not only in
the complicated phase of the disease, but also in the early stage.
Several activities are now available for patients, with a proven
efﬁcacy in PD.
Therefore, it is possible to individualize the type of exercise in
relation to patient’s preferences and stage of disease.
Some programs of conventional physiotherapy can present the
desirable features but it is rarely available in a continuous manner
and it is often perceived as not rewarding.
Alternatively, several other activities are proposed, collectively
named ‘‘non conventional’’ or ‘‘psycho-motor’’ or ‘‘body-mind’’
therapies. These are complex interventions integrating physical,
psychosocial, emotional, spiritual, and behavioral elements and
promoting the mind-body interaction.
Mind–body therapies focus on the relationships among the
brain, mind, body, and behavior, and their effect on health and
disease. Mind–body therapies are often implemented by patients
because of the playful aspects and the possibility to play a more
active role. These therapies are often carried out in groups, favoring
socialization. Moreover, they are organized in order to modulate
their intensity, they are performed with an increasing complexity
during the activity learning and can be selected on the basis of the
speciﬁc symptoms that need to be targeted, as well as patients’
tastes and characteristics.
References:[1] Petzinger GM, Fisher BE, Van Leeuwen JE, Vukovic M, Akopian
G, Meshul CK, Holschneider DP, Nacca A, Walsh JP, Jakowec
MW. Enhancing neuroplasticity in the basal ganglia: the role of
exercise in Parkinson’s disease. Mov Disord. 2010;25 Suppl
1:S141-5.[2] Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL.
The effectiveness of exercise interventions for people with
Parkinson’s disease: a systematic review and meta-analysis.
Mov Disord. 2008 Apr 15;23(5):631-40. Review.[3] Hirsch MA, Farley BG. Exercise and neuroplasticity in persons
living with Parkinson’s disease. Eur J Phys Rehabil Med. 2009
Jun;45(2):215-29.[4] Ang ET, Tai YK, Lo SQ, Seet R, Soong TW. Neurodegenerative
diseases: exercising toward neurogenesis and neuroregenera-
tion. Front Aging Neurosci. 2010 Jul 21;2. pii: 25.
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Occupational and alternative therapies in the management of
Parkinson’s disease: rewiev of literature
Nicola Modugno
Istituto Neuromed, Pozzilli (IS)
Occupational or alternative therapies are unconventional
approaches that clinicians use to improve motor and non motor
symptoms control when conventional medical and rehabilitative
therapies produce only a partial recovery. The general impression
is that as the disease progresses, a parkinsonian patient needs to be
not only treated and rehabilitated but also assisted, because too
often he is socially isolated, has a bad quality of life and lack of self
conﬁdence. When this is the case, PD patients worsen motor andnonmotor control and alternative therapiesmight help. The aim of
this approaches is to preserve as longermotor and nonmotor skills,
recreate self conﬁdence and improve relations and the quality of
life. It is not possible, at the moment, to provide recommendations
based on evidence even if different studies demonstrated that
physical activity, training and artistic activities can improvemotor
and non motor symptoms, unexpectedly.
Several activities such as physical activities, tai chi, yoga, music,
dance and tango and acupuncture have been tested in PD patients.
Each study has demonstrated variable clinical improvements after
a period of activity but all studies have a limited power for
methodological reasons. It can be however suggested that physical
activity, balance and proprioceptive training, music therapy, tango
and tai chi are useful to ameliorate the physical and mental status
of the patients and eventually motor and non motor symptoms.
Improvements can be small and limited in time but also quite
signiﬁcant and for longer time. Generally, when the training is
interrupted the improvements decaywith time. Some studies have
also tested acupuncture, biofeedback, osteopathy, Trager Therapy
but a signiﬁcant effect has not been demonstrated. Speech therapy
can improve signiﬁcantly voice disorders but it is still unclair
which is the best method. In conclusion, also supported from
recent Scottish Guidelines (SIGN), it can be suggested that
multidisciplinar alternative activities are a good practice for PD
patients. It is still not possible to provide recommendations based
on evidence and further controlled studies need to be performed.
References:[1] Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T,
Weiner WJ. Quality Standards Subcommittee of the American
Academy of Neurology. Practice parameter: neuroprotective
strategies and alternative therapies for Parkinson disease (an
evidence-based review): report of the Quality Standards
Subcommittee of the American Academy of Neurology.
Neurology 2006 Apr 11;66(7):976-82.[2] Diagnosis and pharmacological management of Parkinson’s
disease. A national clinical guideline ‘‘Scottish Intercollegiate
Guidelines Network’’ 2011[3] Dixon L, Duncan DC, Johnosn P, Kirkby L, O’Connell H, Taylor H,
Deane K. Occupational therapy for patients with Parkinson’s
disease. CochraneDatabase of Systematic Reviews 2007, Issue 3.[4] The professional guide to Parkinson’s Disease. Parkinson’s
Disease Society 2011[5] Diagnosis and pharmacological management of Parkinson’s
Disease. A national clinical guideline. Scottish intercollegiate
guidelines network. 2010
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Motor activity promotion, musicotherapy and social theatre as
alternative therapies for Parkinson’s disease
Ernesto Gastaldo1, Francesca Mancini2, Nicola Modugno3
1Unita` Operativa Complessa di Neurologia, Azienda ULSS 12 Vene-
ziana, Ospedale dell’Angelo, Mestre (Venezia)
2Parkinson’s Disease and Movement Disorders Center, San Pio X
Clinic, Milano3Istituto Neuromed, Pozzilli (IS)
Physiotherapy in PD should play a signiﬁcant role in the
maintenance of the physical state of patients and improve the
motor and nonmotor symptoms. At themoment there is lacking of
recommendations about which is best approach and, even if it is
not possible to give recommendations, there is a general
impression that alternative therapies and more olistic approaches
might help signiﬁcantly patients in improving the control of their
symptoms.
Basal Ganglia 2S (2012) e1–e87e22Alternative therapies are different activities such as music,
dance, theater and physical activities that have the aim to help
patients in enjoying, developing new skills and projects.
In the ﬁrst part brief extracts of ‘‘health promotion motor
activity’’ sessions videos with ipokinetic movement disorders
patients will be showed. Motor activity promotion is an adapted to
pathology proposal, based on music and dance: through complex
movement motor and cognitive skills are trained with a conse-
quent improvement of motor and cognitive ﬁtness and mood. The
aim therefore is not to reduce the neurologic disability (as in the
sanitary approach) but to train and to expand people’s potentials
and health. Such activity should be paired to the sanitary approach
(pharmacological and physical therapy), by inducing pleasure in
movement and by stimulating people’s activity.
The typical session (in these videosmanaged by a dancer, Giulia
Brugnoli) is in group, with four deﬁned steps:Warm-up, First step:
«cleaning the movement», Second step: «choreography», Cool-
down. These activities have been evaluated in numerous studies
conﬁrming the subjective improvement referred by the patients,
both on motor and quality of life items.
The concept of the importance of complex movements in PD
patients are also well explained by videos on activities such as
Musicotherapy, Tai Chi, Pilates, that will be showed.
In the second part brief extracts of the activities organized by
Parkinzone Onlus (ww.parkinzone.org) will be showed. Parkin-
zone Onlus have developed a model to rehabilitate and to assist
patients with PD through the active participation to laboratories of
social theater alone or integrated with dance and music.
In a recent paper [5] we demonstrated that a patient who
participate regularly to these activities can improve signiﬁcantly
non motor symptoms such as anxiety, apathy, anhedonia, social
retire and the quality of life, and successivelymotor symptoms too.
In the extracts learning activities in the laboratories, rehearsals
and other activities will be shown.
References:
[1] Pacchetti C,Mancini F, Aglieri R, Fundaro` C,Martignoni E, Nappi
G. Active music therapy in Parkinson’s disease: an integrative
method for motor and emotional rehabilitation. Psychosom
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2010, 10:2301-13.[6] COURSE ‘‘Management of cognitive and behavioral distur-
bances in Parkinson’s disease and movement disorders’’
C19
Cognitive evaluation
Gabriella Santangelo
Department of Psychology, Second University of Naples, Caserta and
Neurodegenerative Diseases Center, University of Salerno, SalernoParkinson’s Disease (PD) is a neurodegenerative disease
characterized by motor symptoms and non motor symptoms
(sleep disorders, gastrointestinal disorders, affective and beha-
vioural disturbances, cognitive dysfunctions including selective
Cognitive Deﬁcits (CD), [1] Mild Cognitive Impairment (MCI) and
frank dementia). The MCI is common in PD patients (mean
prevalence, 27%) and it is associated with several demographic
(advanced age) and clinical (disease duration and severity) aspects
[2,3]. Four clinical subtypes of MCI exist (amnestic vs. nonamnes-
tic, and single- vs. multiple-domain); among these subtypes, non-
amnestic, single-domain impairment (i.e., any single nonmemory
domain) is the most common subtype. The MCI-PD is a predictive
factor for dementia; therefore the evaluation of DC or MCI in PD
patients seems to be relevant in order to identify individuals at
high risk for developing dementia and who may beneﬁt from
preventive strategies.
Recently, the Movement Disorders Society Task Force has
proposed and delineated diagnostic criteria useful for identifying
ofMCI-PD [4]. These criteria utilize a two-level operational schema
depending on the comprehensiveness of neuropsychological
testing. Level I and II categories differ regarding method of
assessment and level of diagnostic certainty. Level I is based on an
abbreviated cognitive assessment by means of screening tools
(Montreal Cognitive Assessment, Parkinson’s Disease-Cognitive
Rating Scale, Scales for Outcomes of Parkinson’s Disease-Cognition,
Mattis Dementia Rating Scale) or limited neuropsychological
battery including less than two tests within each of the ﬁve
cognitive domains, or assessing less than ﬁve cognitive domains.
Level I criteria provide less diagnostic certainty than level II. This
latter level is based on administration of formal, comprehensive
neuropsychological testing that includes at least two tests for each
of the following ﬁve cognitive domains: attention and working
memory as well as executive, language, memory, and visuospatial
functions. Impairment should be present on at least two tests,
either within a single cognitive domain or across different
cognitive domains. The MDS task force recommends the use of
two cognitive tests for each of the cognitive domains and proposed
examples of tests to assess cognitive domains: Word list learning
test with delayed recall and recognition conditions, Prose recall
test with a delayed recall condition, Brief Visuospatial Memory
Test–Revised (BVMT-R) to assess memory domain; WAIS-IV (or
earlier version) Letter Number Sequencing, WAIS-IV Coding (or
earlier version) or other substitution task, Trail Making Test, Digit
span backward or digit ordering, Stroop color-word test to assess
attention andworkingmemory;Wisconsin Card Sorting Test (CST),
or modiﬁed CST (Nelson’s modiﬁcation), Tower of London test–
Drexel version, or Stockings of Cambridge (CANTAB), Verbal
ﬂuency test and 10 points Clock Drawing Test to assess executive
functions; WAIS-IV (or earlier version) Similarities, Confrontation
naming task to assess language; Benton’s Judgment of Line
Orientation, Hooper Visual Organization Test and Clock copying
to assess visuospatial functions.
The proposed MDS Task Force PD-MCI criteria provide a
uniform method to characterize and diagnose the MCI-PD. These
criteria are not validated, but they represent useful guidelines to
perform a correct assessment to identify parkinsonian patients at
high risk for developing of dementia.
Reference:[1] Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub
D. Cognitive impairment in nondemented Parkinson’s disease.
Mov Disord 2011;26:2483-2495.[2] Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder
K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock
L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre
Basal Ganglia 2S (2012) e1–e87 e23M. Mild cognitive impairment in Parkinson disease: a
multicenter pooled analysis. Neurology 2010;75:1062-9.[3] Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J,
Mollenhauer B, Rodriguez-Oroz MC, Tro¨ster AI, Weintraub D.
MDS Task Force on mild cognitive impairment in Parkinson’s
disease: critical review of PD-MCI. Mov Disord 26:1814-24.[4] Litvan I, Goldman JG, Tro¨ster AI, Schmand BA, Weintraub D,
Petersen RC,Mollenhauer B, Adler CH,Marder K,Williams-Gray
CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ,
Barker RA, Emre M. Diagnostic criteria for mild cognitive
impairment in Parkinson’s disease: Movement Disorder
Society Task Force guidelines. Mov Disord 2012;27:349-56.
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Among the common non-motor symptoms in Parkinson’s
disease (PD) impulsive and compulsive behaviour (ICBs), have
surged to relevance as they may develop in relationship to
dopaminergic drug therapy. It is important to recognize ICBs
because they are underreported (more than 10-15% of PD patients
may develop ICDs) and because of the considerable distress they
cause to patients and caregivers.
Also known as repetitive and reward-seeking behaviours, ICBs
include impulse control disorders (ICDs) namely pathological
gambling, binge or compulsive eating, pathological hypersexuality
and compulsive shopping, punding (non-goal oriented behaviors
consistent with prior work or hobby experiences), dopamine
dysregulation syndrome (DDS) (compulsive use of dopaminergic
treatmentwith secondary cognitive and behavioural disturbances)
and more recently hoarding (failure to discard large numbers of
possessions that appear to be useless), kleptomania (failure to
resist urges to steal items) and impulsive smoking.
The multicentre North American DOMINION cross-sectional
study (3090 patients) is the largest epidemiological study of ICDs
in Parkinson’s disease although the study was retrospective and
diagnosis was based on a telephone interview. The authors
reported a 6-month ICDs prevalence of 13.6% (pathological
gambling 5.0%, compulsive sexual behaviour 3.5%, compulsive
buying 5.7%, and binge eating disorder 4.3%) [2]. In an Italian case
control study, the prevalence of ICD in PD was 28% vs. 20% in
healthy non-PD controls highlighting the importance of using a
structured interview with patient and caregiver in the assessment
of these disturbances [6]. Although similar frequencies of ICDs
have also been identiﬁed in other dopamine agonist (DAA) treated
conditions such as restless-leg syndrome or ﬁbromyalgia, the
prevalence of ICDs in PD onDAAs is found to bemore common than
in the general population. ICDs frequencies did not differ between
‘‘de novo’’ PD patients and non-PD controls [3], suggesting that
maladaptive behaviours may be the result of an interaction
between predisposing factors and dopaminergic medication and
that the presence of Parkinson’s disease alone can not be
considered neither the cause nor a protective factor for ICDs.
Among the potential risk factors for the development of ICBs there
are the use of levodopa and dopamine agonists (specially when
given in combination), gender (male seems to bemore predisposed
to develop hypersexuality and gambling, women more prone to
develop compulsive shopping and being eating), younger age at PD
onset, a pre-PD history of ICBs symptoms, personal or family
history of substance abuse, and high impulsivity and novelty-
seeking personality traits. Recently, the akinetic-rigid PD pheno-
type was suggested to be associated with greater impulsivity andrisk taking traits than the tremor-dominant phenotype. Moreover
other studies showed that presence of ICDs in PD are associated
with depressive, anxiety and obsessive symptoms and impaired
activities of daily living and that different ICDs subgroups may be
differently associated with personality traits (gambling and
compulsive shopping subgroups score higher in novelty seeking
compare to binge eating and hypersexuality ones).
Brain regions functionally involved in these aberrant beha-
viours are the basal ganglia, orbitofrontal cortex, ventrolateral
prefrontal cortex, the amygdale and the hippocampus. These
regions are known to play a role in reward-based learning,
response inhibition and decision-making and several theories in
impulsivity and addiction underlined their role in the development
of repetitive reward-seeking maladaptive behaviours. The prefer-
ence of small immediate over delayed rewards of larger value is
known to be associated with impulsivity and impaired decision-
making and to be a common feature shared by ICDs and substance
use disorders.
Functional neuroimaging studies in healthy subjects showed
that activities in medial orbitofrontal cortex, amygdale and ventral
striatum increase during reward events [4], while increased
activities in ventrolateral prefrontal cortex, ACC and ventral
striatum is associated with decision making under risk [5]. These
ﬁndings support the concept of reduced engagement of brain areas
involved in the prevention of negative outcomes (VLPFC) (bottom-
up regulation) and an increased role of areas mediating goal-
directed behaviour via motivational circuits (medial OFC) (top-
down regulation). In non-PD population with gambling, substance
disorders and binge eating, a reduced activation of the mesocorti-
colimbic ‘‘reward’’ system has also been reported.Weintraub et al.,
[13] found reduced ventral striatal activity in PD with ICDs,
suggesting that ICDs in all these population share the same
common mechanism.
Fronto-striatal circuits based cognitive tests such as planning,
attention and set shifting are more commonly impaired in PD [2]
and could be associated with ICDs in normal population and in
untreated PD [1]. However cognitive studies focusing on frontal
lobe function alteration in PD with ICDs are controversial.
Santangelo et al., [9] showed executive dysfunction associate to
maladaptive behaviour in PD while Siri et al., [10] found no
differences in frontal lobe functions between gamblers vs. no
gamblers. One possible explanationmay be associated to the use of
Frontal Assessment Battery (FAB), a brief screening instrument
with limited speciﬁcity for dorsal or ventral prefrontal function.
Using a more comprehensive neuropsychological battery, Biundo
et al., [2] showed relatively preserved function in PD-ICDs with the
exception for slower performance in the Trail Making Test B-A
suggesting difﬁculties to maintain goal-directed tasks and
suppress irrelevant responses. Pathological gamblers seem to
have reduced response shifting after losses supporting the
hypothesis of impaired sensitivity to negative reinforces. Other
studies showed visuo-spatial working memory impairment in PD
‘‘on’’ medication with ICDs compared to PD controls [11]. Overall,
these data suggest the involvement of dorsolateral cortico-striatal
network in PD with ICDs as well as the inﬂuence of DA hyper/
hypoconcentration also on this circuit. In non-PD subjects with
ICDs, there is reduced decision-making abilities and executive
dysfunction compared to controls [7]. However, further studies are
needed to clarify the cognitive proﬁle of PD with or without ICDs.
Patients and caregivers should be warned about the risk of
development ICDs at treatment onset and actively questioned on
follow up. Patients with family history for ICBs are at greater risk
and should be followed more accurately. There are limited options
in terms of assessment instruments for ICDs and related disorders
in PD. Some of them investigate the whole ICDs spectrum
[diagnostic criteria from DSM IV TR, the Minnesota Impulsive
Basal Ganglia 2S (2012) e1–e87e24Disorders Interview (MIDI)], others are disorder-speciﬁc screening
instruments used in PD [the South Oaks Gambling Screen (SOGS),
the Buying Questionnaire, a clinician designed hypersexuality
questionnaire, a punding questionnaire, and the Questionnaire for
Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP)].
Thesequestionnaires donot investigate the severity of ICDs but only
the presence/absence of maladaptive behaviors. However assessing
the severity of these behaviors is important. In this regard the
Questionnaire for Impulsive-Compulsive Disorder in Parkinson’s
Disease-Rating Scale (QUIP-RS) has been recently validated and
promises to be a useful tool to establish an optimal diagnostic cut-
off point as well as to monitor changes over time [12].
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compulsivity in drug-naı¨ve patients with Parkinson’s disease.
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Pharmacologic treatment and clinical cases
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The currently available evidence supports the use of choline-
sterase inhibitors in patients with Parkinson Disease Dementia
(PDD), with a positive impact on global assessment, cognitive
function, behavioural disturbance and activities of daily living ratingscales. The effect of these drugs in Lewy body disease remains
unclear.
On the other hand, memantine has been shown to improve
global clinical status and behavioural symptoms and QOL in Lewy
body dementias, while no effect was noticed in patients with PDD.
Pharmacological treatment with clozapine has proved effective
against psychosis in Parkinson’s disease, but is associated to the
risk of agranulocytosis; quetiapine does not require any special
precaution or plasmatic paramentersmonitoring, thus nowadays it
is considered the elective therapy for psychosis in PD; due to safety
issues, olanzapine is not currently employed.
Recently, ziprasidone has been shown to be at least as effective
as clozapine to ameliorate psychotic symptoms in PD in a 4-week,
randomized, single-blind comparison with clozapine; this evi-
dence worth further conﬁrmation, due to the methodological
limits of this study.
As regards non pharmacologic approaches, some studies have
reported improvements in patient performance using cognitive
stimulation programs.
Finally, we should point out the possible positive and negative
effects of dopaminergic drugs on cognitive and behavioral
features: therapy simpliﬁcation, instead of add-on of new
stimulating or sedative drugs, remains the ﬁrst choice approach
for the treatment of neuropsychiatric complications of PD.
References:[1] Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase
inhibitors for dementia with Lewy bodies, Parkinson’s disease
dementia and cognitive impairment in Parkinson’s disease.
Cochrane Database Syst Rev. 2012[2] Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients
with Parkinson’s disease dementia or dementia with Lewy
bodies: a randomised, doubleblind, placebo-controlled trial.
Lancet Neurol 2010; 9: 969 – 77.[3] Schneider LS, Dagerman KS, Insel P. Risk of death with atypical
antipsychotic drug treatment for dementia: meta-analysis of
randomized placebocontrolled trials. JAMA 2005; 294: 1934 –
43.[4] Pintor L, Valldeoriola F, Baille´s E, Martı´ MJ, Mun˜iz A, Tolosa E.
Ziprasidone versus clozapine in the treatment of psychotic
symptoms in Parkinson disease: a randomized open clinical
trial. Clin Neuropharmacol. 2012 Mar-Apr;35(2):61–6.[5] Rand D, Eng JJ, Liu-Ambrose T, Tawashy AE. Feasibility of a 6-
month exercise and recreation program to improve executive
functioning and memory in individuals with chronic stroke.
Neurorehabil. Neural Repair 2010; 24: 722–29.
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Movement disorders: suggestions for a clinical diagnosis
Anna Rita Bentivoglio
Istituto di Neurologia, Universita` Cattolica, Roma
The dystonic movements are jerky, rhythmic, or may be
irregular, slow or fast, but they are structured and always show a
certain repetitiveness; this clinical feature distinguishes the
movement from other dystonic hyperkinesis. Furthermore, the
dystonic movements have a prevalent direction. When dystonia
affects long muscles (trunk, limbs) generally produces a torsional
movement along the major axis.
These aspects are not present in choreic movements, which are
more irregular and give the impression of ﬂowing from onemuscle
to the contiguous ones. Furthermore, some choreicmovementmay
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peculiar of choreic dyskinesias.
The atetosic movement is a distal movement of the limbs.
Myoclonus is fast (shock-like), can be repetitive, intermittent,
or rhythmic, but does not produce twisting. Tics are involuntary
movements, simple or complex (comprising structured
sequences), their phenomenology is very variable: they can be
short and quick as myoclonic jerks (clonic tics), or may result in
prolonged contractions (‘‘dystonic’’ tics). The latter may be
indistinguishable from dystonic movements, whereby the diagno-
sis of tics is renforced when it is noted that: the patient can
voluntarily control the movements, movements are also present
during sleep, and when rapid tics or other features of Gilles de la
Tourette syndrome are evident.
Besides motor tics are, also phonic tics may occur; similarly to
motor tics can be simple (guttural sounds, vocalizations) or
complex (words, phrases).
References:[1] A.Kishore & D.B. Calne. Approach to the patient with a
movement disorder and overview of movement disorders.
Chapter 1. In:Movement Disorders, 2nd Edn. R. L.Watts andW.
C. Koller (editors). Published by McGraw Hill Medical Publish-
ing, Columbus. ISBN 0-07-137496-5[2] Elia AE, Lalli S, Albanese A. Differential diagnosis of dystonia.
Eur J Neurol. 2010 Jul; 17 Suppl 1:1-8. Review. PubMed PMID:
20590801.[3] Ha AD, Fung VS. Huntington’s disease. Curr Opin Neurol. 2012
Aug;25(4):491-8. PubMed PMID: 22772878.[4] A.R. Bentivoglio, R. Di Giacopo. Malattia di Parkinson ed altri
disturbi del Movimento. In: Trattato di Medicina Interna. G.
Gasbarrini. Ed. Verduci. Vol.2, Sez. XVI, Cap. 200. 2010 ISBN 8-
87-6208324-8
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Instrumental and genetic diagnosis
Peter Pramstaller
Centro di Biomedicina, EURAC Research, Bolzano
Hyperkinetic movements represent a group of disorders very
heterogeneous from an etiological, phenotypic and genotypic point
of view. Their diagnosis is often complex, being able to occur both
in isolation or in combination with each other, and requires, in
addition to a proper semeiological classiﬁcation, a series of
diagnostic investigations. They are represented by tremor, dysto-
nia, chorea, myoclonus, and ICT. Since they can be a symptom of
systemic and/or nervous system disorders, the initial phase of the
diagnostic process often requires the exclusion of secondary causes
by mean of both biochemical and instrumental procedures. The
differential diagnosis of primary forms is also often complex, both
because of the wide phenotypic overlap between the various
syndromes, and for the partial etiological knowledge in this ﬁeld. A
key role is represented by molecular biology investigation: many
of these movement disorders have a genetic basis, in some cases
well characterized (Huntington’s disease, some forms of primary
dystonia), in other hypothesized based on the detection of genetic
factors susceptibility (some forms of focal dystonia, Tourette’s
syndrome).Moreover imaging studies play an important role in the
diagnostic workup of hyperkinetic syndromes: functional neuro-
imaging, structural investigations of nuclear medicine and
neurophysiological type can help in the differential diagnosis
between various hyperkinetic syndromes, and they also brought
more knowledge of the pathophysiological basis of this type
disorders.References:[1] Mascalchi M, Vella A, Ceravolo R. Movement disorders: role of
imaging in diagnosis. Journal of magnetic resonance imaging
2012; 35: 239-256.[2] Phukan J, Albanese A, Gasser T, Warner T. Primary dystonia and
dystonia-plus syndromes: clinical characteristics, diagnosis
and pathogenesis. Lancet neurology 2011; 10: 1074-85;[3] Walker FO. Huntington’s disease. Lancet 2007; 369: 218-228.
[4] Robottom BJ, Factor SA, Weiner WJ. Movement disorders
emergencies Part 2: hyperkinetic disorders. Arch Neurol. 2011
Jun;68(6):719-24.
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Iperkinetic movement disorders: treatment
Paolo Del Dotto
U.O.C. Neurologia, Ospedale Versilia, Az. USL12, Viareggio (Lucca)
The most common hyperkinetic movement disorders are
represented by L-dopa induced dyskinesias, choreic sindromes,
particularly Huntigton’s disease, tardive dyskinesias and dystonias.
L-dopa-induced dyskinesias in advanced Parkinson’s disease
are the prevailing hyperkinetic disorders in clinical practice. Early
therapy with dopamine agonists is associated with delayed
appearance of these complications. Once dyskinesias develop,
dopaminergic treatment manipulation can be made (L-dopa dose
reduction and dopamine dose increase). Amantadine, an NMDA
receptor antagonist, is so far the only approved compound with
evidence of providing a sustained antidyskinetic beneﬁt, support-
ing the hypothesis of glutamate overactivity in the development of
L-dopa induced dyskinesias. More continuous delivery of dopami-
nergic medications, such as through intestinal (Duodopa) or
subcutaneous route (apomorphine), has been associated with less
dyskinesias. New nondopaminergic agents, particularly glutamate
and A2A adenosine antagonists, have shown promising antidyski-
netic effects in early clinical trials, but long-term safety, tolerability
and efﬁcacy studies are still required. In most severe cases deep
brain stimulation of subthalamic nucleus usually is able to
dramatically abate the severity of dyskinesias.
Choreic movements associated with Huntington’s disease and
tardive dyskinesias are treated with classic and atypical neuro-
leptics. Recently, tetrabenazine, a reversible dopamine depleting
agent that is highly selective for the central vesicular monoamine
transporter type 2 (VMAT2), has been aprroved for the treatment of
these disorders. Sometimes, amantadine can also be beneﬁcial.
Currently, there are no known treatment that can reverse the
course of primary dystonia. However, symptoms may usually be
managed with a combination of treatments, such as atypical
neuroleptics and botulin toxin. Surgical treatment, particularly
deep brain stimulation of the globus pallidus, is another option to
consider in more severe cases.
References:[1] Elahi B, Phielipp N, Chen R. N-methyl-d-aspartate antagonists
in levodopa induced dyskinesia: a meta-analysis. Can J Neurol
Sci. 2012;39:465-72.[2] Gottwald MD, Aminoff MJ. Therapies for dopaminergic-
induced dyskinesias in Parkinson disease. Ann Neurol.
2011;69: 919-27[3] Chen JJ, Ondo WG, Dashtipour K, Swope DM.Tetrabenazine for
the treatment of hyperkinetic movement disorders: a review of
the literature. Clin Ther. 2012; 34:1487-504[4] Kartha N. Therapeutic challenges in dystonia. Neurol Clin.
2010;28:927-40
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Pathophysiology and mangement of dysphagia in Parkinsonian
symndromes
Enrico Alfonsi, D. Fontana
Unita` Operativa di Neuroﬁsiopatologia del Territorio, Istituto Neuro-
logico Nazionale, IRCCS ‘‘Casimiro Mondino’’, Pavia
Epidemiologic studies show that dysphagia is present in about
53-54% of patients with Parkinson’s Disease (PD). This frequency is
alsounderestimatedasneurogenicdysphagia is observed inquiteall
patients in late phases of the disease. Dysphagia can be showed by
clinical examination or as subjective complaints in these patients.
Occasional investigations used to explore the deglutition as the
ﬁberoptic endoscopic evaluation of swallowing (FESS), the video-
ﬂuoroscopy (VFS), themanometry, or the recent electromyographic/
electrokinesiographic investigation of swallowing can reveal
abnormalities responsible for dysphagia in PD. In about 15-20% of
PD patients without clinical ﬁndings of dysphagia radiological (VFS)
signsof inhalationhavebeenobserved.Dysphagia severity is related
to illness duration In PD. In these patients dysphagia appears most
frequentlyatabout10th-11thyearsofdisease. Theonsetofdysphagia
is clearly different among the parkinsonian syndromes. This aspect
couldbe veryuseful since dysphagia appears very early, at about3-4
years from the onset of illness, in parkinsonian syndromes as
multiple system atrophy (MSA), progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), Lewy-body disease (LBD).
Latency of dysphagia is related to survival in all parkinsonian
syndromes. Most of the pathophysiological abnormalities related to
the oral phase of swallowing (voluntary phase) can be related to
typical symptoms of the parkinsonian syndromes due to dysfunc-
tion of sensory-motor integration as bradykinesia, hypokinesia,
rigidity, and start hesitation. In the early phase of the disease these
alterations are not yet able to cause dysphagia. Early swallowing
abnormalities in PD can be corrected, almost in part, by L-Dopa and
dopamine agonists. When pathophysiological mechanisms involve
automatic/reﬂexive phases of deglutition (pharyngeal and esoph-
ageal phases) this therapybecomes ineffective. In this case logaoedic
treatments with adequate nutrition, selective treatments as
botulinum toxin injected in the upper esophageal sphincter,
myotomy of the cricopharyngeal muscle or, most deﬁnitively, the
percutaneous endoscopic gastrostomy (PEG) could represent
effective therapeutic options.
References:
[1] Barer. J Neurol 1989;52:236-241.
[2] Bird et al. Age Ageing 1994;23:251-254
[3] Muller et al. Arch Neurol (2001);58:259-264
[4] Pfeiffer, Lancet Neurology (2003), 2: 107-116.
[5] Baijens and Speyer. Dysphagia (2009), 24:91–102
[6] Alfonsi et al. Neurology (2007), 68: 583-590
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Malabsorption and movement disorders
Paolo Stanzione
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gata’’, Rome
L-dopa (LD) orally administered, is absorbed by the neutral
amino acid transport system at duodenal level.The gastric environment including: gastric motility, ph,
inﬂammatory disease of gastric mucosa, amount and quality of
food present in the gastroduodenal tract, may substantially affect
of amino acid as well as L-dopa absorption.
Afterwards the cross of the blood brain barrier may be a second
variable inﬂuencing the kinetic of L-dopa arrival to the cerebral
tissue. The cross is regulated by neutral amino acid transport
system as well.
From the clinical point of view reduction, delay, or any other
change in the modalities of L-dopa transition through these two
barriers is not evident in the initial stage of the disease. Intracellular
storage capacity of residual dopaminergic terminals may largely
buffer thepossible reductionor lackof transitionof a single doseof L-
dopa from the intestine to the brain tissue. The large storage allow
the dopamine to be released when necessary from the intracellular
vesicles replete by previous L-dopa administrations. Thus in early
stage a prolonged L-dopa treatment may still improve motor status
after more than 15 days of withdrawal. Disease progression further
reduces surviving dopamine ﬁbres thus reducing or nullifying
storage capacity. At this stage all factors able to affect the single dose
absorption may affect motor performance during the day/night
cycle. At this stage food (mainly protein food) in the gastroduodenal
tract, may produce motor effect preventing the absorption of the
single dose necessary to maintain an adequate level of L-dopa/
dopamine at brain level. This is the classic after lunch lack of effect of
L-dopa dose very often observed in advanced PD patients, if an
adequate diet is not observed. Apart from food in the gastro-
duodenal tract, inﬂammatory conditions of stomach or duodenum,
such as those produced by helicobacter pylori infection, may also
substantially reduce L-dopa absorption independently from the food
impact. Treatments able to eradicate inﬂammatory conditions, such
as those due to helicobacter pylori, have been demonstrated to
improveof about20% theAUCafter L-dopaadministration.Theeffect
is time locked and proportional to inﬂammation disappearance.
L-dopa solubility is maximal at 2-3 of ph. Treatment or
conditions reducing gastric acidity may negatively affect L-dopa
absorption. In particular treatment reducing gastric ph through
proton pump inhibitors may double affect L-dopa absorption:
through pump inhibition and through ph increase.
Gastroduodenal motility is also essential in order to let L-dopa
progress from the stomach to the duodenum where it is absorbed.
Intestinal motility is affected by disease itself so that constipation
is a very common feature of the disease. Dopaminergic stimulation
of intestinal autonomic system further reduce intestinal motility
further reducing transition of L-dopa from stomach to duodenum.
A correct treatment for constipationmay also help to obtain amore
constant L-dopa absorption.
References:[1] Pierantozzi et al. Neurology 2006; 66: 1824-1829.
[2] Lee et al. Mov Dis 2008; 23(12): 1696-1700.
[3] Nutt JG Mov Dis 2008; 23 Suppl. 3: S580-S584.
[4] Travagli et al. Ann. Rev. Physiol. 2006; 68: 279-305.
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Nutrition and Dementia
Alessandra Nicoletti
Dipartimento G.F. Ingrassia, Sezione di Neuroscienze Universita` di
Catania, Catania
The prevalence of dementia in theWestern world is about 1% in
individuals aged 60–64 years, but shows an almost exponential
increase with age. Alzheimer’s disease (AD) is the most frequent
neurodegenerative dementia in the elderly, and it is probably due
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factors. Epidemiological studies have identiﬁed several environ-
mental risk factors potentially associated with the development of
AD such as low educational, ipercholesterolaemia, hypertension,
atherosclerosis, coronary heart disease, smoking, obesity, diabetes
and malnutrition, while APOE 4 allele thought to account for most
of the genetic risk.
Recently there are growing evidences concerning the possible
role of dietary factors in the development of AD and the age-related
cognitive decline. In particular, several epidemiological studies
suggest that the risk of AD may be reduced in people with a high
dietary or supplemental intake of antioxidant vitamins such as
vitaminEandCoromega-3 fattyacids. Similarly, lowserum levels of
vitamin B12, vitamin C, folic acid, folate as well as hyperhomocys-
teinaemia have been associated with an increased risk of AD [1].
Epidemiological evidences concerning the possible role of
nutritional factors are also supported by animal studies showing
that administration of polyunsaturated fatty acids, uridine
monophosphate (UMP) and choline increases the level of
phosphatides, speciﬁc pre- or post-synaptic proteins and the
number of dendritic spines – a requirement for new synapse
formation [2-3]. This multi-nutrient approach in animals has also
shown to decrease amyloid beta protein (Ab) plaque burden, to
improve learning and memory through increased cholinergic
neurotransmission and to have a neuroprotective effect in several
mouse models of AD. Similarly, in vitro cell-culture studies have
shown that both vitamin E and C can inhibit Ab deposition,
neuronal cell death and apoptosis [4].
Although several evidences support the association between
nutrition and cognitive status, the relevance of nutritional factors
in AD has not been extensively studied to date and only few clinical
trials using nutritional approaches in AD have been performed
reporting conﬂicting results.
Current treatment options offer often only symptomatic relief,
however, there is a growing body of evidence that nutritional
intervention may be able to play a key role in the management of
the disease. However, randomized clinical trials are needed to test
this approach.
References:[1] Ramesh BN, Rao TS, Prakasam A, Sambamurti K, Rao
KSNeuronutrition and Alzheimer’s disease. J Alzheimers Dis.
2010;19(4):1123-39[2] Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff
G. Synaptic proteins and phospholipids are increased in gerbil
brain by administ ring uridine plus docosahexaenoic acid
orally. Brain Res 2006; 1088: 83–92.[3] Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation
with docosahexaenoic acid and uridine-5’- monophosphate
increases dendritic spine density in adult gerbil hippocampus.
Brain Res 2007; 1182: 50–59.[4] Yatin SM, Varadarajan S, Butterﬁeld DA. Vitamin E prevents
Alzheimer’s amyloid beta-peptide (1-42)-induced neuronal
protein oxidation and reactive oxygen species production. J
Alzheimers Dis 2000; 2: 123–131.
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Hereditary ataxias
Alessandro Filla
Department of Neurological Sciences, Federico II University, NaplesWe have recently proposed a pathogenic classiﬁcation of
hereditary ataxias (HA) in ﬁve main categories: 1. mitochondrial;
2. metabolic; 3. impaired DNA repair; 4. impaired protein folding
and degradation, 5. channelopathies. Other pathogenic mecha-
nisms have been recently recognized. Mitochondrial ataxias can
be caused by mutations in nuclear DNA (Friedreich Ataxia;
MItochondrial Recessive Ataxia Syndrome; Infantile Onset
Spinocerebellar Ataxia; Autosomal Recessive Cerebellar Ataxia
2) or inmitochondrial DNA (Myoclonus Epilepsywith Ragged Red
Fibers; Neuropathy, Ataxia, and Retinitis Pigmentosa). Metabolic
ataxias can be intermittent or progressive. They can be caused by
hereditary disorders of the urea cycle, aminoacids, pyruvate,
vitamin E and lipid metabolism, liposome and peroxysomal
disorders. Ataxias associated with impaired DNA repair may be
separated in ataxias caused by impairment of single strand break
repair (Ataxia with Oculomotor Apraxia; Spinocerebellar Ataxia
with Neuropathy 1; xeroderma pigmentosum; Cockayne syn-
drome) or double strand break repair (ataxia telangiectasia [AT];
AT-like disorder; possibly Ataxia with Oculomotor Apraxia 2).
Ataxias associatedwith abnormal protein folding anddegradation
include ataxias caused by abnormal chaperones (Autosomal
Recessive Spastic Ataxia of Charlevoix-Saguenay; Marinesco-
Sjo¨gren), by mutations in PRNP gene (Gerstmann-Stra¨ussler-
Scheinker disease) or by expanded CAG triplet sequence. An
expanded CAG encoding for poliglutamine sequence is responsi-
ble for SCA1–3, 6–7, 17. This is the most common cause for
Autosomal Dominant Spinocerebellar Ataxias. Channelopathies,
involving Ca and K channels, may cause episodic ataxias which
have dominant transmission and early onset (Episodic Ataxia 1–
2). Other possible causes of HA include RNA toxic gain of function
(Fragile X-associated Tremor Ataxia Syndrome); endonnabinoid
pathway (Polyneuropathy, Hypoacusia, Ataxia, Retinitis Pigmen-
tosa, Cataract); opioid pathway (SCA23); structural proteins and
vescicular trafﬁcking (SCA5; Autosomal Recessive Cerebellar
Ataxia 1; Salih ataxia); transglutaminases (SCA35); tau phos-
phorilation (SCA11).
References:[1] Arnheim M.Tranchant C, Koenig M. The autosomal recessive
cerebellar ataxias. N Engl J Med 2012;366:636-46.[2] De Michele G, Coppola G, Cocozza S, Filla A. A pathogenetic
classiﬁcation of hereditary ataxias: is the time ripe? J Neurol.
2004;251:913-22.[3] Durr A. Autosomal dominant cerebellar ataxias: polyglutamine
expansions and beyond. Lancet Neurol. 2010;9:885-94.[4] Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia
and the structure and function of frataxin. J Neurol. 2009;256
S1:9-17.[5] Klockgether T, Paulson H. Milestones in ataxia. Mov Disord.
2011;26:1134-41.
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Imaging of ataxias
Mario Mascalchi
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Imaging techniques including computed tomography (CT),
magnetic resonance imaging (MRI) and spectroscopy (MRS), single
photon emission computed tomography (SPECT), and positron
emission tomography (PET) have been widely applied to the
investigation of patients with acute or chronic ataxias. Fundamen-
tally, CT has a role in the emergency evaluation of the patient with
acute ataxia to ascertain brainstem or cerebellar hemorrhage and
Basal Ganglia 2S (2012) e1–e87e28to exclude a mass lesion in the posterior cranial fossa.
Conventional MRI is the most frequently performed imaging
investigation in patients with ataxia. It can support the diagnosis
of acute cerebellitis and Wernicke encephalopathy by revealing
T2 signal changes with a typical distribution. In patients with
inherited or sporadic chronic ataxia it reveals three fundamental
patterns of atrophy of the brainstem, cerebellum, and spinal cord
which match the gross neuropathological descriptions. These are
represented by olivopontocerebellar atrophy (OPCA), cortical
cerebellar atrophy (CCA), and spinal atrophy (SA). A substantial
correspondence exists among these patterns of atrophy shown
by MRI and the etiological classiﬁcation of inherited or acquired
chronic ataxias. This, along with demonstration of T2 signal
changes characteristic of some diseases, makes conventional MRI
potentially useful for the diagnostic work-up of the single
patient, especially in the case of a sporadic disease. MRS and non-
conventional MR techniques including diffusion MR and func-
tional MR have been used in patients with acute or chronic
ataxia, but their exact role in the evaluation of the single patient
is not yet established. They are currently investigated as
potential tools to monitor progression of neurodegeneration in
chronic ataxia and to serve as ‘‘surrogate markers’’ in clinical
trials. Several radiotracers have been utilized in combination
with SPECT and PET in patients with ataxia. Perfusion SPECT can
reveal cerebellar blood ﬂow abnormalities early in the course of
cerebellitis. It has also been utilized to investigate perfusion of
the brain in several inherited or sporadic chronic ataxic diseases,
contributing to improved understanding of the pathophysiology
of these conditions. Recently, perfusion SPECT has been tested as
a ‘‘surrogate marker’’ to verify the effects of newly developed
therapies in patients with a variety of chronic ataxias. Whole-
body FDG-PET is recommended in patients with suspected
paraneoplastic cerebellar degeneration to detect the primary
malignancy. Brain FDG-PET has provided important information
on the pathophysiology of several acquired and inherited
conditions. PET and SPECT with radiotracers able to assess the
nigrostriatal system or the density of D2 dopamine receptors in
the striatum are increasingly used in patients with adult-onset
sporadic ataxia for the differential diagnosis between multiple
system atrophy in which overt striatal abnormalities are found
and idiopathic late-onset cerebellar ataxia in which no abnor-
mality is detected.
References:[1] Mascalchi M et al. MR spectroscopy of the cerebellum and pons
in patients with degenerative ataxia. Radiology 2002; 223:371-
378.[2] Mascalchi M, Vella A. Magnetic resonance and nuclear
medicine imaging in ataxias. Handbook of Clinical Neurology
2012;103:85-110[3] Ginestroni A, et al. Neurodegeneration in Friedreich’s ataxia is
associated with a mixed activation pattern of the brain. A fMRI
study. Hum Brain Mapping 2011 Jun 14. doi: 10.1002/
hbm.21319. [Epub ahead of print]
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Pisa, Pisa
Hereditary spastic paraplegias (HSP) are a heterogeneous
group of neurological disorders. Insidiously progressive spastic
weakness of the lower extremities is the common criterion in allforms described. Clinically, HSP is differentiated into pure
(uncomplicated) and complex (complicated) forms. Whilst pure
HSP is predominantly characterized by signs and symptoms of
pyramidal tract dysfunction, additional neurological and non-
neurological symptoms occur in complicated forms. Autosomal
dominant, autosomal recessive, and X-linked pattern of inheri-
tance have been described and at least 50 subtypes, termed SPG1-
50, have been genetically deﬁned. Although in autosomal
dominant HSP families 50–60% of etiologies can be established
by genetic testing, genotype predictions based on the phenotype
are limited with a high degree of intrafamilial variability and
reduced penetrance. Autosomal recessive forms appear to be
more heterogeneous and single forms fairly stereotyped in clinical
terms.
We offer an overview on clinical, neurophysiologic, and
neuroradiologic characteristics of themore commonHSP subtypes.
For quick reference, we also propose a laboratory strategy to help
clinicians in prioritizing genetic testing.
COURSE ‘‘Functional assessment and program objectives in reha-
bilitation physiotherapy: what problems to which patients with
Parkinson’s disease?’’
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Parkinson disease is not a motor disturbance only
Giovanni Fabbrini
Dipartimento di Neurologia e Psichiatria, Sapienza, Universita` di
Roma, Roma
Parkinson’s disease is characterized by rest tremor, bradyki-
nesia, rigidity and postural instability. Recently it has become clear
that non motor symptoms are also very frequent in parkinsonian
patients. Some of these symptoms such as hyposmia, depression,
constipation and REM behavior disorders may antedate the
appearance of the typical motor signs. Non motor symptoms
more frequently complicate the advanced phases of the disease.
The most important non motor symptoms are: sleep disturbances
(excessive daytime somnolence, sleep attacks, insomnia, para-
somnias), neuropsychiatric disturbances (anxiety, depression,
hallucinations, psychosis, impulse control disorder), cognitive
disturbances (changes in executive functions, dementia), vegeta-
tive disturbances (urinary disturbances, constipation, sexual
dysfunction, orthostatic hypotension) and sensory disturbances
(particularly pain). Some nonmotor disturbances are related to the
dopaminergic deﬁcit (for example, motor disturbances during
sleep), some are adverse events of the treatment (for example
impulse control disorders) and others are the consequence of the
degeneration of other neurotrasmettitorial systems (for example,
depression, dementia). A better knowledge of non motor
symptoms is important for a complete assessment of patients
with Parkinson’s disease.
References:[1] Chaudhuri KR, Healy D.G, Schapira AHV. Non-motor symptoms
of Parkinson’s disease: diagnosis and management. Lancet
Neurol 2006; 5:235-45[2] Adler CH. NonMotor Complication in Parkinson’s disease. Mov.
Disord. 2005; Suppl 11; S23-S29.[3] Schrag A. Psychiatric aspects of Parkinson’s disease. J Neurol
2004 251: 795-804.[4] Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in
Parkinson’s disease: prevalence, phenomenology and risk
factors. Brain 2000;123:733-745
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Themultidimensional assessment of rehabilitation for the clinical
complexity of Parkinson’s disease: new perspectives?
Simone Cecchetto
Azienda ULSS 5 Ovest Vicentino, Arzignano (Vicenza) and Corso di
Laurea in Fisioterapia, Universita` di Verona, Verona
The rehabilitation of patients with Parkinson’s disease (PD)
presents various aspects and levels of complexity. The physio-
therapy process, as important part of the rehabilitative process,
also reﬂected inside this complexity.
According to Systems theory, the patient is interpretable as a
complex adaptive system. The various methods and schools of
physiotherapy have developed over the years different models
of interpretation, that is partial and simpliﬁed representations of
reality, through which they interpreted from different points of
view of the complexity of patient-oriented and consequently the
rehabilitation treatment. It is felt the need to overcome the
fragmentation of knowledge in rehabilitation, by building a
conceptual framework and models of clinical reasoning to
enable the sharing of language and experience between
professionals, both within the physical therapy profession, both
with other disciplines. The International Classiﬁcation of
Functioning Disability and Health (ICF) proposed by the
WHO can contribute concretely to respond to this need. It
propose a systematization of the body Structures and Functions
and the actions and the interactions that a person can do,
assessed in a standard environment (Activities), such as the
rehabilitation gym, or in the context of the patient’s life
(Participation).
It is interesting the distinction between ‘‘Capacity’’, as indicator
of the component Activities, and ‘‘Performance’’, as indicator of the
component Participation. Capacity describes functioning of the
person in a standard setting, without barriers or facilities; the
capacity is an intrinsic characteristic of the person and it express
what a person can do, regardless of the environment. The
Performance describes functioning of the person in involvement
in a life situation (home, work, etc.); the performance expresses
what the person can actually do in their life contexts and depends
on the impact that environmental factors have on the functioning
[2].
In this context, it is possible to deﬁne the physical therapist (PT)
aims primarily to an improvement in capacity by reducing the
functional impairments resulting from the PD; however, since the
ultimate goal is to maximize the Social Participation of a person,
the PT should carefully consider, in collaboration with other
multidisciplinary team members, as environmental factors affect
the levels of performance, in order to plan appropriate interven-
tions on these elements.
The adoption of the perspective proposed by the ICF suggests
that the PT ‘‘widens the look’’ beyond the simple motor aspects,
usually regarded as the only ﬁeld of functional impairments of
patients with MP of physiotherapist’s interest, but also to
cognitive, emotional and environmental factors. In particular,
attention to environmental factors could be useful whenever
barriers in the environment are not explicitly reported or it may
not achieve a reasonable level of performance [3]. This allows to
highlight aspects not considered such as the relationship between
MP and ability to work, not usually regarded by the common scale
for assessing disability in MP [3].
This assessment is a multidimensional process that does not
exhaust its importance in early sessions but it’s present in all
phases of physical therapy process. They can be divided into:
physiotherapy evaluation, which aims to quantify and describe,through various strategies, patient’s functional impairments,
activity limitations and participation restriction; physiotherapy
diagnosis, aimed to suggest and describe the causal relations
between elements of interest detected in the patient, in order to
plan properly sequencing of therapeutic interventions; physiother-
apy prognosis and planning of the goals, with associated outcome’s
indicators, which are based, as well as on the physiotherapy
diagnosis and prognosis, also on patient expectations and on
structural, temporal and cultural available resources; selection and
implementation of interventions of functional rehabilitation,
compensation, education and secondary/tertiary prevention,
based on evidence; monitoring and verifying the achievement of
goals through the outcome indicators revaluation at deﬁned
intervals.
Multidimensional assessment of each element may acquire
different meanings: central role is taken by the identiﬁcation, in
that patient, of the critical aspects that can be modiﬁed through a
physiotherapy intervention. Next to them, other elements will be
interpreted as predictors of functional recovery or as factors
inﬂuencing physiotherapy intervention. Other elements will be
interpreted as risk factors for deterioration of critical aspects
interesting in physiotherapy and their assessment will be needed
to plan interventions for secondary prevention. Still others,
ﬁnally, as the expectations of the patient and their family
members and related psycho-emotional impairments, should
be considered when formulating the objectives of the physio-
therapy program [4].
For example, a large systematic review [1] found that
depressive symptoms and abilities in performing activities of
daily life, have a high correlation with the quality of life,
while weak correlations were found with aspects usually consid-
ered crucial such as postural instability, gait abnormalities,
dyskinesia, bradykinesia, tremor, cognitive impairments. These
weak correlations seem to support the need for an individualized
multidimensional evaluation aims to identify, or at least to
suppose, the causal relations that exist between the restrictions
of the participation, levels of activity in a standard environment,
environmental factors and functional impairments (motor and non
motor) that the MP has led in that particular patient.
Based on ICF, on scientiﬁc contributions of the different
physiotherapy schools and techniques, and new ﬁndings in the
literature, particularly on issues of cognitive problems of PD and
the impact of MP on the levels of social participation, we can deﬁne
an interpretative framework of the complexity of the patient,
aiming to systematize the complexity of physiotherapy, to lead the
physiotherapist in evaluation, plannig and implementing phases of
the rehabilitative process and to facilitate possible future research
in different areas so far unexplored.
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Evaluation process for physical therapy in Parkinson’s disease
(PD) is very important, in order to assess its severity and patient’s
health problems, which can be correlated to and lead to
considerable disability. Designing treatment programs could be
rather complex, because of considerable variation across individ-
uals with PD in their movement disorders, as well as variations of
motor performance over time.
Indeed M.E. Morris [1] believes that assessment becomes
mandatory in order to understand the extent to which physical
therapy can inﬂuence patient’s motor behavior, while designing a
rehabilitation program, tailored to changing needs of patients and
their caregivers, because of disease progression. In her model for
physical therapy of people with PD, in addition to establish the
importance of stadiation (HY), she emphasizes the necessity to
consider and be able to recognize speciﬁc symptoms: rigidity,
bradykinesia, tremor, balance disorders and postural control,
dyskinesia, freezing episodes.
Dutch Guidelines for physical therapy in patients with
Parkinson’s disease (2004) provide useful indications to assess
physical impairments such as physical ability, transfers, body
posture, reaching and grasping, balance and gait. Anyway, taking
medical history is considered an essential starting point, in order to
better understand this pathology, related to very individual
symptoms. Patients’ interview is also the ﬁrst step to deﬁne
quality of care according to the model of patient-centered
healthcare, even if, despite individual effort of professional
caregivers, it is far to be implemented in clinical practice.
Especially in PD this model is important to attend disease
complexity and not only motor, but cognitive and emotional
worsening of patients.
In the Netherlands, M. Van der Eijk [4] showed that data, from
focus group patients and caregivers interviews, underline their
necessity to be emotionally supported from healthcare profes-
sionals and desire to be actively involved in choices concerning
their treatment.
In the same study, another relevant ﬁnding was the perceived
lack of multidisciplinary collaboration between healthcare provi-
ders and expecially insufﬁcient expertise of physical therapists in
assessment and treatment of patients, as showed in other studies.
Cultural and psychosocial limitations for care providers (low level
of knowledge of disease and technical skills) and for patients (low
level of information about opportunity to apply for rehabilitation
and prejudices on exercise efﬁcacy) represent a barrier for
improvement of assessment and taking charge of subjects and
implementation of guidelines.
Through a questionnaire aimed to develop quality indicators for
physiotherapy, submitted to expert and general physiotherapists,
M.J. Nijkrake et al [2,3] showed a great difference between groups,
both for use of PD speciﬁc outcome measures and for speciﬁc
rehabilitation interventions (cueing or cognitive movement
strategies).
Therefore medical history is of great importance to set patients’
treatment expectations and outcomes and could be a good help to
develop quality indicators for a tailored rehabilitation program,
sometimes difﬁcult to design, because of pathology complexity
and of different symptoms appearance across patients. Moreover,
shared outcomes, deﬁned in the very early phase of rehabilitation
program, let patients be able to constantly verify their changes.Indeed, in physical therapy, it is increasingly necessary to
consider subjective outcome measures too. In 2009, the authors of
a study proposed a different Patient-Speciﬁc-Instrument version in
Parkinson’s disease (PSI-PD), recommended by Dutch guidelines. It
consisted of three different sections, where ﬁrst, patients must
select most relevant limitations based on a predeﬁned list, as well
as one self-report item. Then patients rank their selected items in
order of importance and rate the severity of the ranked items on a
Numeric Rating Scale from 0 to 10. The study showed that PSI-PD is
a valid and reliable instrument, able to detect limitations in daily
living activities and to be very helpful in designing proper physical
therapy intervention in Parkinson’s disease patients.
Objective outcome measures, always reliable and valid instru-
ments to evaluate rehabilitation intervention, sometimes are not
speciﬁc for Parkinson’s disease patients. Therefore it could be
necessary to use some clinical tests aside, able to underline some
peculiar disease aspects. For example, in assessing Freezing of Gait
(FOG) we can use a standard gait trajectory, with possible
circumstances that may provoke FOG, like walking while crossing
a door or another narrow space, full turning 3608, or walking while
performing a dual task.
In order to design a rehabilitation program, physical therapist
must be able to detect even other non motor symptoms of the
disease. We need to take into account cognitive impairments and
analyse patient’s behavior during functional tasks, to identify
speciﬁc treatments.
Because of promising evidences about use of Action observation
and Motor Imagery during exercise, we should consider patients’
ability of Motor imagery performance, especially during the ﬁrst
stage of disease, when they still have effective chances of motor
learning. Some questionnaires, based on visual-analogue scales,
could represent reliable tool to assess ability in Parkinson’s patients.
Moreover it is essential to assess changes on movements in
response to medication, concurrent pathologies, secondary adap-
tive changes in musculo-skeletal and cardiovascular system,
environment and quality of life.
Therefore evaluation of these patients results in a quite long
process, often impossible to be fully concluded in the same session.
It is deﬁnitely necessary for physiotherapists to consider opinions
and requests of patients and their caregivers as fundamental
assessment steps, in order to improve quality and efﬁcacy of
physical therapy intervention.
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In 1967 Hoehn and Yahr [1] developed the simplest clinical
scale to assess Parkinson’s disease (PD) severity, based upon on the
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involvement with no or minimal disability (stage 1) to
conﬁnement to wheelchair or bed (stage 5). In a modiﬁed form,
it is still the most commonly used discriminative scale to depict
the course of the disease and to group patients samples for
comparisons. Though reliable and valid, however, this scale has
poor sensitivity to changes, therefore it is inadequate to be used
as an evaluative scale to assess the effectiveness of interven-
tions. Over the years a number of clinical rating scales have been
developed for this aim, mainly focusing on the core signs of
rigidity, tremor, bradykinesia and postural instability [2]. To
tackle the variability between clinical scales, a standardized
scale was developed in 1987 [3] by a committee in order to
produce a uniﬁed measurement tool. This instrument, named
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS), is a composite
of different pre-existing tools and comprises four sections
(mental status, activity of daily living, motor signs, complica-
tions of drug therapy), besides a modiﬁed Hoehn-Yahr staging
system and a disability scale. The UPDRS is the most frequently
used scale in drug trials for PD [4] and together with the most
recent version, the MDS-UPDRS (Movement Disorders Society-
Uniﬁed Parkinson Disease Rating Scale) [5], is currently
considered the ‘‘gold standard’’ tools for assessing the severity
and the advancement of the disease [6].
However, the potential impact of PD on individuals is very
wide and encompasses a number of problems not directly
addressed by clinical scales, e.g. fear of falling or lack of social
support. Moreover, there is increasing support concerning the
importance of assessing outcomes from the patient’s perspective
[7]. For example, both the presence and severity of Freezing of
Gait (FOG) episodes are likely more accurately evaluated when
reported by patients rather than judged by a rater. Conversely,
for disability assessment the opposite may be true, since many
external (e.g. caregivers support) or internal (patient’s insight)
factors may inﬂuence patient’s judgement [8]. When PD patients
were asked to rate their disability, they were found to
underestimate it in the early stages of the disease and to
overestimate it in the advanced stages [9]. In that case,
performance tests (i.e., directly observed, standardized tests of
functional ability) may offer information not accurately provided
from self-reported ratings [10].
The use of the UPDRS as the only primary outcome measure in
trials aimed at verifying the efﬁcacy of physiotherapy for PDmight
also be questioned for the reason that such interventions, unlike
drugs, usually focus on speciﬁc functional limitations and have no
effect on neurological signs like tremor, rigidity or dyskinesias.
Therefore the UPDRS should be conveniently associated to other
measurement tools more focussed to functions that are the
primary targets of rehabilitation.
Several physical therapy rehabilitation core areas have proven
to be efﬁcient in PD. Among these, four areas have reached ‘‘level
2’’ practice recommendations [11]: 1) use of visual or auditory
cueing strategies to improve gait, 2) application of cognitive
movement strategies for improving transfers, 3) speciﬁc balance
exercises associated with muscle strengthening to improve
postural control, 4) join mobility and power training associated
with task-oriented exercises to improve physical capacity. From
these data it is evident thatmuch effort has been directed towards
investigating the effectiveness of exercises and training programs
aimed at improving lower limb functioning, such as gait and
transfers.
When rehabilitation focuses on gait and gait-related activi-
ties, the UPDRS should be used together with one or more of the
following performance measures: the Short Physical Perfor-
mance Battery (SPPB) [12], the Timed-Up and Go (TUG) [13], theFunctional Reach (FR) [14], the Berg Balance Scale [15]. All these
measures, though originally developed for assessment of older
people, have been repeatedly employed in PD. However, the
measures differ in terms of tasks and scoring system, therefore
the choice must rely upon the speciﬁc aim of the intervention.
For example, the BBS and the FR focus exclusively on balance,
whereas the SPPB comprises three tasks (gait speed, balance
and repeated chair stand) that are all commonly affected in PD.
A self-reported measure of freezing, the Freezing of Gait
Questionnaire (FOGQ) [16], should also be employed when
exercises are aimed at attenuating the frequency and the
severity of FOG episodes. Recently, the FOGQ was found to be
reliable and more sensitive than the corresponding item of the
UPDRS for detecting freezing and assessing the effect of
treatment [17].
Upper limb functioning is also affected in PD. Though the
effectiveness of speciﬁc upper limb interventions in patients with
PD has not been extensively evaluated, limited evidence exists that
PD patients can improve the speed of arm movement through
practice [18,19]. When the physiotherapy treatment aims at
improving manual dexterity and arm functioning a suitable
outcome measure should be selected among performance mea-
sures like the Purdue Pegboard Test (PPT) [20] or other tests using
similar apparatus. The PPT has been used to compare manual
dexterity in PD and healthy controls [21] and was found to be able
to detect the effect of medications [22].
Finally, a complete evaluation of outcomes of interventions in
PD, as in any chronic disabling disease, should include a measure
able to detect the impact on perceived health-related quality of life.
Though generic health statusmeasures have been also successfully
employed, the current opinion is that generic measuresmay be not
as sensitive as speciﬁc measures to detect the impact on health
quality of a speciﬁc disease[7]. Among the speciﬁc instruments for
PD, the Parkinson’s Disease Questionnaire (PDQ-39) [23], has been
extensively validated and at present is considered the most
appropriate tool [24].
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Despite considerable progress in biomedicine, Parkinson’s
Disease (PD) is a chronic disease that involves progressive
disability. Drug therapy has changed the natural history of patients
and ensures the same life expectancy of the general population.
However, the absence of a causal treatment and the presence of
dopamine-resistant symptoms (freezing, postural instability and
non-motor symptoms, like cognitive dysfunction), justify the use
of non-pharmacological therapeutic approach, in different stages
of disease, to ensure recovery and functional independence. In fact,
even with best medical therapy, patients are faced with progres-
sive activity limitations and participation restrictions in the
domestic and social life.
To date, a growing number of scientiﬁc evidence has pointed
out, also on experimentalmodels, the potential beneﬁts of physical
therapy intervention in the MP. However indications about the
best model of treatment (i.e. type of exercises) and the dosing
timing (when to start and how long to continue) are still lacking.
Therefore it is necessary to question on the mechanisms under-
lining the basis of the exercise efﬁcacy. First we need to deﬁne
correct rehabilitative hypothesis through an up to date knowledge
of altered motor control process at the basis of the symptoms and
mechanisms of re-learning new skills. Applying physiological
concepts to rehabilitation becomes essential prerequisite of
effective intervention.
Which should be the exercise characteristics in Parkinson’s
Disease? In 2000 Morris described a theoretical framework
supporting the use of physical therapy in PD. The model was
based on the pathophysiology of movement disorders in basal
ganglia disease, on scientiﬁc evidence and on personal observa-
tions of physical therapy interventions in PD. Converging data from
the scientiﬁc literature suggest that the patient with PD is able to
realize themovementwith the focus of attention to the task (use of
task ‘‘goal directed’’ vs. habitual movements). The use of external
stimuli (cues visual, auditory, tactile) and the anticipated
preparation of successive movements also with cognitive facilita-
tion strategies (Motor Imagery, Action observation) would bypass
the insufﬁcient production of internal stimuli from basal ganglia.
Use of task-speciﬁc strategies has a double meaning: compensa-
tory movement strategies (to bypass the defective basal ganglia)
and learning strategies to improve performance through practice.
Their efﬁcacy and use are still related to the presence of cognitive
impairment and then designed in different ways in relation to
different stages of disease.
Another key issue for planning the rehabilitation treatment for
patients with PD is the answer to the following question: patients
with Parkinson’s disease can re-learn motor skills through exercise?
Studies in experimental models of PD suggest possible existence of
regenerative mechanisms mediated by exercise and learning.
Increasing evidence underlines the efﬁcacy of motor rehabilitation
in MP, also if the acquisition of new skills requires more exercise.
However, the short duration of beneﬁt raises doubts about the
integrity of the learning mechanisms in patients with PD. From
meta-analysis of Nieuwboer on ‘‘behavioral studies’’, while
emerging a certain maintenance of acquisition capacity of new
skills in these patients, their learning process is characterized by a
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increased dependence on the environment). Therefore it gets
important consequences in physiotherapy program. Patients may
beneﬁt from new treatments with functional relevant goals, more
ecological and with a reinforcement effect due to sensory
information, with frequent references helping retention.
However if learning new skills remains the ﬁrst goal of
rehabilitation, we must not forget the management of secondary
adaptive changes that affect the musculoskeletal system after the
onset of a process of ‘‘learning non use’’. Reduced physical activity
being present however in early stages, requires constant preven-
tion of complications. Finally, a third rehabilitation objective is an
education program aiming to develop patients’ ability to recognize
and manage their altered movement and their necessity to
maintain a constant physical activity. Thus, the physical therapist
needs to shift his role from being a ‘‘coach’’ to a role of ‘‘consultant’’
as the patients takes on the responsibility of his motor activity.
Planning physical therapy treatment. A tailored rehabilitative
program in subjects with MP is a tricky challenge. Disease shows a
multifaceted progressive course, whose severity and clinical
manifestation vary across individuals a lot and especially over
time. However, the rehabilitation program is primarily based on
some general principles Rehabilitation process should be tailored to patients (according
to stage, disease course, clinical condition, effects of drug
therapy, cognitive impairment, co-morbidity) based on their
needs and of their caregiver. In planning rehabilitation objectives, active participation of
patients and their family is strictly required. Changes in motor performance, ADL (Activities Daily Living) and
QoL (quality of life) should be measured after treatment through
speciﬁc outcome measures. Rehabilitation must have the continuity of a long term care
despite different context conditions and intensity of treatment.
It is essential to answer with different rehabilitation programs,
according to quality process indicators, to such a complexity of
problems, as proposed by the Dutch Guidelines for Physical
Therapy in patients with Parkinson’s disease (2004) and several
authors (Keus 2007). In the model proposed, three phases in the
course of the disease were identiﬁed, early (HY 1 to 2.5), middle
(HY 2–4) and late (HY 5) in which the six ‘‘core’’ areas of
physiotherapy intervention (transfers, balance, walking, posture,
reaching and manipulation) have to be declined.
Many authors identify the early stage (HY 1 to 2.5) as a key
moment for the rehabilitative treatment (as a secondary preven-
tive care) due to more effective learning opportunities and
maintenance of correct motor patterns. Cognitive strategies such
as Motor Imagery and Action observation could ﬁnd a more
effective use in the maintenance of complex functions such as
walking and postural control. Prevention of inactivity and
improvement of physical capacity should be guaranteed already
at this stage. Even a sport, without fatigue, stress and competition,
can provide good integrity of the musculoskeletal and cardiovas-
cular system. Increasing evidence of the literature emphasizes
activities efﬁcacy, such as dance (tango) and tai chi, in maintaining
motor function. In this early phase the educational objective is to
inform the patient and his caregiver about the disease and how to
manage future complications for a better patient’s self control over
the disease process.
In themiddle phase (HY2–4) physiotherapy treatment is always
planned aiming to facilitate learning and therefore the mainte-
nance of proper motor performance through compensatory
movement strategy to bypass altered fronto striatal control.
Different rehabilitation approaches are proposed in literature.Cueing (e.g auditory to improve gait cadence also in dual task
condition, visual to change stride length) and treadmill training
with or without cues, are current best practices. Motor Imagery
and Action observation are a new challenge in physical therapy,
also in this phase. Aim of cues and cognitive strategies is to
maintain gestures ‘‘goal directed’’ even at home reducing
multitasking, especially in more advanced stages. Prevention of
falls is proposed as an indicator of adequate therapeutic process in
this phase. Using a diary of falls is an important tool.
Aim of treatment at this stage is to ensure the best
musculoskeletal condition as a prerequisite for using alternative
strategies as reported in the literature.
Caregivers should always learn use of cues, for encouraging
patient’s active cooperation. Use of aids need to be supervised.
Their efﬁcacy may be compromised by their own use, because of a
dual task condition. The target of the last phase (HY5) is
rehabilitation ‘‘nursing’’ at home and at hospital. It is a key tool
in order to maintain the best patient’s active collaboration in
changing pattern of movement in activities of daily living.
Clinical experience in stroke indicates that training effects
highly depend on the intensity of physical therapy, both in terms of
frequency and duration of treatment. However, in Parkinson’s
disease we are not able to provide indicators about best treatment
frequency and duration yet, despite many studies. The proposed
newmodels of ‘‘chronic-term care’’, whosemerits are supported by
evidence for other chronic neurological disorders, could be an
interesting research ﬁeld.
References:[1] Morris ME. Movement disorders in people with Parkinson
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(6):578-97[2] KNF Guidelines for physical therapy in patient with Parkinson
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Munneke, PT, PhD, Evidence-Based Analysis of Physical
Therapy in Parkinson’s Disease with Recommendations for
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DuringDeep Brain Stimulation (DBS) procedure, it ismandatory
that the recognition of the target to neurostimulate it is identiﬁed
by the best degree of patient collaboration, and thus is performed
Basal Ganglia 2S (2012) e1–e87e34while the patient is awake. This proceduremay need long time and
it result very stressfull for the patient that is awake, fasting and
24 hours off-medication. On the other side, it is needed the best
degree of collaboration to reach the best postsurgery outcome. For
this reason, we decide to try to reduce the intraoperatory stress, by
preparing the patient to the surgery, by a virtual immersion on
each single step of the procedure. In this video we report a case of a
person with Parkinson’s disease (PD), who performed the Virtual
Deep brain stimulation (VDBS), which reproduces in 3-D all the
real stages of the intervention by the exact view of the patient.
Sounds, voices and times of the operating room are lived in an
immersive session, by simulating the operating bed position. We
videoregistered the surgery scenario by a double prospective:by an
external moving camera and by a microvideocamera mounted on
glasses of the patient himself.
The simulating session includes the same stress conditions of
the real one, so that the patientwill perform it in the earlymorning,
after an overnight fasting without assuming breakfast, and a drug
withdrawal of 12 hours. During the simulation some clinical
parameters are noted down, such as blood pressure, heart
frequency, glucose blood level, skin temperature, oxygen satura-
tion that are continuously updated in a dedicated display. This, by
mean of a biofeedback approach, may affect the control of the
stress of the virtual surgery scene.
We believed that this tool will signiﬁcantly reduce the
intraoperatory stress of the patient, improving his collaboration
and thus the outcome of the intervention.
References:[1] Anthony E. Lang, M.D., and Andres M. Lozano, M.D. Parkinson’s
Disease. N Engl J Med 1998; 339:1130-1143 October 15, 1998.[2] Appleby BS, Duggan PS, Regenberg A, Rabins PV (2007).
‘‘Psychiatric and neuropsychiatric adverse events associated
with deep brain stimulation: A meta-analysis of ten years’
experience’’. Movement Disorders 22:1722–1728.[3] Ferroli P, Tringali G, Acerbi F, Aquino D, Franzini A, Broggi G.
Brain surgery in a stereoscopic virtual reality environment: a
single institution’s experience with 100 cases.Neurosurgery.
2010 Sep; 67.
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Background and Objectives: Pure tone audiometry testing (PTA)
have been evaluated in patients with Parkinson’s disease (PD) with
conﬂicting results. We have recently demonstrated age-dependent
peripheral, unilateral or bilateral hearing loss in PD patients by
means of PTA. PTA provides only a partial picture of the patient’s
auditory status and gives no information about patient’s ability tohear and understand speech. To ﬁnd out hearing ability and speech
discrimination of PD patients, we expanded audiologic evaluation
by means of Speech Audiometry (SA). Speech Test are currently
used in clinical practice in order to: 1) check the validity of pure
tone audiometry; 2) determine speech discrimination; 3) establish
rehabilitation needs; 4) determine the site of lesion of the hearing
impairment (central vs peripheral).
Patients and Methods: 40 consecutive patients with clinical
diagnosis of PD were screened. Severity of motor symptoms and
stagingweremeasuredwith theUniﬁed Parkinson’s Disease Rating
Scale (section III) and the Hoehn and Yahr scale. Audiometric
evaluation consisted of a comprehensive audiologic case history
and questionnaire, visual otoscopic examination, acoustic immit-
tance measures (tympanogram and acoustic reﬂexes), pure tone
and speech audiometry. Healthy age- and sex-matched subjects
were selected as control group.
SA is a technique where standardized samples of language are
presented through a calibrated system in order to measure some
aspects of hearing abilities. The speech material may be presented
monaurally or binaurally, live voice or by using a recording. There
are lists of words that have been devised for this purpose
(Monosyllabic words, Disyllabic words, Paired words, Sentences
with key words). A performance intensity (PI) function (i.e. the
discrimination score achieved at a number of different intensity
levels [dB]) is plotted on a graph. If the speech discrimination
reaches a maximum point and then gets worse as the intensity is
increased this shows rollover phenomenon and points to central
more than peripheral site of hearing dysfunction.
SA of both patients and controls were compared with their own
PTA according to Fletcher’s equation (PTA + 20 = SRT 100%;
SRT = Speech Reception Threshold is deﬁned as the intensity
[dB] at which simple speech material, usually can be detected 50%
of the time).
Results: 32/40 patients were enrolled (18 M e 14 F; average age
68 ys), 8 were excluded because of middle ear disease. PTA
conﬁrmed our previous ﬁnding of age-dependent high-frequency
hearing loss in PD patients as compared with both normative
values and healthy age- and sex-matched controls (p = 0.005 and
p < 0.001, respectively).
Conclusion: Our results conﬁrmed an age-dependent, sensori-
neural hearing loss in PD patients as compared with healthy
subjects. Moreover, SA showed impaired speech discrimination in
PD patients as compared with control group. Increased tonal-vocal
dissociation together with a weak rollover phenomenon suggest a
peripheral more than central origin of hearing impairment in PD
patients. The ﬁnding that a-synuclein is located predominately in
the cholinergic efferent neuronal system within the inner ear
(basal inner hair cell) raises the possibility that its dysfunction
might interfere with cochlear transduction mechanisms thus
promoting speech discrimination impairment in PD patients.
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Introduction: Impulse Control Disorders (ICDs) are behavioural
complications of PD triggered by dopaminergic medication. STN
Basal Ganglia 2S (2012) e1–e87 e35DBS is an effective treatment for advanced PD which allows great
reduction of dopaminergic medication. To date the data regarding
the relationship between ICDs and STN DBS are unclear as both
resolutions and de novo-onsets were reported after implant.
Aim: We aimed to observe the outcome of ICDs in a group of PD
patients after three years of continuous STN stimulation.
Methods: We followed a group of 37 PD patients in whom
detailed assessment of ICDs was carried out at baseline and after
three years of STN stimulation. The difference between baseline
and follow-up prevalence of ICDs was calculated. At follow-up
patients with ICDs and patients without ICDs were compared
based on demographical and clinical features. Further, among the
patients with ICDs at baseline we compared those who resolved
ICDs and those who did not.
Results: After three years of STN stimulation motor improve-
ment (60%) and dopaminergic medication reduction (50%) was
observed. At baseline 40% of patients had ICDs. At follow-up the
prevalence decreased to a non-signiﬁcant 32%. The 16% of patients
resolved their symptoms and the 8% of patients reported a de novo
onset after implant. PD patients with ICDs at follow-up took an
higher baseline dopamine agonist dose compared to patients
without ICDs after implant. Such difference was conﬁrmed
comparing patients who resolved their behavioural symptoms
with thosewho did not.We found an association between a history
of hypomania and the occurrence of ICDs.
Conclusion: In keeping with previous ﬁndings we observed
both resolutions and new-onsets of ICDs after implant. The
dopamine agonist dose before the surgery and a history of
hypomania seem to be predictors of the ICDs outcome. We
recommend the routine pre-operative neuropsychiatric assess-
ment and we emphasize the importance of post-operative
neuropsychiatric monitoring.
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Introduction: The recent literature emphasizes the impor-
tance of a multidisciplinary approach in the rehabilitation
treatment of Parkinson’s disease (PD)[1,2]. In 2011, our centre
recruited 98 patients with PD for the rehabilitation treatment.
We proposed a rehabilitation approach that provides for the
application of at least two types of individual/group treatment
for each patient and a evaluation at the beginning and end of
treatment.
Objective: The aim was to evaluate the efﬁcacy and tolerability
of a multidisciplinary rehabilitation approach in patients with PD.
Methods: 98 patients were examined before and after the
treatment by a physician. The following scales were assessed:
UPDRS I-IV, BBS, FAC, WHS, Tinetti, TUG. A total of 80 patients
(mean age 72  8 y) took part in the multidisciplinary rehabilitation
program; 18 patients were unable to participate. The rehabilitation
treatments were: individual and/or group physiokinesi (phy-t) and
hydrokinesi (hyd-t) therapy, music-therapy, individual and/or group
speech therapy, massages, cognitive stimulation group. Two treat-
ments could take place on the same day. In particular, for the group
approach it was necessary to separate patients in homogeneousgroups with respect to the severity of PD, in this manner, for each
group were assigned exercises compatible with the motor resources
of patients (5 groups; duration: 10months). Themain programwas: 5
months of phy-t alternating hyd-t (biweekly) and 5months of music-
therapy (once a week).
Results: The data did not show signiﬁcantly changes of the
clinical features, in particular we observed the absence of
worsening of typical signs and symptoms such as rigidity,
bradykinesia, balance etc.
Conclusions: Most patients has been able to adhere and
complete the program. We observed that, in a program that
provides more hours of treatment in a day, the ‘‘on fase’’ is crucial
to the success of the session, otherwise the patientmay experience
difﬁculty in endurance and performance.
References:[1] van der Marck MA et al., Multidisciplinary care for patients
with Parkinson’s disease, (2009) Parkinsonism Related Dis-
orders, 19-23.[2] CarneW. et al, Efﬁcacy of multidisciplinary treatment program
on long-term outcomes of individuals with Parkinson’s disease,
(2005); Journal of Rehabilitation Research & Development,
779-86.
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Introduction: Non-motor symptoms (NMS), including psychotic
symptoms, fatigue and sweating, afﬂict up to 98% of patients with
Parkinson’s Disease (PD). In contrast to motor ﬂuctuations, NMS
related to wearing off (WO) are poorly researched.
Objective: In an Italian sample of PD patients, to report
occurrence of NMS in relation to the presence of WO.
Methods: We performed an observational cross-sectional study,
involving 37 movement disorders clinics across Italy, recruiting
634 consecutive ambulatory non-demented PD patients, who had
been under dopaminergic agents for at least one year. Clinicians
administered the NMS scale (NMSS), composed by 9 NMS domains
and a total score ranging 0-108 (no-severe NMS).WOwas assessed
both by the neurologist as well as by the patients using the self-
administered Italian validated version of the 19-items WO
Questionnaire (WOQ-19), 10 items of which regard non-motor
symptoms; WO was deﬁned for scores > 2.
Results: NMSS was ﬁlled in by 568 patients. WO was diagnosed
by neurologists and by self-assessed WOQ-19 > 2 in 57% and 67%
of patients, respectively (p 5 years NMS score was signiﬁcantly
higher in patients withWO. The score in PDwith > 10 year disease
was 47.4 (35.5) in subjects with vs. 39.4 (27.9) in those without
WO. There was a signiﬁcant difference in the pattern of NMS
severity between patients with and without WO based on
neurologist or patient evaluation. WO was associated with worse
sleep/fatigue, pain, urinary function and excessive sweating if the
WOwas evaluated by the neurologist. Based on patients self-rating
the symptoms reported to be worse in association with WO were
fatigue and mood.
Basal Ganglia 2S (2012) e1–e87e36Conclusions: NMS are more severe in patients affected by WO.
Fatigue is the symptombest associatedwithWO irrespective of the
assessmentwhilemood changesmay be perceived as expression of
WO mainly by patients. These results may help predict NMS that
aremost likely to improve as consequence of therapeutic strategies
aimed at controlling WO.
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Background: Anecdotical cases of subacute peripheral neuropa-
thies (PN) have been reported during treatment with levodopa/
carbidopa intestinal gel (LCIG) infusion.
Clinical case: Here we describe a 69 year-old Parkinson’s
disease (PD) patient who developed a subacute PN four months
after the start of Duodopa infusion. The subject was affected by
PD for 13 years at the time of surgical selection and he was
taking a levodopa equivalent daily-dose of 1440 mg/day. An
accurate clinical and electrophysiological assessment was
performed before the placement of Duodopa enteral tube,
excluding signs of PN. Duodopa infusion was then started with
good clinical results on the main PD cardinal symptoms, until
the patient developed a subacute sensory-motor PN four months
later. The electrophysiological assessment revealed prolonged
distal motor latencies, motor nerve conduction blocks in both
peroneal and ulnar nerves and reduced sensory and motor nerve
conduction velocities in the range of demyelination. No
alterations were found in homocysteine and vitamine B12
plasmatic levels or in the cellular and protein cerebrospinal ﬂuid
levels.
Duodopa treatment was interrupted and the patient switched
back to oral dopaminergic therapy with a supplementation of Vit
B1, Vit B12 and folate. A partial recovery of symptoms was
observed after onemonth, although only a slight improvementwas
observed at the electrophysiological evaluation performed two
months later.
Conclusion: Several hypotheses have been proposed to explain
the pathogenesis of LCIG-related PN, including a vitamin adsorb-
tion deﬁciency or immune-mediated reactions. However, the
underlying mechanisms still remain unclear and further prospec-
tive clinical studies are therefore required.
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Introduction: Patients with focal hand dystonia present
cognitive abnormalities of motor control such as impairment inthe temporal discrimination between tactile stimuli and in pure
motor imagery tasks, such as mental rotation of corporeal and
inanimate objects. However, only limited information is available
on the ability of patients with dystonia to process the time-
dependent features (speed and duration) of movement in real
time. This topic is quite relevant, since the processing of time-
dependent features of movement has a crucial role in predicting
whether the outcome of a complex motor sequence, such as
handwriting or playing a musical passage, will be consistent with
its ultimate goal, or results instead in an execution error. In this
study we evaluated the ability to perceive the temporal outcome
of different movements in a group of patients with focal hand
dystonia.
Methods: Subjects (14 patients and 17 healthy subjects, age and
gender matched) were asked to predict the end of visually
perceivedmovements, either of a body segment (handwriting, that
is the action that speciﬁcally engages the human body segment
speciﬁcally affected by dystonia) or of an inanimate object (a
moving circle reaching a spatial target). Further, we also included a
non-movement-related task of temporal reproduction into the
paradigm as control task. All tasks have been programmed using a
dedicated software (E-Prime 2.0).
Results: Results showed that the accuracy of the performance on
biological motion temporal processing was lower in patients with
focal hand dystonia than in controls, whereas no difference was
detected on inanimate object motion temporal processing and on
temporal reproduction.
Conclusion: Our ﬁndings could be explained by an alteration of
the writing movement representation at a central level and nicely
ﬁt in the idea that dystonia is not a pure motor problem, but
involves sensory and cognitive aspects related to movement
processing and planning.
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Myoclonus with rash and hyperalgesia during fever treated with
ceftriaxone: cephalosporin-induced neurotoxicity?
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We describe the clinical case of a young man (24 years) with
history of fever treated from the 5th day with ceftriaxone 1 g im.
After a few minutes administration of antibiotic therapy, he
developed rash, itchiness, altered mental state, myoclonus,
asterix, ataxia and diffuse hyperalgesia. Ceftriaxone was discon-
tinued.
First clinical evaluation revealed blood monocytosis, mild
alterations of coagulation tests, mild lymphadenopathy and
splenomegaly. Renal function was normal. Mono test for diagnosis
of mononucleosis was negative.
Cerebrospinal ﬂuid analysis was normal. No neurotropic virus
was detected. Brain MRI showed hyperintensity in T2/FLAIR
sequences of claustrum and external capsule bilaterally; there was
not enhancement after the intravenous administration of a
gadolinium-based contrast material. Spine MRI was normal. EEG
showed slow semiperiodic activity. After administration of
gabapentin neurological symptoms and EEG activity progressively
improved.
Patient was also treated with steroid. One month later brain
MRI follow up was normal and patient complained exclusively
very mild hyperalgesia. Our patient was a young healthy man who
developed hyperlagesia and myoclonus after the appearance of
fever. The incipient clinical picture, with fever preceding the onset
of movement disorders, and detection of monocytosis, alterations
Basal Ganglia 2S (2012) e1–e87 e37of coagulation tests, mild lymphadenopathy and splenomegaly,
could suggest an infective aetiology, but cerebrospinal ﬂuid
analysis was normal and we failed to ﬁnd any infective agent.
Patient received a brief treatment with ceftriaxone. It is known as
cephalosporins may cause neurotoxicity syndrome with myoclo-
nus, altered mental state, asterix, EEG alterations and sometimes
coagulation deﬁcit. Our patient also complained rash and
itchiness, symptoms close related to reactions drug adverse.
Further, the favourable answer to treatment with gabapentin
could conﬁrm this hypothesis. However, patient was also treated
with steroid and, in our knowledge, at present there were not
report of MRI alterations of basal ganglia related to cephalospor-
ins toxicity.
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Introduction: A positive levodopa responsiveness is one of the
required criteria for a deﬁnite Parkinson’s disease (PD) diagnosis.
Acute levodopa or apomorphine drug challenges have been
proposed to quickly diagnose PD or parkinsonisms. However,
due to the relatively few and heterogenous studies with a follow-
up usually less than one year, the usefulness of an acute
dopaminergic challenge test for the diagnostic workout of PD is
still matter of debate.
Aim of our study was to evaluate sensibility, speciﬁcity and
predictive value of acute dopaminergic tests to identify PD
patients in a clinic setting population followedup for a long period
of time.
Materials and methods: 226 consecutive patients (M/F: 136/
90; age: 58 + /- 10yy) with denovo parkinsonian syndrome were
evaluated at baseline with acute L-dopa or apomorhine tests or
both. The patients were subsequently followed-up for at least 5
years for a ﬁnal reliable diagnosis. The UPDRS motor component
and the tapping test were used to evaluate the acute
dopaminergic response. Apomorphine s.c. was administered at
the dose of 50 mg/kg with clinical evaluations every 10 minutes
for 2 hours. Acute levodopa test was performed at the dose of
250 mg p.o. with clinical evaluations every 20 minutes for
4 hours.
Results: 159 acute levodopa tests and 131 apomorphine tests
were performed; 64 patients underwent both tests. After an at
least 5 year follow-up an established diagnosis of PD was made in
141 patients. The sensitivity for the diagnosis of PD was:
apomorphine 0.94, levodopa 0.91, and both 0.92. The speciﬁcity
values were: apomorphine 0.79, levodopa 0.76, and both 0.94. The
positive predictive value was: apomorphine 0.95, levodopa 0.90,
both 0.97. The predictive negative value was: apomorphine 0.76,
levodopa 0.68, both 0.79. No statistical signiﬁcant differences were
found between groups (patients tested with apomorphine,
levodopa, and both). Side-effects were signiﬁcant more present
in the apomorphine group.
Conclusion: Acute challenge tests either with levodopa or
apomorphine help in the diagnosis of PD with equivalent
sensitivity and speciﬁcity. The acute levodopa administration
resulted in less side-effects. Therefore, in the clinical practice it
may be preferred.SC10
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Introduction: Recent reports suggested that Parkinson’s disease
(PD) patients may present clinical and/or neurophysiological
features of polyneuropathy. However, a deﬁnitive conclusion could
not be reached on the role of levodopa (LD) as a risk factor for
neuropathy.
Methods: A multicentre study of a large sample of PD patients
(n = 330) and age-matched controls (n = 137) was performed,
stratifying the PD population according to duration of LD exposure:
144 patients had LD exposure longer than 3 years (LELD), 103
patients had LD exposure shorter than 3 years (SELD), and 83
patients no exposure to LD (NOLD). Nerve function was evaluated
by the reduced total neuropathy score. Right sural sensory
antidromic and peroneal motor nerve conduction was measured
by a neurophysiologist blinded to the subject’s condition.
Results: 1940% LELD patients, 680% SELD, 482% NOLD, and
876% controls were diagnosed with neuropathy (axonal, predom-
inantly sensitive). Multivariate logistic analysis indicated that the
risk of neuropathy was not inﬂuenced by disease duration
(p = 091; OR = 101), UPDRS III (p = 0.20; OR = 1.02), gender
(p = 025; OR = 164). The risk of neuropathy increased by about
8% for each year of age (p < 0001; OR = 108; CI 1037–1128).
Conclusion: Our results demonstrate that both the duration of
exposure to LD and its daily dose, along with age, are the main risk
factors for the development of neuropathy. Periodical homocyste-
ine and vitamin B12 screening, and clinical-neurophysiological
monitoring for neuropathy may be advisable in PD patients
receiving LD treatment.
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Introduction: Parkinson’s disease (PD) patients exhibit over
disease course a complex impairment of speech, ranging from a
hypokinetic to a hyperkinetic dysﬂuent type (also labeled as
stuttering).
Objective: Aim of the present study is to deﬁne the phenome-
nology of speech disorder in PD in different disease stages and to
Basal Ganglia 2S (2012) e1–e87e38clarify which clinical variables are correlated to stuttering
dysarthria.
Methods: Forty-ﬁve consecutive patients with Parkinson’s
disease according UK Parkinson’s Disease Society.
Brain Bank criteria were recruited. Demographical and clinical
features were collected and the following clinical evaluations were
performed: UPDRS, Hoehn-Yahr (HY) staging, New Freezing of Gait
Questionnaire (NFQQ), PDQ-8. Neuropsychological assessment of
executive functions was carried out. Speech was evaluated in its
motor and procedural component respectively with the Italian
version of the Dysarthria Proﬁle (DP) and the screening battery for
aphasia (SBA). DP is a scale composed of 7 sub-sections assessing
the following features of speech. Intellibility/rate/prosody section
of DP is composed of sub-scores investigating presence of
stuttering. Patients were categorized according to the stability
of their drug response (stable responders = 22; complicated
PD = 23).
Results: articulation (DP part V), intellibility, rate and prosody
(DP part VI) were signiﬁcantly lower in patients with HY > 2
compared to HY < 2 (p < 0.001), independently by co-occurrence
of motor complications. Sub-section prosody of DP correlated with
NFGQ score (p < 0.0001); indeed, more severe FOG was associated
to worst prosody/rate and intellibility of speech. This correlation
was not inﬂuenced by disease duration. None of the sub-scores of
SBA was more impaired in PD patients according to disease stage,
duration and occurrence of motor complication, excepted for
phonemic and categorical ﬂuency (decreased in more advanced
disease stages).
Conclusions: our data suggest that stuttering speech disorder in
PD is a marker of disease progression and is strongly correlated
with presence of FOG, possibly sharing common pathophysiologi-
cal mechanisms.
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Treatment-responsive and non-responsive freezing of gait in Par-
kinson’s disease and relationship with Wearing Off: results from
the DEEP study
M. Amboni1, Paolo Barone2, F. Stocchi3, G. Abbruzzese4, M. Attar5, D.
Colombo5, A. Antonini6 on behalf of DEEP study group.
1IDC Hermitage-Capodimonte, Napoli
2School of Medicine, University of Salerno, Salerno
3IRCCS San Raffaele Pisana, Roma
4Universita` degli Studi di Genova, Genova
5Novartis Farma Italia S.p.A., Origgio (VA)
6IRCCS Ospedale San Camillo, Venezia
Introduction: Freezing of gait (FOG) is a paroxysmal event
during which patients feel their feet glued to the ground. FOG is
frequent in patients with advanced Parkinson’s disease (PD), and
has been found in up to 26% of early stage PD patients. Little is
known about the actual prevalence of FOG in the outpatient
setting, given the clinical variability and its unpredictable nature.
Objective: To estimate the prevalence of FOG, and its relation to
the presence of Wearing-Off (WO) symptoms in PD.
Methods: We performed an observational cross-sectional study,
involving 37 movement disorders clinics across Italy, recruiting
634 consecutive ambulatory non-demented PD patients, who had
been under dopaminergic agents for at least one year. The
clinicians administered the FOG Questionnaire and asked the
patient whether FOG was treatment-responsive (FOGOFF), non-
responsive (FOGONOFF), drug-induced (FOGON), and never
present (NOFOG). WO symptoms were identiﬁed by the validated
Italian version of the Wearing-Off Questionnaire (WOQ-19); WOwas deﬁned for scores2. Furthermore patients were assessed
with UPDRS, Non-Motors Symptoms Scale (NMSS) and Parkinson
Disease Questionnaire (PDQ-8).
Results: 599 patients were evaluated for FOG: NOFOG patients
were 46%, FOGOFF and FOGONOFF patients were 33% and 20%,
respectively. Six patients had FOGON. WOQ-192 was found in
49% of NOFOG patients, in 71% and 93% of FOGONOFF and FOGOFF
patients, respectively. Mean (SD) UPDRS part I score was 1.7 (1.7)
in NOFOG patients vs 2.9 (2.1) and 2.4 (2.0) in FOGONOFF and
FOGOFF, respectively (ANOVA’s p < 0.0001). Different UPDRS part
II, III and total scoreswere found betweenNOFOG and FOGpatients
(ANOVA’s p < 0.0001). Presence of FOG correlated with disease
duration, H&Y stage, NMSS and PDQ-8 score.
Conclusions: As compared to FOGOFF, FOGONOFF was associat-
ed with higher UPDRS part I scores. FOG signiﬁcantly correlated
with WO, non-motor symptoms, and worse quality of life.
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The Hybrid Bike Project: an innovative exercise for Parkinson’s
Disease patients
G. Grazzi1, Eva Bernardi1, S. Uliari1, G. Mazzoni1, E. Groppo2, E. Cesnik2,
I. Casetta2, G. Granieri2, M. Manca3, E. Granieri2
1Centro Studi Biomedici applicati allo Sport Universita` di Ferrara,
Ferrara
2Sezione di Clinica Neurologica, Dipartimento di Discipline Medico-
Chirurgiche della Comunicazione e del Comportamento, Universita` di
Ferrara, Ferrara
3Laboratorio Analisi del Cammino, UO di Medicina Riabilitativa,
Azienda Ospedaliera Universitaria di Ferrara, Ferrara
Introduction:Many studies have shown the beneﬁcial effects of
physical activity on brain health and function. However, the
association between physical activity and chronic neurodegenera-
tive diseases is less well established, particularly for the better
‘‘dose’’ of exercise prescription. It has been recently documented
that an active and assisted tandem cycling (Forced Exercise) can
provide signiﬁcant improvements in motor and central nervous
system function in patients with Parkinson’s Disease (PD).
Aim: To compare the effects of an innovative Active-Assisted
cycling exercise (AAE) and of a usual Voluntary Exercise (VE) on
clinical and functional parameters in PD patients.
Methods: 24 patients with mild-to-moderate PD will be
randomly assigned to an 8-wks exercise intervention of AAE or
VE training: three 1-h sessions weekly (10 min: warm-up, 40 min:
main exercise and 10 min: cool-down). Patients in VE group will
train on a traditional electromagnetically braked cycle ergometer
at a pedalling cadence of 60 rpm. The AAE subjects will train at
30% to 40% higher pedalling rate on an electric motor-driven
bicycle (Hybrid, Carrera-Podium, Italy), clamped to an electro-
magnetic roller (Realaxiom CT, Elite, Italy), simulating real outdoor
cycling. Both groups will exercise at similar aerobic intensities.
Cardiorespiratory ﬁtness, Uniﬁed Parkinson’s Disease Rating Scale,
body acceleration, dynamic gait index, and Quality of Life (QoL 36)
questionnaire, will be assessed before and after training. In order to
evaluate the long-term effects of AAE, clinical testing will be
performed four and eight weeks after cessation.
Expected Results and Conclusion: Cycle exercise at higher
pedaling cadence would improve training effects on motor and
central nervous system function. These data could help in the
deﬁnition of the optimal exercise prescription for neurologic
patients. From a practical point of view, AAE is an easy, safe,
relatively low-cost and could be used by specialized center and for
home program.
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GPI DEEP brain stimulation 8 years after STN DBS: cases report
Ilaria Bertaina1,2, A. Fasano3, B. Minafra1,2, N.G. Pozzi1,2, D. Servello4, R.
Zangaglia1,2, C. Pacchetti1,2
1Parkinson’s Disease and Movement Disorders Unit, National Insti-
tute of Neurology Foundation ‘‘C. Mondino’’, Pavia
2Interdepartmental Research Center for Neurodegenerative Disease,
National Institute of Neurology Foundation ‘‘C. Mondino’’, Pavia
3Department of Neurology Catholic University, Rome
4Functional Neurosurgical Unit, IRCCS ‘‘Galeazzi’’, Milano
The main targets for deep brain stimulation (DBS) in advanced
Parkinson’s disease (PD) are the subthalamic nucleus and the
globus pallidus interna. Anyway the most source of information
about the efﬁcacy of this procedure came from STN DBS and there
are limited data to resolve the debate on the comparison between
GPi and STN DBS. The long-term follow-up of STN DBS patients
shows that the improvement of motor complications are main-
tained, while freezing, postural instability, falling, cognitive and
speech difﬁculties are the major source of disability. Nevertheless
the information emerging from latter studies, some patients
manifest a motor disease progression need increasing of dopami-
nergic therapy after many years of STN DBS. We describe three PD
patients who underwent STN DBS with good clinical outcome and
in whom GPi DBS has been done as ‘‘rescue therapy’’ after 8 years,
in order to manage the disease progression. This procedure was
performed after various and unsuccessful adjustments of dopami-
nergic therapies and STN DBS parameters. Two years after GPi
surgery, the patients’ motor condition did not present any
considerable change in terms of total score of the motor section
of the UPDRS. However, GPi DBS led to a substantial improvement
of motor function due to the reduction of dystonia and dyskinesias,
especially in two of our patients. In these patients, painful
dystonias disappeared andmotor ﬂuctuationsmarkedly improved.
In our cases GPi-DBS, performed 8 years after STN DBS, could still
improve persistent dyskinesias and dystonia leading to a global
clinical improvement with no need to increase the dopaminergic
therapy. Our experience expands the current knowledge on the
management of these patients.
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Rehabilitation of the cognitive impairment in Parkinson’s disease
Liana Bestavashvili, S. Ippolito, M.F. Ioni, E. Volpe, R. Ricci, I. Clemenzi
Department of Neurological Rehabilitation, San Raffaele Portuense,
Rome
Almost all patients with Parkinson’s disease (PD) suffer from
selective cognitive impairments, including attention deﬁcits,
concentration impairment, problem solving, impaired executive
function and memory. We have elaborated a cognitive rehabilita-
tion protocol speciﬁc for the PD patients.
The aim of this study was to evaluate the improvement of the
cognitive impairment in PD and observe if there is any correlation
with the drug therapy. We observed 36 patients with mild
cognitive impairment who received the cognitive treatment
according to our protocol using selected exercises for the impaired
cognitive functions peculiar for PD. All patients received 40
individual training sessions of 45 min duration. All of them
underwent a neuropsychological testing before and after treat-
ment and evaluation by UPDRS.
The drug therapy of our patients: 19 patients took levodopa (L-
DOPA) and rotigotine (4-6 mg), 8 patients L-DOPA and ropinirole(4-8 mg prolonged release), 5 patients L-DOPA and pramipexole
and 4 patients only L-DOPA. The patients mean age was between
65-75 years old with min-max 6-10 years of PD duration. We did
not consider patients with severe concomitant diseases, which
could limit cognitive performances, as well as patients with a
second neurodegenerative disease.
Our evaluation in discharge showed improvements in the
following areas: memory, attention, concentration and executive
function. We have also noticed that patients with rotigotine and
ropinirole therapy had the better outcome in various cognitive
areas, 15 patients with rotigotine therapy improved memory,
attention and concentration, 2 patients improved attention and
short term memory, other 2 patients did not demonstrate any
beneﬁt. 6 patients with ropinirole improved memory and
attention, other 2 patients improved only short term memory.
Further studies are needed to conﬁrm the preliminary
experience and verify the long term effects after the cognitive
treatment.
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Motor Decision-Making in Parkinson Disease
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Human daily life is a chain of decisions that are modulated by a
variety of environmental factors and intrinsic contexts. It has been
proposed that normal decision-making requires coordinated
activity within a wide variety of brain areas and neural networks
that includes also the frontostriatal and limbic loops, and basal
ganglia (Gleichgerrcht et al., 2010). For this reason, Parkinson’s
disease (PD) has become a popular model for studying decision-
making mechanisms. Indeed, signiﬁcant impairment in making
proﬁtable decision were obtained when PD patients performed
tasks involving explicit decision-making as the Iowa Gambling
Task (Pagonabarraga et al., 2007). Mazzoni et al. (2007) tested the
unconscious decision-making processes adopted by the motor
system during movement planning showing that patients’ reluc-
tance to move faster in absence of physical constraints might
represent an implicit decision due to a distortion of speed selection
mechanisms caused by dopamine deﬁcit. Aiming to more deeply
investigate the principles that govern motion planning in PD
patients we applied theManifold Reaching Paradigm (MRP - Berret
et al., 2010) on a group of eight PD patients (age = 68.1  10.7;
UPDRSIII = 20.2  10.9) and eight healthy age-matched controls
(age = 69.1  2.3). In a sitting position, starting from three initial
ﬁnger’s points, participants were asked to perform thirty pointing
movements toward a horizontal target wooden bar placed on a table.
To leave participants free to choose the more comfortable pointing
position no target point was emphasized on the bar. The analysis on
movement kinematics showed that, although PD patients performed
the pointing movement as fast as the control, motion planning was
altered as suggested by the increment of the reaction time, the time to
Basal Ganglia 2S (2012) e1–e87e40reach the maximum of velocity, and also the pointing variability
especially from right starting position.
Our results suggest that the MRP could represent an innovative
technique to test motor decision-making in PD patients.
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Neuropsychological proﬁle of Mild Cognitive Impairment in
Parkinson’s Disease
Roberta Biundo, M. Pilleri, S. Facchini, L. Weis, P. Formento-Dojot,
A. Antonini
Fondazione Ospedale San Camillo, Venice Lido (Venezia)
Introduction: Prevalence of mild cognitive impairment (MCI) in
Parkinson’s Disease (PD) is variable in different studies, likely due
to methodological differences in classiﬁcation criteria and in
neuropsychological tests used for cognitive proﬁling.
Objectives: This study was aimed to determine MCI frequency
using a standardized method and to investigate the usefulness of
different neuropsychological tests to detect MCI and to character-
ize different MCI proﬁles.
Methods: A series of consecutive PD patients without dementia
were included in the study. All the patients performed an extensive
neuropsychological evaluation. Individual test values were con-
verted into z scores using relative normative data. Patients
performing 1.5 SDs below the mean score were classiﬁed as
MCI, according to published criteria (Litvan et., 2012). Two
different cognitive MCI proﬁles were deﬁned: MCI Frontal type
(MCI-F) (patients without memory impairment) andMCI Posterior
type MCI-P) (patients with at least one memory task impairment).
Results: In our series of 89PDpatientswe found55PD-CNT (62%)
and 34 PD-MCI (38%) (19 MCI-F and 15 MCI-P). PD-MCI showed
higher disease duration, lower educational level and higher
prevalence of hallucinations compared to PD-CNT. Analysis of
cognitive performance showed signiﬁcant differences in several
tasksbetweenthe twogroups, howeveronlyTrailMaking test (TMT)
A, B and B-A discriminatedwith good sensitivity and speciﬁcity PD-
MCI from PD-CNT. MCI-P patients performed signiﬁcantly worse in
verbal ﬂuency and verbal memory tasks and showed higher
prevalence of hallucinations compared to MCI-F.
Conclusions: Standardized methodology based on z scores is a
suitable procedure for deﬁnition of cognitive impairment in PD.
Among all tests of our extensive neuropsychological battery only
TMT discriminated PD-MCI from PD CNT. MCI-P proﬁle is
characterized by impairment of speciﬁc cognitive tasks.
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Where do dyskinesias begin in Parkinson’s disease?
Maria Carmela Bloise, A. Latorre, M. Sarchioto, G. Fabbrini, A. Berardelli
Dipartimento di Neurologia e Psichiatria, Sapienza Universita` di
Roma, Roma
Background: Observations in PD patients chronically treated
with L-dopa suggest that levodopa induced dyskinesias (LID)
usually manifest in the body site most affected by Parkinsonian
symptoms.
Objective: To investigate the relationship between the body
region inwhich LIDﬁrst appeared and the body regionwheremotor
symptoms started in Parkinson’s disease (PD) patients in which LID
were observed for the ﬁrst time during our clinical observation.
Methods and patients: We included patients in which we
directly observed the onset of LID. Onset of parkinsonian motor
symptoms was evaluated retrospectively. Motor signs and LIDwere classiﬁed as manifesting unilaterally or bilaterally in the
limbs, in the head, neck and trunk.
Results: We observed the onset of LID in 58 patients (31 males,
mean age 72.2  8.2 years, symptoms duration 9.4  5.5 years). In
these patients,motor symptoms started unilaterally in the right limbs
in 29 patients (50%); unilaterally in the left limbs in 25 (43,1%) and
bilaterally in the limbs in 4 (6,9%). LID started unilaterally in the right
limbs in 8 patients (13,8%); unilaterally in the left limbs in 4 patients
(6,9%) and bilaterally in the limbs in 7 patients (12,1%). LID started
both unilaterally in the limbs and in the cranial-cervical-trunk region
in 17 patients (29,3%) and only in the cranial-cervical-trunk region in
22 patients (37,9%).
Discussion: Our study shows that there is only a partial
relationship between the body region ﬁrst involved by LID and
the body part ﬁrst affected by motor symptoms. In fact, in 37% of
patients, despite the onset ofmotor symptomswas always referred
to the limbs, LID begun in the cranial-cervical-trunk region. The
onset of LID and motor symptoms in PD may follow different
anatomical patterns. This clinical ﬁnding probably reﬂects
‘‘abnormal focussing’’ and reduced somatotopic speciﬁcity in
basal ganglia and cortical motor areas.
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Rotigotine in motor and non-motor symptoms in Parkinson’s
disease: a case report
Stefania BrotiniNeurology Unit, Department of Medicine, Empoli (FI)
Background: Advanced Parkinson’s Disease (APD) is character-
ized by decreased response to oral dopaminergic treatment, wors-
ening in motor and non-motor symptoms. Sleep disorders are
amongst the most common non-motor symptoms in Parkinson’s
disease (PD). They occur during the pre-motor stage and throughout
all the stagesof thedisease.Depressionaffects 30–50%of individuals
with Parkinson disease (PD), often preceding the appearance of
motor symptoms, and reducing health-related quality of life.
Case Report: A 48-year-old womanwas admitted to the hospital
because of severe bradykinesia, frequent dyskinesia, mood
disorder and sleep disturbances. The patient has been followed
with PD for 6 years.
Rotigotine therapy was titrated to 16 mg during 24 hours daily
in addition to levodopa and ICOMT-inhibitor. The patient was
clinically evaluated at baseline, and then every 3 months to 12
months. She was assessed using UPDRS, Hamilton Scale for
Depression, Epworth Sleeping Scale (ESS) and Parkinson’s Disease
Sleep Scale-2 (PDSS-2). MRI examination was normal and SPECT
DaTSCAN demonstrates an asymmetric decrease of the uptake in
the putamen of the left. UPDRS-motor score reduced from baseline
43,0 to 5,0. Hamilton scale reduced from 18 to 2. ESS from 16 to 3,
and PDSS-2 score falling by an average of 55%.
Conclusion: Rotigotine may be an effective treatment in
advanced Parkinson’s disease, ameliorating sleep disorders,
reducing mood disorder and motor symptoms. Rotigotine may
play an important role in the quality of life.
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A possible corticobasal degeneration syndrome of atypical
etiology
Alexandra Brunetti, N. Modugno, D. Lanni, S. Ruggieri
IRCCS Neuromed, Pozzilli (Isernia)
We present the case of a 71 years old patient who present a
parkinsonian syndrome in the left hemibody predominantly with
ideo motor apraxia.
Basal Ganglia 2S (2012) e1–e87 e41The case would be suggestive of possible cortico basal
degeneration. However we observed calcium metabolism abnor-
malities with deposits in the putamen bilaterally.
We discuss possible differential diagnosis.
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Cerebellar intermittent theta burst stimulation modulates
cerebellar-cortical-subcortical connectivity in patients with
Progressive Supranuclear Pulsy (PSP)
Livia Brusa, V. Ponzo, C. Mastropasqua, S. Picazio, M. Bozzali, A. Stefani, C.
Iani, P. Stanzione, G. Koch
UOC Neurologia Ospedale Sant’Eugenio, Roma
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Introduction. Progressive Supranuclear Pulsy (PSP) is a an
atypical degenerative parkinsonism clinically characterized by
postural instability, supranuclear gaze pulsy and frontal deﬁcits.
Recent imaging studies revealed speciﬁc cerebellar abnormalities
when measuring the volume of the cerebellum, superior
cerebellar peduncles (SCPs) and midbrain, that were all signiﬁ-
cantly reduced in PSP. On the basis of these ﬁndings an MRi
parkinsonism index obtained by the pons area-midbrain area
ratio (P/M) and the MCP width -SCP width ratio was identiﬁed to
discriminate PSP patients from PD and MSA. Moreover, a
transcranial magnetic stimulation (TMS) study by Yuichiro [1]
recentlydemonstrated a subclinical cerebellar involvement in PSP
compatible with the severe degeneration of dentate nucleus,
showing an impairment of functional connectivity between the
cerebellar hemisphere and the contralateral motor cortex
(cerebellar-brain inhibition, CBI).
Objective: in the current study we applied intermittent theta
burst stimulation (iTBS), a novel form of repetitive transcranial
magnetic stimulation (TMS), over the lateral cerebellum in a
population of PSP patients, in order to investigate the functioning
of the cerebello-thalamo-cortical circuits in these patients.
Methods: Two iTBS trains, one in each cerebellar hemisphere,
were applied during two weeks daily from monday to friday.
Before and after the iTBS session, we used standard TMSmethods
to explore the functional connectivity between the cerebellar
hemisphere and the contralateral motor cortex (CBI), and to
measure the excitability of the contralateral primary motor
cortex assessing intracortical inhibition (SICI) and intracortical
facilitation (ICF). Moreover we also performed resting state
functional magnetic resonance (fMRI) to investigate changes in
other remote interconnected areas. Finally PSP patients included
in our study were submitted to a clinical evaluation by
administering the clinical rating scale [3] for PSP before and
after the cerebellar iTBS.
Results: Cerebellar iTBS increased the deﬁcient functional
connectivity as assessed by CBI. No effects was seen for SICI and
ICFmeasurements. Resting-state fMRI revealed an increased signal
in the head of the caudate nucleus bilaterally. Finally all patients
reported a signiﬁcant improvement of dysarthria as stated by the
item 12 of the scale; two out of ten obtained a signiﬁcant
improvement of gait (item 26).
Conclusion: These results provide further functional evidence
for the abnormal anatomical changes observed in cerebellar
structures in PSP patients. Increasing the excitability of the
cerebellar hemispheres by means of iTBS resulted in an improve-
ment of the functional connectivity between the cerebellar
hemisphere, the caudate nucleus and the cortex, that was
paralleled by some mild clinical improvement.References:
[1] Yuichiro S, Masashi H, Ritsuko H et al Cerebellar dysfunction in
progressive Supranuclear Palsy: a transcranial magnetic Stimu-
lation Study. Movement Disorders 25, 14, 2010:2413-2419.[2] Litvan I, Agid Y, Calne D et al. Clinical research criteria for the
diagnosis of progressive supranuclear pulsy: report of the
NINDS-SPSP international Workshop. Neurology 1996;47: 1-9.[3] Golbe L, PA Ohman-Strickland. A clinical rating Scale for
Progressive Supranuclear Pulsy. Brain 2007; 130: 1552-1565
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Adverse drug reaction to dopamine agonists (DA) or appearance of
a typical sign of Parkinson’s Disease induced by DA
Francesco Maria Cacciatore, M. De Simone, D. Patrocinio, V. Sallustio,
L. Serlenga
ASL Lecce, Lecce
ASL Bari, Bari
Introduction: Hypokinetic dysarthria (HD) is a common
manifestation of Parkinson’s Disease (PD) and has reported to
be present in all stages of the diseasewith an increasing prevalence
in the more advanced stages; to date it has been also reported as a
complication appeared after STN DBS, but never as a drug-induced.
Patient andmethods:Wepresenta79yearsoldmanwithPDwho,
on our initial consultation, had a mild hypokinetic – rigid
extrapyramidal syndrome, after three years of illness. He was on
L-DOPAand IMAO-B treatment; sixmonths later, due to aworsening
of bradykinesia, we added a dopamine agonist (DA) – Rotigotine
patch2 mgoncedaily; after twodayshe suddendeveloped a Speech
dysfunction diagnosed by Motor Speech Proﬁle (MPS) as an
hypokinetic dysarthria (HD). It improved moderatly, but not
disappeared completely, after interruption of patch application;
meanwhile a cranial mdc-MRI revealed only multiple areas of
vascular gliosis in fronto-parietal lobe bilaterally but none of these
seems to be related to the speech dysfunction; after twenty dayswe
introduced a different DA Pramipexolo ER cpr 0,26! 0,52!
1,05 mg once daily; on the third day the HD worsened quickly
and severely; again, after interruption of the last therapy, speech
dysfunction improved spontaneously until to disappear completely
after two months of Lee Silverman Voice Treatment (LSVT).
Conclusions: Hypokinetic dysarthria is a typical sign of advanced
stages of PD. Transient and reversible HD is also reported as a
collateral effect in patients treated with STN DBS consequently at a
stimulation of posterior subthalamic area. Our case suggests that
the speech dysfunction (transient and reversible) could be also an
unknown adverse drug reaction to DA to date never reported in the
Pharmacovigilance database.
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Mechanical stimulation of the feet improves motor function and
freezing of gait in Parkinson’s disease: follow up to 96 hours
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Basal Ganglia 2S (2012) e1–e87e42Background: Foot mechanical stimulation (FMS) has recently
shown his efﬁcacy in improving gait and autonomic control of
heart up to 24 hours in Parkinson’s disease patients (PD).
Nevertheless no data were collected about neurological evaluation
bymeans UPDRS immediately after FMS and up to 48 hours of FMS.
The pathogenetics mechanism of FMS is already not known but
alterations in sensorimotor central integration and/or peripheral
sensory function might play a role in movement disorders in PD.
Aims: We tested the hypothesis that motor functions can
improve immediately after and up to 96 hours the FMS respectively.
Methods: Consecutive outpatients fulﬁlling UK Brain Banking
criteria for idiopathic PD and attending the Parkinson Institute
(Istituti Clinici di Perfezionamento, Milan, Italy) were enrolled in
this study.
Inclusion criteria included age from 35 to 85 years, modiﬁed
Hoehn & Yahr staging (HY) between 1 and 3, andMMSE score> 24.
All patients were taking stable doses of dopamine replacement
therapy since at least one month. Clinical workout included the
complete UPDRS and the HY stage, assessed after 90 minutes
levodopadose; theVisualAnalogueScale (VAS)wasused toevaluate
well-being. Every subject underwent mechanical pressure (0.8 kg/
mm2) at the big toe tip and at the big toemetatarsal joint (true FMS)
onboth feet. ShamFMSwasperformed inadifferentareaofbothsole
(heel). An experienced therapist performed this procedure. PD pts
and the neurologist expert in movement disorders were blinded to
FMS throughout the studyperiod. PDpatientswere randomized into
two groups true and sham FMS groups (FMS-t and FMS-s
respectively). Three visits were performed: before FMS (FMS-T0),
three hours after FMS (FMS-T1) and after 96 hours FMS (FMS-T2).
Results: The two groups with true and sham stimulation did not
differ in demographic, motor and therapy features at baseline
(T = 0) (see Table 1). Signiﬁcant data we obtain in the FMS-t group
immediately after (three hours after FMS, T1) and after 96 hours of
FMS (T2) in UPDRS part III (motor score) and in item 14 (FOG) and
VAS when compared to baseline data. Activity of Daily Living
measured bymeans of UPDRS part II signiﬁcant improved at T2 No
signiﬁcant differences we collected in UPDRS-I and UPDRS-IV after
96 hours of FMS (T2).
Conclusions: Immediately after and after 96 hours of FMS PD
patients showed signiﬁcant changes in motor score measured by
means of UPDRS-III, in activity of daily living measured by means
of UPDRS part II, in FOG (item 14) and in wellness measured by
means of VAS. FMS may improved motor function and FOG in a
relative long-term period.
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Different clinical phenotypes, neuroimaging, SPECT-DAT-SCAN
and levodopa response in four patients with mutation and
parkinsonism
Antonino Cannas, P. Solla, G. Borghero, G. Floris, E. Costantino, G. Oroﬁno,
R. Puddu, M.G. Marrosu, F. Marrosu
Centro per i Disordini del Movimento, Dipartimento di Scienze
Cardiovascolari e Neurologiche, Sezione Neurologia, Universita` di
Cagliari, Cagliari
Background: The nosology of primary neurodegenerative
diseases suggests diagnostic categories based on clinical symp-
toms and their progression. However, in recent years, new
discoveries in genetics are revolutionizing the traditional nosology,
documenting how different clinical phenotypes may be correlated
with the same mutation.
Objective:We describe the different clinical phenotypes of four
patients with parkinsonism and the c.1144G > A (p.A382T)missense mutation of TARDBP gene. An interesting variability
was also observed regard to SPECT-DAT-SCAN, neuroimaging,
neuropsychological performances and levodopa response.
Case reports: Patient 1 showed resting tremor, muscular rigidity
with hypomimia and important pyramidal dysarthria and dyspha-
gia, DAT-SCAN negative, and absent levodopa response.
Patient 2 showed a clear asymmetric parkinsonism CBD-mimic
with alien-like arm and hand in the right side, poor levodopa
response, mild bulbar signs (dysarthria and dysphagia), severe
postural instability, and DAT-SCAN positive. The patient’s brother
was previously diagnosed with ALS.
Patient 3 presented with symmetric parkinsonism PSP-mimic,
severe rigidity and postural instability with frequent falls,
impaired upward and downward gaze, mild bulbar signs,
moderate dementia. Two sisters have a similar clinical picture.
Patient 4 presented with symmetric parkinsonism with resting
tremor, diffuse muscular rigidity, hypomimia, postural instability,
evident bulbar signs and progressive cognitive impairment,
mimicking FTD. In the same family, three of ﬁve children have a
similar clinical picture.
Conclusions: These ﬁndings suggest that phenotypical clinical,
DAT-SCAN, neuroimaging, neuropsycological state, levodopa
response are widely variable in patients with parkinsonism and
the A382T TARDBP missense mutation. These forms of parkinson-
ism have an atypical presentation and an uncertain nosology,
although the crucial core of the disease and the involvement of the
basal ganglia are frequently clinically dominant.
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Introduction: Timed Up-and-Go (TUG) test is a widely used
clinical test to assess mobility and fall risk in Parkinson Disease
(PD). Recently theyhavebeenproposed instrumental versions of the
test, using inertial sensors to evaluate various features of move-
ments during the test.
Objective: To verify if instrumental measures recorded with a
non-invasive single accelerometer could help in the early diagnosis
of PD and to evaluate postural and gate impairment in PD.
Material and methods: Twenty early-mild PD patients (62  7
years old, eight women) and twenty age-matched control subjects
were tested. The PD subjects were tested in OFF-medication status. A
single accelerometerwaswornwith a belt at the level of L5 during the
test. Each subject performed three classical TUG sessions followed by
three additional TUG sessions performed with a Dual-task (DT)
condition (loud voice consecutive calculation task). Acceleration
signals from the antero-posterior (AP), medio-lateral (ML) and
vertical (V) direction were considered for the analysis.
Results: Several postural instrumental measures were found
statistically signiﬁcant between groups. Combining two of those
measures (namely: vertical harmonic ratio and antero-posterior
normalized jerk) it was found a statistically signiﬁcant difference
between PD patient and normal control.
Conclusion: The applicance of two postural parameters
recorded during the test with the accelerometer was found
signiﬁcant in recognize early PD from normal subjects. One of
Basal Ganglia 2S (2012) e1–e87 e43those measures was found sensitive to variations in gait and
posture clinical scores. This data suggest that using a simple
portable accelerometer may help in distinguish early PD from
normal subjects, and may be useful even in follow-up phase,
helping in evaluate the evolution of the gait and postural
impairment in PD or response to therapy.
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Brain tumors are uncommon etiologies of parkinsonism. The
clinical manifestations of tumoral parkinsonism may sometimes
resemble those of idiopathic origin. Increased awareness of this rare
entity is important for an earlier prompt diagnosis and treatment.
We report on a 43-year-old man presenting with loss of dexterity
and rigidity in the right limb starting two months prior to
admission. Neurological examinations showed left anosmia, slight
rest tremor of the right hand, rigidity on the right side and a reduced
right arm swing. An initial diagnosis of essential tremor was made
in another institution. We made a clinical diagnosis of right
hemiparkinsonism suggesting a complete diagnostic work up.
Routine hematological and biochemical examination was normal.
We performed a MRI scan that demonstrated a huge high-density
mass in the left frontal lobeoriginating fromolfactory groove,with a
marked surrounding edema causing compression of the basal
ganglia, expecially of the head of the caudate. Before surgery,
neurophysiological tests were performed, showing a dysexecutive
syndrome with mild apathy, poor working memory for verbal and
spatial information, mild verbal short and long term memory and
visuo-spatial long term memory impairment, ideomotor apraxia,
perseveration and irritability. The patientwas successfully operated
and his symptoms resolved partially, with a slight persisting rest
tremor. This case points to the signiﬁcance of structural neuroim-
aging in the evaluation of parkinsonism even in cases that fulﬁll all
the necessary clinical criteria for idiopathic PD.
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Clinical case: a 38-year-old man presented with a twenty-year
history of upper limbs postural tremor. He had been treated foressential tremor for a year (propranolol 80 mg/die) with poor
clinical beneﬁts. He has familiar history of tremor: his grandfather
was affected by upper limbs tremor since youth; his mother (60
y.o.) and his daughter (6 y.o.) are affected by upper limbs tremor.
His neurological examination revealed myopathic face,
mild waddling gait; atrophy of right pectoralis major muscle,
bilateral winging scapula (dx > sn); hypotrophy of anterolateral
muscles of legs; tetra-hypotonia and tetra-hyporeﬂexia; upper
limbs postural, hypostenic tremor. Creatine kinase levels were
normal. ECG and echocardiography were normal. Electromyogra-
phy showed amyopathic pattern in upper and lower limbmuscles.
Muscular biopsy is consistent with muscular dystrophy. Family
and clinical history, neurological examination and instrumental
ﬁndings prone to hypothesize a diagnosis of autosomal dominant
primitive myopathy. A deletion of FRG1 gene (4q35) was ﬁnd.
Diagnosis: upper limbs postural tremor in patient affected by
facio-scapulo-humeral dystrophy.
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Background: After more than 40 years of clinical use, levodopa
(LD) remains the gold standard regarding symptomatic efﬁcacy in
the drug treatment of Parkinson’s disease (PD). Compared with
other available dopaminergic therapies, dopamine replacement
with LD is associated with the greatest improvement in motor
function, as assessed by reduced scores in the Uniﬁed Parkinson’s
Disease Rating Scale [UPDRS]). In addition, responsiveness to LD
(required to exceed 25%–30% reduction in the motor part of the
UPDRS) is a diagnostic criterion for PD. In clinical practice, LD slows
the progression of disability as assessed by the Hoehn and Yahr
staging system, and is associated with a reduction in mortality.
Importantly, LD is one of the best tolerated drugs to treat PD,
particularly in the elderly population. However, accumulated
evidence shows that the therapeutic efﬁcacy of LDOPA is gradually
lost over time, and abnormal involuntary movements, dyskinesias,
gradually emerge as a prominent side effect of the previously
beneﬁcial doses of the drug.
Case report: We report the case of a male patient of 82 years of
age, without previous history of neurological diseases, who came
to our attention in January 2009 for progressive resting tremor,
started about 5 years ago. At admission, his neurological
examination was positive for right upper limb resting tremor,
micrographia, diffuse hypokinesia, decreased physiological syn-
cinesis in left arm and gait difﬁculties with tendency to festination.
DATscan showed bilateral qualitative and quantitative nigrostria-
tal dopaminergic impairment. At the clinical follow-up in June
2010 he presented with reduced motor autonomies and was thus
started on Levodopa–Carbidopa. At the beginning of therapy, the
patient showed reduction of hypokinesia and rigidity but also a
signiﬁcant reduction in leukocytes count (2,470xmm3), particu-
larly neutrophils (0,710xmm3), conﬁrmed by a second control
three weeks later. After these ﬁndings, Levodopa-Carbidopa
therapy was stopped with normalization of blood studies. On
April 2011, the patient began treatment with Levodopa-Benser-
azide to control motor symptoms. For the second time the blood
Basal Ganglia 2S (2012) e1–e87e44tests underscored an important neutropenia (2,40xmm3), that
forced the suspension of therapy followed by normalization of
leukocyte count. To date, the patient is taking dopamine agonists
with beneﬁt and no evidence of hematological or other adverse
effects. By means of rt-PCR we showed that, in comparison to
circulating neutrophils from healthy subjects, cells from our
patient underexpressed mRNA for D2-like dopamine receptors
(DR) and overexpressed mRNA for D1-like (D5) DR as well as for
tyrosine hydroxylase, the ﬁrst and rate-limiting enzyme in the
synthesis of dopamine.
Discussion and conclusions: Our case shows an adverse reaction
to LD that our knowledge has not been previously reported.
Normalization after LD dechallenge as well as relapse after
rechallenge with LD in association with a different inhibitor of
L-Dopa decarboxylase supports a strong causal relationship
between LD and leukopenia. Additional studies are warranted to
assess whether DR and/or TH mRNA expression in circulating
neutrophils may be a marker of vulnerability to LD-induced
leukopenia.
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Background: Dysautonomic disorders and axonal sensory-
motor polineuropathy (ASMP) are not uncommon complications
in patients affected by type II Diabetes Mellitus (DM). At the
same time, dysautonomic symptoms can be present in
Parkinson’s disease (PD), while an ASMP has been observed,
although rarely, in PD patients with enteral levodopa/carbidopa
infusion. These considerations raise several issues about
possible contraindications to enteral levodopa/carbidopa infu-
sion in PD patients.
Objective: To report our experience in a PD patient affected by
type 2 DM with dysautonomic symptoms treated with duodenal
levodopa infusion.
Case report: A 75-year-old man with a 17-year history of PD
complicated by severe motor ﬂuctuations, such as wearing off,
sudden on-off, gait freezing with falls in off period, and disabling
dyskinesias in on period, was being treated with oral dopami-
nergic therapy without sufﬁcient control of motor complica-
tions. He has also been affected by Type 2 DM and related
marked (mainly cardiovascular) dysautonomic symptoms since
two years. Hoehn and Yahr stage was 4 in off state, while
UPDRS-III score was 64 of 108 in off period. No signs of ASMP
were noted. Treatment with duodenal levodopa infusion was
started with the following parameters: starter dose of 10 ml:
continuous infusion: 3.0 ml/h; extra dose 2.0 ml and satisfying
control of motor complications. Besides, dysautonomic symp-
toms were improved by the continuous administration of
enteral levodopa/carbidopa.
Discussion: Type 2 DM with dysautonomia, but without ASMP,
does not represent a contraindication to the enteral levodopa/
carbidopa infusion through percutaneous endoscopic gastrostomy
in PD patients. In fact, the continuous administration of enteral
levodopa/carbidopa might represent a factor of stabilization of
dysautonomia. In this regard, from a theoretical point of view, we
hypothesize that the concomitant presence of ASMP could bemore
problematic.SC30
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Background and Aims: Abnormal postures of the trunk represent
a typical feature of Parkinson’s disease (PD). These include Pisa
syndrome (PS), a tonic lateral ﬂexion of the trunk associated with
slight rotation along the sagittal plane. In this study we describe
the clinical and instrumental features of PS, together with the
effect of rehabilitation in a representative group of PD patients.
Methods: All patients with trunk deviation underwent EMG and
radiological (RX and CAT scan) investigations. Clinical character-
istics of patients with PSwere comparedwith a control group of PD
without trunk deviation. The rehabilitative program consisted in a
4-week standard approach associated with a speciﬁc protocol for
core muscles strengthening.
Results: PDwith PS showed a signiﬁcantlyhigher score of disease
asymmetry when compared with the control group. In the majority
of patients with PS, trunk bending was contralateral to the side of
symptom onset. EMG showed an abnormal tonic hyperactivity on
the side of the deviation in the paravertebral thoracicmuscles and in
theabdominal obliquemuscles. CTof the lumbarparaspinalmuscles
showed muscular hypotrophy more marked on the side of the
deviation, with a cranio-caudal gradient. Rehabilitation induced an
improvement in the range of motion and the posture of all subjects.
Conclusions: PSmay represent a complication of advanced PD in
a subgroup of patients that show a more marked asymmetry of
disease and who have a detectable hyperactivity of the dorsal
paravertebral muscles on the less affected side. This postural
abnormality deserves attention and proper early treatment to
prevent comorbidities and pain.
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Basal Ganglia 2S (2012) e1–e87 e45Introduction: Resting-state functional magnetic resonance
imaging (RS-fMRI) allows to investigate the spatiotemporal
distribution of the spontaneous coherent ﬂuctuations of blood
oxygen level-dependent (BOLD) signals within and between
functionally related cortical regions, representing the so-called
resting-state networks (RSN). In patients with Parkinson’s
Disease (PD), functional cortical changes, as assessed by
fMRI, are thought to be secondary to a functional deafferentation
caused by dopamine neuron degeneration of nigrostriatal
system which results in a disruption of basal ganglia–thalamo-
cortical loops underling the classical motor signs and symptoms
of PD.
Objective: To reveal, through resting-state functional MRI (RS-
fMRI), acute changes in the cortical sensori-motor RSN (SMN)
connectivity induced by a single dose of levodopa in drug-naı¨ve
Parkinson’s disease (DNPD) patients.
Methods: 10 DNPD patients, were scanned twice in the same
morning, immediately before (‘‘drug-off’’ condition) and 60 min-
utes after (‘‘drug-on’’ condition) levodopa administration; control
RS-fMRI data were recorded in 18 healthy, age-matched control
subjects. RS-fMRI data were collected with a 3Tesla MRI scanner.
Independent component analysis (ICA), using Brain Voyager, was
performed on all scans to extract SMNmaps. A statistical threshold
of p < 0.05 corrected for multiple comparisons was used for both
within and between groups analyses.
Results: Acute levodopa administration increases the connec-
tivity at rest in the SMA of DNPD patients, a region where the same
signals were found suppressed in untreated DNPD patients,
compared to healthy normal controls; within the SMA, the
levodopa effect is maximally selective in the so called ‘‘pre-
SMA’’, a cortical area specialized for motor control.
Conclusions: In contrast to previous studies our results did not
imply or require the choice of a speciﬁc motor task or deﬁning the
lay-out of the seeding region(s): therefore pertains to the entire
intrinsic distribution of the SMN functional connectivity at rest in
DNPD patients.
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Background: Postural Instability (PI) is a core feature of
Parkinson’s Disease (PD) and a major cause of falls and disabilities.
Impairment of executive functions has been called as an
aggravating factor on motor performances. Dance therapy has
been shown effective for improving gait and has been suggested as
an alternative rehabilitative method.
Aims: To evaluate gait performance, spatial-temporal (S-T) gait
parameters and cognitive performances in a cohort of patients
with PD and PI modiﬁcations in balance after a cycle of dance
therapy.
Methods: Eight patients with PD and PI (mean age 66,1  9.2
years, mean Hoehn & Yahr 2.0  0.75) underwent: comprehensive
neurological examination with administration of UPDRS; balanceevaluation through Berg Balance Scale, Gait Dynamic Index, TimedUp-
and-Go (TUG), Four-Step-Square Test; neuropsychological evaluation
through Frontal Assessment Battery (FAB), Trail Making Tests A&B
(TMT-A&B) and Stroop Test. Gait parameters such as cadence, gait
velocity, stride length anddurationweremeasured by a portable linear
and angular accelerometer (FreeSense, Sensorize, Rome) worn at the
belt during the 6-Minutes Walking Test. Such tests were made before,
immediately after, and after one month from a cycle of dance therapy
(one-hour tango sessions, twice weekly for 9 weeks) supervised by a
professional dance instructor.
Results: Patients participated enthusiastically in the training.
One drop-out was due to difﬁculties in attending the class. The
most notable ﬁnding was a remarkable improvement of neuro-
psychological performances (TMT-A & B both p = < 0.0001 and
Stroop p = 0.009, while FAB p = 0.30, with comparable Effect Sizes).
An amelioration of all motor scores was also found, although only
the TUG reached statistical signiﬁcance (p = 0.02). No signiﬁcant
changes on gait S-T parameters were found.
Conclusions: Dance therapy seems to be an effective rehabilita-
tive method for PI in PD which, in our sample, improved cognitive
performances and on fall risk.
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Introduction: Writing and drawing are the ﬁnal output of a
complex neurological, psychological, and motor action and can
therefore be used to investigate both the movement capabilities
and the cognitive functions of the subjects. Simple drawing tests
are commonly used for the clinical evaluation of cognitive
capabilities, especially in the elderly, in order to assess the
presence of dementia and to estimate its extent.
Aims: The realization of an experimental set-up for the
quantitative and objective description of drawing using optoelec-
tronic systems, which could be used when a quantiﬁcation of the
realization of speciﬁc drawing tests is required.
Methods: Healthy subjects, subjects with Parkinson’s Disease
and subjects with Parkinson’s Disease and Dementia were
evaluated by the Mini Mental Scale Evaluation and by a new
approach to the Clock Drawing Test, based on an optoelectronic
acquisition. The new protocol hereby described aims to deﬁne a
parameter related to the movement kinematics in the Clock
Drawing test execution.
Results: The experimental set-up revealed to be valid
introducing new objective measurements beside the subjective
Clock Drawing Test. This paper suggests the applicability of this
protocol to other ﬁelds of motor and cognitive valuation, as well
as the introduction of new parameters related to the graphic
movement.
Conclusions: In this study, an experimental setup was deﬁned
for the quantitative and objective assessment of cognitive
drawing tests. This setup was ﬁrstly applied to a group of healthy
subjects (CG), then to a group of subjects with Parkinson’s Disease
(PD), and to a group of subjects with Parkinson’s Disease and
dementia (PDD), to assess the validity of the setup in the clinical
usage.
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Introduction: ‘‘Erigo’’ device is made up of a traditional tilt-
table with an integrated robotic step system, which is used in the
recovery of the standing posture and of the dynamics of walking.
Gait impairment is a common cause of disability in Parkinson
disease and it is associated with increased disease severity, poor
quality of life and increased caregiver’s workload. Falls during
walking are a common complication of Parkinson disease. Our
aim was to investigate whether and how the use of the ‘‘Erigo’’
may inﬂuence gait performance in patients with Parkinson’s
disease.
Materials and methods: Seven PD patients hospitalised at our
Neurological Rehabilitation Unit were recruited and underwent a
traditional rehabilitation treatment associated with Erigo robotic
treatment. During the rehabilitative sessions with Erigo, the
inclination and the frequency of steps were gradually increased.
Assistance to the lower limbs movement by Erigo was regulated
according to the patient’s ability. All patients were evaluated with
gait analysis and outcome scales at the beginning and the end of
the hospitalization.
Results: We observed a decrease in the number and duration of
strides measured in milliseconds, with an increase in walking
speed. Outcome scales showed signiﬁcant clinical improvement at
the end of rehabilitative treatment.
Conclusions: These preliminary data suggest the potential
usefulness of adopting the ‘‘Erigo’’ to improve walking ability in
patients with Parkinson disease, in particular in those subjects
with signiﬁcant impairment of gait.
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Introduction: A 70-years old woman with a palatal myoclonus
started about 17 months ago arrived to our clinic. The myoclonus
produces an ear click that troubles the patient during the all day
and does not stop during the night. No hypertrophy of inferior olive
was found at MRI exam.
This patient also presents Darier disease, an autosomal
dominant skin disorder, caused by mutations of the gene ATP2A2.
The ATP2A2 encodes the sarcoplasmic/endoplasmic reticulumCa2+ ATPase (SERCA2) pumps. SERCA 2 belongs to a family of
p-type membrane bound ATPase which pump Ca2+ from the
cytoplasm in to reservoirs in the endoplasmic reticulum lumen,
using energy from ATP hydrolysis. Moreover she was affected by
Tako-Tsubo Cardiomyopathy. A recent study provides evidence
that an altered gene expression of the Ca2+ regulating proteins,
as SERCA 2a, contributes to the heart contractile dysfunction in
this disease and an increased PNL(phospholamban)/SERCA2a
ratio represents a major determinant of contractile dysfunction.
Alternative splicing of the ATP2A gene produces three isoforms,
SERCA2a, 2b and 2c. The SERCA 2b is expressed ubiquitously and
the major isoform is in the skin; SERCA 2a is expressed
predominantly in cardiomyocyties, smooth muscle cells and in
Purkinje cells. Most of the ATP2A mutation affects the three
isoforms of SERCA 2. Symptomatic drug-induced myoclonus
have been associated with Ca2+ channels-blocker such as
Diltiazem.
Result: The coexistence in the same patient of palatal
myoclonus, Tako-Tsubo Cardiomyopathy and Darier disease, three
uncommon conditions, brings us to suppose a possible correlation
between them, with a possible common ground based on SERCA
calcium pump dysfunction.
Conclusion: The dysfunction of the dentate-olivary pathway is
considered the cause of the palatal myoclonus, and we suggest
that, in this patient, this dysfunction is probably related to an
abnormal function of SERCA2 pump that are well represented in
Purkinje cells.
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Introduction: Myelinolysis can result from rapid correction of
hyponatriemia and is generally located central in the pons central
pontine myelinolysy (CPM). Extrapontine myelinolysis (EPM) is
also described and generally involves basal ganglia. Parkinsonism
and dystonia are rarely seen in EPM.
Case report: We report the case of a 73 years old lady who
was admitted at the Nephrologic Department because of
confusional state and somnolence associated with severe
hyponatremia occurred during antidepressant treatment with
paroxetine. During the following days hyponatriemia was
rapidly corrected and the mental state of the patient improved.
10 days after admission the patient developed subacute
parkinsonism with dysphonia followed by progressive dysar-
thria and dysphagia.
A ﬁrst brainMRI showed bilateral symmetrical hyperintensities
of caudate nucleus and putamen with sparing of the pons in T2-
weighted images. Diagnosis of EPM was posed. Other cause of
hyponatriemia were excluded suggesting a role of paroxetine in its
genesis. Levodopa treatment was started with beneﬁt on
parkinsonsim.
A second MRI perfomed 2 weeks later showed typical central
pontine hyperintensities together with basal ganglia hyperinten-
sities.
At 2 months follow-up parkinsonism appear to be improved
with persistence of prominent axial symptoms, the patient
referred nomore dysphagiawhilemoderate dysarthria still persist.
Sodium levels remained between normal range.
Conclusion: EPM sould be considered as a cause of subacute
parkinsonism in patient with hyponatremia due to its good
Basal Ganglia 2S (2012) e1–e87 e47prognosis. In patients with otherwise unexplained hyponatremia
paroxetine should be considered as a possible cause.
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Background: Rapid eye movement (REM) sleep behavior
disorder (RBD) is strongly associated with synucleinopathies,
often haralding and later accompanying motor symptoms of
Parkinson’s disease (PD) and Lewy Body Dementia (DLB) [1].
Previous neuropsychological assessment revealed in idiopathic
RBD patients without dementia the visuo-perceptual and verbal
memory dysfunctions similar those observed in patients with
PD and DLB [2]; it suggests a common pathophysiological
mechanism between these conditions, according to Braak’s
hypothesis. However, these theory is not conﬁrmed in all PD
cases.
Our objective is to assess the relationship between the
presence of RBD and the cognitive proﬁle of non-demented
patients with PD.
Methods: 47 patients with PDwithout dementiawere evaluated
by a standard neuropsychological battery assessing intelligence,
episodic verbal and spatial memory, recall capacity, ﬂuency,
executive and visuospatial abilities. 25 patients satisﬁed clinic and
polysomnographic criteria for RBD. Two-sided t tests were
performed to compare differences between PD with RBD group
and PD without RBD group.
Results: No signiﬁcant differences between groups were found
for age, schooling, depression assessment, Hoehn and Year (H&Y)
stage (I-II), motor score of Uniﬁed Parkinson’s Disease Rating Scale,
disease duration, levodopa equivalent daily doses. Groups differ
signiﬁcantly in interference condition of the Stroop color word test
(p = 0,002).
Conclusions: Our data conﬁrm a previous study [3] in that PD
with RBD patients showed a lower cognitive performance
compared to PD without RBD. The cognitive involvement in
executive functions is very early, because our patients presented a
mild motor phenotype (H&Y:1,87 + /-0,49) compared to literature.
In agreement with these data, the RBD phenomenon can be an
indicator of a more pervasive neurodegenerative process underly-
ing the Parkinson’s disease and can increase the risk of cognitive
impairment in patients.
References:[1] Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of
neurodegeneration in idiopathic rapid eye movement sleep
behaviour disorder and Parkinson’s disease. Brain 2009;132(Pt
12):3298–307.[2] Fantini ML, Farini E, Ortelli P, Zucconi M, Manconi M, Cappa S,
Ferini-Strambi L. Longitudinal study of cognitive function in
idiopathic REM sleep behavior disorder. Sleep 2011;34(5):619–
25.[3] Vendette M, Gagnon JF, De´cary A, Massicotte-Marquez J,
Postuma RB, Doyon J, Panisset M, Montplaisir J. REM sleep
behavior disorder predicts cognitive impairment in Parkinson
disease without dementia. Neurology 2007;69(19):1843–
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Computer-assisted cognitive remediation for Parkinson’s disease
Valeria Dibilio1, A. Nicoletti1, M. D’Amelio2, A. Cerasa3, G. Bellavia2,
L. Di Gesaro2, M.C. Gioia3, T. Maci1, F. Le Pira1, S. Realmuto2, M. Salsone4,
C. Sanﬁlippo1, G. Savettieri2, A. Quattrone3,4, M. Zappia1
1Dipartimento G.F. Ingrassia, Sezione di Neuroscienze, Universita` di
Catania, Catania
2Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche,
Universita` degli Studi di Palermo, Palermo
3Consiglio Nazionale delle Ricerche, Unita` di Ricerca Neuroimmagini,
Catanzaro
4Clinica Neurologica, Universita` degli Studi ‘‘Magna Graecia’’, Catan-
zaro
Background: Cognitive dysfunction, principally involving exec-
utive performances, represents a cardinal non-motor symptom of
Parkinson’s disease which inﬂuences patients quality of life.
However, few studies have focused on rehabilitation of cognitive
performances in PD patients.
Objective: This study aimed to assess the compliance and
efﬁcacy of a computer-assisted cognitive rehabilitation program
on cognitive performances of patients.
Methods: Non-demented PD patients were assigned to twelve
1-hours individual sessions (twice per week) of computer-assisted
cognitive rehabilitation. Remediation was performed using Reha-
Com1 software. This software has a speciﬁc interface consisting of
a special keyboard that has been designed to minimize the
interferences due tomotor and coordination disabilities. The study
treatment focused on the rehabilitation of three different
attentional processes: selective attention, divided attention and
vigilance. All PD patients enrolled in the study were assessed
neuropsychologically using a standardized battery, before and at
the end of the cognitive rehabilitation program.
Results: Eight PD patients (fourmen;mean age 66.1  6.8;mean
disease duration 4.7  3.0) were enrolled in the study. All patients
completed the cognitive assessment battery before and after the
rehabilitation program. An improvement in memory and executive
functions, particularly attentive performances and working memory,
was detected after the cognitive rehabilitation program even if
average score differences between assessments were statistically
signiﬁcant only for the Frontal Assessment Battery and Trail Making
Test (p < 0.05)
Conclusions: Cognitive rehabilitation for PD patients has shown
to improve performance in subjects with executive functions
disorders. Further studies in larger sample and with a longer
follow-up are needed to conﬁrm our results.
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Clinical features of onset in monogenic Parkinson’s disease
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Introduction: Genetic causes of Parkinsons’s disease (PD)
account for a signiﬁcant number of early-onset and familial cases.
The most frequently involved genes display both autosomal
dominant (PARK1, 8) and recessive (PARK2, 6) patterns of
inheritance. Moreover, mutations in the b-Glucocerebrosidase
gene (GBA) have been recently found to be associated with PD.
Basal Ganglia 2S (2012) e1–e87e48Objective: 1) To analyze clinical features at onset in a cohort of
Italian patients affected by monogenic PD; 2) to compare onset
features in different monogenic forms of PD.
Methods: A consecutive series of 962 PD patients was recruited
at the Movement Disorder Unit, Besta Institute, Milan (period
2002-2012). Inclusion criteria were: diagnosis of PD (Gelb, 1999),
age at onset < 50 years and/or positive family history. Exons and
ﬂanking regions of PARK2, PARK6, PARK8 and GBA were analysed
by direct sequencing. MLPA was performed for PARK1 and PARK2.
Clinical features at onset in mutation positive patients were
obtained from by clinical records and interview. Non-parametric
statistical analysis was performed.
Results: Records of 85 patients who carrymutations in PD genes
were reviewed: 2 with PARK1 duplication, 42 with homozygous
PARK2, 4 with homozygous PARK6, 12 with heterozygous PARK8
and 25 with heterozygous GBA mutations. Differences in onset
features were observed among groups: PARK2 patients showed the
earliest age at onset (p < 0.01); GBA patients displayed the highest
frequency of non-motor onset (p < 0.05); onset with dystonia was
observed only in PARK2 and PARK6 groups. The highest frequency
in lower limb onset was detected in recessive forms (p < 0.01).
Two patients resulted co-mutated in both PARK2 and GBA, they
presented with motor onset but developed prominent non-motor
features during follow up.
Conclusions: In PD patients with early onset or positive family
history lower limb onset is associatedwithmutations in autosomal
recessive genes. Non-motor onset is suggestive for GBAmutations.
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Theory of mind in essential tremor
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Introduction: The Theory ofMind (ToM) is the ability to attribute
mental states to oneself and others and to understand that others
have beliefs, desires and intentions different from one’s own.
Objectives: The aim of the present study was to explore the
neuropsychological correlates of cognitive and affective ToM in
patients affected by Essential Tremor (ET).
Methods: Thirty consecutive ET outpatients and 30 healthy age-,
sex- and education-matched control subjects underwent tasks
assessing short-term memory, verbal learning and executive
functions, as well as tasks assessing ‘‘cognitive’’ and ‘‘affective’’
ToM (by means of Advanced ToM Task and Emotion Attribution
Task, respectively); questionnaires evaluating behavioral disorders
(Frontal Behavioral Inventory, Apathy Evaluation Scale) and
quality of life (36-Item Short Form Health Survey, SF-36) were
also administered.
Results: Although the two groups did not differ on demographic
variables, ET patients scored worse on memory tasks, and showed
more apathy and worse quality of life than controls. After
covarying for mnestic, behavioral and quality of life scores, ET
patients achieved signiﬁcantly lower scores than controls on task
assessing cognitive ToM, whereas no difference was found
between the two groups on task assessing affective ToM. In ET,
‘‘Cognitive’’ ToM was signiﬁcantly associated with frontal tasks,
whereas ‘‘Affective’’ ToM was not correlated with cognitive,
behavioral and quality of life scales.Conclusion: Our results demonstrate that cognitive aspects of
ToM are selectively impaired in ET. Deﬁcits in cognitive
subcomponent of ToM might be linked to dysfunction of
dorsolateral prefrontal cortex-cerebellum network.
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patients: a DAT-Scan study
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5University Parthenope, Naples
6University of Salerno, Center for Neurodegenerative Diseases –
CEMAND, Salerno
Background: Anxiety is a common non motor symptom among
patients with Parkinson’s disease (PD). Although the etiology of
anxiety in PD is likely multifactorial, a dysfunction in the dopami-
nergic systemmightbe implicated in itspathogenesis. Theaimofour
study was to investigate a possible dopaminergic mechanism in-
volved in anxiety in newly diagnosed never-medicated PD patients
using SPECT and 123I-FP-CIT as dopamine transporter ligand.
Methods: Thirty-four newly-diagnosed untreated PD patients
with asymmetric motor symptomswere included in the study: the
group was constituted by 17 patients with right- and 17 with left-
motor onset, matched for age, disease duration and motor
disability. They were all evaluated for anxiety and depression
and underwent a SPECT with 123I-FP-CIT. Dopamine transporter
(DAT) availability values for right and left caudate and putamen
were calculated and compared between patients with and without
anxiety. Regression analyses were also performed in order to
correlate DAT availability with anxiety symptoms severity.
Results: Comparison between PD patients with and without
anxiety revealed signiﬁcant differences of DAT availability in all
the examined regions except the right putamen. In the group of
patients considered as a whole, a signiﬁcant correlation was found
between increased anxiety severity and decreased DAT availability
in right caudate.
Conclusions: We reported an association between nigrostriatal
DAT availability deﬁcits and anxiety symptoms in newly-
diagnosed untreated PD patients. Our results suggest that
hypofunction of nigrostriatal dopaminergic system may represent
a possible mechanism involved in anxiety in PD since the earliest
stages of disease and irrespective of any therapy.
SC42
An uncommon case of pediatric chorea
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Here we present the case of a 9 years old boy showing upper
limb hyperkinetic involuntary movements. His parents were
Basal Ganglia 2S (2012) e1–e87 e49unrelated and came from Bulgaria having gypsy origin. The child
sustained a birth asphyxia, at 9 months was operated for congeni-
tal cataracts and showed a motor and cognitive development
delay. The patient was referred to our clinic because of walking
difﬁculties and frequent fall. When he came at our observation the
main clinical feature was the occurrence of hyperkinetic involun-
tary movements affecting especially the upper limbs with brief,
random and sometimes shaking movements of the hands resem-
bling choreic disorders; parents reported the onset of this disorder
few years ago and there was not deﬁnite progression. On physical
examination the boy showed mild facial dysmorphism, wild based
and slow gait, distal muscle wasting with bilateral pes cavus; deep
tendon reﬂex were absent and the plantar reﬂex showed an
extensor response. Then the child underwent radiological and
neurophysiological investigations. Brain MRI scan was normal.
Nerve conduction studies showed severe motor and sensory nerve
conduction velocity slowing consistent with a primary demylinat-
ing peripheral neuropathy. These features were very suggestive of
the ‘‘congenital cataracts facial dysmorphism neuropathy
(CCFDN)’’ syndrome often described in Balkan gypsies. The genetic
testing for the CCFDN showed a homozygous single nucleotide
substitution of the CTDP1 gene conﬁrming the diagnosis.
Conclusions: This case shows a rare cause hereditary neuropathy
in a complex genetic syndrome where chorea appeared one of the
main clinical feature. CCFDN syndrome is not used to be included
in the list ofmain causes of paediatric chorea published in scientiﬁc
literature and wewould suggest to consider this genetic disease as
a possible further cause of paediatric movement disorders.
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Evalutation of neuroprotective effects in PC12 cells of polyphenols
expressed by experimental cultivation of sardinian vines
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Oxidative stress produced by reactive oxygen species ROS may
partecipate in the cell death of dopamine neurons distinctive of
Parkinson’s disease (PD). One of the plausible ways to prevent the
ROSmediated cellular injuries is to augment or fortify endogenous
defense against oxidative stress through dietary or pharmacologi-
cal intake of antioxidants. Many studies has been focused on red
grape polyphenolic components that are able to scavenge ROS and
protect cells from oxidative damage.
In the present work, several sardinian vines (bovale, carignano
and mazuela), exposed to different light conditions (full wave-
length and UV-deprived spectra) have been studied in order to
increase red wines nutraceuticals (poliphenols). The potential
neuroprotective capacity of red grape skins and seeds-derived
polyphenols have been studied on cell death induced by H2O2 in
PC12 cells widely used as model for neurobiological and
neurochemical studies. At the start of experiments, PC12 were
seeded at 1x105 cells/ml in 24-well plates and treated 24 h later
with red grape skins or seeds-derived polyphenols and H2O2. After
24 h, cells were processed with MTT reduction assay to evaluate
cell viability andwith LDH release assay, trypan blue dye exclusion
test to evaluate cytotoxicity.
Our results showed that only the polyphenolic fraction derived
from seeds was cytoprotective and statistically signiﬁcant
decrease in percentage cell viability was detected following 24 hexposure of H2O2 (100mM). However, a signiﬁcant increase in
percentage cell viability (+15-30% vs control) was recorded after
pretreatment with the polyphenolic fraction derived from seeds
(50mM – 100 mM).
Although no differences have been found exposing the
cultivations to different light conditions, differences in neuropro-
tection were observed among vines. Our preliminary results
support the role of these natural polyphenols in preventive and/or
complementary therapies for several human neurodegenerative
diseases, such as PD.
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The diagnosis of Parkinson’s disease (PD) is currently based on
the clinical evaluation of extrapyramidal signs, such as tremor,
rigidity and bradykinesia, with a considerable error rate. In this
study, we used two-dimensional electrophoresis to identify
proteome alterations in T-lymphocytes. (T)-Lymphocytes express
some features of the dopaminergic system (they express dopamine
receptors and transporters, and store catecholamines into vesi-
cles), so in PD patients they could carry some protein alterations
peculiar to dopaminergic cells. In particular, patients affected by
familial forms of PD (about 20% of all PD cases) may express, also at
the peripheral level, alterations that mirror the pathogenic process
at the central level. In the discovery phase, we examined 17 control
subjects and 15 PD patients. We identiﬁed 20 protein spots and
assigned their identity. The observed changes were used to build
predictive models that were veriﬁed by the leave-one-out cross-
validation, with sensitivity and speciﬁcity approaching 99%. We
further built two functions able to stage the subjects in terms of
disease duration and Hoehn and Yahr score. We chose to verify the
identity of spots corresponding to g-ﬁbrinogen and transaldolase,
two recurrent proteins in six out of 20 spots. By Western blotting,
we found that g-ﬁbrinogen levels are lowered in PD patients,
whereas a heavy transaldolase set of isoformswasmore abundant.
Eventually, we identiﬁed a list of seven proteins showing different
levels in early-onset with respect to late-onset PD patients.
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Background: Previous neurophysiological studies pointed out
different EEG patterns in DLB patients respect to AD, mostly
Basal Ganglia 2S (2012) e1–e87e50expressed by a reduction of alfa-wave activity with a prevalence
of theta and delta wave activity. EEG abnormalities may repre-
sent a valid tool for discriminating between the two types of
dementia.
Aim: To map distributed sources of cortical EEG rhythms in DLB
respect to AD patients and to study the neurophysiological
correlates of VH in DLB.
Methods: 63 DLB and 25 AD patients were analyzed. Among
63 DLB patients, 32 had VH. Standard EEG was performed and
processed with the software sLoreta in order to detect the
cortical source of EEG rhythms registered on the scalp. The
following standard band frequencies were considered: delta (2–
4 Hz), theta (4–8 Hz) and alpha (8–13 Hz). This map was
superimposed to the Talairach’s map of cortical grey matter
to detect the corresponding anatomical source of the band
frequency.
Results: Upon EEG analysis, comparing DLB vs AD patients, DLB
patients showed a source of delta activity in the posterior cingulate
(BA 23–30), visual cortex (BA 17–19), and fusiform gyrus (BA 37)
(100% of these cortical areas are involved in DLB, p < 0.01), and a
source of theta activity in the temporal gyri (BA 20–21). A source of
theta activity in BA 23–30 and in BA 17–19 was signiﬁcantly more
represented in DLB VH+ respect to VH (100% of BA 30 is involved
in VH+, p < 0.05).
Conclusion: Diagnosis of DLB is signiﬁcantly associated with a
source of delta wave activity in areas involved in the processing of
visual information, and in parahyppocampus and fusiform gyrus.
The presence of VH in DLB patients is associated with a source of
‘‘lesional’’ band frequencies (delta and theta waves) in the
parieto-occipital cortex (involving both primary and associative
visual areas), and in the limbic system (occipito-amygdaloid
pathway).
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Background: Functional imaging of the dopamine transporter
(DAT) deﬁnes the integrity of dopaminergic system and provides a
marker for pre-synaptic neuronal degeneration. Dopamine loss is
seen even in the earliest presentation of true parkinsonism.
Abnormal uptake progresses from putamen to caudate and
matches contralaterally the clinically more affected side. A normal
DAT SCAN in patients with a clinically undeﬁned parkinsonism,
does not rule out later conﬁrmed PD.
Objective: To investigate SCAN DAT imaging in assisting the
differentiation between conditions with and without presynaptic
dopaminergic deﬁcit. In patients with clinical diagnosis of PD, to
evaluate the effect on DAT results of performing the test at
different time of individual history.
Method: We study 48 patients. Speciﬁc activity of putamen and
caudate were obtained by [123-I] FP-DAT SCAN imaging. Image
analysis uses quantitative region of interest (ROI) to occipital
reference site.
Results: Twenty-seven patients underwent DAT SCAN within
one year of symptom onset. Speciﬁc activity of putamen > 2.3
bilaterally was found in three patients in which PD diagnosis wasclinically rule out. Contralateral putamen and caudate uptake to
affected clinical side was signiﬁcantly lower than the other one
(respectively p = 7.83564E-05, p < 0.0001); ﬁfteen patients under-
went DAT scan within 2–5 years of symptom onset. Contralateral
putamen and caudate speciﬁc activity to affected clinical side was
signiﬁcantly lower than the other one (respectively p < 0.0002, p
2.3 bilaterallywas found in two patients inwhich PD diagnosiswas
clinically rule out. Contralateral putamen and caudate speciﬁc
activity to affected clinical side was signiﬁcantly lower than the
other one (respectively p < 0.0002, p < 0.0004). There is not any
signiﬁcant difference between values comparing tests at different
time.
Conclusion: In typical asymmetric parkinsonism, DAT imaging
provide quantitative, clinically-related information. Normal
values, also later in course of movement disorder, ruled out true
parkinsonism. Putamen involvement is clearly worse than caudate
one, in each time of testing DAT SCAN.
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Background: Primary blepharospasm (BSP) is characterized by
involuntary spasms in the orbicularis oculi (OO) muscles and an
increased blink rate (BR) can be also present in some of these
patients.
Objective: Whether patients with increased BR but without
muscle spasms in OO should also be considered BSP patients is still
unclear. Aim of the study was to investigate whether increased BR
belongs to the clinical spectrum of BSP.
Methods: We enrolled 34 patients (10 patients with increased
BR but without typical OO spasms, 10 patients with both increased
BR andOO spasms and 14 patientswithOOmuscle spasmswithout
increased BR) and 18 healthy subjects. Blink reﬂex recovery cycle
and somatosensory temporal discrimination threshold (STDT)
were tested in patients and controls.
Results: Statistical analysis for blink reﬂex recovery cycle
showed a signiﬁcant effect of factor ISI (F = 88.54, p < 0.00001) and
a signiﬁcant interaction of factor group and ISI (F = 6.89, p < 0.001).
Post-hoc analysis showed that BSP patients with involuntary
muscle spasm and those with increased BR and spasms had an
altered blink reﬂex recovery cycle, whereas patients who had only
increased BR had a normal blink reﬂex recovery cycle. STDT values
were higher in BSP patients than in healthy subjects and the STDT
abnormalities did not differ in the three groups of BSP patients.
ROC curve analysis performed to investigate diagnostic accuracy of
BR, R2 recovery index and STDT in discriminating patients with
muscle spasms from those without spasms but increased BR
yielded high diagnostic accuracy for R2 recovery index (82.61%
sensitivity and 100% speciﬁcity with a cut-off value of 64%),
whereas it yielded lower diagnostic accuracy for BR (65%
sensitivity and 100% speciﬁcity with a cut-off value of 33.5%)
and STDT (78% sensitivity and 45% speciﬁcity with a cut-off value
of 147%).
Conclusions: Patients with increased BR should be
considered a form of BSP as shown by altered STDT but they
Basal Ganglia 2S (2012) e1–e87 e51differ from typical BSP patients for a normal blink reﬂex
recovery cycle.
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Introduction: Patients with Parkinson’s disease can have
impaired sexual function. Although the disease itself likely
contribute to sexual dysfunction, antiparkinsonian drugs can also
have an effect.
Objective: To investigate the interactions between Sexual
Function and drug therapy in patients with Parkinson’s disease.
Methods: 121 patients [(aged 40-80)(male = 70; female = 51)]
diagnosed as having idiopathic PD and recruited from four
Italian Movement Disorders Clinics. The therapy included the
range of drugs commonly used in the treatment of PD:
Dopamine Agonist, L-DOPA, Monoamine Oxidase Inhibitor
(MAOI-B). To assess sexual function in PD we used the Brief
Index of Sexual Functioning (BISF-M for man; BISF-W for
woman).
Results: Females assuming MAOI-B had increased BISF score
than those not assuming MAOI-B. Female patients taking MAOI-B
had higher scores for sexual thoughts and desire (p = 0.05),
arousal (p = 0.03) and frequency of sexual activity (p = 0.01) than
patients not assuming MAOI-B. Males assuming MAOI-B had
increased BISF score than those assuming L-DOPA (p = 0.05). The
assumption of other antiparkinsonian drugs did not modify BISF
scores.
Conclusion: MAOI-B could positively inﬂuence sexual function
in patients with Parkinson’s disease. Sexual anamnesis is therefore
relevant for the choice of the most appropriate drug in patients
with PD.
SC49
A voxel-based morphometry study of disease progression in a
cohort of patients with Parkinson’s disease
Valentina Fioravanti, F. Benuzzi, L. Codeluppi, S. Contardi, F. Cavallieri,
P. Nichelli, F. Valzania
Department of Neuroscience, University of Modena and Reggio Emi-
lia, Nuovo Ospedale Sant’Agostino Estense, Modena
Background: Using voxel-based morphometry (VBM) we
investigate structural brain differences between group of early-
mild PD patients at different phase of disease and healthy subjects.
Objective: To investigate, usingMRI and voxel-basedmorphom-
etry (VBM), whether speciﬁc patterns of gray matter (GM) loss are
associated with progression of disease in patients with Parkinson
disease (PD).
Methods: 20 mild PD subjects (Hoen&Yahr < 2,5, non-fallers,
62  7 years old, 12 males) in OFF state, compared to 15 healthycontrols. The OFF condition was obtained by a medication
washout (a levodopa washout of at least 18 hours and a dopamine
agonist washout of at least 36 hours). All patients underwent MRI
scan, physical examination (UPDRS scale, H&Y scale) and
neuropsychological assessment at baseline and after 2 years of
disease. The topographic distribution of brain tissue loss was
assessed using VBM as implemented in Statistical Parametric
Mapping (SPM8).
Results: At baseline patients had reduced brain volume in right
putamen and right parietal cortex (angular gyrus and precuneus).
After 2 years, the same patients conﬁrmed GM loss in putamen
and parietal cortex; moreover, a signiﬁcantly difference was
evidenced in posterior midbrain, referable to the area of
peduncolopontine nucleus (PPN) and of the mesencefalic loco-
motor region (MLR).
Conclusions: In this study we demonstrate that parietal cortex
and putamen are early affected in PD patients and that these
structural brain changes seems to occur gradually during disease
progression. Another structure which undergoes atrophy is the
part of the inferior-posterior midbrain attributable to the PPN and
MLR. The structures that control posture and gait may be involved
at an early stage in Parkinson disease, although usually not evident
at clinical examination.
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Introduction: The LSVT1 voice treatment was speciﬁcally
created and tested to comply with the needs of individuals with
Parkinson’s disease (PD) and other neurological problems (PSP,
MSA). This is an intensive treatment aiming at increasing vocal
intensity through the increase of subglottal air pressure for a better
cordal vibration. Experimental data from over 15 years’ research,
ﬁnanced by the American National Institute of Health (NIH), have
produced evidence that a speciﬁc speech therapy, LSVT1, is
effective.
Purpose: The main goal of this study is to compare whether the
positive impact of LSVT1, proven in years of experience with PD
individuals, is equally valid with PSP patients.
Method: 14 patients with PSP and 25 patients with idiopathic
Parkinson’s disease were treated with 16 sessions of speech
therapy following the LSVT1 treatment. Initially the two groups of
patients had similar voice problems, i.e. low volume and bad
articulation of speech.
Results: Statistically signiﬁcant results were found among the
data collected during and after treatment in the two groups.
Increase in maximum phonation duration and volume of voice in
reading were similar in the two groups. Improvement in quality of
voice and articulation were more signiﬁcant in the PD group as
compared to the PSP group.
Conclusion: These results, along with previous ﬁndings, add
further support to the generalized therapeutic impact of intensive
voice treatment on respiratory and laryngeal functions along with
improvement of speech intelligibility in individuals with PD and
also, in a certain measure, in individuals with PSP.
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randomized controlled study with 12 months follow-up
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Introduction: A major focus of PD research is on ‘‘disease-modi-
fying’’ or ‘‘neuroprotective’’ agents to slow PD progression. No
drugs has so far given a clear proof of a neuroprotective activity.
Increasing evidence suggests that ongoing vigorous exercise may
favourably inﬂuence disease progression.
Objective: To test the efﬁcacy on the disease progression in early
stage of disease of the association of rasagiline and intensive
rehabilitation treatment.
Methods: Thirty-ﬁve ‘‘de novo’’ parkinsonian patients were
enrolled and randomly assigned to two groups: Group_1 (20 pts)
began therapy with rasagiline and underwent an intensive
rehabilitation treatment (IRT); Group_2 (15 pts) started only
rasagiline. Patients were evaluated at the beginning of study and at
6–12-month follow-up. The primary outcome measures were:
UPDRS II-III, Berg Balance scale (BBS), 6-Minutes Walking Test
(6MWT), Timed up and go test (TUG). The secondary outcome
measure was the dosage of Levodopa-equivalent.
Results: All patients who underwent IRT showed a signiﬁcant
improvement in all primary outcome measures at the end of
treatment. At 12-month follow-up, patients in Group_1 showed a
signiﬁcant improvement in UPDRS II-III scores, BBS and TUG, while
Group_2 patients showed an improvement in 6MWT and TUG. The
19 pts Group_1 were still treated only with rasagiline, while in the
Group 2 only 3 patients were in monotherapy with rasagiline and
12 patients had to add other drugs (dopamineagonist or levodopa).
Conclusions: It is possible to hypothesize that intensive exercise
could lead, as seen in the animal models, to an increase in
dopamine production and number of D2 receptors in dorso-lateral
region of striatum acting in synergy with the rasagilina which also
raises the extracellular dopamine concentration in the striatum.
Our data suggest that IRT in association with rasagiline can slow
the progression in early stage of disease.
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Autoimmune syndromes of CNS with subacute onset and move-
ment disorders: proposal of a diagnostic and therapeutic
approach
Simone Gallerini, M. Bartalucci, L. Giovanditti, C. Scarpini, S. Pieri, K.
Plewnia, R. Marconi
Unit of Neurology, Ospedale della Misericordia, Grosseto
Autoimmnue syndromes of CNS are a heterogenous group of
diseases in evolution. The onset can be acute ore subacute withrapid progressive disease evolution and the clinical features are
extremely variable ranging from cognitive or psychiatric symp-
toms and seizures to movement disorders. Even if in many cases
antineuronal antibodies are not found some of these conditions
can beneﬁt from immunomodulatory therapy. We describe seven
patients admitted over the last 2 years in the Neurological Unit of
Grosseto from Emergency Department with complex movement
disorders or neuropsychiatric syndromes and an acute or
subacute onset and a rapid evolution: 1) opsoclonus-mioclo-
nus-ataxia; 2) progressive hemiataxia; 3)mioclonus and delirium
(two patients); 4) sensitive ataxia and delirium; 5) non convulsive
SE; 6) paraneoplastic motoneuron disease. An extensive diagnos-
tic program was done. It included brain and spinal MRI, EEG,
neurophysiological studies, CSF examination, chest, abdomen and
pelvis CT and PET to reveal associated tumors, detection of
antineuronal antibodies. Finally an alternative diagnosis was
excluded and an autommiune basis was considered. The patients
were treated with corticosteroids, intravenous immunoglobulin,
plasma exchange with improvement in ﬁve of them. In our
opinion, an autoimmune basismay be considered in patients with
such signs and symptoms moreover when the following condi-
tions are associated: 1) Hystory of infection or tumor; 2) Normal
brain MRI or presence of signs of an autoimmune disease; 3)
Normal CSF examination or presence of signs of inﬂammation; 4)
Detection of antineural antibodies; 5) Improvement with
immunotherapy.
We believe that in presence of a patient with the above
mentioned characteristics an autoimmune basis must be consid-
ered and treatment with steroids and intravenous immunoglo-
bulins (IVIG) or plasma exchange should not be delayed.
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Comparison of the gait patterns of young Parkinson’s disease
subjects with healthy elderly subjects
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Background: The gait of healthy elderly and of subjects with
Parkinson’s disease (PD) displays some common features, suggest-
ing that PD may be a model of ageing.
Aim: The aim of the study was to quantify highlight the
differences and similarities between the gait patterns of young PD
and healthy elderly, to uncover if PD could be assumed as a model
of ageing.
Design: An optoelectronic system was used for 3D gait analysis
evaluation.
Population andmethods:We compared the gait parameters of 15
young PD (YPD) with the gait of 32 healthy elderly subjects (ES)
and 21 healthy subjects age-matched with the PD subjects.
Results: Common features between YPD and ES were majorly
found in the parameters that reﬂect the presence of an unstable,
uncertain gait, and of corrective strategies employed to reduce
instability. On the other side, typical features were present in the
gait patterns of PD subjects.
Conclusions: Our study helped identifying some typical
characteristics of the onset disease, and to unravel the symptoms
of ageing from those of PD by comparing young PD subjects to
elderly healthy subjects. This allows a deeper understanding of the
mechanisms underlying the gait in ageing and PD.
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Training program associated with dual tasking in Parkinson
disease patients: Effects on executive functions and gait
Michele Gennuso1, V. Codazzi1, P. Nicardi2, S. Ghirardi1, A. Prelle1
1Department of Neurology ‘‘Ospedale Maggiore di Crema’’, Crema
2Department of Rehabilitation ‘‘Fondazione Benefattori Cremaschi’’,
Crema
Gait impairments and walking limitations are common among
people with Parkinson disease (PD). Gait abnormalities are not
pronounced in the early stages of PD; their prevalence and severity
increases with disease progression. In the early stages of disease,
patients have difﬁculty in walking, especially during situations of
dual tasking. In fact gait is no longer considered an automated
motor activity that utilizes minimal higher-level cognitive input.
The relationship between gait and speciﬁc cognitive faculties, in
particular executive function (EF) and dual tasking abilities, has
been described in healthy adults and in patients with Parkinson’s
disease. Impairments in executive capacities are frequently
observed in Parkinson patients: they have an increased risk of
falls, during walking, if they are doing other tasks. We conducted a
study on a training program to improve gait in Parkinson patients
undergoing dual tasking in order to evaluate both motor and
neuropsychological effects. Fifteen patients (Hoehn and Yahr
stage < 2) were evaluated before and after two months of DT
training. The training program included 20 sessions of 45 minutes
each, during which patients had to walk while performing several
distinct cognitive tasks. We evaluated the speed of walking, the
frequency of steps and the length of the step during usual walking
and during two DT conditions. We also assessed the executive
functions through a battery of tests before and after the training
period.
At the end of treatment patients showed a motor improvement
even under dual tasking. Also neuropsychological evaluations
showed an improvement in the majority of studied patients. In
conclusion our study demonstrates that in Parkinson patients a
training program can produce dual taskingmotor effects and also a
cognitive performance improvement.
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Introduction: Deep brain stimulation (DBS) for patients with
Tourette Syndrome (TS) is effective in reducing tics and comorbid
conditions. Despite intense research, TS pathophysiology is still
largely based on models and indirect evidence. Neural activity
from DBS target structures can provide direct information about
neural dysfunction in TS. The three structures preferentially
chosen as targets for DBS in TS are the thalamus, the globus
pallidus internus (GPi) and the nucleus accumbens (NA). Local ﬁeld
potentials (LFPs) from ventralis oralis/centromedian-parafascicu-
lar (Vo/CM-Pf) nucleus of the thalamus showed oscillations at low
frequencies (LF, 2–15 Hz) band (Marceglia et al., 2010) and neuralactivity recorded from GPi showed irregular neuronal activity
correlated with motor tics (Zhuang et al., 2009).
Objectives: To investigate TS neurophysiology studying neural
activity recorded through electrodes implanted for DBS in brain
structures.
Methods: We recorded LFPs in three patients with TS: (1) from
Vo/CM-Pf during severe vocal tics three days after DBS surgery, (2)
from Vo/CM-Pf at rest 12 months after DBS surgery, and (3) from
Vo/CM-Pf and NA at rest in a patient with TS and obsessive
compulsive syndrome (OCD).
Results: (1) Bilateral LFP recordings from Vo/CM-Pf showed an
abnormal frequency modulation from the LF band activity to the
high beta band (20-35 Hz) activity only in the dominant
hemisphere in the time frame corresponding to tic. (2) The Vo/
CM-Pf LFPs recorded twelve months after DBS surgery shows
activity within the LF band (2-7 Hz). (3) NA LFPs show strong
activity within the beta band (8-20 Hz) whereas in Vo/CM-Pf LFPs
beta activity is virtually absent.
Conclusions: Although the abnormal frequency modulation
observed in the Vo/CM-Pf was not time-locked to the tic, but it is
lateralized on the same side of language function, it could be
causally related to tic. We also found that Vo/CM-Pf LFPs are
stationary over time, suggesting that the Vo/CM-Pf LF activity is a
speciﬁc rhythm of TS in time. The abnormal NA beta LFP activity
observed could be associated with OCD and, in turn, can drive the
thalamo-cortical activity ultimately resulting in behavioral dys-
functions. Hence, Vo/CM-Pf and NA DBS in patients with TS could
induce its beneﬁcial effects by modulating speciﬁc pathological
neural rhythms in the cortico-basal ganglia-thalamic network.
SC56
Clinical and cognitive correlations of regional graymatter atrophy
in patients with progressive supranuclear palsy: a VBM-DARTEL
study
Alfonso Giordano1,2, A. Tessitore1, D. Corbo1, G. Cirillo1, R. De Micco1,
A. Russo1,2, S. Liguori1, M. Cirillo3, F. Esposito4,5, G. Tedeschi1
1Department of Neurology, Second University of Naples, Naples
2IDC Hermitage Capodimonte, Naples
3Department of Radiology, Second University of Naples, Naples
4Department of Neuroscience, University of Naples Federico II, Naples
5Department of CognitiveNeuroscience,Maastricht University,Maas-
tricht, The Netherlands
Background and Purpose: Progressive supranuclear palsy (PSP) is
the most common neurodegenerative bradykinetic-rigid syn-
drome after Parkinson’s disease (PD). Several volumetric studies
have revealed a widespread cortical and subcortical gray matter
(GM) atrophy, however the correlations between GM pattern loss
and clinical-cognitive features have been poorly investigated.
Materials and Methods: By using 3-Tesla magnetic resonance
imaging and voxel-based morphometry we compared GM volume
in 12 patients with probable PSP, 12 patients with PD and 12
healthy controls. All patients underwent a clinical and neuropsy-
chological evaluation aimed at exploring mainly the executive
functions (EF).
Results: Patients with PSP, compared to patients with PD
showed a reduced GM volume in several cortical and sub-cortical
areas including left and right cerebellum, left superior frontal
gyrus, middle and inferior occipital gyrus, left globus pallidus and
right middle temporal gyrus; moreover patients with PSP
performed signiﬁcantly worse than patients with PD on cognitive
tests exhibiting lower scores on Mini Mental Status Examination
(MMSE), Frontal Assessment Battery (FAB), Phonological Verbal
Basal Ganglia 2S (2012) e1–e87e54Fluency (pVF) and Ten Point Clock Test (TPCT). Interestingly,
among different signiﬁcant correlations between motor and
cognitive features and GM loss, we detected a signiﬁcant positive
correlation between FAB and pVF scores with cerebellar atrophy
and between pVF score and superior frontal gyrus GM loss;
interestingly, we did not detect a correlation between frontal
cortex GM loss and FAB score.
Discussion and conclusions: Our ﬁndings conﬁrm, in patients
with PSP, the pattern of GM tissue loss and corroborate the
presence of frontal cognitive dysfunction. Correlation analyses
suggest that cerebellar atrophymay play a role in the pathogenesis
of executive impairement in patients with PSP due to a disruption
of its modulation on executive functions. Several studies have
conﬁrmed that cerebellum is critical not only for movement
coordination but also for cognitive processes; the well-known
cerebellar cognitive syndrome refers to impairment of EF in
patients with cerebellar damage.
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involvement: analysis of the effects on walking and on the quality
of life
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Objectives: To verify the long-term impact of an adapted motor
activity based on emotional involvement through pleasant
exercises with dance or music, on motor performances and health
related quality of life in subjects with Parkinson Disease (PD).
Material and Methods: We enrolled 53 outpatients with PD. The
mean age was 71.44 (9.27). Patients were stable responders or
early ﬂuctuators to levodopa, in Hoehn and Yahr stage 2 or 3, and
not affected by severe sensory (auditory or visual) deﬁcits, or
cognitive deterioration, or disease affecting movement. The
examination protocol included a detailed clinical quality of life
questionnaire (QoL SF -36), the third part of the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS III), the tapping test and the
measurement of patient’s acceleration with a triaxial accelerome-
ter (applied on the chest and pelvis while patients are walking at a
comfortable speed). 53 patients were evaluated two times, among
these 43 patients have been reassessed for the third time. The
adapted motor activity session based on emotional involvement,
with enjoyable exercises as music or dance, was held twice a week
for months, each time for 60 minutes and was followed by a 4
months rest period. Patients were assessed at baseline, at the end
of the treatment and after the stop-from-activity period.
Results: Comparing the values after 4 months of adapted motor
activity, the evaluation of the acceleration parameters, with a chest
accelerometer, showed an improvement from amean value of 0.72
(SD 0.22) m/sec to a mean value of 0.77 (SD 0.26) m/sec (p < 0.05).
On the basis of the pelvic accelerometer we found a mean
acceleration of 1.40 (SD 0.37) m/sec and of 1.57 (SD 0.45) m/sec
before and after treatment (p < 0.01). The mean UPDRS score had
signiﬁcantly improved (p < 0.001). The QoL SF-36 score improved
in all sections (p < 0.01), especially in these subscales: social
functioning (p < 0.01), physical functioning (p < 0.01), vitality
(p < 0.001), general health (p < 0,001) role physical (p < 0.05), and
with lower score in the section regarding the emotional role
(p < 0.05). The dominant and non-dominant hand tapping test hadsigniﬁcantly improved (p < 001). After 4 months of rest of
treatment, the values of the tests were drown again to those at
baseline, only the improvement of QoL SF-36 score continued after
the resting period. The acceleration parameters, with the chest and
pelvic accelerometer, showed a decrease to a mean values of 0.71
(SD 0.24) m/sec (p < 0.005) and 1.45 (SD 0.40) m/sec (p < 0.01),
similar to those at baseline. Also the mean UPDRS score and the
tapping tests had decreased (p < 0.05) when compared with those
of the end of motor activity.
Conclusions: These results suggest that an adapted motor
activity, based on emotional involvement through pleasant
exercises with music or dance, performed for several months
could improve the quality of life perception, also after a long
discontinuation. Moreover, after the stop-from-activity period, the
motor performances of the patiens seem to return to the starting
conditions, after the improvement obtained before. A periodical,
but repetitive, adapted motor activity in PD and other neurode-
generative diseases could be considered an alternative and
concomitant approach to support the social and self-perception
of physical performances.
Work supported by the Fondazione Cassa di Risparmio di Cento,
Town of Cento and Gruppo Estense Parkinson.
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Analysis of non motor symptoms in patients with progressive
supranuclear palsy
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Introduction: Progressive supranuclear palsy (PSP) is a rare
neurodegenerative disorder that include supranuclear, initially
vertical, gaze dysfunction accompanied by extrapyramidal symp-
toms, swallowing and language abnormalities and cognitive
dysfunction.
Objective: The aim of this study was the clinical evaluation of 40
patientswith probable PSP diagnosis, with particular regards to the
analysis of Non Motor Symptom and the clinical subtypes (PSP-
Parkinsonism, Richardson’s Sindrome, PAGF – Pure Akinesia with
Gait Freezing).
Materials andMethod: The analysis of frequency and typology of
NonMotor Symptomswas evaluated through the use of nonmotor
symptoms scale and questionnaire. The neuropsychological
evaluation included MOCA and Hamilton scale for depression
(HAM-D). Clinical evaluation of patients was based on PSP-scale.
28 patients with probable PSP were enrolled into the study: 20
with conﬁrmed diagnosis and complete neuropsychological
evaluation; 4 patients with probable PSPwere not able to conclude
all the assessment due to the severe cognitive impairment; in 4
patients the diagnosis was converted to cortico-basal degenera-
tion.
Results and Conclusion: The study showed: duration of disease
between 2.77 and 3.36 years, equal sex distribution, age at onset
between 50-65 years, subdivision of the population observed in 2
subtypes (classic PSP and PSP-P) respected the percentage reported
in literature; patients with PAGF have not been observed. The
analysis of the MOCA showed deﬁcit of delayed memory, language
with particular regards to ﬂuency and visuospatial area. According
to Hamilton scale scores all patients showed mild depression. The
NMS questionnaire in patients with classical PSP showed preva-
lence of symptoms such as drooling, dysphagia, constipation and
sadness. All patients reported falls, unlike the PSP-P group inwhich
falls were reported only by 55% of patients.
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Neurophysiological assessement in two unreported Italian fami-
lies with autosomal dominant cortical tremor, myoclonus, and
epilepsy
Rosa Iodice, A. Coppola, M. Esposito, L. Santoro
Dipartimento di Scienze Neurologiche, Universita` Federico II, Napoli
On a clinical basis ‘‘autosomal dominant cortical tremor,
myoclonus and epilepsy’’ (ADCME) is mainly characterized by
distal action tremor and myoclonus. Neurophysiological ﬁndings
often show a giant somatosensory evoked potential, enhanced C
reﬂex and a postural high frequency irregular tremor. Here we
describe the neurophysiological assessment of few members
belonging to two Italian unreported families with ADCME.
Methods: 3 members of one family (2F, 1 M) and 2 (2 M) of the
other onewere studied. All patients were under antiepileptic drugs
(AED) andwere free from epileptic seizers since several years. They
all showed hyperkinetic involuntary movements of the upper
limbs against gravity and during voluntary movement. Somato-
sensory evoked potentials (SEP), C-reﬂex and a video-multichannel
EMG recording were performed.
Results: A giant SEP and an enhanced C-reﬂex were both
recorded in two patients. The video-EMG multichannel recording
showed cortical jerks mainly against gravity and during move-
ments but there was no deﬁnite tremor activity in most of the
patients. Only for two patients an irregular postural tremor could
be recorded. Spectral analysis of the tremor showed a mean
frequency around 8 Hz but the there was a high dispersion of the
signal.
Discussion: Our reports are coherent with neurophysological
features early described in ADCME. The video-EMG multichannel
recording showed that these patients present very frequent
cortical jerks not producing a regular tremor. This ﬁnding and
the lack of detection of giant SEP and C reﬂex in every patient could
be ascribed to long term treatment with AED.
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Introduction: Pisa Syndrome (PS) is clinically deﬁned as a
sustained lateral bending of the trunk, worsened by a prolonged
sitting position or by walking. Abnormal postures of the trunk
(including also camptocormia and anterocollis) are a typical
feature of extrapyramidal disorders, especially Parkinson’s Disease
(PD). In PD, PS can be sometimes observed, both after dopaminer-
gic drugs implementation or spontaneously, but the precise
pattern of muscles activation leading to the lateral trunk ﬂexion
has not been clearly elucidated.
Objective of the study: To investigate the pathophysiological
mechanisms leading to PS in patients with PD, by combining anelectromyographic (EMG) assessment of both paraspinal and non-
paraspinal muscles with radiological ﬁndings obtained by Mag-
netic Resonance Imaging (MRI) of paraspinal muscles.
Patients and methods: We examined thirteen (n = 13) PD
patients with a lateral trunk ﬂexion diagnosed as PS. A speciﬁcal-
ly-designed wall goniometer was used to measure the lateral (and
anterior, when present) ﬂexion of the trunk. We performed an
enlarged EMG study of paraspinal (lumbar and thoracic) muscles,
abdominal muscles (m. obliquus externus) and other muscles
potentially involved in trunk stabilization in physiologic condition
(m. iliopsoas, m. rectus femoralis). All EMG traces were recorded in
laying position, during standing and during voluntary ﬂexion of the
trunk. Eventually, all patients underwent a high resolution MRI of
the thoracic and lumbar tract, by using T1 (with and without
gadolinium), T2, STIR and DWI sequences.
Results: Two main muscles activation patterns were observed
by EMG. The ﬁrst group of patients (n = 6) showed a hyperactivity
of lumbar paraspinal muscles ipsilateral to the leaning side,
combined with a hyperactivity of the ipsilateral (subtype 1) or
contralateral (subtype 2) thoracic paraspinal muscles. A hyperac-
tivity of non-paraspinal muscles (ileopsoas and/or rectus femor-
alis) ipsilateral to the leaning side was observed in 4 of 6 patients.
Coexisting lumbar hypertrophy of the ipsilateral paraspinal
muscles and hypotrophy of the contralateral lumbar paraspinal
muscles could be seen on spinal MRI, accompanied by slight signs
of inﬂammation of the paraspinal muscles of both sides.
The second group of patients (n = 7) showed contralateral
thoracic and lumbar paraspinalmuscles hyperactivity on EMG. The
non-paraspinal muscles (m. iliopsoas, m. rectus femoralis and m.
obliquus externus) were hyperactivated ipsilaterally to the trunk
leaning side in all patients. Spine MRI revealed hypotrophy of the
ipsilateral lumbar paraspinal muscles and widespread signs of
inﬂammation on both sides.
Discussion: According to our ﬁndings, muscles activation
pattern underlying PS is likely to be different among PD patients.
In some patients, themost important role is probably played by the
dystonic hyperactivity of the lumbar (and thoracic in some cases)
paraspinal muscles ipsilateral to the ﬂexion side, whereas the non-
paraspinal muscles may have an additive role for the trunk ﬂexion.
In other patients, a primary pathogenetic role might be
hypothesize for ipsilateral non-paraspinal muscles, with a compen-
satory activation of paraspinal controlateral muscles. MRI ﬁndings
are consistent with EMG data, showing hypertrophy of hyperacti-
vated muscles and hypotrophy of under-utilized muscles.
Conclusion: PS is a heterogenous condition from a pathophysi-
ological point of view. The muscles involved in trunk ﬂexion are
probably more widespread than suspected initially, involving not
only parapsinal muscles, but also abdominal end lower limbs
muscles. This could be important for a deeper comprehension of
the phenomenon and for a more personalized treatment.
References:[1] Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleur-
othotonus): epidemiology and management. NS Drugs 2002,
16(3):165–174.[2] Yokochi F. Lateral ﬂexion in Parkinson’s disease and Pisa
syndrome. J Neurol 2006, 253(Suppl 7):VII17–VII20.[3] Djaldetti R, Mosberg-Galili R, Sroka H et al. Camptocormia
(bent spine) in patients with Parkinson’s disease-characteriza-
tion and possible pathogenesis of an unusual phenomenon.
Mov Disord 1999, 14(3):443–447.[4] Umapathi T, Chaudhry V, Cornblath D, et al. Head drop and
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Parkinson’s disease, multiple system atrophy, and progressive
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Parkinson’s disease (PD) is characterized by motor and non-
motor symptoms including nocturnal akinesia, sleep disorders and
impulse control disorders (ICD). These disorders may be directly
related to the underlying disease pathology but may also be a
consequence ofmedication use and pharmacologicalmanagement.
Rotigotine is a non ergoline dopamine agonist (DA) applied once a
day using a transdermal continuous delivery patch. Several studies
demonstrated signiﬁcant treatment beneﬁt of rotigotine on motor
and non-motor symptoms. Objective of this study is to evaluate the
beneﬁt on ICD and sleep disorders on PD patients swithching from
other dopamine agonist to rotigotine. We collected data from 59
subjects with PD treated with DA except from rotigotine in stable
management for at least 3 months. Motor functions were assessed
using Uniﬁed Parkinson’s Disease Rating scale (UPDRS) part III.
Sleep disorders and ICDs were assessed with Parkinson’s Disease
Sleep Scale (PDSS), Epworth Sleepiness Scale (ESS) and modiﬁed
Minnesota Impulse Disorders Inventory (mMIDI). DA was shifted
after baseline evaluation and titrated to optimal dose without any
other pharmacological modiﬁcation. Each patients was evaluated
after 3 month from baseline. UPDRS Part III score had decreased -1
point from baseline (P = 0.0073).
Greater improvement was obtained in PDSS score (-2.9 points;
p < 0.0001), ESS score (-203 points; p < 0.0001) and mMIDI score
(-3.3 points; p < 0.0001). This represent a signiﬁcant improvement
in sleep disorders and ICDwith rotigotine compared with other DA
resulting in improved quality of life for PD patients.
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Lateral stepping and rear walking on treadmill for the treatment
of freezing of gait and postural instability in Parkinson’s disease:
randomized controlled trial
Manuela Maieron1, S. Mezzarobba2, R. Ballestriero1, E. Cascio1,
L. Paviotti3, D. Marin1, L.M. Bragadin1
1Istituto Medicina Fisica e Riabilitazione ASS 4 Medio Friuli, Udine
2Corso di Laurea in Fisioterapia Universita` degli Studi di Trieste,
Trieste
3Corso di Laurea in Fisioterapia Universita` degli Studi di Udine, Udine
Introduction: Treadmill training represent currently the best
practices in the treatment of gait disorders in Parkinson disease.
Objective: The aim of the study was to compare the results
obtained through two different types of treatment: treadmill
training with variable walking and classic treatment. The purpose
is to reduce freezing and postural instability in patients with
Parkinson’s disease.Material and methods: We recruited 28 patients (mean age 72;
H&Y 2.5-3; MMSE  24) and evaluated by clinical tests such as
UniﬁedParkinson’sDiseaseRating Scale (UPDRS), BergBalance Scale
(BBS), Tinetti, Timed Up and Go Test (TUG), Freezing of Gait
Questionnaire (FOGQ), 6 Minute Walk Test (6minWT), 10 meters
walk test (10mt.WT), Fall Efﬁcacy Scale (FES), and PDQ39. Finally,
some posturographic tests were performed. Theywere then divided
randomly into two groups. Group 1 performed exercises of walking
(forward, sideways, backwards, and with no hands) on a treadmill
withhighdifﬁculties.Group2hasperformedclassical rehabilitation.
The treatment was performed with one-hour session three times a
week for a total of 14 sessions. Assessmentsweremade pre and post
treatment and follow-up to one month after treatment.
Results: After treatment, the comparison between two groups
showed signiﬁcant results in favor of Group 1 in the following
indeces: follow up BBS (P = 0.000), 10mtWT (post P = 0.001, follow
up P = 0.002), TUG (post P = 0.031, follow up P = 0.001), Tinetti
follow up (P = 0.048), Six min.WT (post P = 0.016, follow up
P = 0.004). In intragroup evaluation the results were signiﬁcant
for Group 1 for all indices investigated comparing post vs pre and at
follow-up vs pre.
Conclusions: Patients treated with use of variable walking on
treadmill training improve signiﬁcantly gait performance and
maintain the results in follow up.
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Impaired deception in essential tremor
Francesca Mameli1, E. Scelzo3, E. Tomasini3, M. Fumagalli3, F. Cogiama-
nian2, G. Ardolino2, R. Ferrucci1, L. Bertolasi4, A. Priori1,3
1Centro Clinico per la Neurostimolazione, le Neurotecnologie ed i
Disordini del Movimento, Fondazione IRCCS Ca` Granda–Ospedale
Maggiore Policlinico, Milano
2U.O. Neuroﬁsiopatologia, Fondazione IRCCS Ca` Granda - Ospedale
Maggiore Policlinico, Milano
3Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti,
Universita` degli Studi di Milano, Milano
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Introduction: Neuropsychological research conducted in the
past decade has challenged the traditional view of movement
disorders as a mono-symptomatic condition characterized by
movement dysfunction and increasingly showed that deﬁcits in
cognitive and behavioral functioning are consistently present in
these patients.
Objective: In order to deepen our understanding of cognitive
dysfunctions in movement disorders, we aimed to examine those
functions that regulate the complex activity of lying in patients
with Essential Tremor (ET).
Methods: In this study we investigated the lie cognitive
processes in 15 ET patients compared to 20 patients with
Parkinson’s disease (PD) and 17 healthy subjects (HS) using the
Guilty Knowledge Task (GKT), a simple, fast and computerized task
to test the ability to lie.
Results: Results showed that in GKT, ET patients have a
signiﬁcant worse performance in deception when compared to
HS, but performed remarkably similar to PD group (F(2.49) = 3.38,
p = 0.042), whereas we found no differences between groups in
true responses (F(2.49) = 0.73, p = 0.488). In addition, reaction
times in ET patients were signiﬁcantly longer than PD and HS, both
in true (F(2.49) = 10.79; p = 0.0001) and lie responses
(F(2.49) = 5.91; p = 0.005).
Conclusion: Our ﬁnding showed that both ET and PD had
difﬁculty giving deceptive responses relative to HS and showed for
Basal Ganglia 2S (2012) e1–e87 e57the ﬁrst time that ET patients may have more cognitive difﬁculties
than PD patients consistent with the hypothesis wherein ET
patients require additional cognitive effort to achieve the same
level of performance of PD patients. Future studies focused on
cognitive and behavioral processes in movement disorders should
provide valuable new insights about the clinical nature of such
conditions to identify possible areas of intervention in cognitive
and behavioral disorders.
SC64
Percutaneous endoscopic gastrostomy for continuous intestinal
delivery of levodopa for the treatment of complicated Parkinson’s
disease: gastroenterlogic issues
Francesca Mancini1, P. Campagnoli2, D. Calandrella1, L. Manfredi1,
A. Antonini3, M. Dal Fante2
1Parkinson’s Disease and Movement Disorders Center, San Pio X
Clinic, Milano
2Endoscopy Unit, San Pio X Clinic, Milano
3Department for Parkinson Disease, IRCCS San Camillo, Venezia
Introduction: Continuous intestinal levodopa infusion (CILI)
through a percutaneous endoscopic gastrostomy and a jejunal tube
(PEG/J) is an useful treatment for complicated Parkinson’s disease
(PD).
Methods: The aim of this retrospective study is to analyze
features and outcome of PD patients with PEG/PEJ placed for CILI.
Results: Between 2006 and 2012, PEG-J was positioned in 38 PD
patients, without acute complications. Patients’ mean agewas 64.4
years, disease duration 13 years and UPDRS III in ON 17. PEG-J was
removed in 9 patients (4 patients underwent different treatments;
1 patient developed dementia, 2 patients developed a polyneuro-
pathy). For the ﬁrst 3 years, devices were replaced only on demand
(tube deterioration or complications) and mean time between
PEG-J positioning and the ﬁrst request of replacement was 885,25
days. Since 2010, PEG-J replacement was programmed every 12
years, even in absence of complications (mean time 382,5 days).
Mean time between intestinal tube replacement and previous PEG-
J positioning or substitution for complications was 135,6 days, (24
times for migration of the jejunal extension, jejunal tube block due
to a knot or a bezoar or accidental removal of the external tube).
Four times the intestinal tube was repositioned because of
dislocation. One patient needed PEG-J complete replacement for
a bumper-buried syndrome. Complications (tube replacement)
concerned 15 patients, from 1 to 4 times. Two of these patients
presented also a more serious complication: gastric and duodenal
pressure ulcers caused by the tension of the PEJ tube, anchored to
the proximal ileum because of a bezoar or a knot. No signiﬁcant
differences were found in clinical features between patients with
device complications and patients without.
Conclusions: PEG-J for CILI doesn’t present major adverse
events. An accurate monitoring of minor complications onset is
needed. Further studies have to better identify patientsmore likely
to develop complications.
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Neuropsychological assessment signiﬁcance in the treatment of
cognitive disorders in Parkinson’s disease: preliminary data and
our experience
Pietro Marano, M. Seminara, L. Ravida`
Unita` Operativa di Neuroriabilitazione, Casa di Cura Villa dei Gerani,
CataniaObjective: Our study was a perspective non-interventional that
aims to evaluate the neuropsychological performance of patients
with idiopathic Parkinson’s disease using an evaluation protocol
that we normally apply to these patients to deﬁne the stage of
disease and follow longitudinally. Were evaluated neuropsycho-
logical changes over time as attention, memory, orientation,
executive function, motor programming in outpatients with
idiopathic Parkinson’s disease.
Design: Perspective non-interventional study. Setting: Our
department of Neurorehabilitation; Neuropsychology room. Parti-
cipants:30patientswithidiopathicParkinson’sdisease, chosenatthe
discretionofthe investigator,or inapositiontoaccedetotheProtocol.
Interventions: The tests were administered as follows: V1 start
of the study, V2 after 6months, V3 after one year.We did not make
drug changes, because this is not an interventional study.
Main Outcome Measures: We used the following tests: Mini
Mental State Examination (MMSE), Frontal Assessment Battery
(FAB), Short Neuropsychological Assessment (SNA), Montreal
Cognitive Assessment (Mo CA).
Results: The study is still under way, but we ﬁrmly believe that
an evaluation must be carried out by using all the tests under
consideration, as each of them has its own limits and strong points
which give advantage to some speciﬁc cognitive areas but damage
some others.
Conclusions: Our study, to suggest a proposed protocol high-
lights the need for administration of all tests used, because the four
batteries of tests seem to be able to assess, within a reasonable
period of time, both domains cognitive speciﬁc global cognitive
functioning in patients with idiopathic Parkinson’s disease. The
administration of these tests in a protocol, designed by us, allows
to overcome limitations of each battery providing a comprehensive
picture of the investigated areas.
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Impaired primarymotor cortex LTP/LTD-like plasticity inmultiple
system atrophy
Luca Marsili1, A. Suppa1,2, F. Di Stasio1, A. Latorre1, P. Khandker1,
C. Colosimo1, G. Fabbrini1,2, A. Berardelli1,2
1Department of Neurology and Psychiatry, Sapienza University of
Rome, Rome
2Neuromed Institute, Sapienza University of Rome, Rome
Objective: In humans intermittent and continuous theta-burst
stimulation (iTBS and cTBS) are currently used for inducing long-
term changes in motor evoked potential (MEP) amplitudes
reﬂecting long-term potentiation (LTP)- and depression (LTD)-like
plasticity in primary motor cortex (M1). In this study we
investigated possible abnormalities of LTP/LTD-like plasticity in
M1 in patients with Multiple System Atrophy (MSA). Recent
studies have reported that LTP/LTD-like plasticity as tested by TBS
is reduced in Parkinson’s Disease (PD) (Suppa et al., 2011) and
increased in patients with Progressive Supranuclear Palsy (PSP)
(Conte et al., 2011). There are no previous studies testing M1
plasticity with TBS in patients with MSA.
Materials and Methods: We studied 10 patients with MSA, six
with the Parkinson-variant (MSA-P) and four with the Cerebellar-
variant (MSA-C) and 10 age-matchedhealthy subjects.We clinically
evaluated patients using the Uniﬁed Multiple System Atrophy
Rating Scale (UMSARS). To exclude cognitive impairment patients
were also evaluated with the Frontal assessment Battery (FAB). The
left M1was conditioned in separate sessions with iTBS (20 trains of
2 sec repeatedevery10 sec, inburstsof3pulses at50 Hz, repeatedat
5 Hz, 600pulses in total) and cTBS (bursts given ina continuous train
lasting 40 sec) at intensity of 80% of activemotor threshold. Twenty
Basal Ganglia 2S (2012) e1–e87e58MEPs were recorded from right ﬁrst interosseous muscle before, 5,
15 and 30 minutes after iTBS and cTBS at the intensity able to evoke
at baseline MEPs of about 1 mV amplitude.
Results: Repeated measures analysis of variance (ANOVA)
showed that in healthy subjects after iTBS, MEPs increased
whereas after cTBS, they decreased in amplitude signiﬁcantly at
5, 15 and 30 minutes (P Discussion: M1 LTP/LTD-like plasticity is
impaired in patients with MSA.
Conclusions: Mechanisms underlying abnormal M1 plasticity in
MSA are similar to those present in PD rather than in PSP.
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Orthostatic tremor in a patient with Graves disease
Sonia Mazzucchi, D. Frosini, M. Giuntini, C. Del Gamba, U. Bonuccelli,
R. Ceravolo
Dipartimento di Neuroscienze, Universita` di Pisa, Pisa
Introduction: Orthostatic Tremor (OT) is a rare disorder
characterized by high frequency tremor affecting lower limbs and
unsteadiness on standing with remission during sitting or lying.
A 70-year-old woman presented with a sense of unsteadiness
and tremor in her legs mainly during standing and walking, which
gradually worsened over a year without any beneﬁt after
administration of clonazepam.
Neurological exam showed tetrahyperreﬂexia, gait impairment
with paraparethic features and inability to perform tandem gait.
Her cognition and mental state was normal. She also reported
intolerance of heat, excessive sweating and recent loss of weight
with increased appetite, dysphagia and dysphonia.
Methods: Motor evoked potentials did not demonstrate im-
pairment of the cortico-spinal tract. Brain and cervicodorsal MRI
were normal. Electromyographic recordings from vastus medialis
and tibialis anterioris, performed during standing, showed a
rhythmic contractile activity at about 8 Hz. After prolonged supine
rest a rhythmic contractile activity at lower amplitude re-appeared
in both lower legs. Due to atypical phenotype and EMG activity and
low frequency of tremor, a symptomatic origin was hypothized.
Her thyroid function exams revealed severe hyperthyroidism
(thyroid stimulating hormone (TSH) < 0.004mU/ml [0.400-
4.000 mU/ml], fT3 9.25 pg/ml [1.80-4.80 pg/ml], fT4 5.05 ng/dl
[0.80-1.80 ng/dl]), increased values of thyreoglobulin antibodies
(451 UI/ml, [1020 [<10 UI/ml] and positivity of TSH receptor
antibodies (19.10 UI/L). A chest and neck CT scan revealed an
increase in thyroid size involving the upper mediastinum and
affecting the left side of the esophagus.
Result: A diagnosis of Graves disease was performed and she
was started on Carbimazolewith dramatic improvement of tremor.
Conclusion: Graves syndrome has been recently described as a
possible cause of OT, and should be taken into account mainly
when OT presents with atypical phenotype.
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A case of acute onset postural deformity in Parkinson’s disease:
Pisa Syndrome or post-traumatic lateral trunk ﬂexion?
Mario Meloni1, K.S. Paulus1, E.R. De Natale2, V. Agnetti1
1Institute of Clinical Neurology, University of Sassari, Sassari
2Dept. of Biomedical Sciences, University of Sassari, Sassari
Pisa Syndrome (PS) and scoliosis are reported in Parkinson’s
Disease (PD): some authors deﬁne PS as a subacute-chronic
marked lateral ﬂexion of the trunk (LTF), generally contralateral to
the affected side, which can be corrected by passivemobilization orsupine positioning, whereby scoliosis is deﬁned as a pathologic
posture due to a lateral curve of the spine, usually combinedwith a
rotation of the vertebrae not relieved by passive movement; yet,
this separation is not straight. In PS, two EMG patterns may be
identiﬁed: hyperactivation of paravertebral muscles ipsilateral to
the bending side, both at rest and during contraction and a
different one, in which activation is seen contralaterally to the
bending site. No denervation patterns have been reported.
We describe the case of a 72 year-old man with a 6-year history
of PD ensued with right rigidity, tremor and bradykinesia with
postural instability and longstanding good response to L-DOPA and
Pramipexole. He developed acutely (1week) a 308 LTF ipsilateral to
the disease side, unresponsive to passive mobilization, supine
positioning or therapy changes. Few days before onset, he reported
repeated minor right ﬂank traumas. Dorsal and lumbar paraspinal
muscles looked hypertrophic on the left side, but hardly palpable
on the right. Standing EMG showed hyperactivity on the left
paravertebral muscles (opposite to the leaning side) at rest,
enhanced after activation and neurogenic denervation on the right.
Dorso-lumbar CT disclosed left-convex rotoscoliosis, left muscle
hypertrophy and right muscular atrophy with fatty degenera-
tion.This case features characteristics referable to both PS and
scoliosis but also atypical signs: very rapid onset, previous traumas
and ipsilateral neurogenic denervation at EMG. We speculate that
an insult to the ﬂank may have triggered the picture in an affected
context and the electrophysiological data seen on EMG would be
explained by a compensative muscular response.
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Levodopa/Carbidopa intestinal gel and subthalamic nucleus deep
brain stimulation: a 3 years comparison follow-up study
Aristide Merola, M. Zibetti, C.A. Artusi, S. Angrisano, L. Rizzi, M. Lanotte,
M.G. Rizzone, L. Lopiano
Department of Neuroscience, University of Torino, Torino
Background: In a previous study we compared the effectiveness
of Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) and
Levodopa/Carbidopa intestinal gel (LCIG) after 15 months of treat-
ment, observing an equal efﬁcacy between the two procedures in
two cohorts of parkinsonian patients with similar clinical features
at baseline, apart from cognitive functions. Here, we report the
clinical data of the same cohorts of patients after 3 years of follow-
up.
Methods: Two groups of 20 patients each, treated either with
STN-DBS or LCIG and matched for age, follow-up duration and
motor complications duration were evaluated by means of a
complete Uniﬁed Parkinson’s Disease Rating Scale and a battery of
neuropsychological tests.
Results: Clinical data were available for 17/20 patients of both
groups (3 patients treated with LCIG died and 3 STN-DBS patients
were lost at follow-up), showing a sustained clinical efﬁcacy on
motor complications, with a similar reduction of the ‘‘OFF’’ periods,
but a greater efﬁcacy of STN-DBS on dyskinesia duration. The
autonomy in Activities of Daily Living decreased over the years in
LCIG patients, as the baseline differences in cognitive proﬁle
became more evident. An higher number of procedure-related
complications was observed with LCIG, mostly related to recurrent
technical issues.
Conclusions: The two therapeutic procedures showed a similar
sustained efﬁcacy on motor ﬂuctuations, but a lower effectiveness
of LCIG on dyskinesia duration. However, the retrospective non-
randomized clinical study design and the baseline cognitive
differences in cognitive functions between groups should be
considered in the interpretation of our ﬁndings.
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Neurocognitive rehabilitation with motor imagery vs treadmill
training for freezing of gait in Parkinson’s disease: a pilot study
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Introduction: Freezing of gait (FoG) is a highly disabling
symptom of Parkinson’s disease (PD) characterized by brief,
episodic absence or marked reduction of forward progression of
the feet during walking. FoG pathogenesis is not completely
understood and pharmacological treatments generally have a poor
outcome. For this reason many rehabilitation treatments have
been proposed with contrasting results. Actually cueing and
treadmill training are considered the best practice. Since motor
imagery (MI) has been successfully used in stroke rehabilitation to
enhance the beneﬁcial effects of motor training, it could be useful
to test it as a potential tool in PD rehabilitation.
Objective: Aim of our study was to test the efﬁcacy of a
rehabilitationprogrambased onMI in improving FoG inPDpatients.
Materials and methods: 14 PD patients with FoG (median age
72  4, disease duration years 10  4, H&Y 1,7 range 1-3) with no
evidence of dementia (MMSE > 24) or depression (BDI < 16), were
enrolled and randomly assigned to different treatment groups.
Selected patients performed 20 sessions of a rehabilitation program,
Group 1 based on MI while group 2 underwent treadmill training.
Disease stage (H&Y and UPDRS III), FoG (FOGQ), quality of life (PDQ-
39), locomotion (Timed up and go-TUG, six minute walk test-6MWT),
balance (Berg balance test-BBT) and disability (Modiﬁed Parkinson’s
Activity scale-MPAS) were assessed at baseline and after treatment;
furthermore patients underwent a brief neuropsychological test to
assess frontal and execution functions.
Results: At baseline the two groups did no differ for clinical
variables, neuropsychological scores or rehabilitation scales. After
treatment a signiﬁcant reduction in FoGQ (p = 0,01) and an
improvement in others rehabilitation scales (MPAS = 0,01 BBT
p = 0,02 TUG = 0,04), were detected in group 1 while no signiﬁcant
changes were shown in group 2.
Conclusions: The rehabilitation programwithMI could represent
an interesting rehabilitation strategy to treat FOG in PD patients.
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Sleep alterations in dementia with Lewy bodies: sleep patterns
and clinical correlates, a descriptive video-PSG study
Brigida Minafra1,2, M. Terzaghi2,3, I. Bertaina1,2, N.G. Pozzi1,2, D. Arnaldi4,
R. Zangaglia1,2, R. Manni3, C. Pacchetti1,2
1Parkinson’s Disease and Movement Disorders Unit, National Insti-
tute of Neurology Foundation ‘‘C. Mondino’’, Pavia
2Interdepartmental Research Center for Neurodegenerative Disease,
National Institute of Neurology Foundation ‘‘C. Mondino’’, Pavia
3Sleep Unit, National Institute of Neurology Foundation ‘‘C.Mondino’’,
Pavia
4Department of Neurosciences, Ophthalmology and Genetics, Clinical
Neurophysiology Unit, University of Genoa, GenoaSleep disorders are very common in dementiawith Lewy bodies
(DLB). However, knowledge of sleep architecture and disorders of
nocturnal sleep in DLB is limited by the absence of systematic
video-polysomnographic investigations. We describe the video-
polysomnographic ﬁndings in twenty-three subjects diagnosed
with probable DLB submitted to face-to-face clinical interview and
overnight in-hospital video-polysomnography. A Spearman’s Rank
correlation was run to test the relationship between clinical and
cognitive features and sleep-related measures. All the patients
reported at least one sleep disturbance, which was the presenting
symptom in eight subjects (34.7%). Video-polysomnography
documented, within a pattern of reduced sleep continuity and
REM sleep, sleep apnea in 35%, periodic limb movements in 80%
and disruptive motor behavioural manifestations in 75.0% of the
subjects.
Motor behavioural events consisted of REM Sleep Behaviour
Disorder (RBD) in 53%, episodes mimicking RBD but related to
arousal from NREM or REM sleep in 13% and confusional events in
34% of the cases, isolated or in the framework of parasomnia
overlap disorder. No consistent correlations were found between
analysed clinical, cognitive and sleep-related variables. Clinicians
should be aware of the complexity of sleep alterations in DLB,
which encompass an overlap of impaired sleep structure, sleep
comorbidities and various motor-behavioural abnormal events,
and bear in mind the possibility of misleading symptoms and that
of overlooking sleep comorbidities; they should consider the
possibility of polysomnographic sleep investigations in order to
obtain a correct diagnosis and optimize treatment of disrupted
sleep.
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Prevalence of tremor in patients with adult celiac disease
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4IDCHermitage Capodimonte – ScuolaMedica Salernitana, Universita`
di Salerno, Salerno
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Introduction: Coeliac disease (CD) is a chronic immune-
mediated disorder that primarily affects the gastrointestinal tract.
Anyway there is an increasing number of reports describing
neurological complications of coeliac disease, especially ataxia,
peripheral neuropathy, restless legs syndrome and epilepsy.
Objective: The aim of the present study was investigating
prevalence and characteristics of tremor in CD.
Methods: CD patients attending Referral Regional Center for CD
were consecutively evaluated at Movement Disorder Unit of
University ‘‘Federico II’’ of Naples from January to May 2012. CD
diagnosis was based on duodenal biopsy and on the presence of
speciﬁc antibodies in serum (tTG, EMA, AGA). Exclusion criteria
were uncertain CD diagnosis, history of neuroleptic exposure,
other neurological or medical conditions know to be causative of
tremor, alcohol or drug abuse. All patients underwent a complete
neurological examination. In particularwe investigated prevalence
and clinical features of tremor.
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average age was 34,4 year. Gluten free diet was followed by 28 of
them, while 22 with a recent diagnosis of CD were on free diet.
Postural tremor was found in 13 patients (26%; M:1; F:11) with an
average age of 29,1 years. Three of themwere found as having both
postural and kinetic tremor (6%; M:1; F:2). No one was found as
having symptoms or signs of neuropathy, or additional elements of
cerebellar impairment. No relationwas found between presence of
tremor and gluten free diet adherence.
Conclusions: This is the ﬁrst study investigating prevalence and
clinical features of tremor in celiac disease. The mechanisms
leading to neurological disorders in CD are not yet understood. Two
different mechanisms have been proposed: a) a malabsorption-
related deﬁciency of neurotrophic and/or neuroprotective factors;
b) an autoimmune disregulation. Our preliminary results broaden
the spectrum of neurological disorders associated with CD and
indicate that tremor should be sought in all patients with CD.
Anyway further studies are needed to increase our knowledge on
‘celiac tremor’ and, in particular, to ﬁnd out possible mechanisms.
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Serpentine tongue
Marcello Moccia
Dipartimento di Scienze Neurologiche, Universita` di Napoli ‘‘Federico
II’’, Napoli
‘‘Serpentine tongue’’ has been recently described in a patient
with Multiple System Atrophy and in a patient with Parkinson’s
disease after initiation of levodopa therapy.We describe the case of
a 37 year old woman with progressive gastrointestinal disorders
associated to weight loss and decrease in daily life activities. After
4 months from symptom onset a movement disorder was
described as strictly restricted to the tongue. Movements were
sinuous, regular, stereotyped, relatively slow and primarily present
when the tongue was kept on the ﬂoor of the mouth.
An evaluation of the patient in relation to the wide range of
tongue movement disorders was made. The discussion highlights
different clinical and instrumental approaches to the case.
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Experience with transdermal rotigotine in patients affected by
atypical parkinsonian disorders
Davide Vito Moretti
IRCCS Fatebenefratelli S. Giovanni di Dio, Brescia
Background: Rotigotine (RTG) is a non-ergot dopamine agonist
(D3 > D2 > D1) developed as a new transdermal formulation, and
it is indicated for use in early and advanced Parkinson’s disease
(PD). The potential advantages of the RTGpatch include immediacy
of effect onset as intestinal absorption is unneeded, constant drug
delivery, better tolerability avoiding drug peaks and easy of use,
helping patient’s compliance. Based on this, RTG patch appears to
be a suitable candidate in the treatment of elderly patients.
Moreover, data about RTG use in atypical parkinsonian disorders
are scant.
Aim of the study: Observational study to evaluate the efﬁcacy
and tolerability of RTG in elderly patients affected by atypical
parkinsonian disorders.
Methods: We evaluated all subjects with diagnosis of atypical
parkinsonian disorders admitted to our institute and treated with
transdermal RTG. Patients were evaluated by UPDRS (part III), NPI
and all adverse events (AEs) were recorded.Results: 36 patients (mean age = 68,9 years;min = 52,max = 82)
were evaluated. 30/36 (83%) presented cognitive impairment
(mean MMSE = 18,9; min = 4, max = 30). Diagnosis was: parkin-
sonism in dementia (6), MSA-P (6), MSA-C (1), PSP (4), CBD (6),
vascular parkinsonism (3), LBD (6) and FTD with parkinsonism (2),
Farh’s disease (1), iatrogenic Parkinson (1). At baseline, mean
UPDRS-III score was 34,2/56 (min = 21/56;max = 49/56) andmean
NPI score was 52,4/144 (min 0/144; max 98/144). 31/36 (86%)
patients completed 6 months of treatment with RTG (mean
dose = 3.4 mg/24 h; min = 2;max = 16), mean UPDRS- III score was
26,2/56 (min = 12/56; max = 43/56) and mean NPI score 46,2/144
(min = 18/144; max = 45/144). 21/31 (67,7%) patients completed
12 months of treatment with RTG (mean dose = 4,2 mg/24 h;
min = 2 mg/24 h; max = 16 mg/24 h) mean UPDRS-III score was
26,9/56 (min = 15/56; max = 40/56) and mean NPI score was 43,3/
144 (min = 18/144; max 45/144). Reported AEs were: hypotension
(11 patients), nausea (7 patients), dystonia (3 patients, all treated
with concomitant L-dopa). 5 patients suspended RTG treatment
due to AE (vomiting, tachycardia and sleepiness).
Conclusions: In our population transdermal RTG seems to be
effective andwell tolerated. Due to its system of drug delivery, RTG
appears to be a suitable therapy in elderly patients as it has a good
tolerability proﬁle, improves patient’s compliance and helps
management of fragile patients.
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Transient parkinsonism in a patient with non convulsive status
epilepticus due to nonalcoholic steatohepatitis cirrhosis: a case
report
Vincenzo Moschella1, C. Gerace2, V. Cozzolino3, F.M. Corsi2, G. Cerasari4
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Background: Acquired hepatocerebral degeneration (AHD) is a
chronic and progressive neurological syndrome, characterized by
movement disorders, especially parkinsonism and ataxia, second-
ary to portosystemic shunt from numerous different genesis,
usually liver dysfunction. Non-alcoholic steatohepatitis (NASH) is
rarely reported to cause AHD.
Aims: To describe a case of transitory parkinsonism in a patient
with non convulsive status epilepticus and NASH-cirrhosis.
Methods and Results: A 60years oldwomanpresentedwith acute
confusional statewithout focal neurological deﬁcits. Electroenceph-
alogram revealed a non convulsive status epilepticus. Patient was
subsequently treated with several antiepileptic drugs (AEDs;
pheynitoin, valproate, phenobarbital, carbamazepine, clonazepam)
because of difﬁculty in discontinuing the state. Brain MRI showed
bilateral pallidal hyperhintensity in T1-weighted sequences. Serum
ammonium level was very high, a liver biopsy revealed NASH with
cirrhosis and abdominal CT scan revealed porto-caval shunt and
hepatosplenomegaly. Hepatotoxic AEDs were replaced with leve-
tiracetam and therapy for cirrhosis were started. General condition
signiﬁcantly improved but patient developed hypomimia, hypo-
phonia, generalized symmetric bradykinesia and mild asymmetric
resting tremor. These extrapyramidal symptoms were levodopa-
unresponsive, lasted for several weeks and ended gradually.
Conclusions: Deep relationship between brain and liver has been
known for a long time: in 1912 Wilson and in 1914 van Woerkom
described two forms, respectively hereditary and acquired, of
hepatic and cerebral pathology, and in 1965 AHD was deﬁnitively
Basal Ganglia 2S (2012) e1–e87 e61illustrated by Victor, Adams and Cole. Portosystemic shunt seems
to be the root of AHD, related to hepatic or non-hepatic diseases.
NASH is rarely reported to bring it on. Moreover, usually AHD
arises subacutely and carries on insidiously. In our case, AHD arose
abruptly in course of hepatic encephalopathy in a patient with a
misunderstood liver disease. This case should excite clinicians to
consider liver dysfunction in case of atypical parkinsonism and/or
encephalopathy of unknown origin, also in patient without history
of liver disease.
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Usefulness of waking day clinical-instrumental monitoring of
motor ﬂuctuations in Parkinson’s disease
Giovanni Mostile, G. Sciacca, A. Nicoletti, V. Dibilio, A. Luca, E. Bruno, L.
Raciti, D. Contrafatto, M. Zappia
Dipartimento GF Ingrassia, Sezione di Neuroscienze, Universita` degli
Studi di Catania, Catania
Background: Patients with advanced Parkinson’s disease (PD)
may experiment motor and non-motor ﬂuctuations during the
waking day which may affect subjective perception of their motor
conditions. A diurnal monitoring of their motor status performed
in a clinical setting has been proposed to correctly identify L-dopa
induced motor ﬂuctuations.
Objective: To evaluate agreement between historical informa-
tion and objective evaluations of motor ﬂuctuations in PD patients
by a diurnal clinical-instrumental motor status monitoring.
Methods: Patients admitted to our clinic were evaluated every
2-hours for 12 hours from 8:00 AM using the motor examination
section of the UPDRS (UPDRS-ME) and the Abnormal Involuntary
Movement Scale (AIMS) as clinical tools coupled with the
Movement Time (MT) as objective index of bradykinesia. Historical
information about patients motor condition and treatment were
collected before the evaluation.
Results: Ninety one patients were evaluated (age: 69.6  10.2;
39 women). Average UPDRS-ME at the baseline before taking the
daily dopaminergic treatment was 40.7  13.8. Forty two patients
(46.1%) referred a predictable motor deterioration of their motor
status during the day while 43 (47.2%) patients referred L-dopa
induced dyskinesia during the waking day. Wearing-off, clinically
deﬁned as a gradual emergence of parkinsonian disability between
therapeutic doses, was observed in 71 (78%) patients. Waking day L-
dopa induced dyskinesia were clinically detected in 48 (52.7%)
patients,with an average AIMS score of 7.5  4.8. Agreement between
historical and clinically-assessed wearing-off was 63.7% (k = 0.3;
S.E. = 0.08; p = 0.0001), while for the L-dopa induced dyskinesia
agreement was 90.1% (k = 0.8; S.E. = 0.1; p < 0.0001).
Conclusions: While L-dopa induced dyskinesia may be accu-
rately described by advanced PD patients during their interview,
wearing-off phenomena may require a daily clinical monitoring of
PD patients motor conditions to be identiﬁed and treated.
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A study of incidence of Restless Legs Syndrome (RLS) in the course
of DAergic therapy in de novo Parkinson’s disease (PD) patients
Anna Negrotti1, M. Angelini1, E. Marchesi1, M. Goldoni2, S. Calzetti1
1Dip. Neuroscienze, UO Neurologia, Azienda Ospedaliero-Universi-
taria di Parma, Parma
2Dip. Clinica Medica, Nefrologia e Scienze della Prevenzione, Labor-
atorio di Tossicologia Industriale, Universita` di Parma, ParmaBackground: The cross-sectional studies reporting an increased
prevalence of RLS in patientswith PD have shown that the sensory-
motor disorder had emerged in the great majority of them
following the onset of the neurodegenerative disease [1,3] and so
very likely after the starting of DAergic therapy. However,
prospective follow-up studies aimed at the assessment of the
occurrence of RLS in the course of DAergic therapy in de novo PD
patients are as yet lacking. We report the incidence rate of RLS in
the course of PD as from the starting of DAergic therapy in de novo
patients.
Patients and methods: 106 newly diagnosed according to UKPDS
brain bank criteria and previously unmedicated outpatients with
PD (67 male and 39 female) were enrolled in the study. None of
them had suffered from RLS in their life-time, as ascertained
according to IRLSSG criteria. RLS assessment was carried out every
six months and the ongoing antiparkinsonian drug regimen was
recorded. Incident cases were deﬁned those reporting at least one
episode of RLS in the six months preceding assessment.
Results: An incidence rate of overall RLS by 4.7 per 100 per year
and by 3.7 per 100 per year after the exclusion of ‘‘secondary’’ cases
of RLS was found, raised to 6.1 per 100 per year in the age bracket
from 55 to 64 years. 83.3% of incident cases occurred within 24
months from the starting of DAergic therapy.
Conclusions: An increased incidence rate of overall RLS as
compared to those reported in two recent population-based
studies [4] was found and it further increased in the age bracket
from 55 to 64 years after the exclusion of ‘‘secondary’’ cases of RLS,
supporting the view of a co-morbid association between PD and
RLS in patients on chronic DAergic therapy. We hypothesize that
the increased occurrence of RLS in the course of PD could result
from the interaction between a predisposing condition, i.e. PD, and
the effect of chronic DAergic therapy in patients in which the
neurodegenerative process has involved the DAergic hypothalamic
A11 area, site of origin of the diencephalo-spinal pathway.
References:
[1] Ondo WG et al. Arch Neurol 2002; 59: 421-4.
[2] Krishnan PR et al. Mov Disord 2003; 18: 181-5.
[3] Nomura T et al. Mov Disord 2006; 21:380-4.
[4] Szentkiralyi A et al. Sleep Med 2011; 815-20.
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Progressive external ophthalmoplegia, sensory ataxia and parkin-
sonism in a patient with POLG gene mutation
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ative and Neuromuscular Disorders Unit, Calambrone (PI)
Introduction: Disorders of oxidative phosphorylation affects 1/
5000 individuals and present heterogeneous involvement of
tissues (such as brain, muscle and peripheral nerves) highly
dependent upon ATP production.
Objective: To characterize themolecular defect of a patient with
progressive external ophthalmoplegia (PEO), peripheral neuropa-
thy, sensory ataxia, and parkinsonism.
Methods: After obtaining written informed consent, genomic
DNA was extracted from peripheral blood. The whole sequence of
Basal Ganglia 2S (2012) e1–e87e62themitochondrial genome and analysis of POLG, the gene encoding
mitochondrial DNA polymerase gamma, were performed using
standard Sanger methodologies.
Results: We present a 48-year-old Italian woman born to non-
consanguineous parents, with a negative family history, who was
received a diagnosis of bilateral PEO at the age of 26 years. At age
38 years she developed proximal and distal symmetrical limb
weakness and sensory ataxia. Electromyography showed myogen-
ic features and limb skeletal muscular biopsy was consistent with
mitochondrial myopathy. Brain MRI was normal. A diagnosis of
demyelinating sensory-motor neuropathy was made on the basis
of nerve conduction studies and sural nerve biopsy. Symptoms of
depression and anxiety-mood disorders were evident and treat-
ment with SSRI was started with beneﬁt. At age 48 years the
patient was examined because of recent onset of resting and
attitudinal hand tremor, and Parkinsonism. A homozygous
missensemutation (p.Ala889Thr) in exon 17 of POLGwas detected.
Conclusion: Mutations in POLG should be looked for in cases of
parkinsonism, especially when multisystem neurological involve-
ment is found.
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Expanding the clinical presentation of DYT5 mutations: is multi-
ple system atrophy a possible one?
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Introduction: Dopa responsive dystonia (DRD) is a clinically
deﬁned movement disorder characterized by childhood dystonia. It
generally involves a lower limb with a typical diurnal ﬂuctuation,
improving with sleep and worsening during the day. DRD is caused
by an autosomal dominant mutation in the GTP-cyclohydrolase 1
(GCH1) located on chromosome 14q22.1-q22.2. It causes a
deﬁciencyof tyrosinehydroxylaseat the terminal of thenigrostriatal
dopamine neurons. More than 100 mutations are known.
Objective: To evaluate clinical spectrum of DYT5 in a kindred
with different clinical phenotypes.
Methods: A 70-years old woman presented at our clinic with a
progressive ataxia associated to urinary incontinence and ortho-
static hypotension. At neurological examination the patient pre-
sented ataxic gait and parkinsonian signs such rigidity at upper
limbs, mild resting tremor and bradykinesia. Her nephew was
diagnosed as having DRD and her brother had Parkinson’s Disease
diagnosed 10 years earlier, since then on L-dopa therapywith a good
response and without complications. The FP-CIT SPECT of the latter
showed nigrostriatal degeneration. The woman was subjected to a
FP-CIT SPECT, positive, and to a heart MIBG SPECT, negative for
noradrenergic degeneration. L-dopa did not improve her symptoms.
A diagnosis of Multiple System Atrophy (MSA) was made. All the
subjects underwent molecular testing of the GCH1 gene.
Results: While GCH1 sequence analysis was normal, Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA) analysis, a PCR-
based method for detecting exon deletions or duplications,
revealed a heterozygous deletion of exons 5 and 6 in the nephew
(DRD) and in the brother (PD) of our patient. Therefore the same
analysis was performed on the woman, which resulted positive for
the same mutation.
Discussion: Parkinson’s disease but also focal dystonia or
recurrent tendonitis were previously described associated to
GCH1 gene mutations. This is the ﬁrst case report of MSA
phenotype associated to GCH1 mutation, expanding the clinical
spectrum.SC80
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Introduction: Defects of mitochondrial complex III (CIII) are a
relatively rare cause of mitochondrial dysfunction. The complex
catalyzes the electron transfer from reduced coenzyme Q to
cytochrome c and is composed of 11 subunits, one of which (MT-
CYB) is mtDNA encoded. Mutations in MT-CYB and in assembly
factor BCS1L account for the vast majority of cases with low CIII,
and are associatedwith awide range of neurological disorders. The
gene coding for human tetratricopeptide 19 (TTC19) produces a
poorly characterized protein thought to be involved in the correct
assembly of CIII. Recently, mutations in TTC19 have been described
in three unrelated Italian kindred in association with a severe
neurodegenerative disease.
Objectives: We studied a consanguineous Portuguese family
where a severe neurometabolic disorder occurred in four
siblings (three men and one woman) in association with a
slowly progressive disorder characterized by dystonia of hands
and feet, ataxic gait, severe olivo-ponto-cerebellar atrophy
documented at brain MRI, and relentless psychiatric manifesta-
tions. Variability in age at onset and disease course was
observed.
Methods: The enzymatic activity of CIII was determined in
muscle using a reported spectrophotometric method. Sequence
analysis of genomic DNA was performed to identify disease-
causing mutations in TTC19. Immunodetection analysis in muscle
homogenate and skin ﬁbroblasts allowed the detection of the
amount TTC19 protein using a commercially available anti-TTC19
antibody.
Results: In this family, we identiﬁed a novel homozygous TTC19
mutation predicting frameshift and early protein truncation. The
mutation was heterozygous in parents and healthy siblings, and it
was absent in ethnically-matched controls. The protein was
undetectable in tissues by Western blot analyses.
Conclusion: This is the fourth kindred presenting mutations in
TTC19. The clinical phenotype of such condition is severe,
embraces neurological and psychiatric symptoms, and represents
a further example of autosomal recessive ataxia of metabolic
origin.
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Axonal sensory-motor polineuropathy in two patients with duo-
denal levodopa infusion. To stop or not to stop the infusion?
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Basal Ganglia 2S (2012) e1–e87 e63Background: A severe complication of the duodenal levodopa
infusion in patients with Parkinson’s disease (PD) is the onset of an
axonal sensory-motor polyneuropathy (ASMP) that may worsen
substantially the quality of life of patients. The exact physiopatol-
ogy is uncertain, although the most likely hypothesis is that of
deﬁciency, in particular vitamin B12 and folate deﬁciency.
Objective: To open up a discussion and offer our experience on
an inescapable question when diagnosis of ASMP is made: ‘‘Should
the duodenal levodopa infusion be or not be suspended?’’ At the
moment there are no guidelines.
Clinical cases: Among 10 patients (6 males and 4 females)
implanted in recent years with a duodenal levodopa infusion
pump, 2 males, respectively of 75 and 70 years, have developed
an ASMP. Both had an advanced PD (stage IV of the Hoehn/Yahr
score and an UPDRS-III score respectively of 69 and 62 in OFF-
phase) and complicated by frequent motor ﬂuctuations, with a
few hours in the on phase, and major choreo-ballic dyskinesias.
In the ﬁrst patient the initial clinical sign of ASMP appeared
about eight months after placement of the pump (dose starter of
12 ml: continuous infusion 5.3 ml/h; extra dose 3.5 ml), in the
second case (dose starter of 12 ml: continuous infusion 6.1 ml/h;
extra dose 3 ml) about six months later. Diagnosis of ASMP was
conﬁrmed by EMG. In the ﬁrst case the duodenal levodopa
infusion was maintained, in the second interrupted.
Discussion: In the absence of guidelines, our choice was dictated
by practice. In the ﬁrst case (in agreement with family members)
we chose to continue infusion, with vitamin supplementation,
because the worsening of patient life’s quality did not allow an
alternative; in the second case, paroxysmal painful symptoms of
polyneuropathy did not leave any other choice than suspending
duodenal levodopa infusion and returning to the previous oral
therapy.
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Aims: There aren’t precise data regarding symptoms at PSP
onset and, if there are, they are incomplete or include a single
symptom.Moreover, they are not correlated to age. The aims of the
study is to investigate the symptoms at the onset.
Materials and Methods: Were enrolled all patients alive with
initial diagnostic suspect of PSP followed in the outpatients,
totalling 120. During the follow-up 33 patients were eliminated,
due to a diagnosis modiﬁcation or because medical records were
insufﬁcient. These satisﬁed the diagnostic criteria for PSP
(Litvan, 1996). These onset symptoms were considered:
psychiatric, parkinsonian, dystonic, ocular, axial, gait akinesia,
eyelid apraxia.
Results and discussion: The most frequent symptoms have been:
extrinsic ocular motility disorders (97,7%), falls without loss of
consciousness (100%), parkinsonism (100%). The most frequent
onset symptoms were axial, both single (19,54%) or in association
(68,96%). Psychiatric symptoms were the second in order of
frequency as only symptom (11,49%). Parkinsonian symptomswere the second in order of frequency, in association (40,2%).
Extrinsic ocular motility abnormalities appeared as initial symp-
tom in a very low percentage (2,29%). Gait akinesia represented the
onset symptom in a low number of cases (5,74%). The patients who
presented at onset only psychiatric symptoms (54 years) or gait
akinesia (56,6 years) were younger.
Conclusion: This study concentrated on the clinical phenotypes
of PSP at its onset, considered both as single and associated, and
with age. We highlight how gaze paralysis appeared only in a very
low number of cases at onset. The most frequent symptoms during
the course were: ocular motility, axial and parkinsonism.
Psychiatric symptoms were the second most frequent at onset,
as only symptom. Parkinsonian symptoms were the second most
frequent at onset, as associated symptoms. Patients who mani-
fested the pathology at its onset with psychiatric symptoms or gait
akinesia were younger.
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EEG in Alzheimer’s disease: what beneﬁt?
Cristina Paci, R. Gobbato, G. D’Andreamatteo, T. Carboni, S. Sanguigni,
S. Sobrini, A. Brandimarti, V. Urbano, B. Moretti
U.O.C. Di Neurologia, Ospedale Civile ‘‘Madonna del Soccorso’’ San
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Aims: EEG examination is used very frequently in Alzheimer’s
disease. The aim of our study was to determine whether there is
a directly proportional correlation between the rate of back-
ground EEG and the MMSE score in patients with Alzheimer’s
disease.
Materials andMethods:We studied 30 patientswith Alzheimer’s
disease, according to the NINCDS ADRADA criteria, 15 mild and 15
moderate. All patients have performed at same dayMMSE and EEG.
We calculated the MMSE score and the EEG background activity.
The statistical method has been obtained with t-test and Student’s
Test.
Results: In the group of mild EEG background activity was
7.4  1.6 Hz and theMMSE score of 22.20  1.80; group ofmoderates
in the EEG background activity was 7.19  1, 28 Hz and the MMSE
score of 16.06  2.07 (EEG: p = 0.000).
Conclusions: Our results demonstrate the low effectiveness of
EEG monitoring according to the severity of the disease. The
underlying rhythm is slow but we have not shown any difference
in EEG between the two groups, unlike the MMSE score. This
allows us to realize the validity of EEG to discriminate differential
diagnosis but not for follow-up; we conclude that EEG is the
‘‘gold standard’’ in the early stages of a neurodegenerative
disease and to differentiate a rapidly progressive viral encepha-
litis disease.
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The effect of rasagiline on prospective memory in newly diag-
nosed patients with Parkinson’s disease
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Introduction: Prospective memory could be impaired in
Parkinson’s Disease (PD) even at very early disease stages. Recent
evidence has suggested a possible role of rasagiline in modulating
cognitive functions in PD patients, especially in the dominion of
attention.
Basal Ganglia 2S (2012) e1–e87e64Objective: The present study was aimed at investigating the
effect of rasagiline, a monoamine oxidase type-B inhibitor, on the
performance on an event-based prospective memory task by
retrospectively evaluating a cohort of PD patients.
Materials and methods: A cohort of 33 PD patients was
administered an experimental prospective memory task at time
of diagnosis, before starting antiparkinsonian drugs (T0), and after
one-year treatment (T1) with dopaminergic treatment alone
(N = 16, T1: age 70.2  5.4 years, disease duration 24.3  7.1months,
UPDRS-III 15.5  6.0) or in combination with rasagiline (N = 17, T1:
age 64.7  5.5 years, disease duration 25.5  10.4 months, UPDRS-III
12.1  3.3). Separate scores were computed for correct execution of
intended action (prospective component-PC) and for recall of
intention (retrospective component-RC).
Results: Patients without rasagiline (Pts-R) and patients with
rasagiline (Pts + R) were similar in terms of dopamine agonists and
Ldopa doses. After 1 year treatment Pts + R showed an improve-
ment in PC while the group Pts-R worsened the performance
(Pts + R: T0 = 2.9  1.7 T1 = 3.6  1.1; Pts-R: T0 = 2.0  1.7,
T1 = 1.2  1.6). The change was statistically signiﬁcant between
the two groups (p < 0.005). No differences emerged in the RC.
Conclusion: These results are consistent with previous ﬁndings
suggesting that rasagiline may exert beneﬁcial effects on some
aspects of attention and executive functions in non-demented,
cognitively impaired PD patients. According to an explanatory
model previously proposed, the process of prospective remem-
bering involves different phases: intention formation, intention
initiation and intention execution (that rely on executive
processes) and intention retention (that rely on more retrospec-
tive memory storage capacity). Thus, rasagiline could be effective
on the executive processes that support PC of memory for
intention.
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Parkinson’s disease (PD) is a progressive neurodegenerative
disorder. In the ﬁrst stages PD has commonly a satisfactory
response to dopaminergic treatment but with disease duration
the pharmacological control of extrapyramidal signs decreases
progressively with comparison of complications such as wearing
off, on-off ﬂuctuations, dyskinesia, dystonia, and psychiatric
manifestations. Therefore medication has to be continuously
modiﬁed administering various drugs with increasing dosages.
Furthermore, PD commonly appears clinically after the sixth
decade of life and thus the majority of patients are probably
affected by internistical comorbidities which requires further
pharmacological treatment with the growing risk of side effects
and interactions between different drugs. Notoriously this
means worsening of quality of life (QoL). At this stage the
pharmacological management appears to be very difﬁcult. What
can we do? Which kind of possibilities and weapons do we
have?
First of all, the management of the later disease stages begins
with the treatment approach at clinical onset. The correct initial
management with the right use and combination of levodopa,
peripherical and central enzym inhibitors, and dopamine
agonists, optaining an acceptable symptom control is the
indispensable condition which permits a stable future treatmentconduct. The goal must be to delay as late as possibile treatment
complications exploiting strategies of levodopa saving. Then,
simple side effects frequently caused by the combination of
diverse drugs, can often be avoided by knowledge of pharmaco-
kinetics and dynamics. The most important thing for maintaining
a discrete QoL level is given by a global management including
medical therapy, speciﬁc conventional and not conventional
rehabilitation, and psychological support, aswell as integration in
a multidisciplinary team.
Doing so, there may be many advantages. Firstly, the disease
course is monitored and possible therapy revisions can be
performed easily on all treatment levels. Secondly, patients
and cargivers do not feel abandoned which increases the
QoL. Finally, the global management helps to avoid excessive
drug consume, unnecessary instrumental investigation and
hospitalization; in other words, it helps to restrain the health
economics.
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Introduction: Insulin-like Growth Factor-1 (IGF-1) provides
protection against loss of dopaminergic neurons in animal models
of Parkinson’s disease (PD) [1]; Epidermal Growth Factor (EGF)
promotes morphologic and neurochemical development of cul-
tured midbrain dopaminergic neurons [2]. Recently, increased
serum IGF-1 levels were found in early PD patients compared to
controls [3].
Objective: The aim of this study was to evaluate the inﬂuence of
baseline serum IGF-1, EGF and Growth Hormon (GH) on motor
progression in a cohort of ‘‘drug-naive’’ PD patients.
Patients and methods: Serum IGF-1, EGF and GH levels were
measured in 33 ‘‘drug-naive’’ PD patients; subsequently, due to the
observational nature of the study the patients were treated with
antiparkinsonian drugs according to physician’s decision and re-
evaluated in ‘‘on’’ state three times over a period of 24monthswith
UPDRS part III and UPDRS dopa-resistant score.4 Variation within
time and differences between quartiles of serum IGF-1, EGF andGH
levels were analyzed with repeated measures ANOVA. Post-hoc
analysis was performed with Bonferroni test. Analysis was
computed using daily LED as covariate.
Results: Mean age (SD) at diagnosis was 59,7 (8) years, with a
mean of 13,8 (5,5) months since the very ﬁrst putative clinical
manifestation of PD. 42% of patients were women. At the end of the
follow up period all the patients were in treatment. Overall mean
progression on the UPDRS part III was 0,5 point/year (95%CI:-0,5 to
1,53) and on the UPDRS dopa-resistant score was 0,3 point/year
(95%CI:0,13 to 0,55). Overall mean increase in LED was 111,6 mg/
year (95%CI:42 to 300). Repeated measures ANOVA showed no
signiﬁcant progression within time of UPDRS part III (p = 0,2), while
UPDRS dopa-resistant score showed a signiﬁcant progressionwithin
time (p < 0,03). Post-hoc analysis revealed that, excluding patients
with serum IGF-1 levels < 68 ng/ml, patients with higher baseline
value of IGF-1 showed higher UPDRS part III scores during the ﬁrst
two years of disease. No differences between subjectswere found for
UPDRS dopa-resistant score and for baseline serum EGF and GH
levels.
Basal Ganglia 2S (2012) e1–e87 e65Conclusions: In PD higher serum IGF-1 at diagnosis may be
associated with worse motor features during the ﬁrst two years of
disease.
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Introduction: Oro-mandibular dystonia (OMD) is a rare form of
focal dystonia affecting facial muscles. Both subcortical and corti-
cal mechanisms have been implicated in its pathophysiology.
Subcortical factors have been investigated testing brainstem
reﬂexes, whereas cortical excitability of the facial motor area
has not been studied yet.
Objective: To investigate excitatory and inhibitory interneuro-
nal circuits in the brainstem and in the cortical representation of
facial muscles, in patients with OMD.
Methods: Eight patients with OMD and 8 healthy controls were
studied. Short-interval intracortical inhibition (SICI) and intracor-
tical facilitation (ICF) were measured in the most affected
depressor angulis oris muscle, during 10% of maximal voluntary
contraction. The blink reﬂex (BR) and the masseter inhibitory
reﬂex (MIR) recovery cycles were recorded from the most affected
orbicularis oculi and masseter muscle, respectively. The R2 area of
BR recovery cycle and SP2 duration and inhibition of MIR recovery
cycle were measured at 200-1000ms interstimulus intervals (ISI).
To compare individual patients, ‘‘R2 index’’ and ‘‘SP2 index’’ were
calculated as average of recovery values (at ISIs of 200-500ms for
R2; 200-300ms for SP2).
Results: SICI and ICF were evidenced in both patients and
controls. Two way ANOVA using group as between-subjects factor
and ISI as within-subject factor showed a signiﬁcant effect of ISI
(p = 0.001) but no signiﬁcant effect of group. The R2 (n = 7) and the
SP2 (n = 5) duration indiceswere signiﬁcantly (p = 0.037 and 0.033,
respectively) higher in patients than controls, indicating less
suppression in OMD.
Conclusions: SICI and ICF did not differ signiﬁcantly in the facial
motor cortex of OMD and controls. By contrast, BR and MIR
recovery cycles were signiﬁcantly disinhibited in patients, in
agreementwith previous reports. These preliminary data suggest a
minor role for cortical factors with respect to subcorticalmechanisms in OMD pathophysiology, however a larger sample
is needed to draw ﬁrm conclusions.
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Cerebellar ataxia is characterized by an incoordination of
movement and due to cerebellar dysfunction. tDCS is a non
invasive stimulation that can change cortical activity by rather
weak electric currents modulation ion channels and gradients and
hence the resting membrane potential. Anodal tDCS leads to brain
depolarization (excitation) whereas cathodal Tdcs results in brain
hyperpolarization (inhibition). We report a case a 42 years-old
female whit sporadic, low progressive, form of cerebellar ataxia,
treated with tDCS and studied with gait analysis, in double blind,
shame controlled study. A neurological examination show: action
tremor, dysarthria and gait disturbances: enlarged base, ataxic
footing, with a prevalent incoordination on the left side.
On the basis of the potential capacity of tDCS stimulation to
improve asymmetric disturbances we decided to perform tDCS
cycle in attempt to improve ataxia and resynchronize the
execution of the step program. The patient undergoes to a placebo
stimulation for the ﬁrst week, and than a week of anodal tDCS on
the motor cortex (M1) of the right side of the brain and cathodal
simulation on motor cortex of the left side. A gait analysis was
performed preand post tDCS. We observed an improvement in
symmetry of execution and in gait speed after tDCS stimulation;
any change is been observed after shame stimulation. No variation
of cerebellar symptomswas observed. The initial improvement not
sustained at one month follow-up.
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considerations on 24 consecutive patients
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Background: Continuous duodenal levodopa infusion (DLI) is
widely recognized as an effective therapy for advanced Parkinson’s
Disease (PD) and represents a valid alternative for patients not
candidate to surgery. In literature common selection criteria are
lacking and the major inclusion criteria refer to those used for
candidate to Deep Brain Stimulation.
Basal Ganglia 2S (2012) e1–e87e66Methods: We evaluated retrospectively 24 advanced PD
patients treated with DLI from 2008 to 2011. 5 patients died, 2
of them for problems related to surgery and 3 for unrelated
medical conditions. 16 patients were evaluated at baseline and
after 24 months using UPDRS III, Freezing of Gait Questionnaire,
Non-Motor Symptoms Scale, PDQ-8, a complete battery assessing
cognitive and psychiatric status and the speciﬁc PD caregiver’s
quality of life scale (SQLC).
Results: All the 16 patients (9 men, 7 women, mean age 67.9
years) showed amarked improvement of motor complications and
a concomitant improvement in quality of life. Cognitive status
remained stable. All patients showed a signiﬁcative improvement
in depression scale. The impulsive behaviour or dopamine
dysregulation syndrome, present in 3 patients, resolved complete-
ly in the ﬁrst months. Among non motor symptoms we observed a
statistically signiﬁcant improvement in items regarding sleep,
fatigue and mood. 8 patient showed a remarkable reduction of
freezing and falls. Controversial data come from evaluation of
caregivers burden scale, with a critical worsening in the ﬁrst 6-9
months and a slight improvement in the long term follow up.
Conclusions: Our data conﬁrms the long term beneﬁcial effect of
DLI in patients with advanced disease on motor symptoms. The
best outcome was noted in patients not in advanced age, without
other signiﬁcant concomitant illnesses; psychosis but not demen-
tia correlated with a poor outcome. An important issue to be
considered in selection criteria is the impact of DLI on caregivers
stress and burden.
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The effect of mirror visual feedback on hemispheric balance
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Background: The clinical use of mirror visual feedback (MVF)
was initially introduced to alleviate phantom pain, and has since
been applied to the improvement of hemiparesis following stroke.
Neurophysiological mechanisms underlying MVF are still un-
known. To our knowledge only one study demonstrated that MVF
training can induce changes in the plasticity of primary motor
cortex (M1).
Objective: To directly investigate cortical modiﬁcation induced
by MVF training, we studied both the excitability of the two M1s
and transcallosal interaction between them in a group of healthy
subjects.
Methods: 10 healthy right handed subjects were enrolled in this
study. Subjects were asked to participate in MVF training protocol.
MVF training consisted in executing a ﬁnger taping motor training
task using themirror box technique. Subjectswere asked to oppose
thumb and index following an acoustic cue paced at 2 Hz for one
minute per 10 times each with a resting period of 30 seconds
within the training blocks. The subjects performed the training
with the left hand while watching the mirror which gave the
illusion of moving the right hand. Cortical activity changes were
tested before and after the training by means of Transcranial
Magnetic Stimulation (TMS). Both recruitment curve of left and
right hemispheres and Inter Hemispheric Inhibition from left and
right and right to left M1 were tested before and after training.
Results: MVF training induced no change in corticomotor
excitability of left and right hemispheres and in RL-IHI while it
induced an increase of transcallosal inhibition from LR M1s.Conclusions: These preliminary results suggest that transcallo-
sal interaction from the ‘‘illusioned’’ hemisphere to the contralat-
eral one can be modulated by MVF training. One possible
explanation is that transcallosal inhibitory interhemispheric
interaction acts to suppress unwantedmovements in the left hand.
SC91
Deep brain stimulation of subthalamic nucleus for advanced
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Introduction: deep brain stimulation of the subthalamic nucleus
(STN-DBS) is an efﬁcacious treatment in well selected patients
affected by Parkinson’s disease (PD). Several studies describe a loss
in verbal ﬂuency after STN-DBS.
Aim: Aim of the study is to assess the neuropsychological
outcome of bilateral STN-DBS in patients affected by PD.
Method: 37 PD patients selected for STN-DBS (age 60.59  5.81
years, PD duration 13.19  6.52 years, MMSE = 27.44  1, LEDD
1396.77  819.77 mg/die) were assessed twice: one week before
STN-DBS (in med-on condition) and after 12-24 months after STN-
DBS (in med-on condition with stimulator switched on). Neuropsy-
chological tests explored executive functions, attention, short and
long-term memory.
Results: Motor scores signiﬁcantly improved after STN-DBS. Our
study of cognition show an increase of perseverative errors at
Modiﬁed Card Sorting Test, an increase of time in Stroop test-
interfering condition, a loss in verbal ﬂuency, both phonemic and
semantic.
Conclusions: STN-DBS inﬂuences only executive control func-
tions, not causing a global cognitive decline. Our data conﬁrm that
STN-DBS is a safe procedure in a choort of well-selected
parkinsonian patients.
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Syndrome of rostral midbrain dysfunction secondary to ventri-
culoperitoneal shunt malfunction
Veronica Redaelli, M. Furlanetto, L.G. Valentini, F. Girotti
Neurological Institute Carlo Besta, Milano
We describe two cases with rostral midbrain dysfunction
secondary to malfunction of ventriculoperitoneal shunts present-
ing ocular and extrapyramidal signs, mutism, and alterations of
consciousness.
Case 1: a 71-years-old woman was treated with ventriculoper-
itoneal shunt for normal pressure hydrocephalus. After a valve
control she took temporary improvement of gait disturbance, but
after a few months symptoms progressed with severe akinesia,
muscular rigidity of the limbs, vertical gaze restriction, palpebral
retraction, convergence–retraction eye movements and anarthria
with partial alterations in consciousness. No improvement
occurred after third ventriculostomy. DAT scan don’t show
reduction of dopamine transporter density.
MR image showed intracranial hypotension syndrome. After
ventriculoperitoneal shunt closure and a treatment with L-Dopa
the patient began to comunicate and improved in vertical gaze
restriction and muscular rigidity of the limbs.
Basal Ganglia 2S (2012) e1–e87 e67Case 2: a 31-years-old man was treated with endoscopic third
ventriculostomy for triventricular hydrocephalus secondary to
aqueductal stenosis, and with ventriculoperitoneal shunt two
months later. Then he presented somnolence, mutism, vertical
gaze restriction, convergence-retraction eye movements and
severe akinesia with endocranial hypotension signs. He was
treated whit L-Dopa and with another endoscopic third ventricu-
lostomy and ventriculoperitoneal shunt closure. He gradually
resumed a normal state of consciousness and motor autonomy,
which persisted even after the interruption of L-Dopa. He reported
that during the condition of mutism he was able to understand all
verbal delivery but was unable to perform them.
Conclusions: Neurological features of the two patients charac-
terized by vertical gaze restriction, palpebral retraction, conver-
gence-retraction eye movements, severe akinesia, muscular
rigidity of the limbs and trunk and mutism can be justiﬁed by
disfunction of periaqueductal areas of rostral midbrain (posterior
commissure and nuclei, and periaqueductal gray matter). Integrity
of dopamine transporter density show that nigrostriatal dopami-
nergic pathway can’t be responsible of psychic and motor akinesia
that we can deﬁne as an ‘‘akinetic closed-in’’.
SC93
Intensive rehabilitation increases BDNF serum levels in patients
with early Parkinson’s disease
Giulio Riboldazzi, C. Comi, R. Maestri, S. Buttini, E. Bellinzona, F.L.
Lombino, M. Perini, D. Uccellini, R. Cantello, G. Frazzitta
Centro Parkinson e Disordini del Movimento, Ospedale di Circolo e
Fondazione Macchi, Varese
In the last decade, a considerable number of reports showed
that physical exercise is effective in improving balance, gait, and
general motor performance in Parkinson’s disease (PD). Recent
studies highlightened that i) moderate to vigorous activities in
preceding years decrease PD risk and ii) intensive exercise leads to
optimal results in PD rehabilitation. The neuroplastic effect of
intensive exercise may be linked to increased release of
neurotrophic factors, such as brain-derived neurotrophic factor
(BDNF).
The aim of this study is to assess whether intensive rehabilita-
tion treatment (IRT) is able to modulate BDNF serum levels.
Twenty ﬁve patients with early PD and under Rasagiline
monotherapy for at least 2 months were enrolled in the study.
Fourteen patients underwent IRT (group 1), while nine patients
continued taking only pharmacological treatment (group 2). IRT
consisted of a 4-week cycle of physiotherapy that entailed three
daily sessions 5 days a week. BDNF serum levels at enrolment and
1, 2, 3 weeks later were tested in both groups. We found that
baseline BDNF serum levels did not differ signiﬁcantly between the
two groups.
In all patients from group one, BDNF levels showed an increase,
which was statistically signiﬁcant after 10 days of IRT and
remained stable over the treatment period; on the contrary, BDNF
serum levels remained quite stable in patients from group 2.
This study suggests that IRT in patients with early PD is able to
induce an increase of BDNF serum levels, which is maintained over
the whole treatment period. We recently showed that IRT is
effective in patients with early PD, and our current observations
provide a biological basis to the beneﬁcial effect of IRT. Indeed our
ﬁndings are in line with studies on animal models, showing that
intensive exercise is effective in promoting neuronal growth
factors release and eventually cell proliferation and neuronal
differentiation.SC94
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Background: Continuous infusion of intrajejunal levodopa/
carbidopa gel (CIILG) for advanced Parkinson’s disease (PD) has
been proved to be beneﬁcial on motor complications, non-motor
symptoms and quality of life in the short-term follow-up. Aim of
this two-center, retrospective, open-label study was to evaluate
the long-term effect of CIILG on patients’ condition and caregivers’
quality of life.
Materials and methods: The assessments (performed at
baseline and at latest follow-up available after CIILG) included:
the uniﬁed PD rating scale (UPDRS I-IV), the non-motor
symptoms scale (NMSS), the PD questionnaire (PDQ-8), the
PD sleep scale (PDSS), and a battery assessing the cognitive and
psychiatric status as well as caregiver’s quality of life.
Medications were expressed as levodopa equivalent daily dose
(LEDD).
Results: 14 advanced PD patients (age: 67.0  11.5 years, disease
duration: 12.9  4.8 years) were followed for 24.9  14.4 months
after CIILG. Total LEDDwas unchanged at follow-up, however therapy
was globally simpliﬁed by reducing dopamine agonists (DAs). A
statistically signiﬁcant beneﬁcial effect was shown on motor
complications while the severity of motor symptoms did not change
over time. A signiﬁcant improvement of depressive symptoms and
psychiatric side effects caused by DAswas detected. Sleep quality and
diurnal somnolence ameliorated as revealed by the signiﬁcant
reduction of PDDS. Caregivers’ stress and patients’ quality of life
were not signiﬁcantly improved. However, when categorized
according to their outcome, patients with improvement of motor
condition and functionality gained an improvement of quality of life.
Apart from the severity of motor impairment at baseline, no other
predicting factors were detected.
Conclusions: CIILG is an effective treatment option for patients
with advanced PD over the long-term period as it may improve
both the motor complications and the psychiatric side effects
caused by other dopaminergic therapies.
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Myoclonus in a patient undergoing hysteroscopic myomectomy
Steno Rinalduzzi, S. Almonti, A.M. Cipriani
UOCNeurologia e Neuroﬁsiopatologia, Ospedale Sandro Pertini, Roma
Introduction: Transcervical endoscopic surgery uses a new
hysteroscopy technique that entails inserting a scope into the
uterine cavity and instilling a suitable distending medium to
visualize the endometrium. If these ﬂuids are rapidly absorbed
they can cause volume overload, electrolyte imbalance and vari-
able concomitant adverse effects. We describe here a patient in
whom myoclonus developed during hyponatremia after hystero-
scopic myomectomy.
Case report: A 58-years-old woman was admitted for elective
hysteroscopic myomectomy to treat a large submucosal
Basal Ganglia 2S (2012) e1–e87e68leiomyoma. Anesthesia was induced with propofol 150 mg iv.
Three liters electrolyte-free 1.5% glycine solution was instilled
to distend the uterus. At one hour after the distending
medium infusion started, laboratory ﬁndings disclosed low
sodium 120 mmol/L and the procedure was stopped. One hour
later myoclonus developed. Neurological examination showed
myoclonus at rest, generalized myoclonic jerks, predominantly
involving the bilateral sternocleidomastoid and abdominal
muscles and left limbs, but no other focal neurological signs.
The patient was alert and cooperative; jerks were spontaneous
and triggered by sensory stimuli. The electroencephalography
(EEG) recording showed no abnormal EEG activity correlating
with the jerks. Brain computed tomography was normal. The
patient was treated with diazepam, she was immediately
sedated and the myoclonic jerks stopped. Arterial blood tests
2 hours later showed hyponatremia, hypokaliemia and hypo-
calcemia. Electrolyte imbalance normalized within 10 hours
and the myoclonus gradually decreased and resolved within
24 h.
Conclusion: Myoclonic jerks are an extremely rare complication
in a patient undergoing surgical hysteroscopy. The clinical
characteristics of the myoclonus and lack abnormal EEG activity
correlating with the jerks resemble reticular reﬂex myoclonus and
probably reﬂect an electrolyte disorder. The case report we present
underlines the need to detect in time and promptly treat
neurological symptoms, an uncommon event complicating trans-
cervical hysteroscopic surgery.
SC96
Prognostic factors of long term cognitive impairment in Parkin-
son’s disease patients treated with subthalamic nucleus deep
brain stimulation
Laura Rizzi, A. Merola, E. Montanaro, M. Zibetti, M.G. Rizzone, C.A. Artusi,
M. Lanotte, L. Lopiano
Universita` degli Studi di Torino, Dipartimento di Neuroscienze, Torino
Background: Cognitive impairment has been increasingly
recognized as part of Parkinson’s disease (PD) clinical features.
It has been reported an 85% prevalence of dementia after 15 years
since PD diagnosis; age, precocious impairment of neuropsycho-
logical functions and akinetic-rigid disease feature seem to be
negative prognostic factors. Subthalamic nucleus deep brain
stimulation (STN-DBS) is a therapeutic option for a subset of PD
patients with long-lasting preserved cognitive function and
levodopa response. Nevertheless, the medium-long term cogni-
tive effects of STN-DBS are not completely understood. The aim of
this study is to investigate the possible prognostic factors of
cognitive impairment in PD patients treated with STN-DBS,
considering the clinical and neuropsychological evaluations of a
large cohort of patients (182 subjects) up to  5 years since
surgery.
Materials andMethods: The clinical and neuropsychological data
of PD patients treated with STN-DBS in Turin between 1998 and
2010 were collected at baseline and at each follow-up available.
The follow-up data were clustered in four different time-points:
baseline, 1 year, 3 years and  5 years since surgery. A Cox
regression analysis was performed analyzing the prognostic value
of several clinical and neuropsychological baseline factors and
their risk of predict cognitive impairment.
Results: Clinical and neuropsychological data were available for
182 patients at baseline, 155 patients at 1-year, 107 patients at 3-
years and 63 patients at  5-years since surgery. Conclusion: The
interaction of different speciﬁc clinical and cognitive featuresmight predict the risks of developing cognitive impairment in PD
patients treated with STN-DBS.
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for tremor dystonia: a case report
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Objective: To evaluate the efﬁcacy of deep brain stimulation
(DBS) of the subthalamic nucleus (STN) for the treatment of
dystonic tremor (DT).
Background: DBS is a valid therapeutic option for the treatment
of movement disorders unresponsive to pharmacologic measures.
The globus-pallidus-internus and the nucleus-ventralis-interme-
dius of the thalamus are considered the ﬁrst choice target for
dystonia and non-parkinsonian tremors, respectively. STN-DBS is
effective for the treatment of Parkinson’s disease, but its efﬁcacy
for dystonic disorders has been already described too. We
evaluated the efﬁcacy of STN-DBS for the treatment of a patient
with severe DT refractory to medical treatment.
Methods: In 2007 a 63 years old patient with severe DT
underwent bilateral STN-DBS. The disease onset was reported at
age seventeen, with a bilateral postural tremor of the upper limbs
that worsened with time, involving the lower limbs. Severe
dystonia, involving limbs, trunk and cranial district appeared later
on. All pharmacologic treatments failed, and at the time of surgery
the disease was very disabling. Ventriculography, MRI and
intraoperative multi-track microrecording and microstimulation
were performed to individuate the STN. Clinical evaluation was
performed preoperatively, at 2-years and 5-years follow-up by the
Burke-Fahn-Marsden-Dystonia scale (BFM) and the Fahn-Tolosa-
Marin-Tremor scale (FTM).
Results: Both tremor and dystonia signiﬁcantly improved with
STN-DBS, and this improvement was maintained over the time.
Preoperatively, the BFM-movement-score was 53, the BFM-
disability-score was 19 and the FMT-score was 102. At 2-years-
follow-up, in the stim-on condition (3.2V-right-STN, 2.9V-left-
STN; 60us; 130 Hz), the BFM-movement-score was 18, the BFM-
disability-score was 12 and the FMT-score was 58. At the 5-years-
follow-up, in the stim-on condition (3.5V-right-STN, 3.0V-left-STN,
60us, 130 Hz), the BFM-movement-score was 19, the BFM-
disability-score was 12 and the FMT-score was 59.
Conclusions: Despite the necessity of larger studies, STN-DBS
could be considered as an effective long-term therapeutic option
for uncommon movement disorders, as DT.
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Introduction: Acute onset of involuntary movements as hemi-
chorea-hemiballismus caused by basal ganglia dysfunction have
Basal Ganglia 2S (2012) e1–e87 e69been widely described both due to a vascular lesion and in non-
ketonic hyperglycaemia. In the latter condition, movements can
persist despite treatment.
Objectives: To describe acute onset of left-sided hemichorea-
hemiballismus in a lady with underrated type-2 diabetes mellitus
and her dramatic improvement after treatmentwith tetrabenazine
and clonazepam.
Methods: A 85-year-old lady presented at the emergency
department after a fall caused by acute onset of involuntary
movementsof the left limbs. She suffered fromarterial hypertension
but there was no history of diabetes mellitus, other diseases,
exposure to drugs or family history of movement disorders.
Results: On admission she was fully oriented and neurological
examination showed chorea-ballism involving both left limbs
with normal muscle strength and no other neurological im-
pairment. Movements were unsuppressible, increased with
emotions and voluntary movements of the right limbs and
disappeared during sleep. Blood examination showed severe
hyperglycaemia (750 mg/dL - normal values 60-110 mg/dL) and
glycosylated haemoglobin A1c was 112 mol/mol (normal values
20-42). Blood pH and urinary ketones were unremarkable as well
as other routine blood tests (calcium concentration, thyroid
hormones, liver and renal tests). Endocrinological consultancy led
to a diagnosis of type-2 diabetes mellitus. Normal glycaemia was
restored after 3 days on insulin therapy, then treatment with
gliclazide + metformine was started. Brain CT scan was unre-
markable. T1-weighted brain magnetic resonance imaging (MRI)
showed a hyperdensity in the right pallidum-putamen, detectable
on T2-weighted and Flair images, too. After intravenous gadolini-
um administration, subtle contrast enhancement appeared
within and around the lesion. Chorea-ballistic movements
disappeared in the lower limb and improved signiﬁcantly in
the upper one after a week on tetrabenazine 25 mg tid and
clonazepam 8 drp/die.
Discussion: Tetrabenazine has been effective and well-tolerated
in our case of acute-onset hyperglycaemia-related movement
disorders.
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Somatosensory temporal discrimination threshold can differenti-
ate multiple system atrophy patients from Parkinson’s disease
patients
Lorenzo Rocchi, A. Conte, A. Nardella, P. Li Voti, G. Leodori, G. Fabbrini,
A. Berardelli
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Introduction: Somatosensory Temporal Discrimination
Threshold (STDT) is deﬁned as the threshold for perceiving
two tactile stimuli as clearly distinct. STDT physiological
mechanisms include afferent sensory input gating and a time-
locked interplay between cortical and subcortical structures.
STDT is altered in various movement disorders such as Focal
Dystonia, Parkinson’s Disease (PD) and Multiple System Atrophy
(MSA).
Obectives: To investigate whether STDT can be used as a
diagnostic aid in differentiating patients with PD and MSA.
Methods: Nineteen MSA patients, twenty-two PD patients and
eighteen age-matched healthy subjects were tested for STDT.
Clinical evaluation included Hoehn and Yahr Scale, Uniﬁed
Multiple System Atrophy Rating Scale for MSA patients and
Uniﬁed Parkinson’s Disease Rating Scale for PD patients. STDT wasinvestigated by delivering paired electrical stimuli starting with an
inter-stimulus interval (ISI) of 0 msec (simultaneous pair), and
progressively increasing the ISIs in 10 msec steps. Subjects had to
report whether they perceived a single stimulus or two temporally
separated stimuli. Between group ANOVA was used to compare
STDT values in PD, MSA and healthy subjects. A receiver operating
characteristic (ROC) curve analysis was used to assess the
diagnostic accuracy (sensitivity and speciﬁcity) of STDT testing
in differentiating MSA from PD patients.
Results: Between group ANOVA showed a signiﬁcant effect of
factor group (F 2,52 = 19,00; p < 0,00001). Post-Hoc analysis
showed that STDT values inMSA and PDpatientswere signiﬁcantly
higher than those obtained in healthy subjects. The ROC curve
analysis for the STDT value calculated on the right hand in PD and
MSA patients yelded 78,95% sensitivity and 86,36% speciﬁcity with
a cut off STDT value of 140 msec.
Conclusions: The degree of STDT abnormality is higher in MSA
than in PD patients and, due to the high sensitivity and speciﬁcity,
STDT testing can effectively differentiate MSA from PD patients.
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Newclass of nitric oxide donor derived fromPiloty acid as possible
drugs for Parkinson’s disease treatment: an in-vitro microdialysis
study
Gaia Rocchitta1, O. Secchi1, M.D. Alvau1, E. Garribba2, A. Porcheddu2,
L.V. Deluca2, D. Sanna3, P.A. Serra1
1Department of Clinical and Experimental Medicine, University of
Sassari, Sassari
2Department of Chemistry and Pharmacy, University of Sassari,
Sassari
3Institute of Biomolecular Chemistry, National Research Council,
Sassari, Sassari
Nitric oxide (NO) is one member of a new class of gaseous
signaling molecules with fundamental functions in biology.
Several pharmacological implications of NO have been demon-
strated and numerous studies in vitro and in vivo showed that NO-
generating drugs (NO donors) cause an increase of the extra-
cellular level of dopamine in the striatum. This could suggest a
possible application of such NO-donors in the treatment of
Parkinson’s disease. PC12 cells can reproduce experimental model
of Parkinson’s disease, since they are known to synthesize, secrete,
and metabolize DA. The present work aims to study the effects of a
new class of NO donors on the release of dopamine from PC12 cell
suspensions by means of capillary microdialysis. The newly
synthetized molecule are derived from Piloty Acid that spontane-
ously is able to release NO.
Each molecule was synthetized starting from Piloty Acid,
commonly commercially available, by adding different substituent
groups, capable of modulating the release of dopamine from these
molecules.
Themicrodialytic protocol provided the perfusion of NO donors
for 60 minutes and recovered samples were analyzed by means of
HPLC-EC instrument.
All the newly synthetized donor produced a statistically
signiﬁcative increase in dopamine concentrations comprised
between 3.29- and 6.21-fold respect basal levels. The molecule
that had a nitro-group as substituent determined a signiﬁcant
decrease in DA concentration (more than 70% compared to basal
levels).
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Dopamine Transporter expression in patients chronically treated
with rotigotine: results from a preliminary prospective SPECT
study
Carlo Rossi1,2, D. Genovesi3, D. Frosini1, C. Menichetti4, E. Filidei3,
D. Volterrani5, U. Bonuccelli1, R. Ceravolo1
1Department of Neuroscience, University of Pisa, Pisa
2UOC Neurophysiopathology, Ospedale F. Lotti, ASL 5 Pisa, Pisa
3UO Nuclear Medicine, Fondazione Toscana ‘‘G. Monasterio’’, Pisa
4UO Neurology, Ospedale-ASL1 Citta` di Castello (Perugia)
5UO Nuclear Medicine, University of Pisa, Pisa
Background: Neither Ldopa or immediate release dopamine-
agonist have demonstrated to interfere with FP-CIT SPECT binding.
Recently, in order to avoid or reduce the risk ofmotor complication
and to allow a more physiologic continuous dopaminergic
stimulation longer acting and extended release formulations of
dopaminergic drugs have been launched. With once-daily
application, the patch of rotigotine matrix provides constant
non-ﬂuctuating plasma drug levels at steady state, resulting in
continuous and stable plasma and brain levels with a continuous
striatal dopamine-receptor stimulation.
Objective: The aim of this study was to evaluate the effect of
chronic treatmentwith rotigotine on striatal dopamine transporter
(DAT) in patients with Parkinson’s disease (PD) by means of FP-CIT
SPECT.
Methods: In this prospective study, we investigated presynaptic
nigrostriatal function in 8 de novo patients fulﬁlling clinical criteria
for ‘‘probable PD’’ (age 59 6.2 years; M/F 5/3) using FP-CIT SPECT
before and after 3 months of treatment with rotigotine (mean daily
dose 7.75 1.98 mg). For data analysis, speciﬁc (left and right caudate,
left and right putamen) tonon-speciﬁc (occipital cortex)binding ratios,
putamen to caudate ratios and asymmetry indexes were calculated.
Results: During rotigotine treatment, all patients improved
motor symptoms (UPDRS III mean score 11.88  2.59 vs 7.63  1.92
on therapy, p = 0.0022). Striatal FP-CIT levels showed a signiﬁcant
improvement in each patient at the follow up scan. Comparisons
between the whole group before and after treatment showed a
signiﬁcant improvement in FP-CIT uptake in both caudate and
putamen (p < 0.001 in each nucleus). Putamen to caudate ratio and
asymmetry indexes did not show a signiﬁcant difference before and
after treatment.
Conclusions: Our results suggest that rotigotine could affect FP-
CIT binding and should be withdrawn before SPECT examination.
These ﬁndings could be explained as expression of loss of efﬁcacy
of this drug in our PD population. Since DAT serves to maintain
relatively constant dopamine synaptic levels and its expression is
inversely correlated with dopamine turnover, the increase of DAT
after rotigotine might have the effect to preserve DA in the nigro-
striatal terminals.
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Creative thinking in patients with Parkinson’s disease and healthy
controls: does the artistic profession makes the difference?
M. Canesi1, Maria Luisa Rusconi2, R. Cilia1, E. Reali2, F. Moroni2, G. Pezzoli1
1Parkinson Institute, Istituti Clinici di Perfezionamento, Milan
2Department of Human Sciences, Universita` degli Studi di Bergamo,
Bergamo
Introduction: Creative drive and enhanced artistic like produc-
tionmay emerge in patientswith PD during dopaminergic therapy.A recent study (Canesi et al., 2011) suggests that newly acquired
artistic-like production in PD patients might represent the
emerging of innate skills in a subset of predisposed patients and
this is not associatedwith impulsivity or impulse control disorders.
Moreover, changes in painting style after treatment onset have
been described in some case reports. Nonetheless no data are
available in de novo PD patients (PD-dn) and in PD patients with
professional artistic job (PD-art).We investigated creative thinking
in different PD patients and healthy controls by means of the
abbreviated Torrance test for adults (ATTA).
Aims: To evaluate creative thinking in Parkinson’s disease (PD-
dn) patients with any dopaminergic treatment and in professional
artists (PD-art) patients by means of the ATTA.
Method: We investigated creative thinking in a cohort of
cognitively preserved patientswith PD: 11 PD-dn, 10 PD-art and 25
PD-na by means of the ATTA. We also investigated a sample of
healthy controls (HC), with (12 HC-art) and without (47 HC-na)
professional artistic job, by means of the ATTA. All PD patients
underwent the following evaluation: *Neurological assessment:
UPDRS-part III; HY stages. *Cognitive assessment: MMSE, Frontal
Assessment Battery (FAB). *Mood scales: Geriatric Depression
Scale (GDS) Results: Mean ATTA score of PD-art patients was found
to be similar to HC-art (73,6  22,4 vs 97,0  29,1 respectively) and
of PD-dn vs PD-na (54,9  29,6 vs 55,6  24,6). PD-art patients and
HC-art showed a signiﬁcantly higher ATTA score than PD-na and HC-
na respectively (p < 0,01). *No correlation was found with reference
to any demographic and clinical data in PD subgroups.
Conclusion: Our results suggests that creative thinking is not
correlated with dopaminergic therapy in PD patients with and
without professional artistic job. These results are in accordance
with the hypothesis that dopaminergic system is involved in
creative drive but not in idea generation.
References:[1] Canesi M et al, Artistic productivity and creative thinking in
Parkinson’s disease. European Journal of Neurology 2012, 19:
468-472[2] Goff K et al, The Abbreviated Torrance Test for Adults (ATTA). IL
Scholastic Testing Service, 2002[3] Torrance EP, The Torrance Test of Creative Thinking-Stream-
lined Scoring Guide Figural A and B[4] Drago V et al, Creativity in Parkinson’s disease as a function of
right versus left hemibody onset. Journal of the Neurological
Sciences 2009, 15; 179-183
SC103
Insulin sensitivity and early-phase insulin secretion are not
impaired in normoglycemic patients with Huntington’s disease
Cinzia Valeria Russo, E. Salvatore, T. Tucci, C. Rinaldi, M. Massarelli,
F. Rossi, L. Di Maio, A. Filla, A. Colao, G. De Michele
Departments of Neurological Sciences and of Molecular and Clinical
Endocrinology and Oncology, Federico II University, Naples
Background: Huntington’s Disease (HD) is an autosomal
dominant neurodegenerative disorder caused by an expanded
CAG repeat in exon 1 of the Huntingtin gene (HTT)which encodes a
stretch of glutamines in the huntingtin protein. Apart from main
neurological impairment, there is increasing evidence pointing
towards an early involvement of the endocrine system in HD.
Recent studies were conducted to investigate association with an
an increased risk of diabetes mellitus and with an impairment in
insulin sensitivity and insulin secretion in HD patients with
contradictory results.
Basal Ganglia 2S (2012) e1–e87 e71Objective: To investigate the association between diabetes
mellitus and HD by performing an oral glucose-tolerance test
(OGTT) to evaluate the glucose-tolerance status and OGTT-related
insulin release.
Patients and Methods: Twenty-eight consecutive patients with
HD seen at our Clinics and 28 healthy controls were matched for
age, sex and BMI. Diagnosis of HD was conﬁrmed in all patients by
analysis for the CAG repeat expansion. Clinical assessment of
patients was performed using the Uniﬁed Huntington’s Disease
Rating Scale (UHDRS) motor section and the Total Function
Capacity (TFC). Wide basal metabolic investigations and a 2-hour
75-g oral glucose tolerance test (OGTT) were performed. We used
the homeostasis model assessment of insulin resistance (HOMA-
IR) as index of insulin sensitivity. Insulin secretionwas determined
by the Insulinogenic index.
Results: HD patients did not differ from the control group with
respect to fasting plasma glucose level, insulin sensitivity and
secretion. However, HD patients showed lower plasma glucose (-
19%) and insulin levels (-48%) at 30 minutes after oral glucose load
andhigher plasma insulin at 90 (+132%) and120 minutes (+380%) in
comparisonwith controls. CAG expansion size, disease stage or BMI
did not inﬂuence HOMA-IR or insulinogenic index in HD patients.
Conclusions: Our data challenge the assumption of an increased
risk of diabetes among HD patients although they suggest
abnormal glucose regulation.
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Changes in walking performance on people with Parkinson dis-
ease after lower limb robotics rehabilitation
Patrizio Sale1, F. Stocchi1, D. Le Pera1, I. Sova1, M. Galli1, M. Franceschini1,
M.F. De Pandis2
1IRCCS San Raffaele Pisana, Roma
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Introduction: The effectiveness of non-pharmacological options
such as exercises has been demonstrated; in particular an example
for patient tailored exercises is physiotherapy. The goal of
physiotherapists is to enable PD patients to maintain their
maximum level of mobility, activity, and independence. The use
of electromechanical devices such as treadmill training (a
supplement to conventional therapies) in the last years has also
been used with PD patients. The speciﬁc aims of this project are: to
verify whether the robotics lower limb treatment with body
weight support is more effective than the treadmill treatment in
the reduction of motor impairment in PD patients, and to improve
the quality of the gait and the endurance and to analyze possible
improvements in terms of physiological biomechanical gait
through analysis of spatio-temporal parameters.
Materials and methods: Study design: RCT. Subjects: 18 patients
with a diagnosis of PD. Inclusion criteria: evidence of motor deﬁcit
in one lower limb, age between 18 and 79 years. At the beginning of
the treatment and after 20 sessions, optocynematic analysis of gait
and clinical scales Hoehn and Yahr, were delivered. Treatment: all
patients will receive traditional treatment (Physiotherapy, Occu-
pational Therapy and Speech Therapy). All subjects excepted will
undergo inpatient rehabilitation consisting of a treatment cycle
using the G-EO system (Reha Technologies) or treadmill device
GAIT TRAINER, according to individually tailored exercise sched-
uling (Group A and CG.). All the treatment consists of 20 sessions
for the lower limbs, each lasting 45 minutes, 5 days a week for 4
weeks.
Results: The clinical characteristic of the experimental groups
were: Hoehn and Yahr Stage range 2-3median 3, Age 70.00  8.396
yrs, Weight 70.22  17.14 kg, Height 159.6  9.13 cm.The clinical characteristic of the control groups were: Hoehn
and Yahr Stage range 2-3 median 3, Age 70  10,2 yrs, Weight
85,11  19,27 kg, Height 162  11 cm. The ones treated with G-EO
showed a signiﬁcative improvement of Barthel (45 vs 62) and FIM
(57vs 86) scores at discharge compared to admittance. No statistical
difference at T0 were found. The spatio-temporal parameter (Mean
velocity, Stride length, Stance and Swing time) showed a statistical
improvement in Robot group.
Conclusions: Our preliminary results show that G-EO system
treatment is well tolerated by patients with a statistical improve-
ment of intra group performance and compared to Treadmill group.
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Subthreshold depression and subjective cognitive complaints in
Parkinson’s disease
Gabriella Santangelo1,2, C. Vitale2,3, L. Trojano1, M.G. Angrisano1,
M. Picillo4, D. Errico1, P. Barone5
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2IDC Hermitage-Capodimonte, Naples
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Introduction: Subthreshold depression (SD) is characterized by
depressive symptoms, not meeting criteria for major depression;
its prevalence and neuropsychological correlates in Parkinson’s
disease (PD) are not well-established.
Objects: The present study aimed to explore the prevalence of
SD in non-demented PD patients and to investigate the possible
association of SD with cognitive complaints and/or cognitive
impairments assessed by means of a screening instrument
speciﬁcally validated in PD.
Methods: We assessed 109 consecutive PD patients for severity
of depressive symptoms by means of Beck Depression Inventory,
and for objective and subjective cognitive dysfunctions by means
of Montreal Cognitive Assessment.
Results: Established cutoffs of the Beck Depression Inventory
identiﬁed subthreshold depression in 35 patients and major
depression in 38; 36 patientswere classiﬁed as non-depressed. The
three groups did not differ on demographic and clinical aspects.
Subthreshold depressed did not differ from non-depressed
patients on objective cognitive measures, whereas depressed
patients achieved signiﬁcantly lower scores than the other two
groups. Subthreshold depressed and depressed patients reported
more cognitive complaints than non-depressed patients.
Conclusions: Subthreshold depression is a non-motor aspect of
PD that is not related with objective cognitive deﬁcits but is
associated with cognitive complaints, thus impacting on patients’
subjective well-being.
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Dopamine receptors oligomerization: biological signiﬁcance and
potential role in Parkinson’s disease
Marco Scarselli, G.U. Corsini
Dipartimento di Neuroscienze, Universita` di Pisa, Pisa
Accumulating evidence indicates that signaling molecules such
as G protein-coupled receptors (GPCRs) might be organized in
oligomeric or multimeric superstructures. Speciﬁcally, it has been
demonstrated by different groups that dopamine receptors can
Basal Ganglia 2S (2012) e1–e87e72exist as homo- and hetero-dimers or higher-order oligomers.
Despite the high interest related to this ﬁeld, our understanding of
the biological role of these receptor complexes is still controversial
and the question ‘‘Do GPCRs function as monomers, dimers or
oligomers is still unanswered?’’.
One reason why receptor oligomerization is a controversial
topic is because the direct measurement of these protein
aggregates has been outside the resolution of the available
microscopy techniques limited by diffraction barrier. Recent
developments in the ﬁeld of optical super-resolution techniques
allow both a 10-20 fold increase in resolution as well as an
increased ability to quantify the amount of labeled molecules
visualized in the ﬂuorescence measurement. One of these new
microscope techniques is the Photo-activated Localization Micros-
copy (PALM) that is capable to resolve precisely localized
molecules at separations of few nanometers (precision of 10-
20 nm) and to determine the localization of single molecules.
By using PALM, we analyzed the plasmamembrane localization
and distribution of three prototypical class I GPCRs, namely beta2
adrenergic, D2 dopaminergic and M3 muscarinic receptors. We
investigated the assembly in clusters (size and density) of these
membrane proteins, and the effect of agonists and antagonists
upon these domains. The application of these novel super-
resolution techniques could unveil the biological meaning of
dopamine receptor oligomerization with relevant consequences
for the discovery of new selective drugs in Parkinson’s disease.
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Real time amperometric monitoring of neurotoxyn MPTP effects
on oxygen glucose and lactate levels in striatum of freely moving
rats
Ottavio Secchi, G. Calia, R. Migheli, G. Rocchitta, P.A. Serra
Dept. of Clinical and Experimental Medicine, Section of Pharmacolo-
gy, University of Sassari, Sassari
The loss of dopaminergic neurons of Substantia Nigra pars
compacta in Parkinson’s disease, is related to oxidative stress,
mitochondrial dysfunction and impaired energy metabolism. The
neurotoxin MPTP, known to induce a signiﬁcant dopaminergic
neurodegeneration, is converted intoMPP + byMAO-B in glial cells
interfering with complex I of the mitochondrial electron transport
chain. This lead the dopaminergic cell to impaired glucose
metabolism and energetic deﬁcit because of reduced ATP
production. The aim of this study has been monitoring oxygen,
glucose and lactate levels by means of amperometric micro- and
biosensors, integrated to a wireless telemetric system, in order to
evaluate real-time effects of sub-chronic MPTP administration on
physiological metabolism in the brain of freely moving rats.
Oxygen was electrochemically reduced at -400 mV vs Ag/AgCl
reference electrode on carbon-epoxy sensor surface. Glucose and
lactate detection was attained by glucose oxidase or lactate
oxidase-based biosensors polarized at + 700 mV vs Ag/AgCl refer-
ence electrode.
Oxygen microsensor and glucose and lactate biosensors have
been stereotaxically implanted in the right striatum of male
Sprague Dawley rats (250 gr.). MPTP was administered for 3 days
consecutively (25, 15, 10 mg/Kg/2.5 ml saline i.p.).
Oxygen, glucose and lactate baseline of 60 minutes was
recorded every day before MPTP administration. The ﬁrst MPTP
administration led to an increase of oxygen, glucose and lactate
levels. On Day 2 and Day3 a further increase of oxygen and lactate
levels was found, compared to both basal and after MPTP
administration levels recorded on Day 1. Conversely, glucose
showed a statistically signiﬁcant decrease either in basal orfollowing MPTP administration. These results suggest that in
MPTP-related mitochondrial dysfunction oxygen and glucose
cannot be normally used by neurons and increased production
of lactate reﬂect a switch towards anaerobic metabolism.
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Formulation of a treatment protocol for OPCA: two cases descrip-
tion
P. Marano, Mariella Seminara
Unita` Operativa di Neuroriabilitazione, Casa di Cura Villa dei Gerani,
Catania
The rehabilitation of secondary parkinsonism is one of many
possibilities, now sufﬁciently experienced, to interfere with the
debilitating disease that results. It is important to emphasize the
need, as it should always take place in rehabilitation, be clear
objectives attainable, fromboth of the team that part of the patient,
in order to avoid the error of missing the target.
The experience of the writer wants to emphasize the necessity
of proceeding through an appropriate method of work as a team,
which should include clinical assessment, integrated with a
functional assessment, as a prerequisite to identify the objective
ﬁrst thing to attainable.
The ﬁrst thing to do is the global observation of the patient to
assess the interaction with the environment, motivation, orienta-
tion, space-time, any compensation or alternative strategies
already put in place, then we proceed with the observation and
measurement of any volume of muscle mass and tone, ﬁnd for any
changes, this leads to the possible presence of involuntary
movements, there is the existence of postural alteration, taking
into account that posture is the attitude assumed by the body in
space, deﬁned by the relative positions of different body segments
and observed the ability of postural control in key positions, the
ability to independently perform steps postural and movement,
function and implementation of grasping and manipulation, we
also seek balance reactions and parachute in quadruped position,
middle position, while standing, you look at how they are played:
walking, stairs, andwith any travel aids (wheelchair, tripods, staffs,
canadian support).
This is good to understand the importance of a functional
assessment is carried out in quantitative terms, ie by analyzing the
functions and features not found, and in quality, by analyzing the
characteristics of motor behavior implemented by the patient, in
terms of patterns available (poor, stereotypes abnormal), limita-
tions of osteo-articular, compensation used as adaptive features,
the ﬂuidity of modular sequences, the sequences of themonitoring
mode (visual, proprioceptive) and any dystonic or hyperkinetic
components that interfere with the possibility of completing a
sequence efﬁciently.
The program will also deﬁne the practical possibilities of
intervention, so it is necessary to carefully consider when
evaluating each of the qualities making up each stage of the
disease.
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LSTV-BIG: a new rehabilitative approach to Parkinson’s disease
Rita Semprini
Associazione I.P.(Iniziativa Parkinsoniani), Bologna
Introduction: LSTV-BIG is a rehabilitative approach used
speciﬁcally for PD based on the Silverman voice training method
(LSVD LOUD, 1987, USA). Using this approach, increasing vocal
Basal Ganglia 2S (2012) e1–e87 e73loudness results in widespread effects on other interconnected
motor symptoms (sialorrhea, swallowing, facial expressions).
Becky Farley then applied these concepts to the motor system
of the trunk and limbs (LSTV BIG), thus proceeding from vocal
loudness to amplitude of limb and body movement. This
rehabilitative method has recently spread from the USA to several
European countries.
Objectives: To understand how to place this method within
neuroscience studies and research, keeping to the principles of
neuronal plasticity, motor learning, and brain imaging. To extend
knowledge, increase people’s experience, and share results.
Methods: General aspects: Rebuilding and correcting body
awareness and body movements; Acting directly on sensory and
kinaesthetic disturbances, thereby enabling patients to monitor
and calibrate their own movements; Creating the conditions for
the method to be applied in all contexts and at all stages of the
illness.
Characteristics: Standardized protocol both of the exercises and
the results achieved; Continuous assessment of the motivation of
the patient through feedback; Seeking out goals which are of
fundamental importance and also emotionally relevant to the
patient; Aiming for maximum change with minimum cognitive
load.
Results: Signiﬁcant beneﬁts at cerebral level - the reorganisation
of damaged neurological circuits - have been conﬁrmed through
brain imagining. The therapist’s personal experience with a group
of ten people of differing ages and at different stages of the illness
was extremely positive; the training acted on sensory motor
elaboration and on planning movement.
Conclusions: Overall, the method is effective. Self treatment at
home needs to be monitored more carefully; a three-monthly
follow-up to sustainmotivation, verify how closely the programme
is being adhered to, and evaluate that results are being maintained
over time is recommended.
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123I-FP-CIT SPECT and clinical motor features in Sardinian Par-
kinson’s disease patients
Paolo Solla, A. Cannas, F.C. Ibba, E. Costantino, M. Corona, G. Oroﬁno, M.G.
Marrosu, F. Marrosu
Movement Disorders Center, Department of Neurology, Institute of
Neurology, University of Cagliari, Cagliari
Background: Parkinson’s disease (PD) is a neurodegenerative
disease characterized by the loss of dopaminergic neurons in the
substantia nigra. Due to predominant motor symptoms, PD can be
distinguished in a tremor-dominant type (TDT), a bradykinetic-
rigid type (BRT) and a mixed type (MT). TDT patients are supposed
to have a lower rate of decline than patients with BRT.
Objective: To investigate the correlation between 123I-FP-CIT
and clinical features in Sardinian patients with PD.
Methods: We performed a retrospective study in Sardinian PD
patients followed at the Movement Disorders Unit of the
University of Cagliari who had undergone 123I-FP-CIT SPECT in
the last three years. Clinical data and features, such as age at onset,
disease duration, presenting symptoms, Hoehn and Yahr stage and
UPDRS assessment, were retrieved from the patient’s history,
taken during the regular follow up visits. A 123I-FP-CIT SPECT
semi-quantitative analysis for the ipsi and contralateral putamen
and caudate nucleus was used. Patients were subtyped into one of
three clinical groups: TDT, BRT and MT (features of bradykinetic –
rigid and tremor) subtypes. This classiﬁcation was derived from
the UPDRS-motor score. Subtypes were deﬁned according to the
ratio of each patient’s UPDRS III Tremor score (sum of Items 20 and21 divided by 4) to his/her mean UPDRS bradykinetic/rigid score
(sum of items 22–27 and 31 divided by 15). A ratio > 1.0 was
indicative of TDT, a ratio < 0.80 was indicative of BRT, and a ratio
between 0.80 and 1.0 was indicative of MT.
Results: Eighty-two PD patients (39 males and 43 females) with
a mean age of 66.0  8.7 years and mean disease duration of
4.0  2.5 years were included in this analysis. The mean Hoehn and
Yahr stage score was 1.7  0.7. A signiﬁcantly higher dopaminergic
uptake was observed in the TDT group compared with the BRT group
(2.4  0.7 versus 1.8  0.5; p < 0.01).
Discussion and conclusions: We found that the different
subtypes of PD had a different correlation with the differential
123I-FP-CIT SPECT uptake, showing a signiﬁcant separation of PD
subtypes into TDT and BRT. These results are consistent with
previous neuropathological models and could conﬁrm other
studies that suggested a more marked loss of dopamine nerve
terminals in the striatum of patients with predominant rigidity
and bradikynesia.
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A novel mithocondrial TRNAHYS point mutation in a patient with
PSP-like phenotype
Chiara Sorbera, O. Musumeci, S. Romeo, A.M. Ciranni, G. Vita, A. Toscano,
P. Girlanda, F. Morgante
Department of Neuroscience, University of Messina, Messina
Introduction: Mitochondrial disorders are multisystem condi-
tions frequently affecting the skeletal muscle and the central
nervous system (CNS). One of the clinical manifestations of CNS
involvement is a parkinsonian syndrome.
Case Report: A 65-year-old female with positive family history
for juvenile stroke like episodes (mother and 2 siblings) presented
to our observation with a 3-year history of progressive speech
disturbances, dysphagia, balance and gait impairment. One year
before our ﬁrst observation, she experienced an episode of speech
difﬁculty and a CT scan showed an intrasellar neoplasm, treated
with surgery and radiotherapy with partial improvement of
symptoms. General examination demonstrated short stature.
Neurological examination revealed dysarthro-dysphonia with
palilalia, marked dysphagia, short-step gait with several freezing
episodes, postural instability, sopranuclear vertical gaze palsy,
facial hypomimia, moderate bradykinesia and rigidity with
bilateral extensor plantar responses. A diagnosis of probable
Progressive Sopranuclear Palsy (PSP) according to Litvan criteria
was carried out.
Results: MRI revealed cortical atrophy, with diffuse conﬂuent
hypointensities at basal ganglia, brainstem and subcortical
infarcts; speciﬁcally, there was an ischemic area in the dorsal
pons, extending up to the tegmentum. Serum lactate was elevate.
Muscle biopsy showed few ragged red ﬁbers, SDHpositive and COX
negative ﬁbres. Biochemical assay performed on muscle homoge-
nate following standard protocol revealed reduced activity of
succinate dehydrogenase and succinate cit-C-reductase. Muscle
coenzymeQ10was reduced. Southern blotting ofmtDNA showed a
normal band of mtDNA. Whole mitochondrial genome sequencing
analysis inmuscle identiﬁed a novel c.12182A > G transition in the
tRNA hystidine gene. The mutation is in a highly conserved region
of the T(psi)C stem of the tRNA(His) gene and may alter secondary
structure formation.
Conclusion: This is the ﬁrst reported case of a mithocondrial
tRNA mutation manifesting with a PSP-like phenotype. This case
expands the genetic heterogeneity of mitochondrial diseases.
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CSF dopamine and DOPAC, following levodopa challenge, as a new
diagnostic tool in Parkinson’ s disease
Mario Stampanoni Bassi1,2, G. Angileri2, E. Olivola2, T. Pascucci3, P.
Stanzione1,2, M. Pierantozzi1,2, A. Stefani1,2
1IRCCS Santa Lucia Foundation, European Centre for Brain Research
CERC, Rome
2Clinica Neurologica, Universita` di Roma ‘‘Tor Vergata’’, Rome
3Dipartimento di Psicologia and Centro ‘‘Daniel Bovet’’, Universita` La
Sapienza, Rome
In Parkinson’s disease (PD), reliable staging biomarkers are
elusive. Here we tested whether cerebrospinal ﬂuid (CSF)
concentrations of dopamine (DA) and its major metabolites -
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid
(HVA) – correlated with motor performance scores in a group of
non-ﬂuctuating, stage 1-2 PD patients.
Patients were challenged, in washout (CAPIT), with 200 mg
levodopa (LD) and lumbar puncture (LP) was performed after
120 min, when LD concentration in CSF reaches a maximum. DA,
DOPAC and HVA were analysed using high performance liquid
chromatography (HPLC).
DA concentration (mean: 5.6 nM  0.9) was inversely correlated
with UPDRS score. DOPAC was tightly correlated with the motor
impairment, being signiﬁcantly higher in more advanced patients.
Subjects assigned as early stage PD (below 18 months, n = 9) were
signiﬁcantly different from stage 2 PD patients (n = 10, mean UPDRS
27) in the concentration ratio DA/DOPAC (4.9 and 15.3, respectively).
Anedoctical tests in non-PD patients (NIH and cephalalgia) revealed a
DOPAC/DA ratio always < 4.
These observations suggest that early alterations in the pre-
synaptic dopaminergic terminal machinery is a core hallmark of
PD. They support the notion that DA metabolites report disease
progression attributable to nigro-striatal terminals, hence repre-
senting inexpensive biomarkers to support diagnosis speciﬁcity,
and also to monitor effectiveness of on-going therapies.
On-going studies will assess to what extent the metabolite/DA
ratio differs between PD patients with different motor pattern (i.e.,
TD vs PIG) or different degree of asymmetry or reveals peculiar
alterations in other synucleinopathies, such as multiple system
atrophy.
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Bladder dysfunctions in Parkinson’s disease do not imply speciﬁc
24-hours Blood Pressure (BP) monitoring modiﬁcations
L. Brusa1, T. Attanasio4, E. Finazzi Agro`3, F. Petta3, C. Iani1,
Paolo Stanzione2
1UOC Neurologia Ospedale Sant’Eugenio, Roma
2Clinica Neurologica Universita` di Roma Tor Vergata, Roma
3Clinica Urologica Universita` di Roma Tor Vergata, Roma
4Cardiologia Universita` di Roma Tor Vergata, Roma
Objective: Aim of our study was to evaluate if bladder
dysfunctions in patients with Parkinson disease correlate with
blood pressure and heart rate dysregulation as assessed by 24-hour
blood pressure (BP) monitoring.
Methods: 20 patients affected by Parkinson disease according
with Brain Bank Criteria (Hoehn and Yahr stage: 2.5), underwent
24-hour blood pressure monitoring by utilizing a Spacelabes
device during day and night periods. All patients were normoten-
sive without orthostatic hypotension. Ten of the studied patientswere affected by bladder overactivity and ‘‘urge incontinence’’
(group A) as stated by urodynamic evaluations and clinical
interviews; the other ten consecutive patients were not affected
by urologic dysautonomia (group B) as revealed by the same
clinical and instrumental procedures. All patients were studied in
CAPIT condition. The two PD groups did not signiﬁcantly differ for
age, gender and disease duration.
Results: Mean systolic and diastolic 24-hours blood pressure,
diurnal and nocturnal systolic and diastolic BP were within normal
range in both groups and no signiﬁcant difference were detected
between the two groups. Moreover, twelve patients (6 in group A
and 6 in group B) showed a non-dipping BP pattern.
Conclusions: Our data indicate that urologic dysfunctions are
not associated with speciﬁc alterations of ambulatory blood
pressure monitoring, including circadian rhythm of BP and heart
rate variability. Thus, different mechanisms other than autonomic
must be involved to support bladder dysfunction in PD.
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Epidemiological (cross-sectional) study to evaluate and describe
fatigue in patients with Parkinson disease in Italy - The FORTE
Study
Fabrizio Stocchi1, G. Abbruzzese2, R. Ceravolo3, P. Cortelli4, M.F. De
Pandis5, G. Fabbrini6, W. Liboni7, C. Pacchetti8, G. Pezzoli9, M. Canesi9,
C. Iannacone10, M. Zappia11, FORTE Study Investigators
1Institute of Neurology, IRCCS San Raffaele Pisana, Rome
2Department of Neurosciences, Ophthalmology, Rehabilitation and
Genetics, University of Genoa, Genoa
3Department of Neuroscience, University of Pisa, Pisa
4Department of Neurological Sciences, AlmaMater Studiorum, IRCCS,
Institute of Neurological Sciences, University of Bologna, Bologna
5Parkinson Operative Unit, San Raffaele Institute, Cassino (Frosinone)
6Department of Neurology and Psychiatry, and IRCSS Neuromed, ‘La
Sapienza’ University of Rome, Rome
7Complex Structure of Neurology, Gradenigo Hospital, Turin
8Parkinson Operative Unit, IRCCS ‘‘National Neurological Institute
C. Mondino’’ Foundation, Pavia
9Parkinson Institute, I.C.P., Milan
10SPARC Consulting, Milan
11Department ‘‘G. F. Ingrassia’’, Neurosciences Area, University of
Catania, Catania
Introduction: Fatigue is a common non-motor symptom in
patients with Parkinson’s Disease (PD) and one of the most
disabling symptoms of this disease, as reported by patients, with
serious impact on patients’ quality of life. It is generally accepted
that about 50% of PD patients will complain of fatigue and clinical
observation revealed that its severity remained mostly unchanged
during progression of disease. This study aims to assess, in a non-
interventional epidemiological setting, the incidence and severity
of fatigue in PD patients and its correlation with PD severity.
Methods: This is an epidemiological, cross-sectional, multi-
centre study, in patients diagnosed with PD according to the
‘‘UKPDS brain bank diagnostic criteria’’. The primary objectives
included the evaluation of the incidence and severity of fatigue in
PD patients measured by Parkinson Fatigue Scale (PFS-16) and
assessment of its predisposing factors (age, gender, marital status,
disease duration, presence of depression, presence of sleep
disorders, PD severity, UPDRS total score).
Results: 402 patients (mean age: 66.9 years; mean disease
duration: 7.5 years)were enrolled in 27 PD centers in Italy. 33.8% of
them showed fatigue (PFS-16 score  3.3 points). Logistic regression
Basal Ganglia 2S (2012) e1–e87 e75analysis showed that UPDRS total score, gender female, presence of
depression and presence of sleep disorders increase signiﬁcantly the
odds of occurrence of fatigue in patients with PD.
Conclusion: FORTE is the largest study ever conducted in Italy to
assess the fatigue in PD patients. The large amount of data
collected will allow us to investigate in depth the fatigue in these
patients.
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Recovery of motor performance after a demanding ﬁnger motor
task in patients with Parkinson disease with and without fatigue
Tiziano Tamburini1, L. Avanzino2, E. Pelosin1, G. Abbruzzese1
1Department of Neurological Sciences, Ophthalmology and Genetics,
Genova
2Department of Experimental Medicine, Section of Human Physiolo-
gy, Genova
Introduction: Parkinson patients may experience fatigue
among their non-motor symptoms. Recently we described an
experimental paradigm apt to study fatigue at a behavioral level
and recovery of motor performance after a demanding ﬁnger
motor task. Here we evaluated motor performance during a
demanding ﬁnger motor task and recovery in a group of PD
patientswhopresented fatigue and a group of PDpatientswithout
fatigue.
Methods: 7 patients with Parkinson disease and fatigue (F-PD)
and 10 patients without fatigue (NF-PD), age and gender matched,
were included in this study. No differences in UPDRS part III scores
were found between groups. The occurrence of fatiguewas deﬁned
as a score  8 on the Parkinson Fatigue Scale. Subjects were
instructed to sequentially tap the thumb on each of the other
ﬁngers for 5 minutes following an acoustic cue at 2 Hz, and, after
1 minute of rest, to repeat the same task for 1 minute (min REC1)
wearing a sensor-engineered glove on their more affected hand.
We evaluated the inter-tapping interval (ITI), the touch duration
(TD) and the movement rate (MR).
Results: ITI progressively increased from minute 1 to minute 5
and returned to baseline values in the 1-min recovery. However F-
PD and NF-PD showed a different behavior: while in NF-PD ITI
recovered after the demandingmotor task to a level comparable to
baseline (min REC1 vs min1 p = 0.24), in F-PD group ITI decreased
to a major extent with respect to baseline (min REC1 vs min1
p < 0.05).
Discussion: Our ﬁndings may indicate that deterioration of
motor performance during the 5 minutes demanding motor task is
similar in F-PD and NF-PD patients, but recovery is more effective
in F-PD, possibly through compensatory mechanisms involving
basal ganglia.
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Normal lateral inhibition mechanism during sensory-motor plas-
ticity in dystonia
Carmen Terranova, V. Rizzo, F. Morgante, L. Ricciardi, P. Girlanda, A.
Quartarone
Department of Neurosciences, Psychiatry and Anaesthesiological
Sciences, University of Messina, Messina
Object: To explore if sensory information is processed and
integrated during sensory-motor plasticity phenomena by using
lateral inhibition mechanisms in normal humans and in patients
with dystonia.Background: Several evidence suggest that lateral inhibition
is a system within sensory-motor cortex operating during the
acquisition of new motor tasks in order to select the
appropriate muscle sequence to be stored within the ﬁnal
motor engram. This mechanism is thought to be lost in dystonia
and this should explain the development of redundant motor
memories which could culminate in overﬂow phenomena and
overt dystonia.
Methods: We have used transcranial magnetic stimulation to
explore lateral inhibition during sensory-motor plasticity in 12
dystonic patients (7 focal hand dystonia, 5 cranial dystonia) and in
8 healthy subjects. In particular we looked at motor evoked
potential (MEP) facilitation, in the abductor pollicis brevis (APB)
and abductor digiti minimi (ADM), obtained after 5 Hz repetitive
paired associative stimulation after median (PAS M), ulnar nerve
stimulation (PAS U) and median + ulnar nerve (PAS MU) stimula-
tion. In this way we evaluated the ratio MU/M + Ux100 (lateral
inhibition index).
Results: Our data conﬁrmed that patients with dystonia had two
main abnormalities: ﬁrst the amount of facilitationwas larger than
normal subjects; second andmore important the spatial speciﬁcity
was lost. A three-factorial ANOVA demonstrated a signiﬁcant time
x group x conditioning interaction (F = 7.9; p = 0.005). Lateral
inhibition index was similar (about 50%) in healthy subjects and
dystonic patients.
Conclusions: These data suggest that lateral inhibition is
normal in dystonia during sensory-motor plasticity. Another
mechanism could contribute to the formation of motor memories
with redundant information, which could culminate in overt
dystonia.
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Syndrome as onset of autosomal dominant cerebellar ataxia type I
R. De Micco1, Alessandro Tessitore1, G. Cirillo1, A. Giordano1,2,
G. Tedeschi1
1Department of Neurological Sciences, Second University of Naples,
Naples
2Neurological Institute for Diagnosis and Care ‘‘Hermitage Capodi-
monte’’, Naples
Clinical case: a 63-years-old man presenting with a slowly
progressive 5-year history of upper limb tremor, occurring during
voluntary movements; rarely tremor at rest; lower limb tremor,
which was present only during standing position; speech
impairment. His neurological examination revealed mild broad-
based gait; mild dysarthria; action tremor of the upper limb; mild
and inconstant left hand tremor at rest; mild bradykinesia of left
upper limb; ‘‘pseudo-orthostatic’’ tremor of the lower limb. Absent
other neurological signs. Biochemical blood tests, including CBC,
glycemia, thyroid and parathyroid hormones; antigliadin/tissue
transglutaminase/endomysium antibodies; vitamin E, B12 and
folic acid levels, tumor screen, was normal. Brain MRI revealed
olivo-ponto-cerebellar atrophy. A 123Iioﬂupane SPECT was per-
formed and revealed diffuse reduction of the striatal uptake.
Neurological examination and instrumental ﬁndings prone to
hypothesize a diagnosis of late onset autosomal dominant
cerebellar ataxia type I with parkinsonism. Therefore, we have
analyzed CAG repeat expansion in the SCA1, SCA2 and SCA6 loci of
our patient and we have found pathologic trinucleotide expansion
at the SCA2 locus.
Diagnosis: SCA2 with parkinsonism. Addendum: one year later,
the patient’s daughter, a 33-years-old woman, was referred to us
with a slowly progressive six-months history of unsteady gate;
Basal Ganglia 2S (2012) e1–e87e76speech impairment; upper limb kinetic tremor; rarely head
tremor.
SC118
Outpatient rehabilitation treatment in Parkinson’s disease:
Efﬁcacy evaluation
Mattia Tiburzi, F. Tirinelli, M.E. Tondinelli, M. Ernesto, A. Marini,
N. Vanacore, F. Viselli
Ospedale San Giovanni Battista, ACISMOM Roma
Introduction: Patients suffering from Parkinson’s disease show
the gradual loss of motor skills, especially a deﬁcit of gait and
balance reactions. Therefore we planned a speciﬁc outpatients
rehabilitation treatment for PD.
Objective: The aim of this study is to investigate the effective-
ness of outpatient treatment, setting the target on gait, balance and
autonomy improvement.
Methods: We included 20 patients with idiopathic PD 9  5.7
years, 11 males and 9 females, with mean age of 69.1  10.5 and
severity between 2 and 3 of the H&Y scale, stabilized in drug
treatment. The treatment consisted of 10 rehabilitative sessions of
3 hours twice a week, each session was divided into individual
therapy, group therapy and occupational therapy. The individual
treatment steps included training for postural, stretching exercises,
muscle strengthening the trunk and limbs, exercises for balance and
gait. Coordination exercises, strengthening and rhythmic movement
were performed during the therapy group. Autonomy in ADLs,
problem-solving, socialization, handwriting and speech were treated
in occupational therapy. All patients were evaluated in three stages: 3
months before the treatment(T0), at the beginning (T1), and at the
end of the rehabilitation plan (T2). The rating scales used were the
Berg Balance Scale (BBS), the RivermeadMobility Index (RMI) and the
Falls Efﬁcacy Scale (FES).
Statistical analysis were performedwith analysis of variance for
repeated measures.
Results: The BBS evaluation showed a signiﬁcant improvement
in gait and balance (T1 23,2  8,2 vs T2 28,5  7,4 p < 0,001). RMI
evaluation has highlighted a signiﬁcant improvement in ADL
autonomy (T1 11,4  3,3 vs T2 13,3  2,1 p < 0,001). The FES scale,
despite the improvement (T1 29,2  21,2 vs T2 26,7  19,2), did not
produce statistical signiﬁcance.
Conclusions: The results demonstrate that outpatient rehabili-
tation treatment is able to improve the balance and motor
functions, furthermore it represents an indispensable support to
drug therapy.
SC119
Palatal tremor after brachial plexus anesthesia
Pierluigi Tocco, M. Turri, M. Acler, L. Bertolasi
Department of Neuroscience, University of Verona, Verona
Introduction: Palatal tremor, also called palatal myoclonus, is
deﬁned by short, rhythmic contractions of the palatal muscula-
ture and may be associated with synchronous movements of
adjacent structures. It can be distinguished into the essential
form (EPT) and the symptomatic form (SPT). In the EPT ear click
can be present, involuntary contraction stops during sleep and
brain MRI does not detect anomalies, while in the SPT ear clicks
are rarely present and palatal movements are part of a
constellation of clinical ﬁndings, including dysarthria, nystagmusand ataxia. Pathologic studies outlined an important role of
lesions affecting the dentate-rubral-olivary pathway, or Guillain-
Mollaret triangle.
Case presentation: We describe a 49 year-old womanwith acute
onset palatal tremor following brachial plexus anesthesia with
levobupivacaine 0,5% due to surgery of ulnar collateral ligament.
She also presented bilateral, involontary, and rhythmic activity of
chin muscles evoked by the opening of the mouth. The palatal
contraction could not be inhibited by external sensory stimuli,
whereas chin contraction could be suppressed by selective tactile
stimuli of the trigeminal area. The patient also complained
bilateral ear click. The remainder of the neurological and
otorhinolarygologic examinations were normal. Symptoms
appeared immediately after surgery and did not improve after
clonazepam and carbamazepine intake. Brain MRI was unremark-
able, and we conducted a broad electrophysiologic evaluation:
EEG, blink-reﬂex, BAEPs, lower and upper limbs SEPs and MEPs
were all normal.
Conclusion: As previously described, intratecal anestethics could
inducemyoclonus. This casesuggestspossiblepharmacological toxic
effect on the dentate-rubral-olivary pathway (Guillain-Mollaret
triangle) even after local administration of levobupivacaine.
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Effects of Parkinson’s disease and surgery for STN-DBS on the
top-down and bottom-up mechanisms of visual selective
attention
Giorgio Tommasi1,2,4,8, M. Fiorio2, J. Yelnik3, P. Krack4, F. Sala1,
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Verona
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and Movement Sciences, University of Verona, Verona
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4Department of Neurology, University Hospital Joseph Fourier Uni-
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Introduction: Some ﬁndings suggest that patients with Parkin-
son’s disease (PD) may be impaired in visual selective attention
(VSA) tasks, andmay present enhanced distractibility (attentional
capture, AC) in the presence of salient objects/events, which
capture their attention (by bottom-up mechanisms), disrupting
target search (driven by top-down mechanisms). At present, it is
rather unclear to what extent PD, and deep brain stimulation of
the subthalamic nucleus (STN-DBS) can impact on the VSA
mechanisms.
Objective: We aimed to assess the effects of PD and of electrode
placement in the STN on the VSA mechanisms.
Methods: The main instrument for our study was an AC task,
which was suitably combined with a choice reaction and simple
reaction time tasks to assess in isolation the effectiveness of
Basal Ganglia 2S (2012) e1–e87 e77bottom-up and top-down mechanisms of VSA, as well as the
mechanisms of motor response selection and initiation.
We compared the performances on these tasks of two groups
of 12 PD patients, one treated only by drugs, the other also by
STN-DBS, with those of a group of controls. PD patients were
evaluated after antiparkinsonian drugs withdrawal and stimula-
tion arrest.
Results: Both groups of patients showed an equivalent increase
of AC as well as similar delays in target selection and movement
initiation compared to controls, whereas motor response selec-
tion time was signiﬁcantly increased only in the operated
patients. Noteworthy, the daily dose of dopaminergic drugs
was signiﬁcantly lower in the STN-DBS group than the non-
operated group.
Conclusions: Our results suggest that in PD theremight be both a
relative enhancement of the bottom-up mechanisms, and a
weakening of the top-down mechanisms, which mutually could
account for the observed increase in AC. The similar amount of AC
and target selection delay obtained in both groups of our patients
suggest that surgery for STN-DBS should not impact negatively on
the VSA mechanisms. The dysfunctions of the VSA mechanisms
found in PD patients were part of a more composite scenario of
deﬁcits, especially in the surgically treated patients, who present
slowing down of the processes of motor response selection and
movement initiation, possibly related to the decrease in dopami-
nergic drug doses.
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Exploratory approach with ‘‘Neuro-Fragmentation of Movement’’
(NF) in Parkinson’s disease
Maria Elena Tondinelli, M. Tiburzi, F. Tirinelli, M. Egidi, A. Monge,
M. Paradiso, F. Viselli
Ospedale San Giovanni Battista - Cavalieri di Malta, Roma
Objective: To estimate the outcomes of treatment with Neuro-
Fragmentation (NF) in patients with PD, who have difﬁculties with
postural changes. PD presents difﬁculties in motor automatism
and with complex motors sequences (sequence effect-dual task
effect). The category of automatic movements is represented by
anticipated postural reactions. Studies present evidences on using
cueing to improve movements.
Materials: In 5 years we included in our observation 34 patients
affected by PD, between 3–4 HeY, with difﬁculties with passages.
Patients have been assessed at the beginning and to the term of
therapeutic cycle with: UPDRSIII, BBS, RMI.
12 of them have had a balance training and active general
chinesi (age:71; std:6,5; HeY:3,33; std:0,49). 22 were approached
with NF (age:70,77; std6,11; HeY:3,4; std:0,50). After a stabiliza-
tion period of pharmacological treatment the patientswere treated
1 h/day for 30 days.
Patients have not been randomized but the allocation has been
accidental for the inner organization of unit. Two groups are
comparable for age and HeY. Statistic analyses have been
conducted with the t-test between the T0 and T1 inside of
everyone of 2 groups.
The (NF) treatment was carried out with: 1. Anticipated and
reactive reaction (understanding the own possibilities of move-
ment, concept of visual objective and ‘‘motor alternative’’). 2.
Simple motor sequences, starting from the most difﬁcult passage
for the patient, perception of the error store clerks: ‘‘error like
possibility’’ to modify itself, cognitive task, cueing. 3. Self-training:anticipated reaction, divide postural passages in simple move-
ment, visual and cognitive task.
Results: BBS and RMI showed a signiﬁcant improvement (BBS-
T0:22,64; STD:2,81-T1:41,14; STD:4,61 RMI-T0:3,86; STD:2,48-
T1:9,71; STD:1,50). Modiﬁcations were not found in bradykinesia,
rigidity and ability to execute contemporary motor task as
reported by the UPDRSIII.
Conclusion: (NF) is an educational process: reprograms
every automatic movement as voluntary, simple movement;
exalts postural reaction hidden by the lesion, is enriched by
visual and cognitive task; it allows an improvement of self-
sufﬁciency.
This observation has various critical point, as the blindness
operator, the few items sensitive to postural passages. For these
reason, we are designing a RCT, that it will answer to the
requirements of objective analysis.
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Full remission of patological gambling after switch from
pramipexole to transdermal rotigotine: Analysis of a case series
Vincenzo Toni, M.C. Pastore, M.R. Mazzeo, A. Bernardi, R. Scarpello
U.O.C. Neurologia, Osp. ‘‘F. Ferrari’’, ASL LE, Casarano (Lecce)
Introduction: Impulse Control Disorders (ICDs) not rarely occur
in Parkinson’s disease (PD) patients treated with dopamine ago-
nist drugs (estimated prevalence 13,6%). The prevalence of Pato-
logical Gambling (PG) in these PD patients is 6%-8%. Pramipexole
and ropinirole are more likely to induce PG, but a few reports
have been published regarding transdermal rotigotine inducing
PG.
Objective: To describe the improvement of PG in three of four
patients treated with pramipexole I.R. after switch to rotigotine.
Subjects and methods: Four patients (3 M, 1F), mean age
64,2  10.7 years, disease duration 5,8  2.5 years, treated with
pramipexole (mean dose 2,9  0,5 mg), developed PG (mainly scratch
cards). So pramipexole was discontinued and rotigotine was
introduced in all patients (mean dose 14  2,3 mg).
Patients have been followed-up for at least one year (12–26
months) after the switch.
Results: Three out of four patients reported full remission of PG
during the follow-upwithout developing other ICDs. Noworsening
in UPDRS motor score has been observed during the entire follow-
up.
One out of four patient continued to have PG nevertheless the
withdrawal of all dopaminergic medications, except levodopa, and
the introduction of quetiapine (up to 300 mg per day). Adverse
events: application site reactions occurred in two patients; only
one patient discontinued the treatment.
Discussion: Rotigotine, as pramipexole and ropinirole, has a
high afﬁnity to D3 receptors, involved in reward processes, but
differs from the other DA-agonists because of its longer half-life
and more constant plasma levels. In our knowledge there are few
papers reporting PD patients with ICDs related to rotigotine
administration and they mostly show arising of ICDs in these
patients.
Our case series is very limited, but it may suggest that the
peculiar pharmacokinetic proﬁle of rotigotine could lead to a
differential risk of ICDs. Further and larger observations are
requested to conﬁrm our hypothesis.
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Different perception and awareness of LID and other core symp-
toms of Parkinson’s disease between parkinsonian patients and
caregivers
Margherita Torti, F. Stocchi, P. Grassini, L. Vacca, S. Pinnola, M. Casali,
F.G. Radicati
IRCCS San Raffaele Pisana, Roma
Introduction: Approximately 5 years after starting levodopa
therapy, about 40% of patients with Parkinson’s disease can
develop involuntary movements known as Levodopa induced
dyskinesia (LID) and motor ﬂuctuations.
Objective: The purpose of this study was to investigate the
different perception and awareness of LID and other core
symptoms of Parkinson’s disease between patients and care-
givers through the use of a newly developed questionnaire (PD-
C SCL Parkinson’s disease/Caregiver Symptoms check list).
The areas investigated were the following: speech problems,
psychiatric symptoms (apathy, agitation/aggressive behaviour,
gambling and other compulsive disorders), involuntary move-
ments (trunk, limbs, head and face, freezing), off state, falls,
attention or memory dysfunction, and tremor (head and face,
upper and lower limbs).
Methods: The questionnaire was administered at 70 out-
patients (42 male and 28 female, mean age: 65.3, mean disease
duration: 10.4 years) and 70 caregivers by a trained neuropsycol-
ogist.
Patients and caregivers were interviewed separately to
avoid any inﬂuence and interference between their opinion.
Complete neurological assessment included: MOCA, UPDRS,
H&Y.
Results: The preliminary data showed that among patients the
symptoms more recognized and having a negative impact on their
quality of life are freezing, off times, speech problems and limbs
involuntary movements. Among caregivers the more disabilitating
symptoms are limbs involuntary movements, off times and
freezing, and trunk dyskinesia.
Conclusions: Parkinsonian patients tend not to be aware of LID
or to underestimate their severity and their impact on activity of
daily living while family members and caregivers frequently point
at them as the main sign or the most bothersome among
parkinsonian symptoms.
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Valproic Acid for the treatment of aggressiveness and depression
in Huntington disease: one year follow-up
Elisa Unti, S. Mazzucchi, C. Del Gamba, F. Vanelli, U. Bonuccelli,
R. Ceravolo
U.O. Neurologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-
Universitaria Pisana, Pisa
Introduction: Huntington disease (HD) is an autosomic domi-
nant inherited disorder characterized by involuntary movements
resulting from a continuous ﬂow of random muscle contractions,
progressive cognitive decline mainly in latest phase and psychiat-
ric symptoms such as aggressiveness, and depression that
represent one of the most disabling features of the disease. In
most cases involuntary movements and psychiatric symptoms are
controlled by antipsychotic drugs, but sometimes side effects asparkinsonism or worsening of depression and apathy can reduce
the therapeutic window of these drugs.
Objective: To evaluate the beneﬁcial effect of Valproic Acid on
psychiatric symptoms such as agitation and aggressiveness as well
as depression in HD.
Methods: 10 symptomatic genetically conﬁrmed HD patients
(mean CAG repeat 40  2), mean disease duration (8  2 years) on
antipsychotics, all with aggressiveness deﬁned as disabling by the
patients alongwith the caregiver, were included in an open unblinded
trial. Clinical evaluation includingmotor (UniﬁedHuntington Disease
Rating Scale), psychiatric (Neuro Psychiatric Inventory scale) and
cognitive scale (Mini Mental Scale Evaluation) was performed at
baseline and after 6 and 12 months of treatment with Valproic Acid
(from 300 up to 1000 mg die).
Results: In our cases we reported a reduction of 10 points of NPI
score in each patient one year after the introduction of Valproate
without any side effect reported.
Discussion: The beneﬁcial effect of Valproic Acid and its
derivates on aggressive patients is well documented in elderly
aggressive patients and there are only two case reports that
support this effect in such psychiatric disturbances in HD. This
longitudinal study showed the beneﬁcial effect and the safety of
valproate for the treatment of aggressiveness in Huntington
disease.Moreover, the successful use of Valproic acid in controlling
aggressiveness allowed us not to increase the daily dose of
neuroleptic, preventing motor and psychiatric side effects.
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Early ﬂuctuation in de-novo parkinsonian patients
Laura Vacca, P. Grassini, M. Torti, F.G. Radicati, S. Pinnola, M. Casali,
F. Stocchi
I.R.C.C.S. San Raffaele Pisana, Roma
Introduction: Motor complications are a limiting factor in
treatment of Parkinson’s disease. Recent evidence showed that
even patients in the honeymoon phase of drug treatmentmay have
early ﬂuctuations in their response to dopaminergic therapy.
Objectives: This protocol has been designed to evaluate the
presence of pre-clinic motor ﬂuctuations, as ﬂuctuations of motor
ability not detected yet by patient but already present even in the
earlier phases of the disease.
Methods: 10 de novo parkinsonian patients entered the study
and were evaluated for eight consecutive hours in three separate
assessment. A staging of Parkinson’s disease through Hoehn &
Yahr was performed as well as the UPDRS pars I-II-III. The more
affected side was identiﬁed by medical history and by examina-
tion in all subjects. The presence of early ﬂuctuations was
measured by tapping and screw test scores. Tapping rate was the
number of times that a patient could alternately tap two counters
20 cm apart in 30 seconds. SCREWwas assessed by the time taken
to tighten by hand a 6-centimeter screw bolt. Tapping rates and
screw test scores were evaluated before administration and every
20 minutes for eight hours after administration of levodopa:Day 1
(basal): screw test and tapping every 20 minutes after adminis-
tration of 10 mg of domperidone. Day 2 (week 1): screw test and
tapping every 20 minutes after administration of 1 tablet of
domperidone and 1 tablet of Sinemet 100 + 25. Day 3 (week 3):
screw e tapping every 20 minutes after administration of 1amg of
domperidone and Sinemet 200 + 50. Plasma levodopa concentra-
tion (ug/ml) were measured at 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0,
6.0.
Basal Ganglia 2S (2012) e1–e87 e79Results and conclusions: Statistical analysis of data showed a
signiﬁcant ﬂuctuation of motor performance even at the earlier
stage of disease.
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Anodal transcranial direct current stimulation (TDCS) applied to
the motor cortex ameliorates freezing of gait in patients affected
by Parkinson’s disease
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1Dipartimento di Biomedicina Sperimentale e Neuroscienze
Cliniche, Sezione di Neurologia, Universita` degli Studi di Palermo,
Palermo
2Parkinson’s Disease and Movement Disorders Unit, National In-
stitute of Neurology Foundation ‘‘C. Mondino’’, Pavia
3Interdepartmental Research Center for Neurodegenerative Dis-
ease, National Institute of Neurology Foundation ‘‘C. Mondino’’,
Pavia
4Department of Neurophysiology, National Institute of Neurology
Foundation ‘‘C. Mondino’’,Pavia
5Unit of Neurorehabilitation, National Institute of Neurology Foun-
dation ‘‘C. Mondino’’, Pavia
6Department of Public Health and Neurosciences, University of
Pavia, Pavia
7Unita` Operativa di Neurologia, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milano
8Centro Clinico per la Neurostimolazione, le Neurotecnologie ed i
Disordini del Movimento, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milano
9Dipartimento di Scienze Neurologiche, Universita` degli Studi di
Milano, Milano
Background: Progression of Parkinson’s disease (PD) is fre-
quently characterized by the occurrence of freezing of gait (FOG),
which generally does not improve with dopaminergic therapy and
with current available surgical therapies. Recent evidences show
that motor symptoms may be ameliorated by means of non-
invasive brain stimulation techiniques in PD (transcranial current
direct stimulation, TDCS; repetitive transcranial magnetic stimu-
lation, RTMS).
Objective: To investigate the efﬁcacy of anodal TDCS in the
treatment of FOG in PD. Excitatory anodal tDCS was applied
unilaterally to themotor and premotor cortices contralateral to the
most affected leg.
Methods: Randomized, double-blind, sham-controlled study.
TDCSwas applied consecutively for 5 days to 10 patients whowere
randomly assigned to anodal or sham TDCS. Efﬁcacy of the
interventions was investigated after the 1st, the 5th stimulation, 1
week, 2 weeks and 1 month after the start of the trial. Clinical
assessment was performed by Stand Walk Sit test (SWS), UPDRS,
Freezing of Gait Questionnaire (FOG-Q), Gait and Falls Question-
naire (GFQ), and the Parkinson’s Disease Questionnaire (PDQ-39). 5
patients also underwent gait analysis. All patients received
stimulation when ‘‘on’’ medication.
Results: Anodal TDCS compared to the sham signiﬁcantly
improved gait and FOG starting from the ﬁrst stimulation.
The effect was evident up to 1 month from the ﬁrst
treatment.Conclusion: Anodal TDCS of the motor and premotor cortex is
safe and it may have therapeutic potential for FOG in patients
with PD. TDCS might determine release of dopamine in the
caudate and putamen. Alternatively excitation of the less active
motor cortex may restore an inter-hemispheric balance, as it has
been recently hypothesized as possible mechanism at the origin
of FOG.
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A 43-year-old man with hemiparkinsonism, moderate cerebral
asimmetry andnormal echogenicity of the substantia nigra: a case
of hemiparkinsonism-hemiatrophy syndrome?
Emilio Vecchio1, M. Proaspatu2, M.V. Calloni1, A. Giorgetti1, M.C. Guaita1,
P. Perrone1, L. Politini1, P. Secchi1
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2S.C. a D.U. di Radiologia, Azienda Ospedaliero-Universitaria ‘‘Mag-
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A 43-year-old man was evaluated for a slowly progressive left
hemiparkinsonism. He referred moderate bradykinesia and
tremor at the left upper limb of 3-year duration. His family
history was negative for neurologic disorders; there was no
mention of perinatal damage, delayed motor milestones, sub-
stance abuse.
On neurological examination there are mild hemifacial
asimmetry, slowness of hand-grip on the left, evidence of cogweel
rigidity of the left upper limb and tremor of the hand. The swinging
of the left arm was reduced, with a slight distonic posture of the
hand. Amild increase of the deep tendon reﬂexeswas detect on the
left leg. Plantal reﬂexes were downward bilaterally. There was no
evidence of others body asymmetries, skeletal deformities,
abnormal extraocular motility, postural instability or cerebellar
disfunction.
Blood analysis and neurophysiological tests (EEG, EMG, motor
and somatosensory evoked potentials, BAEPs) were normal. Brain
MRI demostratedmoderate skull asimmetry and a dilatation of left
ventricle. SPECT study with DaTSCAN revealed decreased bilateral
striatal transporter binding. A transcranial sonographic evaluation
of the mesencephalon was performed, with normal ﬁndings (no
hiperecogenicity) of the substantia nigra. The patient was started
on pramipexole, which was discontinued due to signiﬁcant side
effects; therapy with rotigotine was well tolerated, with some
motor improvement.
In this young patient, the presence of a strictly lateralized
hemiparkinsonism with distonic posture of the hand, raised the
suspicion of a hemiparkinsonism-hemiatrophy syndrome
(HPHA). HPHA syndrome, described by Klawans in 1981, is a
relatively rare form of parkinsonism characterized by atrophy on
one side of the body, but not necessarily noticed by the patient,
and young onset of hemiparkinsonism on the side of hemi-
atrophy, unilateral and stable for many years. Dystonia is a
common neurologic feature observed initially on the side of
HPHA. As in other reported cases, our patient presented
abnormal SPECT, mild asimmetry of the brain MRI and slight
body asimmetry.
The ultrasound normality of the substantia nigra virtually
rouled out a form of idiopatic Parkinson’s disease, rather
supporting the diagnostic hypothesis of a form of parkinsonism:
the HPHA syndrome was considered secondary to a primary
damage of the striatal structures, possibly perinatal, without
involvement of the substantia nigra.
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Objective: To evaluate hearing impairment in patients affected
by Parkinson’s disease as compared with hearing scores observed
in normal age and sex matched controls.
Methods: 118 consecutive patients with clinical diagnosis of
Parkinson’s disease were screened. Severity of motor symptoms
and staging were measured with the Uniﬁed Parkinson’s Disease
Rating Scale (section III) and the Hoehn and Yahr scale.
Audiometric evaluation consisted of a comprehensive audio-
logic case history and questionnaire, visual otoscopic examination,
acoustic immittance measures (tympanogram and acoustic
reﬂexes), pure tone audiometry and measurement of brainstem
auditory evoked potentials. Healthy age- and sex-matched
subjects were selected as control group.
Results: 106/118 patients were enrolled. Pure tone audiometry
revealed age-dependent high-frequency hearing loss in patients
with Parkinson’s disease as compared with both normative values
and healthy age- and sex-matched controls (75/106, 71%;
x22 = 5.959; p = 0.02 and 92/106 (86.8%) vs 60/106 (56.6%);
x2 = 23.804; p < 0.001, respectively). Pure tone audiometry scores
correlated with Hoehn and Yahr scale scores (p < 0.05). Brainstem
auditory evoked potentials were normal in all patients.
Conclusion: Our patients with Parkinson’s disease showed age-
dependent peripheral, unilateral or bilateral hearing impairment.
Whether these auditory deﬁcits are intrinsic to Parkinson’s disease
or secondary to a more complex impaired processing of sensorial
inputs occurringover the courseof illness remains tobedetermined.
Because a-synuclein is located predominately in the efferent
neuronal system within the inner ear, it could affect susceptibility
to noise-induced hearing loss or presbycusis. It is feasible that the
natural aging process combined with neurodegenerative changes
intrinsic to Parkinson’s disease might interfere with cochlear
transduction mechanisms thus anticipating presbycusis.
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Subjective sleep problems and daytime sleepiness in advanced
Parkinson Disease: effects of intraduodenal levodopa gel infusion
and deep brain stimulation
Maurizio Zibetti, C.A. Artusi, A. Merola, S. Angrisano, L. Rizzi,
E. Montanaro, M.G. Rizzone, L. Lopiano
Dipartimento di Neuroscienze, Universita` di Torino, Torino
Objective: To analyze the impact of continuous intraduodenal
L-dopa/carbidopa gel infusion (LCGI) and deep brain stimulation(DBS) on subjective sleep problems and daytime sleepiness in
advanced Parkinson’s disease (PD) patients.
Background: Sleep problems are common in PD patients and
especially so with disease progression. In advanced PD, nocturnal
akinesia, restless leg syndrome and REM sleep behavior disorder
are frequent and often coexist with daytime sleepiness. Both LCGI
and DBS greatly improve motor complications in advanced PD
patients. Relatively few studies examined the impact of DBS on
sleep and only preliminary data are available for LCGI.
Materials and methods: We prospectively assessed a total of 42
PDpatients, 20 on LCGI and 22 undergoingDBS. The PD Sleep Scale-
version 2 (PDSS-2) was used to assess sleep problems and the
Epworth Sleepiness Scale (ESS) to evaluate daytime sleepiness.
Motor symptoms, activities of daily living andmotor complications
were assessed with the Uniﬁed PD rating Scale (UPDRS) section II,
III and IV. Evaluations took place at baseline and 6-9 months after
the procedures.
Results: Subjective sleep problems improved substantially with
both DBS and LCGI procedures compared to previous oral poly-
therapy. Analyses of PDSS-2 subdomains showed a signiﬁcant
reduction of nocturnal akinesia only for patients treated with DBS.
Measures of daytime sleepiness improved with LCGI and did not
vary signiﬁcantly after DBS.
Conclusion: Subjective measures of sleep improve substantially
with LCGI and DBS in advanced PD patients. Objective polysomno-
graphic recordings are needed in order to characterize the
underlying mechanisms.
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Neuroprotective role of pargyline on energy metabolism in MPTP
model of Parkinson’s disease in freely moving rats
Manuel Zinellu, G. Bazzu, R. Migheli, G. Rocchitta, P.A. Serra
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Mitochondrial dysfunction and oxidative stress are thought to
be crucial in the dopaminergic neuronal death in Parkinson’s
disease. The neurotoxin MPTP, widely used as in vivo model of
Parkinson’s disease. MPTP, activated by astrocytes MAO-B, induce
neurodegeneration and energy metabolism alteration of dopami-
nergic neurons of substantia nigra pars compacta.
Therefore, we deemed of interest the study of neuroprotective
role of pargyline on dopamine and energy metabolism in MPTP-
induced parkinsonism. This study was carried out by an innovative
microdialysis approach for the simultaneousmonitoring of striatal
dopamine (DA) and energy substrates in freely moving animals
using asymmetric perfusion ﬂow rates on a dual microdialysis
probe. Adult male Wistar rats (280-330 g) were used in this study.
The probe was stereotaxically implanted in the right striatum of
rats. Systemic MPTP was administered for three consecutive days
as follows: 25 mg/Kg (day 1), 15 mg/Kg (day 2) and 10 mg/Kg (day
3). Pargyline (15 mg/Kg/day i.p. for 3 days) was intraperitoneally
administered 40 minutes prior the MPTP dose to a second group of
animals. Striatal levels of catecholamines were quantiﬁed by
means of HPLC-EC. Glucose, lactate, pyruvate and L/P ratio were
spectrophotometrically evaluated (CMA Iscus Analyzer).
The ﬁrst dose of MPTP induced an increase in dopamine levels
in both groups while the second and third doses reduced striatal
DA only in animals without pargyline pre-treatment. Furthermore,
animals treated only with MPTP showed a progressive decrease in
glucose and pyruvate levels, and an increase in striatal lactate and
of L/P ratio. Pargyline pre-treatment reduced glucose and pyruvate
loss as well as lactate and L/P ratio increase in the rat striatum.
Basal Ganglia 2S (2012) e1–e87 e81These in vivo results showed MPTP-related mitochondrial
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They also suggest pargyline neuroprotective effects preventing
bioactivation of MPTP and preserving neuronal dopamine and
energy metabolism.Author IndexAbate, T SC2Abbruzzese, G SC5, SC7, SC10, SC12,
SC16, SC28, SC90, SC114, SC115Acler, M SC119Agnetti, V SC32, SC68, SC85Agosti, V SC2, SC40, SC128Agostoni, E SC97, SC98Aiello, E SC32Albanese, A SC1, SC3, SC39Albani, G SC1Alberio, T SC44Albertini, G SC33Alfonsi, E C25, SC30Allena, M SC30, SC34Allocca, R SC2, SC128Allocca, S SC27Almonti, S SC95Alvau, MD SC100Amami, P SC3Amboni, M L8, SC2, SC12, SC41, SC86, SC128Ammannati, F SC91Andretto, F SC4Angelini, M SC77Angileri, G SC112Angrisano, MG SC105Angrisano, S SC69, SC129Annunziato, L SC31Antonello, P SC4Antonini, A L6, SC5, SC12, SC17, SC64Antonutti, L SC70Ardolino, G SC26, SC48, SC63Arnaldi, D SC71Artusi, CA SC6, SC69, SC96, SC129Attanasio, T SC113Attar, M SC5, SC12Avanzino, L SC7, SC16, SC90, SC115Avarello, TP SC8Azevedo, L SC80Azzolini, J SC39Bacci, D SC91Baccini, M C34Bagella, CF SC39Baldacci, F SC9Ballestriero, R SC62Bandettini di
Poggio, MSC10, SC78Barbic, F SC23Barbuto, M SC11Barone, P L16, SC2, SC5, SC10, SC12,
SC40, SC41, SC48, SC60,
SC72, SC86, SC105, SC128Baroni, C SC4Barros, J SC80Bartalucci, M SC52Bartolo, M SC30Barzaghi, C SC39Bazzu, G SC130Bellavia, G SC38Bellinzona, E SC93Bempensanti, MG SC4Bendinelli, M SC4Bentivoglio, AR C22, SC37, SC94Benuzzi, F SC49Berardelli, A L21, SC18, SC47, SC66, SC99Berlangieri, M SC34Bernardi, A SC122Bernardi, E SC13Berret, B SC16Bertaina, I SC14, SC34, SC71, SC88, SC126Berti, C SC9Bertolasi, L SC48, SC63, SC119, SC120Bertotti, G SC51Bestavashvili, L SC15Bet, L SC82Bhatia, K SC87Bisio, A SC16Biundo, R C20, SC17Bloise, MC SC18Bolla, M SC30, SC34Bonanni, L L9Bonetto, N SC45Bono, PS SC91Bonomi, M SC4Bonuccelli, U L17, SC9, SC10, SC35,
SC67, SC79, SC84, SC101, SC124Borelli, P SC10Borghero, G SC24Bove, F SC37Bove, M SC7, SC16Boveri, N SC51Bovi, T SC60Bozzali, M SC21Bragadin, LM SC62Brandimarti, A SC83Brighina, F SC126Brotini, S SC19Brugnoli, G SC57Brunelli, P SC4
Basal Ganglia 2S (2012) e1–e87e82Brunetti, A SC20Bruno, E SC76Brusa, L SC21, SC113Busan, P SC70Buttini, S SC93Cacciatore, FM SC22Cagnin, A SC45Calabresi, P L4Calandra-Buonaura, G C2Calandrella, D SC64Calia, G SC107Calloni, MV SC127Calzetti, S SC77Campagnoli, P SC64Canesi, M SC23, SC102, SC114Cannas, A SC24, SC29, SC81, SC110Cantello, R SC93Carboni, T SC83Carecchio, M SC39Caremani, L SC91Carlucci, S SC4Carnicella, F SC36Carpentras, G SC85Carrabba, G SC26Carrozzo, R SC80Casali, M SC50, SC58, SC123, SC125Cascio, E SC62Casetta, I SC13, SC57Castana, L SC97Castiglioni, D SC50Catalan, M SC70Cavaliere, M SC2, SC128Cavallieri, F SC25, SC49Cecchetto, S C32Cecconi, D SC44Cellotto, N SC78Cenzi, D SC60Cerasa, A SC38Cerasari, G SC75Ceravolo, MG C7Ceravolo, R L3, SC10, SC35, SC67, SC79,
SC84, SC101, SC114, SC124Ceriani, E SC4Cerri, G SC23Cesnik, E SC13, SC57Chelazzi, L SC120Chiari, L SC25Cilia, R SC102Ciocca, M SC26, SC48Cipresso, P SC1Cipriani, AM SC95Ciranni, AM SC111Cirillo, G SC27, SC56, SC117Cirillo, M SC56Clemenzi, I SC15Cocco, A SC81Cocito, D SC6Codazzi, V SC54Codeluppi, L SC25, SC49Cogiamanian, F SC26, SC48, SC63Colao, A SC103Colombo, D SC5, SC12Colosimo, C C14, SC66Comani, S L9Comi, C SC44, SC51, SC93Conforti, R SC31Contardi, S SC25, SC49Conte, A SC47, SC99Contini, E SC89Contrafatto, D SC76Contu, P SC10Coppola, A SC59Corbo, D SC56Cordano, C SC28Corona, M SC110Corsi, FM SC75Corsini, GU SC106Cortelli, P C1, SC114Cosentino, G SC126Cosentino, M SC28Cossu, G SC10Costa, N SC34Costantino, E SC24, SC29, SC81, SC110Cozzolino, A SC2, SC128Cozzolino, V SC75Cristina, S SC34D’Amelio, M SC38, SC126D’Andreamatteo, G SC83Dal Fante, M SC64De Angelis, MV SC33De Icco, R SC30, SC34De Mari, M SC36De Micco, R SC27, SC31, SC56, SC117De Michele, G L11, SC103De Natale, ER SC32, SC68, SC85De Pandis, MF SC33, SC53, SC104, SC114De Paoli, I SC30, SC34De Simone, M SC22De Stefano, G SC72Dedola, S SC43Defazio, G L7, SC7, SC47Dekker, I SC3Del Caro, A SC43Del Dotto, P C24, SC9Del Gamba, C SC35, SC67, SC124Del Prete, E SC35
Basal Ganglia 2S (2012) e1–e87 e83Dell’Aquila, C SC36Deluca, LV SC100Deriu, F SC32, SC85, SC87Di Gesaro, L SC38Di Giacopo, R SC37Di Maio, L SC103Di Matteo, A SC60Di Stasio, F SC66Dibilio, V SC38, SC76Dubbioso, R SC42Ebreo, M SC11Edwards, MJ SC87Egidi, M SC121Elia, AE SC39Ermani, M SC45Erminio, C SC98Ernesto, M SC118Errico, D SC40, SC105Erro, R SC2, SC41, SC86, SC128Esposito, F SC31, SC56Esposito, M SC42, SC59Fabbrini, G L18, C31, SC18, SC47,
SC66, SC99, SC114Facchini, S SC17Fadda, F SC29Fadda, L SC81Falasca, NW L9Falomi, B SC4Fanini, M SC91Farina, D SC43Fasano, A L15, SC14, SC60, SC94Fasano, M SC44Faulisi, F SC126Fava, C SC4Favaretto, S SC45Fazio, P SC57Ferigo, L SC46Ferracuti, S C15Ferrante, E SC98Ferrarese, C SC98Ferrazzano, G SC47Ferre´, F SC3Ferrucci, R SC48, SC63Fiaschi, A SC60, SC120Fierro, B SC126Filidei, E SC101Filla, A C28, SC103Finazzi Agro`, E SC113Fioravanti, V SC25, SC49Fiorillo, C C30Fiorio, M SC120Floris, G SC24Foncke, EMJ SC3Fontana, D C25Forapani, E SC98Formento-Dojot, P SC17Fossati, C SC50Fraix, V SC120Franceschini, M SC53, SC104Franciotti, R L9Franzini, A SC1Frazzitta, G SC51, SC61, SC93Freddi, N SC46Fresia, M SC34, SC88, SC126Frosini, D L10, SC10, SC35, SC67,
SC84, SC101Fumagalli, M SC63Furlan, R SC23Furlanetto, M SC92Galistu, P SC85Gallerini, S SC52Galli, M SC33, SC53, SC104Garavaglia, B SC39, SC79Garribba, E SC100Gasparro, AM SC8Gastaldo, E C18Gennuso, M SC54Genovesi, D SC101Gerace, C SC75Ghirardi, S SC54Giannicola, G SC55Gioia, MC SC38Giordano, A SC27, SC31, SC56, SC117Giordano, F SC72Giorgetti, A SC127Giovanditti, L SC52Girlanda, P SC11, SC111, SC116Girotti, F SC92Giunti, G SC84Giuntini, M SC9, SC67Gnoato, F SC45Gobbato, R SC83Gobbi, B C3Goldoni, M SC77Gorian, A SC70Govoni, V SC57Granieri, E SC13, SC57Granieri, G SC13, SC57Grassini, P SC50, SC58, SC123, SC125Graziosi, A SC11Grazzi, G SC13Groppo, E SC13, SC57Grossi, D SC40Guaita, MC SC127Guzzon, S SC46Iani, C SC21, SC113
Basal Ganglia 2S (2012) e1–e87e84Iannacone, C SC114Ibba, FC SC110Improta, I SC40, SC72Inguaggiato, EF C30Inversi, F SC36Iodice, R SC59Ioni, MF SC15Ippolito, S SC15Jelcic, N SC45Juergenson, I SC60Khandker, P SC66Kiferle, L SC79Koch, G SC21Krack, P SC120La Bua, V SC8Lanfranchi, S SC61Lanni, D SC20Lanotte, M SC69, SC96Latorre, A SC18, SC66Le Bas, JF SC120Le Pera, D SC104Le Pira, F SC38Lena, F SC94Leodori, G SC47, SC99Li Voti, P SC99Liboni, W SC114Ligabo`, M SC4Liguori, S SC56Ling, H L22Lo Russo, G SC97Locatelli, M SC26Logi, C SC9Lombino, FL SC93Longo, K SC2, SC41, SC86, SC128Lopiano, L C11, SC6, SC10, SC44,
SC69, SC96, SC97, SC129Luca, A SC76Lucetti, C SC9Maci, T SC38Maestri, R SC51, SC61, SC93Maieron, M SC62Mameli, F SC63Manca, D SC10Manca, M SC13Mancini, F C16, C18, SC64Manfredi, L SC64Manganelli, F SC10, SC42Manni, R SC71Mannino, M SC8Marano, P SC65, SC108Marceglia, S SC55Marcelli, V SC2, SC128Marchese, R L12, SC10, SC28, SC90Marchesi, E SC77Marciano, E SC2, SC128Marconi, R SC52Marin, D SC62Marini, A SC118Marino`, C SC42Marino, F SC28Marrosu, F SC24, SC29, SC81, SC110Marrosu, MG SC24, SC110Marsili, L SC66Martinelli, P C5Martino, D SC7Martino, I SC7Mascalchi, M C29Masci, MM SC29Mascia, MM SC81Masi, G SC36Massarelli, M SC103Mastronardi, R SC36Mastropasqua, C SC21Mauro, A SC1Mazza, S SC53Mazzeo, MR SC122Mazzoni, G SC13Mazzucchi, S SC67, SC124Melis, M SC10Melis, R SC29Mellone, S SC25Meloni, M SC68, SC85Melotti, L SC4Menicchetti, C SC101Menini, S SC4Meoni, S SC91Mereu, A SC10Merola, A SC6, SC10, SC69, SC96, SC129Meschini, MC SC80Mezzarobba, S C35, SC62, SC70Migheli, R SC43, SC107, SC130Minafra, B SC14, SC71, SC88, SC126Moccia, M SC2, SC41, SC72, SC73,
SC86, SC128Modugno, N C17, C18, SC20, SC94Monge, A SC121Montagnana, B SC4Montanaro, E SC96, SC129Montemezzi, S SC60Moretti, B SC83Moretti, DV SC74Morgante, F SC11, SC111, SC116Morgante, L C10, SC11Moroni, F SC23, SC102Moschella, V SC75Mostile, G SC76
Basal Ganglia 2S (2012) e1–e87 e85Musumeci, O SC111Nagliati, C SC57Nappi, G SC30Nardella, A SC99Negrotti, A SC77Nesti, C SC78, SC80Nicardi, P SC54Nichelli, P SC25, SC49Nicoletti, A C27, SC38, SC76Nicoletti, V SC10, SC35, SC79Nogueira, C SC80Ogliastro, C SC90Olgiati, S SC44Olivola, E SC112Onofrj, M L9Oroﬁno, G SC24, SC81, SC110Pacchetti, C L5, SC14, SC30, SC34, SC71,
SC88, SC114, SC126Paccone, A SC31Pacei, F SC82Paci, C SC83Padovani, A SC48Pagni, C SC84Palmerini, L SC25Panico, F SC4Panzeri, M SC48Pappata`, S SC41Paradiso, M SC121Paribello, A SC10Parodi, B SC28Pascucci, T SC112Pastore, MC SC122Patrocinio, D SC22Pau, R SC29Paulus, KS SC32, SC68, SC85Paviotti, L SC62Pecchioli, G SC91Pedroli, E SC1Pellecchia, MT C6, SC2, SC41, SC86, SC128Pellegrini, L C33, SC70Pelliccioni, G C3Pelosin, E C9, SC7, SC90, SC115Perini, M SC51, SC61, SC93Perrone, P SC127Petrozzi, L SC79Petta, F SC113Pezzoli, G SC23, SC51, SC102, SC114Piacentini, S L13, SC3Picazio, S SC21Piccininni, C SC37Pichiecchio, A SC30Picillo, M SC2, SC10, SC41, SC86,
SC105, SC128Pierantozzi, M SC112Pieri, S SC52Pignataro, G SC31Pignatelli, S SC42Pilleri, M C21, SC17Pilurzi, G SC87Pinnola, S SC50, SC58, SC123, SC125Pippione, AC SC44Pirisinu, M SC43Pisciotta, C SC42Pizzolato, G SC70Plewnia, K SC52Poletti, M SC84Politini, L SC127Polito, C SC91Polizzi, L SC81Pollak, P SC120Polo, A SC46Ponzo, V SC21Porcheddu, A SC100Porta, A SC23Porta, M SC55Pozzi, NG SC14, SC30, SC71, SC88, SC126Pozzo, T SC16Pramstaller, P C23Preda, F SC89Prelle, A SC54Priori, A SC26, SC48, SC55, SC63, SC126Proaspatu, M SC127Puddu, R SC24Quaranta, D SC37Quartarone, A SC116Quatrale, R SC89Quattrone, A SC38Raciti, L SC76Radicati, FG SC50, SC58, SC123, SC125Raffo De Ferrari, A SC90Raffo, A SC16Raglione, LM SC91Ramat, Silvia C4, SC91Ramat, Stefano C4Raoli, V SC48Ravida`, L SC65Reale, C SC79Reali, E SC23, SC102Realmuto, S SC38Recchia, S SC4Redaelli, V SC92Riboldazzi, G SC51, SC61, SC93Riccardi, P SC128Ricci, R SC15Ricciardi, L SC11, SC94, SC116Rinaldi, C SC103
Basal Ganglia 2S (2012) e1–e87e86Rinalduzzi, S SC95Rispo, A SC72Risso, P SC26Riva, G SC1Rizzi, L SC69, SC96, SC129Rizzo, V SC116Rizzone, MG C13, SC6, SC69, SC96,
SC97, SC98, SC129Roccatagliata, DV SC97, SC98Rocchi, L SC99Rocchitta, G SC43, SC100, SC107, SC130Romeo, S SC111Romito, L SC1, SC3, SC82Ronconi, L SC48Rosa, M SC55Rossetto, S SC46Rossi, C SC4, SC101Rossi, F SC103Rothwell, JC SC87Roversi, G SC89Rovescala, R SC51Ruggieri, S SC20Rusconi, ML SC23, SC102Russo, A SC56Russo, CV SC103Russo, T SC72Sa´, MJ SC80Sabbatini, D C3Sacchetti, M SC4Saifee, TA SC87Sala, F SC120Sale, P SC53, SC104Sallustio, V SC22Salsone, M SC38Salvato, L SC61Salvatore, E SC103Sandrini, G SC30, SC34, SC88, SC126Sanﬁlippo, C SC38Sanguigni, S SC83Sanna, D SC100Santangelo, G C19, SC2, SC40, SC41,
SC72, SC105, SC128Santorelli, FM C30, SC78, SC80Santoro, L SC10, SC42, SC59Sarchioto, M SC18Saveriano, F SC36Savettieri, G SC38, SC126Scarpello, R SC122Scarpini, C SC52Scarpino, O C3Scarselli, M SC106Scelzo, E SC63Schembri, L SC28Schenone, A SC28, SC78Schmitt, E SC120Sciacca, G SC76Secchi, O SC100, SC107Secchi, P SC127Seminara, M SC65, SC108Semprini, R SC109Sensi, M SC89Serlenga, L SC22Serra, PA SC43, SC100, SC107, SC130Serusi, M SC85Servello, D SC14, SC55Sgubin, G SC70Simioni, V SC57Sobrini, S SC83Solla, P SC24, SC29, SC81, SC110Sorbera, C SC11, SC111Sorbi, S SC91Sorrentino, G SC2, SC40, SC128Sotgiu, G SC32Sova, I SC104Spissu, Y SC43Squintani, G SC60Stampanoni Bassi, M SC112Stanzione, P C26, SC21, SC112, SC113Stefani, A SC21, SC112Stocchi, F L19, C12, SC5, SC12, SC33,
SC50, SC53, SC58, SC104,
SC114, SC123, SC125Strafella, G SC36Stuppiello, M SC36Suppa, A L1, SC66Tamburini, T SC115Tassorelli, C C8, SC30, SC34Tedeschi, G SC27, SC31, SC56, SC117Terranova, C SC116Terruso, V SC8Terzaghi, M SC71Tessitore, A L2, SC27, SC31, SC56, SC117Theeuwes, J SC120Thomas, A L9Tiburzi, M SC118, SC121Tinazzi, M L14, SC60Tirinelli, F SC118, SC121Tocco, P SC119Tognoni, G SC84Tola, MR SC89Tolu, E SC32Tomasini, E SC63Tomelleri, S SC4Tommasi, G SC120Tondinelli, ME SC118, SC121Toni, V SC122
Basal Ganglia 2S (2012) e1–e87 e87Torti, M SC50, SC58, SC123, SC125Tortora, R SC72Toscano, A SC111Trevisani, L SC89Troiano, M SC6Trojano, L SC40, SC105Truffelli, R SC78Tucci, T SC103Turla, M SC51Turri, M SC119Uccelli, A SC28Uccellini, D SC51, SC93Uliari, S SC13Ulivi, M SC9Unti, E SC124Urbano, V SC83Vacca, L SC50, SC58, SC123, SC125Vacca, M SC29Valente, EM L20Valentini, LG SC92Valentino, F SC126Valzania, F SC25, SC49Vanacore, N SC118Vanelli, F SC124Vattemi, G SC60Vecchio, E SC127Veneziano, G SC61Vergallo, A SC9Vigna, C SC1Vilarinho, L SC80Vimercati, S SC33, SC53Viselli, F SC118, SC121Vita, G SC111Vitale, C L16, SC2, SC40, SC41, SC72,
SC105, SC128Volpe, E SC15Volterrani, D SC101Weis, L SC17Wenning, GK L23Yelnik, J SC120Zangaglia, R SC14, SC30, SC71Zappia, M SC38, SC76, SC114Zarantonello, G SC45Zarcone, D SC61Zarino, B SC26Zibetti, M C10, C12, SC6, SC10, SC44,
SC69, SC96, SC129Zinellu, M SC130Zuccarino, R SC78
